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Investigator’s Agreement 
I have read the attached protocol entitled “A Phase 1 Open-label Study Evaluating the 
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 in 
Subjects With Advanced Solid Tumors with a Specific KRAS Mutation”, 
dated 14 May 2018, and agree to abide by all provisions set forth therein.  
I agree to comply with the International Conference on Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP) and applicable national or regional 
regulations/guidelines.   
I agree to ensure that Financial Disclosure Statements will be completed by: 
• me (including, if applicable, my spouse [or legal partner] and dependent children) 
• my subinvestigators (including, if applicable, their spouses [or legal partners] and 
dependent children) 
at the start of the study and for up to one year after the study is completed, if there are 
changes that affect my financial disclosure status. 
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen Inc.  
   
Signature   
Name of Investigator  Date (DD Month YYYY) 
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Protocol Synopsis 
Title:  A Phase 1, First in Human, Open-label Study Evaluating the Safety, Tolerability, 
Pharmacokinetics, and Efficacy, of AMG 510 in Subjects with Advanced Solid Tumors with a 
Specific KRAS Mutation 
Study Phase:  1 
Indication:  Advanced KRAS p.G12C mutant solid tumors 
Primary Objective:   
• Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant 
solid tumors 
• Estimate the maximum tolerated dose (MTD) and/or a biologically active dose 
(eg, recommended phase 2 dose [RP2D]) within investigated subject population groups 
Secondary Objectives:  
• Characterize the pharmacokinetics (PK) of AMG 510 following administration as an oral tablet 
formulation 
• To evaluate tumor response assessed by CT or MRI using RECIST 1.1 criteria of AMG 510 
as monotherapy in subsets of solid tumors with KRAS p.G12C mutation 
• To evaluate the effect of food on the oral pharmacokinetics of AMG 510 
• To evaluate the relationship between changes in QTc and AMG 510 exposure 
Exploratory Objectives:  
• To explore pharmacokinetic/pharmacodynamic relationships for safety and/or efficacy 
endpoints  
• To characterize AMG 510 excretion in urine 
• To identify metabolites of AMG 510 in plasma and urine 
• To investigate potential biomarkers by biochemical and/or genetic analysis of blood and/or 
tumor samples. 
Hypothesis:   
At least 1 dose level of AMG 510, in repeat oral administrations, will achieve acceptable safety 
and tolerability in subjects with advanced KRAS p.G12C mutant solid tumors, with evidence of 
anti-tumor activity 
Primary Endpoints:   
• Safety: subject incidence of dose limiting toxicity (DLTs), treatment-emergent adverse events, 
treatment-related adverse events, and clinically significant changes in vital signs, physical 
examinations, electrocardiogram (ECGs), and clinical laboratory tests 
Secondary Endpoints:  
• PK parameters of AMG 510 including, but not limited to, maximum observed plasma 
concentration (Cmax), time to achieve Cmax (tmax), and area under the plasma 
concentration-time curve (AUC) 
• Objective response rate (ORR), duration of overall response (DOR), progression-free survival 
(PFS), and duration of stable disease measured by CT or MRI and assessed per 
RECIST 1.1 criteria   
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• PK parameters of AMG 510 including, but not limited to, Cmax, tmax, and AUC in the fed and 
fasted states for the food effect assessment 
• AMG 510 exposure/QTc interval relationship 
Exploratory Endpoints:   
• AMG 510 exposure/safety and exposure/efficacy relationships 
• AMG 510 excretion in urine 
• Characterization of potential metabolites of AMG 510 in plasma and urine, if appropriate 
• Quantification of biomarker expression at protein, RNA, and DNA levels, as appropriate 
• Potential biomarkers by biochemical and/or genetic analysis of blood and/or tumor samples 
Study Design:  This is a first-in-human (FIH), multicenter, non-randomized, open-label, phase 1 
study to evaluate safety and tolerability of AMG 510 in subjects with advanced KRAS p.G12C 
mutant solid tumors.  The study will be conducted at approximately 25 sites in Australia, United 
States, Canada, Brazil, France, Germany, China, Japan, and South Korea.  Other countries or 
regions may participate. AMG 510 will be evaluated as an oral therapeutic. The study will be 
conducted in 2 parts:  Part 1 – Dose Exploration and Part 2 – Dose Expansion.  Part 1 is aimed at 
evaluating the safety, tolerability, PK and pharmacodynamics of AMG 510 and determining the 
MTD of repeat daily (QD) dosing schedule in subjects with advanced KRAS p.G12C mutant solid 
tumors using a Bayesian Logistics Regression Model (BLRM) design. The dose expansion part of 
the study (Part 2) can open once the MTD and/or a biologically active dose (eg, recommended 
phase 2 dose [RP2D]) has been determined in Part 1.  The dose exploration part of the study will 
consist of approximately 50 subjects and the dose expansion part will consist of approximately 
60 additional subjects, including at least 3 groups with specific tumors harboring KRAS p.G12C 
mutations (non-small cell lung cancer [NSCLC], colorectal cancer [CRC], and all other solid 
tumors). Different schedules can be used in the dose expansion part based on clinical and PK 
data from all parts of the dose exploration. The DLT evaluation period will be 21 days. Based on 
emerging clinical efficacy data, the groups explored in the expansion part can be modified. 
Administration of AMG 510 (in part 1 and part 2) may continue until evidence of disease 
progression, intolerance to study medication, or withdrawal of consent. 
 
Dose Exploration – Part 1 
Dose exploration cohorts will estimate the safety, tolerability, PK, and pharmacodynamics of 
different doses of AMG 510 in subjects with advanced KRAS p.G12C mutant solid tumors.  
Subjects will receive AMG 510 daily administered orally.  Enrollment into the dose exploration 
cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects 
treated at the lowest planned dose level of 180 mg. Dose escalation will follow the planned 
Study Schema schedule with 2-4 subjects treated in each cohort. If no DLT is observed, dose 
escalation will continue to the next planned dose cohort as per Study Schema.  Once a subject 
experiences a DLT, dosing for subsequent cohorts will be recommended using the dose level 
recommendation from the Bayesian Logistic Regression Model (BLRM).  The decision to advance 
to the next dose level will be recommended by the Dose Level Review Team (DLRT) using the 
dose level recommendation from BLRM, as appropriate, and by evaluating available safety data, 
laboratory, and PK information.  
Intra-subject dose escalations are allowed on this study.  Subjects who complete the DLT period 
may proceed to a higher dose level for the following treatment cycle once the next dose cohort 
has been deemed safe by the DLRT and after consultation with the sponsor if: 
o no DLT has been reported for this subject during or after completion of the DLT 
period 
o the subject has not experienced any ≥ grade 2 adverse events (deemed treatment 
related by the investigator) during treatment 
Subjects who do not proceed to a higher dose may receive extra cycles at the original dose.   
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Dose exploration will continue until any of the following events. 
• The highest planned dose level is determined to be safe and tolerable (minimum of 
6 DLT-evaluable subjects) 
• The MTD is identified, BLRM recommends a dose level which already has 6 DLT-evaluable 
subjects  
Additional subjects (up to 20) may be enrolled in one or more dose levels that have been shown 
to be safe and tolerable, defined as backfill enrollment.  This backfill enrollment will be done to 
better estimate the RP2D and better characterize the safety, efficacy and pharmacodynamics for 
AMG 510 and may be concurrent with dose escalation to identify the MTD.  Additionally, food 
effect evaluation will be conducted in at least 6 subjects from backfill enrollment in cycle 2 or 
later.   
Dose Expansion – Part 2 
Upon completing the dose exploration part of the study and depending on data obtained, dose 
expansion may proceed with three groups consisting of subjects with KRAS p.G12C mutant solid 
tumors: 
1. Group 1 (NSCLC) - subjects with advanced KRAS p.G12C mutant NSCLC 
2. Group 2 (CRC) - subjects with advanced KRAS p.G12C mutant CRC 
3. Group 3 (Other) - subjects with advanced KRAS p.G12C mutant solid tumor types other 
than the tumor types specified in Groups 1 and 2 
Dose expansion in all three groups may be done concurrently.   
Sample Size:   
Part 1 – Dose Exploration:  No more than 50 subjects will be enrolled to the dose escalation 
cohorts. Approximately 30 subjects will be needed to estimate the MTD.  An additional 
20 subjects may be enrolled by backfill enrollment from which at least 6 subjects will be evaluated 
for food effect.     
Part 2 – Dose Expansion:  Approximately 60 subjects will be enrolled in the dose expansion part 
of the study, which will be conducted in at least 3 groups. Group 1: up to 20 subjects with 
advanced KRAS G12C mutant NSCLC. Group 2: up to 20 subjects with advanced KRAS G12C 
mutant CRC. Group 3: up to 20 subjects with advanced KRAS G12C mutant solid tumor types 
other than specified in Groups 1 and 2. The sample sizes for groups 1 through 3 are based on 
practical considerations.  
 
Summary of Subject Eligibility Criteria: Adult subjects (≥ 18 years old) with advanced solid 
tumors will be eligible for this study.  Enrollment will be restricted to subjects with KRAS p.G12C 
mutant solid tumors as assessed by DNA sequencing of tumor biopsy specimens. Once 
consented to the study, subjects will provide a medical history and undergo screening safety tests 
to confirm all eligibility requirements of the study have been met. Subjects will provide archived 
tumor samples (fresh frozen sample or formalin fixed paraffin embedded [FFPE] sample collected 
within 5 years) or undergo a pre-dose tumor biopsy that enables KRAS testing.  
Investigational Product   
Amgen Investigational Product Dosage and Administration:   
AMG 510 will be manufactured and packaged by Amgen Inc. and distributed using Amgen clinical 
study drug distribution procedures. 
 
Procedures:  After written informed consent has been obtained, all screening tests and 
procedures will be performed within 21 days of administration of the first dose of AMG 510 
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(day 1), unless otherwise noted. Subjects will be seen in clinic where critical clinical safety and 
study evaluations will be performed including physical examination, vital signs, clinical laboratory 
tests, electrocardiograms (ECGs), PK, and biomarker sample collections. 
 
Statistical Considerations:  The primary analysis will occur when target enrollment is complete 
and each subject either completes 6 months on study or withdraws from the study.  
In the dose exploration part, the DLRT will review the safety data after each cohort and make a 
decision on the next dose level to be explored for the estimate of RP2D/MTD based on a BLRM 
design.  
Descriptive statistics will be provided for selected demographics, safety, PK, efficacy and 
biomarker data by dose, dose schedule, and time as appropriate. Descriptive statistics on 
continuous data will include means, medians, standard deviations and ranges, while 
categorical data will be summarized using frequency counts and percentages. ORR will be 
presented with 95% exact CI. Graphical summaries of the data may also be presented. 
 
Sponsor:  Amgen Inc. 
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Schema.  Study Design and Treatment  
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Schema.  Study Design and Treatment  
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Schema.  Food Effect Assessment 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Administration of AMG 510 may continue until evidence of disease progression, intolerance to study medication, or withdrawal of consent. 
 
Food Effect Assessment 
 
Day 1 to Day 3 
 
Continue with 
AMG 510 
dosing* 
Enrollment 
Prior to day 1 of cycle 
2 or later  
AMG 510 in a  
fasted state 
 on day 1  
 
(PK and urine collection 
up to 24 hrs) 
AMG 510 in a fed 
state (after a high-
fat meal) on day 2 
 
 (PK collection up to 24 
hrs) 
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Study Glossary 
Abbreviation or Term Definition/Explanation 
ANC absolute neutrophil count 
AUC area under the concentration-time curve from time  
ALK anaplastic lymphoma kinase 
BCRP breast cancer resistance protein 
Cmax  maximum observed concentration 
CR Complete response 
CRC colorectal cancer 
CT Computed tomography 
CYP3A cytochrome P450 3A 
DDI drug-drug interaction 
DLRM Dose Level Review Meeting 
DLRT Dose Level Review Team 
DILI drug induced liver injury 
DOR Duration of response 
EC50 half-maximal effective concentration 
ECG electrocardiogram 
EGFR epidermal growth factor receptor 
Electronic Source Data 
(eSource)  
source data captured initially into a permanent electronic record 
used for the reconstruction and evaluation of a study 
End of Study  defined as the date when the last subject is assessed or receives an 
intervention for evaluation in the study (ie, last subject last visit), 
following any additional parts in the study (eg, long-term follow-up), 
as applicable  
End of Follow-up defined as when the last subject completes the last 
protocol-specified assessment in the study  
End of Study for 
Individual Subject 
defined as the last day that protocol-specified procedures are 
conducted for an individual subject 
End of Treatment defined as the last assessment for the protocol specified treatment 
phase of the study for an individual subject 
Exposure-Response 
Analysis 
mechanism-based modeling & simulation and statistical analyses 
based on individual pharmacokinetic [PK] exposure (eg, population 
pharmacokinetic modeling) and response, which may include 
biomarkers, pharmacodynamic effects, efficacy and safety endpoints 
FDA Food and Drug Administration 
FFPE formalin-fixed paraffin-embedded 
FIH first-in-human 
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Abbreviation or Term Definition/Explanation 
HNSTD highest non-severely toxic dose 
ICF informed consent form 
ICH International Conference of Harmonization 
IVD in vitro diagnostic 
IR immediate-release 
KRAS Kirsten rat sarcoma viral oncogene homolog (protein) 
KRAS Kirsten rat sarcoma viral oncogene homolog (DNA) 
KRASG12C KRAS protein with a G12C mutation at the protein level 
KRAS p.G12C KRAS DNA with a mutation resulting in a G12C mutation at the 
protein level 
MRI Magnetic resonance imaging 
mRNA messenger ribonucleic acid 
NOEL no observed effect level 
NRAS neuroblastoma RAS viral oncogene homolog 
NSCLC non-small-cell lung carcinoma 
ORR Objective response rate 
PD Progressive disease 
PD-1 programmed cell death-1 
PD-L1 programmed death-ligand 1 
P-gp P-glycoprotein 
PCR polymerase chain reaction 
PK Pharmacokinetic(s) 
PO oral(ly) 
PFS Progression-free survival 
PR Partial respone 
Primary Completion defined as the date when the last subject is assessed or receives an 
intervention for the final collection of data for the primary endpoint(s), 
for the purposes of conducting the primary analysis, whether the 
study concluded as planned in the protocol or was terminated early  
QD once daily 
QTc corrected QT (interval) 
RAS rat sarcoma viral oncogene homolog 
RECIST Response evaluation criteria in solid tumors 
RP2D Recommended Phase 2 Dose 
SD Stable disease 
STD10 severely toxic dose in 10% of animals 
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Abbreviation or Term Definition/Explanation 
Source Data information from an original record or certified copy of the original 
record containing patient information for use in clinical research.  
The information may include, but is not limited to, clinical findings, 
observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained 
in source documents (original records or certified copies).  (ICH 
Guideline (E6)).  Examples of source data include Subject 
identification, Randomization identification, and Stratification Value. 
Study Day 1 defined as the first day that protocol specified investigational 
product(s)/protocol-required therapies is/are administered to the 
subject 
t1/2,z terminal half-life 
Tmax time to reach maximum concentration 
TGI tumor growth inhibition 
VEGF vascular endothelial growth factor 
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1. OBJECTIVES 
1.1 Primary 
• Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C 
mutant solid tumors 
• Estimate the maximum tolerated dose (MTD) and/or a biologically active dose 
(eg, recommended phase 2 dose [RP2D]) within investigated subject population 
groups 
1.2 Secondary 
• Characterize the pharmacokinetics (PK) of AMG 510 following administration as an 
oral tablet formulation 
• To evaluate tumor response assessed by CT or MRI using RECIST 1.1 criteria of 
AMG 510 as monotherapy in subsets of solid tumors with KRAS p.G12C mutation 
• To evaluate the effect of food on the oral pharmacokinetics of AMG 510 
• To evaluate the relationship between changes in QTc and AMG 510 exposure 
1.3 Exploratory 
• To explore pharmacokinetic/pharmacodynamic relationships for safety and/or 
efficacy endpoints  
• To characterize AMG 510 excretion in urine 
• To identify metabolites of AMG 510 in plasma and urine 
• To investigate potential biomarkers by biochemical and/or genetic analysis of blood 
and/or tumor samples. 
2. BACKGROUND AND RATIONALE 
2.1 Disease and Background 
Worldwide, lung cancer (small cell and non-small cell) and CRC are the first and third 
most common types of cancer occurring in both men and women (WHO statistics, 2015).  
It is estimated that in 2018 there will be approximately 234 030 new cases of lung cancer 
and 140 250 new cases of CRC in the United States alone (American Cancer Society, 
2018).  The 5-year survival rate for advanced NSCLC cancer is between 1% and 
10% depending on the stage.  Similarly, the 5-year survival rate for advanced CRC is 
approximately 11% (American Cancer Society, 2018). 
Treatments for both types of advanced cancer typically consist of regimens of cytotoxic 
chemotherapies, either as a single agent or in combination with other agents.  For 
NSCLC, platinum containing doublets, typically cisplatin/pemetrexed are standard 
options (NCCN, 2018a).  Targeted therapies are also an option where molecular testing 
has identified mutations in epidermal growth factor receptor (EGFR), anaplastic 
lymphoma kinase (ALK), or proto-oncogene tyrosine-protein kinase ROS (ROS1), or 
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expression of programmed death-ligand (PD-L1).  In these cases, specific kinase 
inhibitors or programmed cell death (PD-1) inhibitors can be used. 
For unresctable CRC, several cytotoxic agents have demonstrated efficacy, including 
5-fluorouracil (5-FU), folinic acid, irinotecan, oxaliplatin and capecitabine 
(NCCN, 2018b).  These drugs are commonly combined in various regimens, and can be 
further partnered with vascular endothelial growth factor (VEGF) inhibitors or EGFR 
inhibitors in patients with wild-type RAS genes.  Other more recent treatment options 
include the kinase inhibitor regorafenib or a dual agent therapy consisting of trifluridine 
(a nucleoside metabolic inhibitor) and tipiracil (a thymidine phosphorylase inhibitor). 
The RAS proto-oncogene has been identified as an oncogenic driver of tumorigenesis in 
both NSCLC and CRC (Der et al, 1982; Smith et al, 2010; Johnson et al, 2001).  The 
RAS family consists of 3 closely related genes that express GTPases responsible for 
regulating cellular proliferation and survival (Barbacid et al 1987, Simanshu et al, 2017).  
The RAS proteins, KRAS, Harvey rat sarcoma viral oncogene homolog (HRAS), and 
neuroblastoma RAS viral oncogene homolog (NRAS) (Harvey, 1964; Chang et al, 1982; 
Hall et al, 1983; Taparowsky et al, 1983), can be mutationally activated at codons 
12, 13, or 61, leading to human cancers.  Different tumor types are associated with 
mutations in certain isoforms of RAS, with KRAS being the most frequently mutated 
isoform in most cancers (Prior et al, 2012).  Of the KRAS mutations, it is estimated that 
approximately 80% occur at codon 12 (Prior et al, 2012).  
The KRAS p.G12C mutation is a single guanine to thymine substitution that results in a 
glycine to cysteine substitution at amino acid position 12.  This structural change in the 
protein results in a defect in the association of GTPase-activating proteins (GAPs), 
thereby reducing the hydrolysis of GTP by KRAS.  The resulting accumulation of active, 
GTP-bound KRAS leads to enhanced proliferative and survival signaling in tumor cells.  
The KRAS p.G12C mutation has been identified as a putative oncogenic driver in 
several types of solid tumors including NSCLC (Fernández-Medarde and Santos, 2011) 
and CRC (Jones et al, 2017).  KRAS p.G12C mutations have also been identified in 
other solid tumors such as pancreatic, endometrial, bladder, ovarian, and small cell lung 
tumors (Zhou et al, 2016; The AACR Project GENIE Consortium, 2017).  In both NSCLC 
and CRC, mutation of KRAS is an adverse prognostic factor (Bonanno et al, 2010; 
Johnson et al, 2013; Jones et al, 2017), and in CRC, the specific KRAS p.G12C 
mutation is associated with poorer prognosis compared to other KRAS mutations 
(Jones et al, 2017).  Overall, it is estimated that approximately 13% of lung 
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adenocarcinoma (including NSCLC), 3% of CRC, and 1% to 2% of numerous other solid 
tumors (including pancreatic, endometrial, bladder, ovarian, and small cell lung tumors) 
harbor the KRAS p.G12C mutation (Biernacka et al, 2016; Neumann et al, 2009; 
The AACR Project GENIE Consortium, 2017). 
While the role of KRAS mutations in human cancers has been known for decades, no 
anti-cancer therapies specifically targeting KRAS mutations have been successfully 
developed, largely because the protein is intractable for inhibition by small molecules 
(McCormick, 2016).  Therefore, an unmet need currently exists for therapies that can 
specifically target cancers driven by KRAS mutations. 
AMG 510 is a small molecule that specifically and irreversibly inhibits the KRASG12C 
mutant protein.  AMG 510 binds to the P2 pocket of KRAS adjacent to the mutant 
cysteine at position 12 and the nucleotide-binding pocket.  The inhibitor contains a 
thiol-reactive portion which covalently modifies the cysteine residue and locks KRASG12C 
in an inactive, GDP-bound conformation.  This blocks the interaction of KRAS with 
effectors such as RAF proto oncogene serine/threonine-protein kinase (RAF), thereby 
preventing downstream signaling, including the phosphorylation ERK 
(Cully and Downward, 2008; Ostrem et al, 2013; Simanshu et al, 2017).  Inactivation of 
KRAS by RNAi or small-molecule inhibition has previously demonstrated an inhibition of 
cell growth and induction of apoptosis in tumor cell lines and xenografts harboring KRAS 
mutations (including the KRAS p.G12C mutation) (Janes et al, 2018; McDonald et al, 
2017; Xie et al, 2017; Ostrem and Shokat, 2016; Patricelli et al, 2016).  Studies with 
AMG 510 have confirmed these in vitro findings and have likewise demonstrated 
inhibition of growth and regression of cells and tumors harboring KRAS p.G12C 
mutations (Section 5.1).  These data suggest that inhibition of KRAS p.G12C may have 
therapeutic benefit for patients with KRAS p.G12C-driven cancers.  Accordingly, the FIH 
Study 20170543, will evaluate the safety, tolerability, PK, and efficacy of AMG 510 in 
subjects with KRAS p.G12C mutant advanced NSCLC, CRC, and other solid tumors.. 
2.1.1 KRAS Pathway and KRAS p.G12C Mutation 
Mutation of the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene 
(Kirsten and Mayer, 1967), a member of the rat sarcoma viral oncogene homolog (RAS) 
family of proteins, has been identified as an oncogenic driver in numerous types of solid 
tumors, including lung cancer (Fernández-Medarde and Santos, 2011) and colorectal 
cancer (CRC) (Jones et al, 2017).  Historically, the type of therapy used to treat these 
solid tumors has depended primarily on the tissue type of the tumor.  However, more 
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recent therapies have been developed that target tumors dependent on specific genetic 
features of the tumor rather than the tissue type.  
While the role of KRAS mutations in human cancers has been known for decades 
(Hobbs et al, 2016), no anticancer therapies targeting KRAS mutations have been 
successfully developed.  Thus, an unmet need exists for therapies that can specifically 
target cancers driven by KRAS mutations.  AMG 510 is one such small molecule that 
specifically and irreversibly inhibits the KRAS p.G12C mutant which is found in 
approximately 13% of lung adenocarcinoma (including NSCLC), 3% of CRC, and 1% to 
2% of numerous other solid tumors (including pancreatic, endometrial, bladder, ovarian, 
and small cell lung tumors) harbor the KRAS p.G12C mutation (Biernacka et al, 2016; 
Neumann et al, 2009; The AACR Project GENIE Consortium, 2017).  AMG 510 binds to 
a recently characterized pocket (P2) adjacent to the nucleotide-binding pocket of KRAS 
and covalently modifies the cysteine residue at position 12.  Binding of AMG 510 locks 
KRAS in the inactive guanosine diphosphate (GDP)-bound conformation and prevents 
the nucleotide exchange of guanosine triphosphate (GTP) for GDP, thus inhibiting 
downstream signaling.  As inactivation of KRAS has been demonstrated to inhibit cell 
growth and/or promote apoptosis selectively in tumor cells harboring KRAS mutations 
(Janes et al, 2018; McDonald et al, 2017; Xie et al, 2017; Ostrem and Shokat, 2016; 
Patricelli et al, 2016), AMG 510 may provide a therapeutic benefit for patients with 
KRAS p.G12C-driven cancers.  Accordingly, the first-in-human (FIH) Study 20170543, 
will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and 
efficacy of AMG 510 in subjects with KRAS p.G12C mutant advanced solid tumors.  
2.2 Amgen Investigational Product Background  
AMG 510 is a small molecule that specifically and irreversibly inhibits the KRASG12C 
mutant protein.  AMG 510 binds to the P2 pocket of KRAS adjacent to the mutant 
cysteine at position 12 and the nucleotide-binding pocket.  The inhibitor contains a 
thiol-reactive portion which covalently modifies the cysteine residue and locks KRASG12C 
in the inactive GDP-bound conformation.  This blocks the interaction of KRAS with 
effectors like RAF, thus preventing downstream signaling, including the phosphorylation 
of ERK (Ostrem et al, 2013; Simanshu et al, 2017). Inactivation of KRAS through a small 
molecule inhibitor has previously demonstrated an inhibition of cell growth and induction 
of apoptosis in tumor cell lines and xenografts with the KRAS p.G12C mutation 
(Ostrem and Shokat 2016; Patricelli, Janes et al. 2016; Janes, Zhang et al. 2018).  
Likewise, studies of AMG 510 have demonstrated inhibition of growth and regression of 
A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 21 of 95 
CONFIDENTIAL   
cells and tumors harboring KRAS p.G12C (Section 2.2.1).  These data suggest that 
inhibition of KRASG12C may have therapeutic benefit for patients with KRAS 
p.G12C-driven cancers.  Accordingly, the first-in-human Study 20170543, will evaluate 
the safety and efficacy of AMG 510 in subjects with KRAS p.G12C mutant advanced 
NSCLC, CRC, and other solid tumors 
2.2.1 AMG 510 Pre-clinical  
In vitro AMG 510 inhibited nucleotide exchange of recombinant mutant KRASG12C/C118A 
(half maximal inhibitory concentration, IC50 = 0.09 M), but had minimal effect on 
KRASC118A, which is wildtype at G12.  In cells, AMG 510 covalently modified KRASG12C 
and inhibited KRAS signaling as measured by phosphorylation of ERK1/2 in all KRAS 
p.G12C-mutant cell lines tested (IC50 values from 0.01 to 0.12 M), but did not inhibit 
phospho-ERK1/2 in cell lines with various other KRAS mutations.  AMG 510 also 
impaired viability in all but one p.G12C-mutant cell lines (IC50 values from 0.004 to 
0.032 M), but did not affect the viability of cell lines that did not harbor the KRAS 
p.G12C mutation.  The cellular kinact and Ki values for AMG 510 were also experimentally 
determined in MIA PaCa-2 cells to be 0.00133 sec-1 and 6.97×10-7 M, respectively, with 
kinact/Ki ratio of 1.9×103 M-1 sec-1.   
In vivo AMG 510 covalently modified KRASG12C and significantly inhibited 
phospho-ERK1/2 in human KRAS p.G12C MIA PaCa-2 T2 pancreatic and KRAS 
p.G12C NCI-H358 NSCLC tumor xenografts in mice in a dose-dependent manner at 
doses as low as 1 mg/kg in the MIA PaCa-2 T2 model.  After a single, 10 mg/kg dose in 
mice bearing MIA PaCa-2 T2 tumors, exposure of AMG 510 peaked at 0.5 hours, 
followed closely by maximal inhibition of phospho-ERK1/2 by 1 hour to 2 hours.  
Covalent modification of KRASG12C by AMG 510 tracked with inhibition and maximal 
modification occurred after 2 hours.  Significant inhibition and modification of KRASG12C 
persisted for 48 hours after a single, 10 mg/kg dose.  In tumor xenograft studies 
AMG 510 significantly inhibited the growth of MIA PaCa-2 T2 and NCI-H358 tumors at 
doses as low as 3 mg/kg and achieved 62% and 49% regression, respectively, at 
100 mg/kg.  Notably AMG 510 had no effect on SW480-1AC (KRAS p.G12V) tumor 
xenografts at 100 mg/kg and did not impact body weight in any study. 
2.2.2 Pharmacokinetics 
AMG 510 was characterized in vitro and in vivo preclinical studies.  AMG 510 exhibited 
moderate to high clearance (CL), moderate volume of distribution (Vss), and terminal 
elimination half-life (t1/2,z) of 0.34 to 0.71 hours in animal species. The oral bioavailability 
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of the suspension formulation was variable, ranging from 3.3 to 47% across the species 
tested. AMG 510 has moderate binding to plasma proteins in all species including 
humans. AMG 510 did not preferentially distribute into red blood cells in mouse, rat, dog, 
and human whereas it was preferentiallydistributed into red blood cells in monkey.  
These data were used to predict the human AMG 510 PK parameters   
AMG 510 was predominantly eliminated in preclinical species in vivo through 
CYP3A-catalyzed formation of the metabolite, M24. M24 has >1000-fold less 
pharmacological activity than its parent, AMG 510.  AMG 510 was also a substrate of 
P-glycoprotein in vitro. 
AMG 510 has a potential to cause CYP3A-mediated drug-drug interaction (DDI) due to 
reversible and irreversible time-dependent inhibition of CYP3A and induction of CYP3A4 
in vitro.  M24 also has a potential to cause CYP3A-mediated drug-drug interactions due 
to reversible and irreversible time-dependent inhibition of CYP3A and induction of 
CYP3A4 in vitro.  In vitro, AMG 510 was also shown to be an inhibitor of CYP2C8 and 
CYP2D6, but not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP2E1.  
M24 was an inhibitor of CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. In vitro, 
AMG 510 was shown to be an inducer of CYP2B6, CYP2C8, CYP2C9, and CYP2C19, 
while M24 was an inducer of CYP2B6, CYP2C8, CYP2C9 and CYP2C19.   
In vitro, AMG 510 is a P-gp substrate, thus active transport by P-gp may affect AMG 510 
absorption and elimination.  AMG 510 is not a BCRP substrate. Additionally, AMG 510 
and its metabolite M24 was identified as an inhibitor of human MATE1.  AMG 510 was 
also an inhibitor of human OAT3, OATP1B1, MATE2-K and P-gp. Incomplete inhibition 
was observed up to the highest test concentration for human OAT1, OCT1, OATP1B3 
and BCRP, suggesting weak inhibition. M24 was an inhibitor of human OAT1, OAT3, 
OATP1B1, OATP1B3, and P-gp. Incomplete inhibition was observed up to the highest 
test concentration for human MATE2-K and BCRP, suggesting weak inhibition.    
Based on current in vitro data, AMG 510 has a potential to interact with CYP3A4 and 
MATE1.  The DDI potential for other enzymes and transporters is expected to be low.  
2.2.3 Toxicology 
Animal toxicology studies have been completed in both the rat and dog and support 
development of AMG 510 for treatment of KRAS p.G12Cmutated tumors. AMG 510 was 
well tolerated in the GLP 28-day rat toxicology study at 0, 10, 30, and 200 mg/kg and in 
the GLP 28 day dog toxicology study at 0, 10, 30, and 300 mg/kg. Key AMG 510-related 
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changes in the rat were minimal to mild and included kidney tubular epithelial 
degeneration/necrosis; increased spleen weight, increased leukocytes; and a decrease 
in red blood cell (RBC) mass (hemoglobin, RBC count, and hematocrit) that was 
associated with changes in reticulocytes and RBC indices. In the rat, AMG 510-related 
degeneration/necrosis of renal tubule epithelium primarily affected tubules within the 
outer segment of the outer medulla and was characterized by sloughing of 
degenerative/necrotic epithelial cells, tubular dilatation, and/or accumulation of 
eosinophilic material within the tubule. Reversibility data is pending in the rat. The 
degeneration/necrosis observed in the kidney is expected to be fully reversible based on 
the minimal to mild severity, the absence of tubular basement membrane damage, and 
the normal regenerative capacity of the renal tubular epithelium. Key AMG 510-related 
changes in the dog consisted of a minimal to mild decrease in RBC mass associated 
with decreased reticulocytes. Taken together, the AMG 510-related decrease in RBC 
mass and reticulocytes in the rat and dog are most likely due to red blood 
cell/reticulocyte destruction and not decreased hematopoietic production, given the 
absence of light microscopic changes in the bone marrow in dog and the increased bone 
marrow erythroid cellularity in a few rats. The decreases in RBC mass and reticulocytes 
are expected to be reversible based on the normal regenerative capacity of the 
hematopoietic system, and the absence of overt bone marrow toxicity 
(eg, hypocellularity). 
AMG 510 nonclinical safety studies have not identified cardiovascular concerns.  
Clinically significant interaction with the hERG channel are not expected over the 
proposed clinical dose range (hERG IC50 54.8 µM).  AMG 510 at doses up to 300 mg/kg 
did not result in changes to ECG or hemodynamic parameters in a cardiovascular safety 
pharmacology study in telemetered dogs or in a 28-day toxicology study. In exploratory 
genetic toxicology studies, AMG 510 was not mutagenic in the Ames bacterial 
mutagenicity assay but was positive for clastogenicity in vitro.  AMG 510 was not 
phototoxic in vitro. 
There were no AMG 510-related changes in either the rat or dog repeat-dose toxicology 
studies that were considered severely toxic; thus, the severely toxic dose in 10% of 
animals (STD10) in rats was > 200 mg/kg and the highest non-severely toxic dose 
(HNSTD) in dogs was ≥ 300 mg/kg. There was minimal toxicity at exposures up to 9-fold 
above those expected in humans at the highest therapeutic dose. Overall, the results of 
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the nonclinical safety studies support the initiation of AMG 510 clinical trials and the 
initial clinical plan. 
2.3 Risk Assessment 
There are no identified risks associated with the administration of AMG 510. Based on 
nonclinical toxicity studies of AMG 510, the potential risks of AMG 510 include renal 
toxicity, anemia, leukocytosis, and splenomegaly. Clinical signs and symptoms of these 
potential risks, along with safety laboratories, will be monitored during the study to 
ensure subjects’ safety. 
 Please refer to the Investigator’s Brochure, section 7 for a description of important 
potential risks. 
2.4 Dose Selection Rationale 
The proposed AMG 510 doses are 180, 360, 720, and 960 mg administered once daily 
(QD) orally (PO). During dose escalation (Part 1) and dose expansion (Part 2), AMG 510 
will be given QD PO for a treatment cycle of 21 days in length that include 
21 administrations of AMG 510. The planned dose level(s) for dose expansion 
(MTD/RP2D) will be determined based on data collected during dose escalation. 
The proposed clinical starting dose of 180 mg administered QD PO is based on the 
current guidance for starting dose of anti-cancer small molecule drugs (ICH S9) using 
the methodology described by the Food and Drug Administration for calculating the 
human equivalent dose (HED) on a body surface area basis (FDA, 2005).  The rat 
severely toxic dose in 10% of animals (STD10) and the dog highest non-severely toxic 
dose (HNSTD) were 200 mg/kg/day PO and 300 mg/kg/day PO, respectively, as noted 
in the 28-day repeat-dose GLP toxicology studies. The proposed starting dose was 
roughly the maximum recommended starting dose of 195 mg/day PO, which is based on 
the lower value of 1/10th the HED for the rat STD10 (195 mg/day PO) and 1/6th the HED 
for the dog HNSTD (1622 mg/day PO).  To estimate AMG 510 exposures in humans, 
AMG 510 human pharmacokinetics (PK) parameters were predicted using allometric 
scaling of PK parameters for clearance and volume obtained from nonclinical studies in 
mice, rats, monkeys, and dogs and absorption constant and oral bioavailability following 
oral tablet administration of AMG 510, the same tablet formulation to be used in this 
clinical study.  At the starting dose of 180 mg administered QD PO, the predicted 
exposure margins of steady-state maximum plasma concentration (Cmax) and area under 
the concentration-time curve (AUC) exposures relative to the rat STD10 are 62-fold and 
20-fold, respectively. The predicted exposure margins of steady-state Cmax and AUC 
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exposures relative to the dog highest severely toxic dose (HNSTD) are estimated at 
50-fold and 12-fold, respectively, at the starting dose administered orally once daily. 
The highest planned dose is 960 mg QD PO. The exposure margins for the predicted 
human steady state AUC and Cmax exposures of this dose are 12-fold and 4-fold, 
respectively relative to rat STD10 and 9-fold and 2-fold, respectively relative to dog 
HNSTD.  Safety and tolerability data from prior dose levels will guide the dose 
escalations and the planned top dose for AMG 510 in the dose escalation phase. The 
maximum tolerated dose (MTD) identified from the dose escalation phase will inform the 
dose expansion phase. 
Efficacious doses were predicted with 2 PK/tumor growth inhibition (TGI) models that 
describe the anti-tumor activity of AMG 510: (1) a tumor stasis model that estimates 
human exposures to cause tumor stasis (i.e. no net tumor growth) based on PK and TGI 
of MIA-PaCa-2 T2 tumor xenograft mice treated with AMG 510 and (2) a tumor 
regression model that utilizes clinical pancreatic cancer data and PK and TGI in 
AMG 510-treated MIA-PaCa-2 T2 xenograft mice to predict the treatment effects of 
AMG 510 on tumor growth dynamics in humans.  Consolidating the results from both 
models, the minimal efficacious dose for AMG 510 in humans was predicted to be 
between 30 and 240 mg QD PO.   
Integrating the toxicology, pharmacology, human PK and efficacious dose predictions, 
the starting dose of 180 mg QD is expected to be safe as well as potentially efficacious.  
2.5 Clinical Hypotheses 
The following hypotheses will be tested with this clinical protocol. 
• At least one dose level of AMG 510 administered orally is expected to achieve 
acceptable safety and tolerability in subjects with advanced KRAS p.G12Csolid 
tumors 
• A favorable PK profile will be achieved with AMG 510 administered orally. 
• Objective responses will be observed at a dose level that achieves acceptable 
safety and tolerability. 
3. EXPERIMENTAL PLAN 
3.1 Study Design 
This is a first-in-human (FIH), multicenter, non-randomized, open-label, phase 1 study to 
evaluate safety and tolerability of AMG 510 in subjects with advanced KRAS 
p.G12Cmutant solid tumors.  The study will be conducted at approximately 25 sites in 
Australia, United States (US), Canada, Brazil, France, Germany, China, Japan, and 
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South Korea. Other countries or regions may participate. AMG 510 will be evaluated as 
an oral therapeutic. The study will be conducted in 2 parts:  Part 1 – Dose Exploration 
and Part 2 – Dose Expansion.  Part 1 is aimed at evaluating the safety, tolerability, PK 
and pharmarcodynamics of AMG 510 and determining the MTD of repeat daily (QD) 
dosing schedule in subjects with advanced KRAS p.G12Cmutant solid tumors using a 
Bayesian logistics regression model (BLRM) design (Neuenschwander, Branson, & 
Gsponer, 2008).  The dose expansion part of the study (Part 2) can open once the MTD 
and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) has been 
determined in Part 1.  The dose exploration part of the study will consist of 
approximately 50 subjects and the dose expansion part will consist of approximately 
60 additional subjects, including at least 3 groups with specific tumors harboring KRAS 
p.G12Cmutations (non-small cell lung cancer [NSCLC], colorectal cancer [CRC], and all 
other solid tumors).  Different schedules can be used in the dose expansion part based 
on clinical and PK data from all parts of the dose exploration. The DLT evaluation period 
will be at least 21 days. Based on emerging clinical efficacy data, the groups explored in 
the expansion part can be modified. Administration of AMG 510 (in part 1 and part 2) 
may continue until evidence of disease progression, intolerance to study medication, or 
withdrawal of consent. 
Dose Exploration – Part 1 
Dose exploration cohorts will estimate the MTDs, safety, tolerability, PK, and 
pharmacodynamics of different doses of AMG 510 in subjects with advanced KRAS 
p.G12C mutant solid tumors.  Subjects will receive AMG 510 daily administered orally.  
Enrollment into the dose exploration cohorts may be from any eligible KRAS 
p.G12Cmutant soild tumor type. Dose escalation will begin with 2-4 subjects treated at 
the lowest planned dose level of 180 mg. Dose escalation will follow the planned 
Study Schema schedule with 2-4 subjects treated in each cohort. If no DLT is observed, 
dose escalation will continue to the next planned dose cohort as per Table 1.  Once a 
subject experiences a DLT, dosing for subsequent cohorts will be recommended using 
the dose level recommendation from the Bayesian Logistic Regression Model (BLRM). 
After each cohort, the model’s recommended MTD dose level for evaluation is the dose 
level with the highest probability of the target toxicity probability interval (TPI), but with a 
less than 0.25 probability of an excessive TPI. The target TPI is (0.20, 0.33], and a TPI 
of (0.33, 1.00] is defined as excessive. The decision to advance to the next dose level 
will be recommended by the Dose Level Review Team (DLRT) using the dose level 
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recommendation from BLRM, as appropriate, and by evaluating available safety data, 
laboratory, and PK information.  
Intra-subject dose escalations are allowed in this study.  Subjects who complete the DLT 
period may proceed to a higher dose level for the following treatment cycle once the next 
dose cohort has been deemed safe by the DLRT and after consultation with the sponsor 
if: 
o no DLT has been reported for this subject during or after completion of the
DLT period
o the subject has not experienced any ≥ grade 2 adverse events (deemed
treatment related by the investigator) during treatment
Subjects who do not proceed to a higher dose may receive extra cycles at the original 
dose.   
Dose exploration will continue until any of the following events. 
• The highest planned dose level is determined to be safe and tolerable (minimum of
6 DLT-evaluable subjects)
• The MTD is identified, BLRM recommends a dose level which already has
6 DLT-evaluable subjects
No more than 50 subjects will be enrolled to the dose escalation cohorts. Approximately 
30 subjects will be needed to estimate the MTD.  In order to better estimate the RP2D 
and to better characterize the safety, efficacy and pharmacodynamics for AMG 510, an 
additional 20 subjects may be enrolled in one of more dose levels that have been 
deemed to be safe and tolerable, defined as backfill enrollment. Subjects in backfill 
enrollment will be allowed to proceed to higher dose levels when the higher dose levels 
have been deemed safe and tolerable. This backfill enrollment may be concurrent with 
dose escalation to identify the MTD.  
Table 1.  Planned Escalation Dose *Levels 
Cohort Dose (mg) 
1 180 
2 360 
3 720 
4 960 
*Potential intermediate doses of 270 mg and 540 mg
Food effect will be evaluated in cycle 2 or later in at least 6 subjects from backfill 
enrollment.  On day 1 of the cycle in which the assessment will be conducted, subjects 
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will receive their dose of AMG 510 with approximately 240 mL (8 ounces) of water under 
fasted conditions (no food or liquids, except water) for ≥10 hours prior to ingesting their 
dose of AMG 510 at the clinic. The subjects will fast overnight again (no food or liquids, 
except water for ≥10 hours) before returning to the clinic on day 2 to ingest their dose of 
AMG 510 after eating a standardized high-fat, high calorie meal.  Subjects should eat 
the meal in 25 minutes or less; AMG 510 should be administered 30 minutes after the 
start of the meal and after at least 5 minutes of rest.  Carryover of AMG 510 exposure 
from a prior dose is expected to be minimal based on the predicted half-life of AMG 510.  
For both days, no food is allowed for at least 3 hours following AMG 510 dosing.  
Additional water can be consumed as desired, except for 1 hour prior to and 1 hour after 
AMG 510 dosing.  PK will be collected prior to dosing and at various time points over a 
24-hour period after dosing on both days.  Urine will be collected for the 24-hour period 
following day 1 dosing. 
Dose Expansion – Part 2 
Upon completing the dose exploration part of the study and depending on data obtained, 
dose expansion may proceed with three groups consisting of subjects with KRAS 
p.G12Cmutant solid tumors: 
1. Group 1 (NSCLC) - subjects with advanced KRAS p.G12Cmutant NSCLC 
2. Group 2 (CRC) - subjects with advanced KRAS p.G12Cmutant CRC 
3. Group 3 (Other) - subjects with advanced KRAS p.G12Cmutant solid tumor types 
other than the tumor types specified in Groups 1 and 2 
Dose expansion in all three groups may be done concurrently. 
A final estimate of the MTD and RP2D using BLRM will be evaluated and confirmed 
utilizing all DLT-evaluable subjects from the dose escalation and the dose expansion 
cohorts.  For definition of DLT-evaluable, see Section 3.3.  
The overall study design is described by a study schema at the end of the 
protocol synopsis section. 
The study endpoints are defined in Section 10.1.1 
3.2 Number of Sites 
This study will be conducted at approximately 25 sites in Australia, United States, 
Canada, Brazil, France, Germany, China, Japan, and South Korea. Additional countries 
or sites may be added if deemed necessary.   
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Sites that do not enroll subjects into an open cohort within 6 months of site initiation may 
be closed or replaced. 
3.3 Number of Subjects 
Participants in this clinical investigation shall be referred to as “subjects”. 
It is anticipated that up to 110 subjects will be enrolled in the study. Up to 50 subjects will 
be enrolled in dose escalation cohorts and up to 60 subjects will be enrolled in the dose 
expansion cohorts. The rationale for the number of subjects is provided in Section 10.2. 
During dose escalation, a subject that is not DLT-evaluable will be replaced with another 
subject to the same dose level. A  subject is DLT-evaluable if either of the following 
occurs: 
• Subject experienced a DLT or 
• Subject does not experience a DLT and subject received at least 80% of the 
planned doses of investigational product within the first treatment cycle 
(ie, 21 days) 
Subjects will not be replaced after end of the DLT period.   
3.4 Estimated Study Duration 
3.4.1 Study Duration for Subjects 
The duration of this study will be approximately 2.5 years, with about 24 months for 
enrollment (a maximum of 12 months for the dose escalation cohorts, and 12 months for 
the dose expansion cohort) and 6 months protocol treatment period. 
3.4.2 End of Study 
Primary Completion: the time when the last subject is assessed or receives an 
intervention for the purposes of final collection of data for the primary analysis; the 
primary analysis will occur when target enrollment in dose escalation and dose 
expansion is complete and each subject either completes 6 months on study or 
withdraws from the study. 
End of Study: the time when the last subject is assessed or receives an intervention for 
evaluation in the study. The final analysis will occur at this time. 
4. SUBJECT ELIGIBILITY 
4.1 Inclusion Criteria 
101. Subject has provided informed consent prior to initiation of any study 
specific activities/procedures 
102. Men or women ≥ 18 years old  
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103. Pathologically documented, locally-advanced or metastatic malignancy 
with, KRAS p.G12Cmutation identified through DNA sequencing.  
Subjects must have received prior standard therapy appropriate for their 
tumor type and stage of disease, or in the opinion of the Investigator, 
would be unlikely to tolerate or derive clinically meaningful benefit from 
appropriate standard of care therapy. 
104. Part 1 (Dose Exploration) – Subjects willing to provide archived tumor 
samples (fresh frozen sample or formalin fixed, paraffin embedded 
[FFPE] sample collected within 5 years) or willing to undergo pre-
treatment tumor biopsy.  
105. Part 2 (Dose Expansion) – Willing to undergo pre-treatment tumor biopsy. 
Subjects can be allowed to enroll without undergoing tumor biopsy upon 
agreement with Investigator and the Medical Monitor if tumor biopsy is not 
feasible.   
106. Measurable or evaluable disease per RECIST 1.1 criteria (Appendix D). 
107. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 
108. Life expectancy of > 3 months, in the opinion of the investigator 
109. Ability to take oral medications and willing to record daily adherence to 
investigational product 
110. QTc ≤ 470 msec (based on average of screening triplicates) 
111. Adequate hematological laboratory assessments, as follows: 
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L 
• Platelet count ≥ 75 x 109/L 
• Hemoglobin ≥ 9 g/dL 
112. Adequate renal laboratory assessments, as follows: 
• Estimated glomerular filtration rate based on MDRD (Modification of 
Diet in Renal Disease) calculation ≥ 60 ml/min/1.73 m2 
113. Adequate hepatic laboratory assessments, as follows: 
• AST < 2.5 x ULN (if liver metastases are present, ≤ 5 x ULN) 
• ALT < 2.5 x ULN (if liver metastases are present, ≤ 5 x ULN) 
• Alkaline phosphatase < 2.0 x ULN (if liver or bone metastases are 
present, < 3.0 x ULN) 
• Total bilirubin < 1.5 x ULN (< 2.0 x ULN for subjects with documented 
Gilbert’s syndrome or < 3.0 x ULN for subjects for whom the indirect 
bilirubin level suggests an extrahepatic source of elevation) 
114. Adequate coagulation laboratory assessments, as follows: 
• Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x 
upper limit of normal (ULN), OR International normalized ratio (INR) 
< 1.5 or within target range if on prophylactic anticoagulation therapy  
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Food Effect Assessment – Specific Inclusion Criteria 
115. Subject able to eat a standardized high-fat, high-caloric meal within 
25 minutes 
116. Subject able to fast for ≥10 hours 
117. Subject able to handle collection of his/her urine over a 24 hour period. 
Part 2 – Dose Expansion (Criteria 101 to 114, except criterion 104) 
Non-small Cell Lung Cancer – Specific Inclusion Criteria 
118. Pathologically documented, definitively diagnosed KRAS p.G12Cmutant 
NSCLC  
Colorectal Cancer – Specific Inclusion Criteria 
119. Pathologically documented, and definitively diagnosed KRAS p.G12C 
mutant CRC 
Other Solid Tumor Types – Specific Inclusion Criteria 
Pathologically documented, definitively diagnosed, KRAS p.G12Cmutant advanced solid 
tumor  
4.2 Exclusion Criteria 
201. Active brain metastases from non-brain tumors.  Subjects who have had 
brain metastases resected or have received radiation therapy ending at 
least 4 weeks prior to study day 1 are eligible if they meet all of the 
following criteria: a) residual neurological symptoms grade ≤ 2; b) on 
stable doses of dexamethasone, if applicable; and c) follow-up MRI 
shows no new lesions appearing 
202.  History or presence of hematological malignancies unless curatively 
treated with no evidence of disease ≥ 2 years 
203. Myocardial infarction within 6 months of study day 1, symptomatic 
congestive heart failure (New York Heart Association > class II), unstable 
angina, or cardiac arrhythmia requiring medication 
204. Gastrointestinal (GI) tract disease causing the inability to take oral 
medication, malabsorption syndrome, requirement for intravenous 
alimentation, uncontrolled inflammatory GI disease (eg, Crohn’s disease, 
ulcerative colitis) 
205. Active infection requiring intravenous (IV) antibiotics within 1 weeks of 
study enrollment (day 1) 
206. Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic 
Hepatitis B), positive Hepatitis total core antibody with negative HepBsAg 
(suggestive of occult hepatitis B) or detectable Hepatitis C virus 
Ribonucleic acid (RNA) by PCR (indicative of active 
Hepatitis C - screening is generally done by Hepatitis C Antibody 
(HepCAb), followed by Hepatitis C virus RNA by PCR if HepCAb is 
positive) 
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207. Known positive test for HIV 
208. Unresolved toxicities from prior anti-tumor therapy, defined as not having 
resolved to Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0 grade 0 or 1, or to levels dictated in the eligibility criteria with 
the exception of alopecia (Grade 2 or 3 toxicities from prior anti-tumor 
therapy that are considered irreversible [defined as having been present 
and stable for > 6 months], such as ifosfamide-related proteinuria, may be 
allowed if they are not otherwise described in the exclusion criteria AND 
there is agreement to allow by both the investigator and sponsor) 
209. Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted 
therapy, retinoid therapy, hormonal therapy [except for subjects with 
breast cancer], or investigational agent) within 28 days of study day 1; 
concurrent use of hormone deprivation therapy for hormone-refractory 
prostate cancer or breast cancer is permitted 
210. Therapeutic or palliative radiation therapy within 2 weeks of study day 1 
211. Currently enrolled in another investigational device or drug study, or less 
than 28 days since ending another investigational device or drug study(s), 
or receiving other investigational agent(s) 
212. Other investigational procedures are excluded 
213. All herbal medicines (eg, St. John’s wort), vitamins, and supplements 
consumed by the subject within the 30 days prior to receiving the first 
dose of AMG 510, and continuing use if applicable, will be reviewed by 
the Principal Investigator and the Amgen Medical Monitor.  Written 
documentation of this review and Amgen acknowledgment is required for 
subject participation  
214. Major surgery within 28 days of study day 1 
215. Men and women of reproductive potential who are unwilling to practice 
acceptable methods of effective birth control while on study through 
1 week (women) or 90 days (men) after receiving the last dose of study 
drug.  Acceptable methods of effective birth control include sexual 
abstinence (refraining from heterosexual intercourse; men, women); 
vasectomy; tubal ligation; or a condom with spermicide (men) in 
combination with barrier methods, hormonal birth control or IUD (women)  
216. Women who are lactating/breast feeding or who plan to breastfeed while 
on study through 1 week after receiving the last dose of study drug. 
217. Women with a positive pregnancy test. 
218. Women planning to become pregnant while on study through 1 week after 
receiving the last dose of study drug 
219. Subject has known sensitivity to any of the products to be administered 
during dosing 
220. Subject will not be available for protocol-required study visits or 
procedures, to the best of the subject and investigator’s knowledge 
221. Subject has any kind of disorder that, in the opinion of the investigator, 
may compromise the ability of the subject to give written informed 
consent and/or to comply with all required study procedures 
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222. History or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opinion of 
the investigator or Amgen physician would pose a risk to subject safety or 
interfere with the study evaluation, procedures or completion 
223. Use of known cytochrome P450 (CYP) 3A4 sensitive substrates (with a 
narrow therapeutic window), within 14 days or 5 half-lives (whichever is 
longer) of the drug or its major active metabolite, whichever is longer, 
prior to study day 1 that was not reviewed and approved by the principal 
investigator and the Amgen medical monitor 
224. Use of strong inhibitors of CYP3A4 or P-gp within 14 days or 5 half-lives 
(whichever is longer) or grapefruit juice or grapefruit containing products 
within 7 days prior to study day 1 that was not reviewed and approved by 
the principal investigator and the Amgen medical monitor. 
225. Use of strong inducers of CYP3A4 within 14 days or 5 half-lives 
(whichever is longer) within 7 days prior to study day 1 that was not 
reviewed and approved by the principal investigator and the Amgen 
medical monitor. 
5. SUBJECT ENROLLMENT 
Before subjects begin participation in any study-specific activities/procedures, Amgen 
requires a copy of the site’s written institutional review board/independent ethics 
committee (IRB/IEC) approval of the protocol, informed consent form (see Section 11.2).  
All subjects or legally acceptable representatives must personally sign and date the 
informed consent form before commencement of study-specific activities/procedures.  
Adverse Events are to be collected for a subject once they are enrolled in the study.  
Subject is considered enrolled when all eligibility criteria are met and subject is 
administered the first dose of AMG 510. 
The Investigator is to document the enrollment decision and date, in the subject’s 
medical record and in/on the enrollment case report form (CRF). 
Each subject who enters into the screening period for the study (at least 21 days prior to 
first dose of AMG 510) receives a unique subject identification number before any study 
procedures are performed.  The subject identification number will be assigned manually.  
This number will be used to identify the subject throughout the clinical study and must be 
used on all study documentation related to that subject.   
The subject identification number must remain constant throughout the entire clinical 
study; it must not be changed after initial assignment, including if a subject is 
rescreened. 
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5.1 Treatment Assignment 
An Amgen representative will notify the site in writing when a cohort is open to screen 
new subjects. 
All screening tests and procedures must be performed within 21 days of study day 1, 
unless specified otherwise in the study procedures listed in Section 7. Once the site has 
established subject eligibility, a site representative will submit (via email) a completed 
subject Eligibility Worksheet to an Amgen representative.  The Amgen representative will 
acknowledge receipt of the paperwork and assign the AMG 510 dose level to confirm 
enrollment for that individual subject. The investigator or designee is responsible for 
ensuring that confirmation of enrollment from Amgen (including subject number, dose 
assignment and enrollment date) has been received prior to administration of study 
medication on day 1. A subject is considered enrolled on study day 1 when the 
investigational product, AMG 510, is first administered. 
The treatment assignment date is to be documented in the subject’s medical record and 
on the enrollment case report form (CRF).  
To acquire additional safety, efficacy, and pharmacodynamic data to better fully inform 
the RP2D, an additional 20 subjects may be enrolled in one or more dose levels that 
have been shown to be safe and tolerable. For the purposes of dose-escalation 
decisions, these subjects will not be included as part of the DLT-evaluable population. 
Intra-subject dose escalations is allowed for these additional subjects. When the subject 
completes the DLT period the subject may proceed to a higher dose level for the 
following treatment cycle once the next dose cohort has been deemed safe by the DLRT 
and after consultation with the sponsor as described in Section 3.1. For subjects 
participating in food effect evaluation, intra-subject dose escalation should not occur for 
at least 5 days before or during the food effect evaluation. 
6. TREATMENT PROCEDURES 
AMG 510 is the only investigational product administered orally in this study. A separate 
manual containing detailed information regarding the storage and administration of 
AMG 510 will be provided. Refer to the Investigational Product Instruction Manual 
(IPIM). 
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6.1 Investigational Product 
6.1.1 Amgen Investigational Product AMG 510 
AMG 510 will be manufactured and packaged by Amgen Inc. and distributed using 
Amgen clinical study drug distribution procedures.  AMG 510 will be provided as 30 mg 
and 120 mg tablets and will be packaged in bottles of 30 tablets. A diary will be provided 
for subjects to record their adherence to the oral medication.  
6.1.1.1 Dosage, Administration, and Schedule 
AMG 510 will be administered orally daily and repeatedly without any drug holidays. The 
effects of overdose of AMG 510 are not known. AMG 510 will be dispensed at the 
research facility by a qualified staff member. Subjects are required to take AMG 510 at 
the research facility on clinic visit days as described in Table 2. Subjects will take 
AMG 510 at home on non-clinic visit days. AMG 510 must be administered in the fasted 
state (no food or liquids, except water, 2 hours before to 1 hour after dosing).  On cycle 
1 day 1, cycle 1 day 8, and cycle 2 day 1, subjects should eat a standard meal at least 
2 hours before dosing. Subjects may eat the standard meal at home before clinic visit or 
in clinic. 
Subjects participating in the food effect assessment will receive AMG 510 in the fasted 
state on day 1 and fed state on day 2.  Subjects in the fasted state will receive AMG 510 
on an empty stomach (no food or liquids, except water) following an overnight fast of 
≥ 10 hours at home prior to clinic visit for dosing.  Subjects will receive AMG 510 with 
approximately 240 mL (8 ounces) of water.  Water can be allowed as desired except for 
1 hour before and 1 hour after AMG 510 administration.  No food or liquid (except water) 
will be allowed for at least 3 hours post-dose.Subjects in fed state will be fasted 
overnight for at least 10 hours prior to consuming a high fat meal preferably in the clinic. 
Subjects should start the recommended meal approximately 0.5 hours prior to dose 
administration. Subjects should consume the entire meal in 25 minutes or less. 
AMG 510 should be administered approximately 30 minutes after the start of the meal 
with approximately 240 mL (8 ounces) of water. Water can be allowed as desired except 
for 1 hour before and 1 hour after AMG 510 administration. No food or liquid (except 
water) will be allowed for at least 3 hours post dose. See specific assessments for feed 
effect evaluation in Table 2.. 
6.1.1.2 Dose-cohort Escalation and Stopping Rules 
After all DLT-evaluable subjects within a cohort have completed the DLT window, a 
DLRM will be held to review data, monitor safety, and recommend dose change 
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decisions. The review team will be composed of the investigators, Amgen Medical 
Monitor, Amgen Global Safety Officer or designated safety scientist, Amgen Early 
Clinical Development Manager, and Biostatistics representative. Additional members 
may be added as needed (e.g. PK Scientist). A quorum, defined as the majority of 
actively screening and enrolling investigators or their qualified designee 
(ie, sub-investigator possessing hard copy documentation [eg, email] of the 
investigator’s decision regarding the dose level review), must be in attendance for DLRM 
to proceed. The DLRM will be rescheduled if a quorum is not reached. 
Voting members of the DLRM will include the Amgen medical monitor, the Amgen global 
safety officer or designated safety scientist, and all actively screening and enrolling 
investigators or their qualified sub-investigator designee. The team may recommend 
escalation to the next planned dose, escalation to an intermediate dose (a dose lower 
than the next planned dose), continuation or delay in dosing, repetition or expansion of a 
cohort, de-escalation to a lower dose, or termination of the study. The Amgen medical 
monitor and Global Safety Officer or designee and the majority of actively screening and 
enrolling investigators participating in the DLRM must cast a positive vote indicating an 
acceptable safety profile was observed for AMG 510 to allow the dose level modification 
and/or cohort continuation/expansion to proceed. All available study data including 
demographics, medical history, concomitant medications, AEs, electrocardiograms 
(ECGs), vital signs, laboratory results, and emerging PK or pharmacodynamics data will 
be reviewed. Data to be reviewed may be unqueried. 
The dosing schedule is described by a schema in the protocol synopsis. 
6.1.1.2.1 DLT Definition 
A DLT is defined as any AE meeting the criteria listed below occurring during the first 
treatment cycle of AMG 510 (day 1 through day 21) where relationship to AMG 510 
cannot be ruled out. 
The grading of AEs will be based on the guidelines provided in the CTCAE version 4.0. 
A DLT is defined as any of the following events during the first treatment cycle and 
attributable to AMG 510: 
Hematological toxicity 
• Febrile neutropenia 
• Neutropenic infection 
• Grade 4 neutropenia  
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 Grade ≥ 3 thrombocytopenia for > 7 days 
 Grade 3 thrombocytopenia with grade ≥ 2 bleeding 
 Grade 4 thrombocytopenia 
 Grade 4 Anemia 
Non-hematological toxicity 
 Grade ≥ 4, vomiting or diarrhea  
 Grade ≥ 3 nausea for 3 days or more despite optimal medical support  
 Any other grade ≥ 3 AE 
DLT-evaluable is defined as completion of 80% of AMG 510 doses within the first 
treatment cycle (ie, 21 days). A subject who experience a DLT within the first cycle is 
DLT evaluable regardless of number of doses taken. If a subject is withdrawn from study 
for any reason other than a DLT prior to completion of the 21-day safety observation 
period, a replacement subject will be assigned the same dose as the replaced subject.  
6.1.1.3 Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation  
Subjects experiencing any treatment-related toxicity meeting the DLT definition will not 
receive additional AMG 510 treatment and will be followed until resolution of the event or 
toxicity. Subjects will be withdrawn from AMG 510 treatment and will be treated as 
deemed appropriate by the investigator or treating physician. In subjects with a favorable 
response to treatment, an option to continue at the same dose level or 1 dose level 
below that which the toxicity occurred can be considered. If deemed appropriate by the 
investigator in conjunction with the sponsor, AMG 510 treatment can resume once any 
non-hematological toxicity returns to the subject’s baseline value or grade ≤ 1 and 
subject meets the following hematological requirements: ANC ≥ 1.0 x 109/L, platelet 
count ≥ 75 x 109/L and hemoglobin ≥ 9 g/dL. Subjects must not have received a platelet 
transfusion for at least 7 days prior to assessing if re-exposure to AMG 510 can occur.  
If a subject is noted to have ≥ grade 3  thrombocytopenia, grade 4 neutropenia, grade 4 
anemia, grade 4 leukocytosis, or ≥ grade 3 non-hematological toxicity attributable to 
AMG 510 at any point during study treatment, AMG 510 administration will be stopped 
immediately. A repeat blood collection for hematology is to be performed within 3 days. 
AMG 510 treatment can resume once subjects meet the following hematological 
requirements: ANC ≥ 1.0x 109/L, platelet count ≥ 75 x 109/L and hemoglobin ≥ 9 g/dL, 
leukocytosis < grade 3 and the non-hematological toxicity returns to the subject’s 
baseline value or grade ≤ 1.  
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Subjects requiring more than 2 weeks to recover from grade ≥ 3 toxicities will be 
withdrawn from the study. 
6.2 Hepatotoxicity Stopping and Rechallenge Rules 
Subjects with abnormal hepatic laboratory values (eg, alkaline phosphatase [ALP], 
AST,ALT, TBIL) or INR or signs/symptoms of hepatitis may meet the criteria for 
withholding of investigational product. Withholding is either permanent or conditional 
depending upon the clinical circumstances discussed below as specified in the 
(FDA Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, 
July 2009).  
6.3 Concomitant Therapy 
Throughout the study, Investigators may prescribe any concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section 6.5. 
Concomitant use of MATE1 substrates with AMG 510 may result in increase in systemic 
concentrations of a MATE1 substrate as AMG 510 has a potential to inhibit MATE1.  
Gastric acid controllers may reduce the exposure to AMG 510. Consider the risks and 
benefits of concomitant use.  Monitor subjects receiving a MATE1 substrate or gastric 
acid controller with AMG 510. 
6.4 Product Complaints 
A product complaint is any written, electronic or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug(s) or device(s) after it is released for distribution to market or 
clinic by either Amgen or by distributors and partners for whom Amgen manufactures the 
material.   
This includes any drug(s), device(s), or combination product(s) provisioned and/or 
repackaged /modified by Amgen.  Drug(s) or device(s) includes investigational product.  
Any product complaint(s) associated with an investigational product(s) or 
non-investigational product(s) or device(s) supplied by Amgen are to be reported 
according to the instructions provided in the IPIM. 
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6.5 Excluded Treatments, Medical Device Use, and/or Procedures 
During Study Period  
Any known strong inhibitors of cytochrome P450 (CYP) 3A4, P-gp, grapefruit juice or 
grapefruit containing products that were not reviewed and approved by the principal 
investigator and the Amgen medical monitor 
Any known strong inducers of cytochrome P450 (CYP) 3A4, P-gp, grapefruit juice or 
grapefruit containing products that were not reviewed and approved by the principal 
investigator and the Amgen medical monitorHerbal medicines (eg, St. John’s wort), 
vitamins, and supplements that were not reviewed and approved by the principal 
investigator and the Amgen medical monitor 
Any known cytochrome P450 (CYP) 3A4 sensitive substrates (with a narrow therapeutic 
window), that were not reviewed and approved by the principal investigator and the 
Amgen medical monitor 
7. STUDY PROCEDURES 
7.1 Schedule of Assessments 
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Table 2.  Schedule of Assessment: Part 1 Dose Exploration and Part 2 Dose Expansion 
 Screening Treatment EOT SFU LTFU 
Cycle  1 2 
3,5 
(g) 
4,6 
(g) 
QC 
(g) 
Q2C  
  
Day -21 to 1 1 2 8 9 15 1 8 1 1 1 1    
Hours (relative to 
dosing) 
 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 pre 0 0.25 0.5 1       
  
GENERAL & SAFETY 
Informed consent X                                            
Medical history & 
height 
X    
 
          
  
       
  
   
  
           
  
Physical exam & 
weight  
X X  
 
     X  X 
  
       X 
 
X  
  
 X X X X   
X  
ECOG X X        X  X          X  X     X X X X   X  
Vital signs X X        X  X          X  X     X X X X   X  
ECG (a) X(a) X  X X X X X X X  X  X X X X X X X  X  X  X X   X X  X X X X  
Con medications X X ===========================================================================================  
Adverse events X X ===========================================================================================  
LABORATORY 
Chemistry X X          X          X  X     X X X X X    
HbA1c X                                  X(h)      X(h)   
Hematology X X          X          X  X     X X X X     
Coagulation X X          X          X  X     X X X X     
Urinalysis X X                      X      X   X X   
Serum pregnancy test  X                              X   X X   
HBV surface antigen & 
HCV Ab 
X   
 
         
 
       
  
  
  
       
  
Page 1 of 2 
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A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 41 of 95 
CONFIDENTIAL    
Table 2.  Schedule of Assessment: Part 1 Dose Exploration and Part 2 Dose Expansion 
 Screening Treatment EOT SFU LTFU 
Cycle  1 2 
3,5 
(g) 
4,6 
(g) 
QC 
(g) 
Q2C  
  
Day -21 to 1 1 2 8 9 15 1 8 1 1 1 1    
Hours (relative to 
dosing) 
 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 pre 0 0.25 0.5 1       
  
DOSING    
AMG 510 (b)   ===========================================================================================   
IMAGING ASSESSMENTS   
Radiological imaging 
(CT/MRI) and tumor 
assessment (c) 
X   
 
        
  
       
  
  
  
  X(c)   X(c) X(c) 
  
MRI brain (d) X                                    
PK ASSESSMENTS    
AMG 510 PK (e)  X  X X X X X X X  X  X X X X X X X    X  X X X      X   
BIOMARKER SAMPLES   
Plasma ctDNA (j)  X          X            X        X  X   
Cell pellet from plasma  X          X            X          X   
Serum  X          X            X        X  X   
PB Paxgene RNA(i)  X          X            X        X  X   
BIOMARKER DEVELOPMENT   
Tumor biopsy or 
Archived tumor tissue 
(FFPE) for solid 
tumors [f] 
X   
 
        
  
       
  
  
  
      X(f) 
  
Page 2 of 2 
Footnotes defined on next page of the table 
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(a) A set of triplicate ECGs must be performed at screening; all ECGs will be triplicates with each tracing 30 seconds apart 
(b) AMG 510 will be administered daily on a repeated basis with no planned off treatment days. AMG 510 must be administered in the fasted state (no food or liquids, 
except water, 2 hours before to 1 hour after dosing).  On cycle 1 day 1, cycle 1 day 8, and cycle 2 day 1, subjects should eat a standard meal at least 2 hours before 
dosing.  
(c) Radiological imaging and tumor assessments are required at screening and every 6  1 weeks cycle 1 day 1 until disease progression, clinical deterioration, 
intolerance to study medication, withdrawal of consent or start of new anticancer therapy. MRI/CT scans can be obtained earlier if clinical deterioration necessitates an 
earlier scan at the discretion of the managing physician. End of treatment CT/MRI should be performed only for subjects that discontinue treatment for a reason other 
than disease progression per RECIST 1.1 criteria.  Every assessment must include the chest, abdomen, pelvis, and all other known sites of disease. MRI of the brain is 
required at screening or if a subject has signs or symptoms suggestive of CNS metastases.  Tumor burden assessments will be performed based on RECIST 1.1 
guidelines (Appendix D).  Radiographic response (CR and PR) requires confirmation by a repeat consecutive assessment at least 4 weeks after the first detection of 
response. 
(d) All subjects with history of brain metastasis must have MRI of the brain performed within 28 days prior to enrollment.  Only if MRI is contraindicated, then CT with 
contrast is acceptable. Subsequently, MRI brain scans can be performed at any time if clinically indicated or per standard of care. 
(e) PK blood samples should be collected at the exact nominal time point as noted above (see hour postdose column). If unable to collect a blood sample at the 
specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  PK samples not collected at exact nominal 
time point will not be considered protocol deviations.  
(f) Subjects will provide fresh frozen samples or FFPE samples (collected within 5 years) for KRAS p.G12Cmutation confirmation or undergo tumor biopsy that enables 
KRAS p.G12Ctesting prior to starting all other screening procedures; Optional  tumor biopsy can be  performed at response and at time of progression  
(g) Assessments to be performed on day 1 of each cycle. Laboratory Assessments  may be performed within 24 hours before Day 1 of each cycle.  There are no 
allowable windows for dosing time points and other assessments during cycle 1 or cycle 2; A window of ± 2 days is allowable after cycle 2 
(h) HbA1c should be performed once every 4 cycles 
(i) Plasma collection for Paxgene RNA collection required at time of progression 
(j) Plasma ctDNA collection required at the beginning of every cycle predose, at response and at time of progression 
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Table 3.  Schedule of Assessment: Part 1 Food Effect Assessment Only 
 Treatment 
Cycle  2 or later 
Day  1 2 3 
Hours (relative to dosing) (a) pre 0 0.25 0.5 1 2 4 6 pre 0 0.25 0.5 1 2 4 6 pre 0 
DOSING 
AMG 510 (b)  X        X        X 
PK ASSESSMENT 
AMG 510 PK (c) X  X X X X X X X  X X X X X X X  
RENAL EXCRETION ASSESSMENT 
Urine (d)        X X          
(a) Refer to Table 1 for assessments other than for dosing and PK and renal assessments on days 1–3. 
(b) Subjects will be administered AMG 510 on day 1 in the fasted state (no food 10 hours before dosing and 3 hours after dosing) and on day 2 in the fed state (dosing 
with a high fat meal).  On day 3, AMG 510 can be administered with or without food per patient discretion. 
(c) PK blood samples should be collected at the exact nominal time point as noted above (see hour postdose column). If unable to collect a blood sample at the 
specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  PK samples not collected at exact nominal 
time point will not be considered protocol deviations.  
(d) Urine should be collected from 0–7 hours postdose and 7–24 hours postdose. 
Refer to the IPIM, laboratory and site imaging manuals for detailed collection and handling procedures.   
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7.2 General Study Procedures 
A signed and dated IRB/IEC approved informed consent form (ICF) must be obtained 
prior to performing any study specific procedures, including discontinuing standard 
therapy for observing study specific washout periods.  
Subjects will be seen in the clinic for study evaluations.  When ECGs, vital signs, and 
invasive procedures like blood or biopsy sampling occur on the same visit, ECGs and 
vital signs should be collected prior to performing any invasive procedures.  
Blood samples for biomarker and PK assessments should be drawn from a peripheral 
vein and not from a central venous catheter.  The study specific lab manual will provide 
additional detail on lab sampling and handling requirements.  
Study procedures should be performed and samples obtained at the time points 
stipulated in the Schedules of Assessments (Table 2 through Table 3). Acceptable 
deviation windows for study procedures are listed below:  
• ECGs, biomarker blood draws, safety labs, vital signs (incl. pulse oximetry):   
− ± 5 minute window (for time points of 0.25 hr and 0.5 hr postdose), ± 15 minute 
window (all other time points) 
Acceptable deviation windows for study visits are listed below: 
• Visits during treatment ± 1 day 
• SFU:  + 7 days 
• LTFU: ± 2 weeks for remote survival follow-up 
Furthermore, start of a treatment can be delayed for administrative/logistical reasons for 
up to 7 days to allow for appropriate scheduling after discussion with and final approval 
by sponsor.  
Any missed visits, tests not done, or examinations that are not conducted must be 
reported as such on the eCRFs.  Subsequent study visits should resume on the original 
schedule.  Missed assessments at prior visits should not be duplicated at subsequent 
visits.  Every effort should be taken to collect all biomarker and PK samples as described 
in the schedule of assessments.  However, if sample processing/shipment on a 
weekend/holiday is not logistically feasible for a site, this needs to be documented and 
will not be considered a deviation from the protocol.  
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Additional procedures deemed necessary as part of standard of care or as required by 
local laws and regulations may be performed at the Investigator’s discretion. 
Table 4.  List of Analytes 
Local Laboratory 
Central 
Laboratory 
Chemistry Hematology Coagulation Urinalysis Central Lab 
Sodium 
Potassium 
Chloride 
Bicarbonate (HCO3) 
Total protein 
Albumin 
Calcium 
Magnesium 
Phosphorous 
Glucose 
Blood urea nitrogen 
3Urea 
Creatinine 
Total creatine kinase 
Total bilirubin 
Direct bilirubin 
Alkaline 
phosphatase 
Alanine 
aminotransferase 
Aspartate 
aminotransferase 
Serum or Urine 
Pregnancy 
Hepatitis B surface 
antigen 
Hepatitis C antibody 
HIV1 
Hemoglobin 
Hematocrit 
Mean corpuscular 
volume 
Platelets 
RBC 
White blood cell 
Differential 
• Total 
neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
• Monocytes 
 
PT or INR 
PTT or aPTT  
Fibrinogen 
D-Dimer 
Specific gravity 
pH 
Blood 
Protein 
Glucose 
Bilirubin 
Microscopic 
exam 
(performed at 
the 
discretion of 
the 
Investigator) 
PK sampling 
Plasma 
ctDNA 
Plasma cell 
pellet 
Serum  
PB Paxgene 
RNA 
antibody 
Tumor 
biopsy2 
 
 
1Hepatitis B surface antigen, Hepatitis C antibody, PCR for Hepatitis C RNA (if Hepatitis C antibody is 
positive), and HIV assessments are recommended. 
2Archived tumor tissue acceptable in Part 1 (Dose Escalation) only 
3Urea collection is acceptable in absence of BUN 
Additional procedures deemed necessary as part of standard of care or as required by 
local laws and regulations may be performed at the Investigator’s discretion. 
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7.2.1 Screening  
After written consent has been obtained, subjects will be screened in order to assess 
eligibility for study participation.  All screening procedures must be performed within 
21 days prior to start of investigational product administration, unless otherwise noted.  
The ICF may be signed earlier than 21 days prior to start of investigational product in 
case of washout times that have to be observed to meet eligibility criteria.  
Subjects who meet the inclusion and exclusion criteria will be eligible to be enrolled in 
the study.  If a subject has not met all eligibility criteria at the end of the 21-day window, 
the subject will be registered as a screen failure.  Subjects who screen fail may be 
eligible for re-screening at the investigator’s discretion after consultation with Amgen 
(see also below for details on re-screening). 
Laboratory assessments used to determine subject eligibility may be repeated once for 
confirmation during each 21-day screening period before the subject is considered a 
screen failure.  If laboratory assessments are repeated during the screening period, the 
result of the last sample taken prior to start of treatment with AMG 510 will be taken into 
account for determination of subject eligibility.  
The following procedures are to be completed during the screening period at the time 
points designated in the Schedules of Assessments (Table 2 through Table 3).  
Assessments that were performed as standard of care prior to signature of informed 
consent, but within 21 days prior to start of treatment with AMG 510 can be used as 
screening assessments and do not need to be repeated to confirm subject eligibility. 
• confirmation that the ICF has been signed  
• demographic data including sex, age, race, and ethnicity will be collected in order to 
study their possible association with subject safety and treatment effectiveness  
• subjects can be enrolled in the dose exploration based on archived tumor tissue 
(FFPE) or a pre-treatment biopsy if the archived tissue is not available. Positivity of 
the KRAS p.G12C mutation will be determined by each institutions local or central 
test (Section 7.4) 
• subjects in the dose expansion will provide an archived tumor tissue (FFPE) or 
pre-treatment tumor biopsy if the archived tumor is not available and/or 
screening/pre-treatment plasma sample to confirm KRAS p.G12C mutation prior to 
enrollment 
• the tumor tissue samples will be sent to the central lab to determine KRAS 
p.G12C mutation positivity prior to enrollment as explained in Section 7.4 
• medical history (including surgical history) 
• physical examination (including neurological exam) 
• ECOG performance status 
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• height and weight 
• vital signs (ie, blood pressure, heart rate, respiratory rate, temperature) 
• pulse oximetry 
• ECG triplicate measurement  
• radiological assessment must include CT/MRI of the chest, abdomen and pelvis, as 
well as assessment of all other known sites of disease 
• All subjects with history of brain metastasis must have MRI/CT of the brain 
performed within 28 days prior to enrollment 
• laboratory assessments:  hematology, chemistry, coagulation, urinalysis, serum 
pregnancy test (females only and not required if surgically sterile or ≥ 2 years 
postmenopausal), hepatitis serology 
• HIV test  
• biomarker assessments:  
− plasma ctDNA, plasma cell pellet, serum and peripheral blood paxgene RNA 
• disease assessments:  
− for all subjects: Clinical tumor and radiographic assessment (CT/MRI) at 
screening and repeated at week 6, week 12, and every 6 weeks untill EOT 
• serious adverse event reporting 
• documentation of concomitant medication  
Re-Screening: 
Subjects may be re-screened up to 2 times at the discretion of the investigator, after 
consultation with Amgen.  The subject must be re-consented if a re-screening attempt 
occurs more than 30 days after the original signing of the ICF. 
Re-screened subjects must be documented as screen failed in the subject’s medical 
record and subsequently documented as re-screened.  Subjects will retain the same 
subject identification number assigned at the time of initial screening.  Once the subject 
is recorded as re-screened, a new 21-day screening window will begin.  The following 
assessments do not have to be repeated during re-screening, if they were performed as 
standard of care or during the initial screening attempt within the time frames specified 
below: 
• Hepatitis serology does not need to be repeated if it was performed within 6 weeks 
prior to start of treatment with AMG 510. 
• Imaging assessments do not need to be repeated if they were performed within 
4 weeks prior to start of treatment with AMG 510. 
Any other assessments do not need to be repeated if they were performed within 
21 days prior to start of treatment with AMG 510. 
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7.2.2 Treatment 
Treatment begins on Day 1 when the first investigational product is administered to a 
subject. 
During clinic visit days all protocol-required predose assessments have to be performed 
prior to administration of AMG 510. 
Results of any predose laboratory tests will not have to be available before the 
administration of AMG 510.  Laboratory assessments that were done within 24 hours 
prior to AMG 510 administration do not need to be repeated. 
AMG 510 will be dispensed to subjects at the beginning of each cycle and the subjects 
are required to bring the bottle of AMG 510 to clinic during clinic visit days. AMG 510 
administration should be done in the clinic after all pre-dose assessments have been 
performed during clinic visit days. 
A diary will be provided to subjects at the beginning of each cycle and the study staff will 
provide guidance to the subjects on how to complete the diary. 
The following procedures will be completed during the treatment period at the times 
designated in the Schedule of Assessments (Table 2 through Table 3): 
• physical examination  
• ECOG performance status 
• weight 
• vital signs (ie, blood pressure, heart rate, respiratory rate, temperature) 
• pulse oximetry 
• ECG triplicate measurement 
• laboratory assessments:  hematology, chemistry, coagulation, urinalysis, urine/serum 
pregnancy test (females only and not required if surgically sterile or ≥ 2 years 
postmenopausal) 
• AMG 510 PK sample collection  
• biomarker assessments:   
- plasma ctDNA, plasma cell pellet, serum and peripheral blood paxgene RNA 
• serious adverse event reporting 
• disease assessments:  
clinical tumor and radiographic assessment (CT/MRI) at screening and repeated at 
week 6, week 12, and every 6 weeks until EOT 
• adverse event reporting 
• disease-related event reporting 
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 documentation of concomitant medication 
 urine collection (food effect assessment only) 
All other assessments should be performed as per the schedule of assessments 
applicable to the actual cycle  
7.2.3 Safety Follow-up Visit  
The SFU visit should occur approximately 30 (+7) days after the last dose of AMG 510.  
Every effort should be made to conduct this visit for all subjects enrolled into the study, 
including subjects who withdraw from treatment early.  The following procedures will be 
completed during the SFU visit as designated in the Schedules of Assessments 
(Table 2). 
 physical examination 
 ECOG performance status 
 weight 
 vital signs (ie, blood pressure, heart rate, respiratory rate, temperature) 
 pulse oximetry 
 ECG triplicate measurement  
 serious adverse event reporting 
 adverse event reporting 
 documentation of concomitant medications   
7.2.4 Long-term Follow-up 
Following the SFU visit, there will be a LTFU period for clinical evaluation of disease 
status and survival.  Subjects will be followed via telephone every 12 weeks (± 2 weeks) 
for assessment of survival and documentation of anti-cancer treatment. Subjects will be 
followed for a maximum of 2 years from the first dose of AMG 510, or until subject death, 
whichever occurs first.  
Subjects will allow Amgen continued access to medical records so that information 
related to subjects’ health condition, including disease status and survival, may be 
obtained.   
7.2.5 End of Study Visit 
End of study is defined as the date of the final study visit (eg, LTFU) when assessments 
and/or procedures are performed. 
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7.2.6 Pharmacokinetic Blood Sampling  
For pharmacokinetic assessment blood samples for quantitative determination of 
AMG 510, will be collected at time points specified in the Schedule of Assessments 
(Section 7.1). Sample collection, processing, storage, and shipping instructions are 
provided in a separate laboratory manual. 
7.2.7 Urine Collection 
On day 1 of the cycle in which the food effect assessment is conducted, urine will be 
collected for the following time periods: (1) 0–6 hours post-dose, and (2) 6–24 hours 
post-dose.  
7.2.8 High-fat Meal 
For the food effect assessment, the clinical site will provide standardized high-fat meal 
as described in the Schedule of Assessment (Table 3). A standard high-fat meal 
(approximately 50% of the total caloric content of the meal) and high calorie 
(approximately 800 to 1000 calories) meal will be used as a test meal.  The test meal 
should derive approximately 150, 250 and 500 to 600 calories from protein, 
carbohydrate and fat, respectively. An example test meal would be 2 eggs fried in butter, 
2 strips of bacon, 2 slices of toast with butter, 4 ounces of hash brown potatoes, and 
8 ounces of whole milk. Substitutions in this meal can be made as long as the meal 
provides a similar amount of calories from protein, carbohydrate, and fat and has 
comparable meal volume and viscosity. Further details of the high fat meal will be 
recorded in subject medical record and eCRF. 
7.3 Radiological Imaging Assessment 
The extent of disease will be evaluated by contrast-enhanced MRI/CT according to 
RECIST 1.1 (Appendix D). All radiological imaging will be performed as indicated in the 
Site Imaging Manual provided by the central imaging core laboratory. Organ-specific 
imaging protocols or existing diagnostic guidelines should be followed whenever 
possible to evaluate the full extent of the disease appropriately. In order to reduce 
radiation exposure for subjects, low dose CT or MRI should be applied whenever 
possible.  MRI/CT scans should be performed with contiguous slices thickness of 
≤ 5 mm according to the Site Imaging Manual. 
The screening scans must be performed within 28 days prior to enrollment and will be 
used as baseline. All subsequent scans will be performed in the same manner as at 
screening, with the same contrast, preferably on the same scanner.  
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Radiological assessment must include MRI/CT of the chest, abdomen and pelvis, as well 
as assessment of all other known sites of disease. The same modality, field strength and 
contrast used at screening should be used for all subsequent assessments. MRI of the 
brain should be performed if signs or symptoms suggestive of CNS metastases are 
present. 
During treatment, follow-up radiological imaging of the chest, abdomen, pelvis, as well 
as all other known sites of disease, will be performed independent of treatment cycle 
every 6 ± 1 weeks until disease progression, clinical deterioration, intolerance of study 
drug, withdrawal of consent, or start of new anticancer treatment. Imaging may also be 
performed more frequently if clinically necessitated at the discretion of the managing 
physician. Radiographic response (Complete Response, Partial Response) requires 
confirmation by a repeat, consecutive scan at least 4 weeks after the first documentation 
of response and may be delayed until the next scheduled scan to avoid unnecessary 
procedures. 
All subjects with brain metastasis must have MRI of the brain performed within 28 days 
prior to first dose of AMG 510. Subsequently, brain scans may be performed at any time 
if, in the judgement of the managing physician. All brain scans on protocol are required 
to be MRI unless MRI is contraindicated, and then CT with contrast is acceptable. 
Radiological imaging assessment at the end of the study or during the EOT visit should 
be performed only for subjects that discontinue treatment for a reason other than 
disease progression per RECIST 1.1 guidelines.  
Determination of disease response for clinical management of subjects will be assessed 
at the clinical sites per RECIST 1.1. Scans will be submitted to a central imaging core 
laboratory for archival, response assessment including RECIST 1.1, and/or exploratory 
analysis eg, volumetric and viable tumor measurements. Detailed information regarding 
submission of images to the central imaging core laboratory is found in the Site Imaging 
Manual. 
7.4 Biomarker Development 
Biomarkers are objectively measured and evaluated indicators of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.  In oncology, there is particular interest in the molecular changes underlying 
the oncogenic processes that may identify cancer subtypes, stage of disease, assess 
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the amount of tumor growth, or predict disease progression, metastasis, and responses 
to investigational product(s) or protocol required therapies.   
Amgen may attempt to develop additional test(s) designed to identify subjects most likely 
to respond positively or negatively to AMG 510, to investigate and further understand the 
the pharmacodynamic evidence and biological impact of AMG 510 by characterization of 
changes in levels of gene (DNA or RNA) or protein expression of downstream effectors 
of EGFR and related markers.  
Blood Samples 
Blood samples are to be collected for biomarker development as listed in the schedule of 
assessments. Plasma and/or serum may also be used for DNA, RNA, and protein 
expression analysis including somatic mutations in order to correlate levels of 
expression with response. 
Tumor Tissues  
For archival tumor samples within the first 2 weeks after enrollment, FFPE blocks or 
unstained slides of tumor tissue must be collected prior to the study is to be sent to the 
central laboratory along with the corresponding pathology report. Provision of achival 
tumor samples are allowed prior to enrollment in the Part 1 (Dose Escalation). 
Tumor tissue collection following local standard of care procedure is required prior to 
enrollment in Part 2 (Dose Expansion) and the tissue along with the corresponding 
pathology report is to be sent to the central lab or affiliate (based on geographical 
location of the research institution) for testing to establish KRAS p.G12C positivity. 
Collection of tumor tissue following local standard of care procedure for KRAS p.G12C 
testing is not expected to present any additional risk to the health, safety, and welfare of 
the subject. Subjects will be enrolled in Part 2 of this study based on the result of the 
KRAS p.G12C test. G12C positivity will be determined at the central testing lab with an 
investigational in-vitro diagnostic device. 
The tumor block is to be carefully selected by a pathologist or a skilled experienced 
histology associate to include generous tumor tissue using the Pathology Report as a 
guide.  In lieu of a block, 20 unstained sections on charged slides from the same block 
can be submitted.  When the samples of tumor tissues are available, analyses of tumor 
specific mutations or epigenetic changes may be performed (eg, somatic mutations). 
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Tumor biopsies are to be collected and pharmacodynamic changes analyzed to 
determine the effect of the drug on target(s) in the tumor as well as to potentially analyze 
molecular mechanisms associated with acquired resistance. 
Central G12C KRAS Laboratory Methods – Summary 
The therascreen® KRAS RGQ PCR Kit from QIAGEN is a real-time qualitative PCR 
assay performed on the Rotor-Gene Q MDx instrument for the detection of 7 somatic 
mutations in the human KRAS oncogene using DNA extracted from FFPE tissue.  The 
mutations detected are: G12A, G12D, G12R, G12C, G12S, G12V, G13D. The 
therascreen® KRAS RGQ PCR Kit is an investigational in vitro diagnostic device that will 
be used to retrospectively inform subject selection for subjects with KRAS p.G12C 
mutant solid tumors for the Part 1 (Dose Expoloration) and Part 2 (Dose Expansion) of 
this study. 
Patient testing with the therascreen® KRAS RGQ Assay will take place at the 
NeoGenomics Central Testing Laboratory in Houston, Texas.   
The Idylla  KRAS Mutation Test, for use with the Idylla  Platform, is an automated 
real-time PCR based qualitative test for the detection of mutations in KRAS exon 2 
(codons 12 and 13), exon 3 (condons 59 and 61), and exon 4 (codons 117 and 146) in 
DNA extracted from FFPE tissue or plasma.  The mutations detected are: G12C, G12R, 
G12S, G12A, G12D, G12V, G13D, A59T/E/G, Q61K, Q61R/L, Q61H, K117N, 
A146P/T/V. 
Patient testing with the Idylla  KRAS Mutation Test ® KRAS RGQ Assay will take place 
at Q2 Solutions central testing laboratories. The Idylla™ KRAS Mutation Test is an 
investigational in vitro diagnostic device that will be used to inform subject selection for 
subjects with KRAS p.G12C mutant solid tumors for Part 2 (Dose Expansion) of this 
study. 
7.5 Pharmacogenetic Studies 
If the subject consents to the optional pharmacogenetic portion of this study, DNA 
analyses may be performed.  These optional pharmacogenetic analyses focus on 
inherited genetic variations to evaluate their possible correlation to the disease and/or 
responsiveness to the therapies used in this study.  The goals of the optional studies 
include the use of genetic markers to help in the investigation of colorectal cancer, 
non-small cell lung cancer, pancreatics cancer as well as other solid tumors and/or to 
identify subjects who may have positive or negative response to AMG 510. 
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Pharmacogenetic samples are collected for this part of the study.  Subjects who consent 
to this/these analysis/analyses, DNA may be extracted from blood. 
7.6 Sample Storage and Destruction 
Any blood or tissue samples collected according to the Schedule of Assessments 
(Table 2) can be analyzed for any of the tests outlined in the protocol and for any tests 
necessary to minimize risks to study subjects.  This includes testing to ensure analytical 
methods produce reliable and valid data throughout the course of the study.  This can 
also include, but is not limited to, investigation of unexpected results, incurred sample 
reanalysis, and analyses for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assigned to 
the samples for the study.  Results are stored in a secure database to ensure 
confidentiality.   
If informed consent is provided by the subject, Amgen can do additional testing on 
remaining samples (ie, residual and back-up) to investigate and better understand the 
solid tumor cancers (e.g. mCRC, NSCLC, pancreatic cancer) with the dose response 
and/or prediction of response to AMG 510 , characterize antibody response, and 
characterize aspects of the molecule (eg, mechanism of action/target, metabolites).  
Results from this analysis are to be documented and maintained, but are not necessarily 
reported as part of this study.  Samples can be retained for up to 20 years.   
Since the evaluations are not expected to benefit the subject directly or to alter the 
treatment course, the results of pharmacogenetic, biomarker development, or other 
exploratory studies are not placed in the subject’s medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent. 
The subject retains the right to request that the sample material be destroyed by 
contacting the investigator.  Following the request from the subject, the Investigator is to 
provide the sponsor with the required study and subject number so that any remaining 
samples and any other components from the cells can be located and destroyed.  
Samples will be destroyed once all protocol-defined procedures are completed.  
However, information collected from samples prior to the request for destruction, will be 
retained by Amgen. 
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The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject through the investigator, at the end of the storage period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
longer justifies keeping the sample).  If a commercial product is developed from this 
research project, the sponsor owns the commercial product.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample. 
See Section 11.3 
8. WITHDRAWAL FROM TREATMENT, PROCEDURES, AND STUDY 
8.1 Subjects’ Decision to Withdraw 
Subjects have the right to withdraw from the study at any time and for any reason 
without prejudice to their future medical care by the physician or at the institution. 
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product and/or other protocol-required therapies or procedures at any 
time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate processes for discontinuation 
from investigational product, device or other protocol-required therapies and must 
discuss with the subject the options for continuation of the Schedule of Assessments 
(Table 2) including different options of follow-up (eg, in person, by phone/mail, through 
family/friends, in correspondence/communication with other treating physicians, from the 
review of medical records) and collection of data, including endpoints, adverse events, 
Subjects who have discontinued investigational product and/or protocol required 
therapies or procedures should not be automatically removed from the study.  Whenever 
safe and feasible it is imperative that subjects remain on-study to ensure safety 
surveillance and/or collection of outcome data.  The investigator must document the 
level of follow-up that is agreed to by the subject.    
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol-required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and where permitted, publically available 
data can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study.   
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8.2 Investigator or Sponsor Decision to Withdraw or Terminate 
Subjects’ Participation Prior to Study Completion 
The investigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product, medical device(s), and/or other protocol required therapies, protocol 
procedures, or the study as a whole at any time prior to study completion. 
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
and/or other protocol required therapies by a separate protocol or as provided for by the 
local country’s regulatory mechanism, based on parameters consistent with 
Section 12.1.  
8.3 Reasons for Removal From Treatment or Study  
8.3.1 Reasons for Removal FromTreatment  
Reasons for removal from protocol-required investigational product(s) or procedural 
assessments include any of the following: 
• subject request   
• adverse event 
• death 
• lost to follow-up 
• decision by Sponsor  
• non-compliance 
• requirement for alternative therapy 
• disease progression as defined by RECIST 1.1 criteria (Appendix D) or disease 
progression accompanied by worsening of symptoms or deterioration of the 
subject’s general condition. 
• pregnancy 
8.3.2 Reasons for Removal From Study 
Reasons for removal of a subject from the study are: 
• decision by sponsor  
• withdrawal of consent from study 
• death 
• lost to follow-up 
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9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING
9.1 Definition of Safety Events
9.1.1 Adverse Events
An adverse event is defined as any untoward medical occurrence in a clinical trial 
subject.  The event does not necessarily have a causal relationship with study treatment. 
The investigator is responsible for ensuring that any adverse events observed by the 
investigator or reported by the subject are recorded in the subject’s medical record.   
The definition of adverse events includes worsening of a pre-existing medical condition.  
Worsening indicates that the pre-existing medical condition or underlying disease 
(eg, diabetes, migraine headaches, gout) has increased in severity, frequency, and/or 
duration more than would be expected and/or has an association with a significantly 
worse outcome than expected.  A pre-existing condition that has not worsened more 
than anticipated (ie, more than usual fluctuation of disease) during the study, or involves 
an intervention such as elective cosmetic surgery or a medical procedure while on study, 
is not considered an adverse event.   
If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the highest grade on the Events eCRF. 
For situations when an adverse event or serious adverse event is due to to non-small 
cell carcinoma of lung, colorectal cancer, or pancreatic adenocarcinoma  report all 
known signs and symptoms.  Death due to disease progression in the absence of signs 
and symptoms should be reported as the primary tumor type (eg, metastatic pancreatic 
cancer).  
Note:  The term “disease progression” should not be used to describe the adverse 
event.   
The investigator’s clinical judgment is used to determine whether a subject is to be 
removed from treatment due to an adverse event.  In the event a subject, or subject’s 
legally acceptable representative requests to withdraw from protocol-required therapies 
or the study due to an adverse event, refer to Section 8.1 for additional instructions on 
the procedures recommended for safe withdrawal from protocol-required therapies or 
the study.   
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9.1.2 Serious Adverse Events 
A serious adverse event is defined as an adverse event that meets at least 1 of the 
following serious criteria: 
• fatal 
• life threatening (places the subject at immediate risk of death) 
• requires in patient hospitalization or prolongation of existing hospitalization 
• results in persistent or significant disability/incapacity 
• congenital anomaly/birth defect 
• other medically important serious event 
An adverse event would meet the criterion of “requires hospitalization”, if the event 
necessitated an admission to a health care facility (eg, overnight stay).   
If an investigator considers an event to be clinically important, but it does not meet any 
of the serious criteria, the event could be classified as a serious adverse event under the 
criterion of “other medically important serious event”.  Examples of such events could 
include allergic bronchospasm, convulsions, blood dyscrasias, drug induced liver injury 
(DILI) (see Appendix A for DILI reporting criteria), or events that necessitate an 
emergency room visit, outpatient surgery, or urgent intervention. 
9.2 Safety Event Reporting Procedures 
9.2.1 Adverse Events 
9.2.1.1 Reporting Procedures for Adverse Events That do not Meet Serious 
Criteria 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after enrollment  through the end of 
study are reported using the Event CRF. 
The investigator must assign the following adverse event attributes: 
• Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms), 
• Dates of onset and resolution (if resolved), 
• Severity and/or toxicity per protocol, 
• Assessment of relatedness to investigational product and 
• Action taken. 
The adverse event grading scale used will be the CTCAE version 4. The grading scale 
used in this study is described in Appendix A.  The investigator must assess whether the 
adverse event is possibly related to AMG 510.  This relationship is indicated by a “yes” 
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or “no” response to the question:  Is there a reasonable possibility that the event may 
have been caused by AMG 510?   
The investigator must assess whether the adverse event is possibly related to any study 
mandated activity (eg, administration of investigational product, protocol-required 
therapies, use of medical device(s) and/or procedure (including any screening 
procedure(s)).  This relationship is indicated by a “yes” or “no” response to the question:  
“Is there a reasonable possibility that the event may have been caused by a study 
activity (eg, administration of investigational product, protocol-required therapies, use of 
medical device(s)), and/or procedure”?  
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a clinically 
significant change from the subject’s baseline values.  In general, abnormal laboratory 
findings without clinical significance (based on the Investigator's judgment) are not to be 
recorded as adverse events.  However, laboratory value changes that require treatment 
or adjustment in current therapy are considered adverse events.  Where applicable, 
clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse 
event. 
The investigator is expected to follow reported adverse events until stabilization or 
reversibility.  
9.2.1.2 Reporting Procedures for Serious Adverse Events 
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the subject that occur after signing of the informed 
consent through 30 days after the last day of the dosing interval of investigational 
product are recorded in the subject’s medical record and are submitted to Amgen.  All 
serious adverse events must be submitted to Amgen within 24 hours following the 
investigator’s knowledge of the event via the Event CRF. 
If the electronic data capture (EDC) system is unavailable to the site staff to report the 
serious adverse event, the information is to be reported to Amgen via an electronic 
Serious Adverse Event (eSAE) Contingency Report Form within 24 hours of the 
investigator’s knowledge of the event. See Appendix B for a sample of the Serious 
Adverse Event Worksheet/electronic Serious Adverse Event Contingency Report Form. 
The investigator must assess whether the serious adverse event is possibly related to 
the investigational product. This relationship is indicated by a “yes” or “no” response to 
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the question: Is there a reasonable possibility that the event may have been caused by 
the investigational product(s), and/or other protocol-required therapies?  Relatedness 
means that there are facts or reasons to support a relationship between investigational 
product and the event.  
The investigator is expected to follow reported serious adverse events until stabilization 
or reversibility. 
New information relating to a previously reported serious adverse event must be 
submitted to Amgen.  All new information for serious adverse events must be sent to 
Amgen within 24 hours following knowledge of the new information.  If specifically 
requested, the investigator may need to provide additional follow-up information, such as 
discharge summaries, medical records, or extracts from the medical records.  
Information provided about the serious adverse event must be consistent with that 
recorded on the Event CRF. 
If a subject is permanently withdrawn from protocol-required therapies because of a 
serious adverse event, this information must be submitted to Amgen.    
Amgen will report serious adverse events and/or suspected unexpected serious adverse 
reactions as required to regulatory authorities, investigators/institutions, and IRBs/IECs 
in compliance with all reporting requirements according to local regulations and good 
clinical practice. 
The investigator is to notify the appropriate IRB/IEC of serious adverse events occurring 
at the site and other adverse event reports received from Amgen, in accordance with 
local regulatory requirements and procedures. 
9.2.1.3 Reporting Serious Adverse Events After the Protocol-required 
Reporting Period 
There is no requirement to monitor study subjects for serious adverse events following 
the protocol-required reporting period or after end of study.  However, these serious 
adverse events can be reported to Amgen.  In some countries (eg, European Union [EU] 
member states), investigators are required to report serious adverse events that they 
become aware of after end of study.  If serious adverse events are reported, the 
investigator is to report them to Amgen within 24 hours following the investigator’s 
knowledge of the event.  
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Serious adverse events reported outside of the protocol-required reporting period will be 
captured within the safety database as clinical trial cases for the purposes of expedited 
reporting.  
9.3 Pregnancy and Lactation Reporting 
If a female subject becomes pregnant, or a male subject fathers a child, while the 
subject is taking AMG 510 report the pregnancy to Amgen Global Patient Safety as 
specified below. 
In addition to reporting any pregnancies occurring during the study, investigators should 
report pregnancies that occur in a female subject  through 1 week  after the last dose of 
AMG 510 or in a male subject's female partner through 90 days after the last dose of 
AMG 510. 
The pregnancy should be reported to Amgen Global Patient Safety within 24 hours of 
the investigator’s knowledge of the pregnancy.  Report a pregnancy on the Pregnancy 
Notification Worksheet (Appendix C).  Amgen Global Patient Safety will follow-up with 
the investigator regarding additional information that may be requested. 
If a female subject becomes pregnant during the study, the investigator should attempt 
to obtain information regarding the birth outcome and health of the infant.   
If the outcome of the pregnancy meets a criterion for immediate classification as a 
Serious Adverse Event (eg, female subject experiences a spontaneous abortion, 
stillbirth, or neonatal death or there is a fetal or neonatal congenital anomaly) the 
investigator will report the event as a Serious Adverse Event. 
If a female breastfeeds while taking protocol-required therapies report the lactation case 
to Amgen as specified below. 
In addition to reporting a lactation case during the study, investigators should report 
lactation cases that occur through 30 days after the last dose of protocol-required 
therapies.  
Any lactation case should be reported to Amgen Global Patient Safety within 24 hours of 
the Investigator’s knowledge of event.  Report a lactation case on the Lactation 
Notification Worksheet (Appendix C).  Amgen Global Patient Safety will follow-up with 
the investigator regarding additional information that may be requested. 
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If a male subject's female partner becomes pregnant, the investigator should discuss 
obtaining information regarding the birth outcome and health of the infant from the 
pregnant partner. 
10. STATISTICAL CONSIDERATIONS 
10.1 Study Endpoints, Analysis Sets, and Covariates 
10.1.1 Study Endpoints 
Primary Endpoints:   
• Safety: subject incidence of dose limiting toxicity (DLTs), treatment-emergent 
adverse events, treatment-related adverse events, and clinically significant changes 
in vital signs, physical examinations, electrocardiogram (ECG)s, and clinical 
laboratory tests 
Secondary Endpoints:  
• PK parameters of AMG 510 including, but not limited to, maximum observed plasma 
concentration (Cmax), time to achieve Cmax (tmax), and area under the plasma 
concentration-time curve (AUC) 
• Objective response rate, duration of overall response, progression-free survival, and 
duration of stable disease measured by CT or MRI and assessed per 
RECIST 1.1 criteria   
• PK parameters of AMG 510 including, but not limited to, Cmax, tmax, and AUC in the 
fed and fasted state  
• AMG 510 exposure/QTc interval relationship 
Exploratory Endpoints:   
• Pharmacokinetic/pharmacodynamic relationships for safety and/or efficacy endpoints 
• AMG 510 excretion in urine 
• Characterization of potential metabolites of AMG 510 in plasma and urine, if 
appropriate 
• Quantification of biomarker expression at protein, RNA, and DNA levels, as 
appropriate 
• Potential biomarkers by biochemical and/or genetic analysis of blood and/or tumor 
samples 
10.1.2 Analysis Sets 
The analysis of all endpoints, unless noted otherwise, will be conducted on the Safety 
Analysis Set defined as all subjects that are enrolled and receive at least 1 dose of 
AMG 510. 
The analysis of DLT will be restricted to DLT-evaluable subjects (see Section 3.3 for 
definition).   
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The PK Analysis Set will contain all subjects who have received at least 1 dose of the 
investigational product and have at least 1 PK sample collected.  These subjects will be 
evaluated for PK analysis unless the number of data points required for analysis is not 
enough, or significant protocol deviations have affected the data, or if key dosing or 
sampling information is missing. 
10.1.3 Covariates and Subgroups 
The relationship of covariates to efficacy endpoints will be explored if appropriate. 
Biomarker data may be incorporated in additional exploratory subgroup or multivariate 
analyses.  The analyses of biomarkers may be performed after collection of all samples 
during the conduct of the study and therefore may be reported after the primary analysis 
of efficacy endpoints  
10.2 Sample Size Considerations 
Part 1 – Dose Exploration:  Up to 50 subjects will be enrolled in the dose exploration part 
of the study.  Approximately 30 subjects will be used to estimate the MTD. This sample 
size is based on practical considerations and is consistent with conventional oncology 
studies with the objective to estimate the MTD. In order to better estimate the RP2D and 
to better characterize the safety, efficacy and pharmacodynamics,  an additional 
20 subjects may be enrolled to one or more dose levels that have been shown to be safe 
and tolerable from which at least 6 subjects will be evaluated for food effect. With 
2 subjects per cohort, there is a 27-70% probability of observing at least one DLT if the 
true DLT rate is 10-33% and with 4 subjects per cohort, there is a 34-80% probability. 
With 10 subjects in a cohort, there is a 65-98% probability of observing at least one DLT 
if the true DLT rate is 10-33%. The sample size of at least 6 subjects for food effect 
evaluation is based on practical considerations and judged sufficient for the evaluation; 
no formal calculation was made.  
Part 2 – Dose Expansion:  Approximately 60 subjects will be enrolled in the dose 
expansion part of the study, which will be conducted in at least 3 groups. 
Group 1: approximately 20 subjects with advanced KRAS p.G12Cmutant NSCLC. 
Group 2: approximately 20 subjects with advanced KRAS p.G12C mutant CRC. 
Group 3: approximately 20 subjects with advanced KRAS p.G12C mutant all other solid 
tumors. The sample sizes for groups 1 through 3 are based on practical considerations. 
With 20 subjects in each group, there is a 88% to 99% probability of observing at least 
1 adverse event if the true event rate is 10% to 20%. For each group, an exact 
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80% binomial CI will be provided for ORR.  With the 20 subjects in each group and a 
20% ORR, the 80% CI would be 9.0% to 36.1%. 
10.3 Adaptive Design 
The adaptive features of the BLRM design are described in Appendix E. 
10.4 Planned Analyses 
The following data analyses are planned:  (1) the primary analysis after all 
dose-escalation and dose-expansion subjects had the opportunity to receive up to 
6 months of treatment or terminated the study early, and (2) the final analysis after all 
subjects have ended the study. 
10.4.1 Interim Analyses 
Safety data will be reviewed on an ongoing basis.  Based on accumulating toxicity 
information, BLRM will be used to make dosing recommendations. In DLRMs, Amgen, in 
consultation with the site investigators, will review the BLRM recommended dose level 
and will review all available cumulative data by cohort prior to making dose escalation 
decisions.  As a sensitivity analysis, a one-parameter Continual Reassessment Method 
(CRM) model may be used to estimate the dose-toxicity relationship to help making dose 
escalation decisions.  Adverse events and DLTs observed in all subjects will be 
evaluated continually and fully integrated into all DLRMs and considered in all enrollment 
and dosing decisions. 
An interim analysis for efficacy parameters will be conducted after dose escalation is 
completed. 
10.4.2 Dose Level Review Team (DLRT) 
After all DLT-evaluable subjects within a cohort have completed the DLT window, a 
DLRM will be held to review data, monitor safety, and recommend dose change 
decisions. The review team will be composed of the investigators, Amgen Medical 
Monitor, Amgen Global Safety Officer or designated safety scientist, Amgen Early 
Clinical Development Manager, and Biostatistics representative. Additional members 
may be added as needed (e.g. PK Scientist). A quorum, defined as the majority of 
actively screening and enrolling investigators or their qualified designee 
(ie, sub-investigator possessing hard copy documentation [eg, email] of the 
investigator’s decision regarding the dose level review), must be in attendance for DLRM 
to proceed. The DLRM will be rescheduled if a quorum is not reached. 
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Voting members of the DLRM will include the Amgen medical monitor, the Amgen global 
safety officer or designated safety scientist, and all actively screening and enrolling 
investigators or their qualified sub-investigator designee. The team may recommend 
escalation to the next planned dose, escalation to an intermediate dose (a dose lower 
than the next planned dose), continuation or delay in dosing, repetition or expansion of a 
cohort, de-escalation to a lower dose, or termination of the study. The Amgen medical 
monitor and Global Safety Officer or designee and the majority of actively screening and 
enrolling investigators participating in the DLRM must cast a positive vote indicating an 
acceptable safety profile was observed for AMG 510 to allow the dose level modification 
and/or cohort continuation/expansion to proceed. All available study data including 
demographics, medical history, concomitant medications, AEs, electrocardiograms 
(ECGs), vital signs, laboratory results, and emerging PK or pharmacodynamics data will 
be reviewed.    
The following recommendations will be made by the DLRT: 
• dose escalation / de-escalation decisions  
• number of subjects per cohort 
• continuation, delay or termination of dosing 
• change of the dosing schedule 
10.4.3 Primary Analysis 
The primary analysis will occur when target enrollment is complete and each subject had 
the opportunity to receive up to 6 months of treatment or terminated the study early.   
10.4.4 Final Analysis 
A final analysis is planned after all dose-escalation cohorts and dose-expansion subjects 
have ended the study. Primary and final analysis may be combined in case all subjects 
have ended study close to the time point of the primary analysis.  
10.5 Planned Methods of Analysis 
10.5.1 General Considerations 
Descriptive statistics will be provided for selected demographics, safety, PK, 
pharmacodynamics and biomarker data by dose, dose schedule, and time as 
appropriate.  Descriptive statistics on continuous data will include means, medians, 
standard deviations, and ranges, while categorical data will be summarized using 
frequency counts and percentages.  Graphical summaries of the data may also be 
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presented.  A two-parameter BLRM will be used to estimate the dose-toxicity 
relationship. See Appendix E for the description of the two-parameter BLRM design.   
10.5.2 Primary Endpoint(s) 
Safety Endpoints 
Unless otherwise specified, statistical analyses on safety endpoints will be done using 
subjects from the safety analysis set, which includes subjects that are enrolled and 
received at least 1 dose of AMG 510. 
Subject incidence of DLTs will be used to fit the BLRM model to estimate the probability 
of having a DLT across dose levels. 
Adverse Events 
Subject incidence of all treatment-emergent adverse events will be tabulated by system 
organ class and preferred term.  The number and percentage of subjects reporting 
adverse events will be evaluated overall and by dose level and will also be tabulated by 
relationship to study drug. 
Tables of fatal adverse events, serious adverse events, and adverse events leading to 
withdrawal from investigational product or other protocol-required therapies will also be 
provided. 
Clinical Laboratory Tests 
Clinical chemistry, hematology, and urinalysis data will be presented and reviewed for 
each subject.  Values outside the normal laboratory reference ranges will be flagged as 
high or low on the listings.  Depending on the size and scope of changes in laboratory 
data, summaries of laboratory data over time and/or changes from baseline over time 
may be provided.  Tables of maximum shifts from baseline for selected laboratory values 
may also be provided. 
Vital Signs 
Vital signs data will be presented and reviewed for each subject.  Depending on the size 
and scope of changes, summaries of vital signs data over time and/or changes from 
baseline over time may be provided. 
Electrocardiograms 
Summaries over time and/or changes from baseline over time will be provided for all 
ECG parameters.   
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Subjects’ maximum change from baseline in QT interval corrected by Fridericia’s formula 
will be categorized and the number and percentage of subjects in each group will be 
summarized. 
Subjects’ maximum post baseline values will also be categorized and the number and 
percentage of subjects in each group will be summarized. 
All on-study ECG data will be presented, and select parameters of interest may be 
plotted. 
10.5.3 Secondary Endpoint(s) 
10.5.3.1 Pharmacokinetics Data Analysis 
For AMG 510, pharmacokinetic parameters including, but not limited to Cmax, tmax, and 
AUC will be determined from the concentration-time profile using standard non-
compartmental approaches and considering the profile over the complete sampling 
interval.  Based on the review of the data, analyses to describe the relationship between 
AMG 510 exposure and either pharmacodynamic effect and/or clinical outcome may 
also be performed. 
10.5.3.1.1 Food Effect Assessment 
The food-effect cohort PK parameter estimates will help assess the impact of food on 
the pharmacokinetics of AMG 510. The geometric means and 90% confidence interval 
for the ratio of the geometric means (fed state/fasted state) will be estimated using a 
mixed-effects model. The model will use the log-transformed PK parameters as the 
dependent variable (or response) and treatment conditions (fed versus fasted) as the 
independent variable.  The median of tmax will be compared between fasted and fed 
conditions as well. 
10.5.3.2 Efficacy Endpoint Analyses 
The proportion of subjects with an objective response (CR or PR) and disease control 
(CR, PR or SD>xx months) with corresponding exact 95% CI will be calculated using the 
Clopper-Pearson method (Clopper and Pearson, 1934) and tabulated for subjects 
treated at the MTD or RP2D.  The efficacy endpoints: progression-free survival, duration 
of response and duration of stable disease will be presented.  A Kaplan-Meier curve may 
be presented for progression-free survival with estimates for rates and 95% CI at 
selected weeks.  Statistical analyses of efficacy endpoints will be considered 
exploratory.   
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10.5.4 Exploratory Endpoints 
The following statistical analyses will be considered exploratory and will be performed 
only when deemed appropriate.  Relationships between changes in tumor dynamics and 
above biomarkers of interest listed as exploratory endpoints will be explored.  Changes 
in expression levels of biomarkers and their relationship to dose may also be explored.  
Summary statistics over time will be provided and graphical presentations may be used.  
The relationship between AMG 510 exposure and pharmacodynamics effects and 
related biomarkers in blood or tumor specimens and/or AMG 510 exposure and clinical 
outcomes (eg, tumor response) will be also explored if deemed appropriate.  Details of 
analysis will be provided in a supplemental analysis plan for exploratory biomarker 
analysis.   
11. REGULATORY OBLIGATIONS 
11.1 Informed Consent 
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the template are to 
be communicated formally in writing from the Amgen Study Manager to the investigator.  
The written informed consent form is to be prepared in the language(s) of the potential 
subject population. 
Before a subject’s participation in the clinical study, the investigator is responsible for 
obtaining written informed consent from the subject or legally acceptable representative 
after adequate explanation of the aims, methods, anticipated benefits, and potential 
hazards of the study and before any protocol specific screening procedures or any 
investigational product(s) is/ are administered. A legally acceptable representative is an 
individual or other body authorized under applicable law to consent, on behalf of a 
prospective subject, to the subject’s participation in the clinical study.  
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject’s participation in the clinical study.  If the subject agrees to such 
notification, the investigator is to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to 
document such in the subject’s medical record.   
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notification of the primary care physician is to be documented in the subject’s medical 
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records, and the informed consent form is to be signed and personally dated by the 
subject or a legally acceptable representative and by the person who conducted the 
informed consent discussion.  The original signed informed consent form is to be 
retained in accordance with institutional policy, and a copy of the signed consent form is 
to be provided to the subject or legally acceptable representative. 
If a potential subject is illiterate or visually impaired and does not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
informed consent form to the subject and must allow for questions.  Thereafter, both the 
subject and the witness must sign the informed consent form to attest that informed 
consent was freely given and understood. 
11.2 Institutional Review Board/Independent Ethics Committee 
A copy of the protocol, proposed informed consent form, other written subject 
information, and any proposed advertising material must be submitted to the IRB/IEC for 
written approval.  A copy of the written approval of the protocol and informed consent 
form must be received by Amgen before recruitment of subjects into the study and 
shipment of Amgen investigational product. 
The investigator must submit and, where necessary, obtain approval from the IRB/IEC  
for all subsequent protocol amendments and changes to the informed consent 
document.  The investigator is to notify the IRB/IEC of deviations from the protocol or 
serious adverse events occurring at the site and other adverse event reports received 
from Amgen, in accordance with local procedures. 
The investigator is responsible for obtaining annual IRB/IEC approval/renewal 
throughout the duration of the study.  Copies of the investigator’s reports and the 
IRB/IEC continuance of approval must be sent to Amgen. 
11.3 Subject Confidentiality 
The investigator must ensure that the subject’s confidentiality is maintained:   
• Subjects are to be identified by a unique subject identification number.   
• Where permitted, date of birth is to be documented and formatted in accordance with 
local laws and regulations.   
• On the demographics page, in addition to the unique subject identification number, 
include the age at the time of enrollment.   
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• For Serious Adverse Events reported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with 
local laws and regulations), and date of birth (in accordance with local laws and 
regulations). 
• Documents that are not submitted to Amgen (eg, signed informed consent forms) are 
to be kept in strict confidence by the investigator, except as described below. 
In compliance with governmental/ICH GCP Guidelines, it is required that the investigator 
and institution permit authorized representatives of the company, of the regulatory 
agency(s), and the IRB/IEC direct access to review the subject’s original medical records 
for verification of study related procedures and data.  Direct access includes examining, 
analyzing, verifying, and reproducing any records and reports that are important to the 
evaluation of the study.  The investigator is obligated to inform and obtain the consent of 
the subject to permit named such individuals to have access to his/her study related 
records, including personal information. 
11.4 Investigator Signatory Obligations 
Each clinical study report is to be signed by the investigator or, in the case of multi-
center studies, the coordinating investigator. 
The coordinating investigator, identified by Amgen, will be any or all of the following: 
• a recognized expert in the therapeutic area 
• an investigator who provided significant contributions to either the design or 
interpretation of the study 
• an investigator contributing a high number of eligible subjects 
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS 
12.1 Protocol Amendments and Study Termination 
Amgen may amend the protocol at any time.  After Amgen amends the protocol, the 
Investigator is to return the signed Investigator’s Signature page confirming agreement 
to continue participation in the study according to the amendment.  The IRB/IEC must be 
informed of all amendments and give approval.  The investigator must send a copy of 
the approval letter from the IRB/IEC and amended protocol Investigator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site. 
Amgen reserves the right to terminate the study at any time.  Both Amgen and the 
investigator reserve the right to terminate the Investigator’s participation in the study 
according to the Clinical Trial Agreement.  The investigator is to notify the IRB/IEC in 
writing of the study’s completion or early termination and send a copy of the notification 
to Amgen. 
A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 71 of 95 
CONFIDENTIAL   
Subjects may be eligible for continued treatment with Amgen investigational product by 
an extension protocol or as provided for by the local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s), and by what mechanism, after 
termination of the study and before it is available commercially. 
12.2 Study Documentation and Archive 
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the Amgen Delegation of Authority Form. 
Source documents are original documents, data, and records from which the subject’s 
CRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence. 
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study related (essential) documentation, suitable for 
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.   
Elements to include: 
• Subject files containing completed CRF, informed consent forms, and subject 
identification list 
• Study files containing the protocol with all amendments, Investigator’s Brochure, 
copies of prestudy documentation, and all correspondence to and from the IRB/IEC 
and Amgen 
• Investigational product-related correspondence including Proof of Receipts (POR), 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), Final Investigational Product Reconciliation Statement, as 
applicable. 
• Non-investigational product(s), and/or medical device(s) or combination product(s) 
documentation, as applicable. 
In addition, all original source documents supporting entries in the CRFs must be 
maintained and be readily available. 
Retention of study documents will be governed by the Clinical Trial Agreement. 
12.3 Study Monitoring and Data Collection 
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
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upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected. 
The Clinical Monitor is responsible for verifying the CRFs at regular intervals throughout 
the study to verify adherence to the protocol; completeness, accuracy, and consistency 
of the data; and adherence to local regulations on the conduct of clinical research.  The 
Clinical Monitor is to have access to subject medical records and other study related 
records needed to verify the entries on the CRFs. 
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are resolved. 
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Compliance Auditing function (or 
designees).  Inspection of site facilities (eg, pharmacy, protocol-required therapy storage 
areas, laboratories) and review of study related records will occur to evaluate the study 
conduct and compliance with the protocol, ICH GCP, and applicable regulatory 
requirements. 
Data capture for this study is planned to be electronic: 
• All source documentation supporting entries into the electronic CRFs must be 
maintained and readily available. 
• Updates to electronic CRFs will be automatically documented through the software’s 
“audit trail”. 
• To ensure the quality of clinical data across all subjects and sites, a clinical data 
management review is performed on subject data received at Amgen.  During this 
review, subject data are checked for consistency, omissions, and any apparent 
discrepancies.  In addition, the data are reviewed for adherence to the protocol and 
GCP.  To resolve any questions arising from the clinical data management review 
process, data queries are created in the EDC system database for site resolution 
and subsequently closed by the EDC system or by an Amgen reviewer. 
• The investigator signs only the Investigator Verification Form for this electronic data 
capture study.  This signature indicates that the investigator inspected or reviewed 
the data on the CRF, the data queries, and agrees with the content. 
Amgen (or designee) will perform Self-Evident Corrections (SEC) to obvious data errors 
in the clinical trial database.  SECs will be documented in the CRF Standard Instructions 
and the CRF Specific Instructions, both of these will be available through the EDC 
system.  Examples of obvious data errors that may be corrected by Amgen (or designee) 
include deletion of obvious duplicate data (ie, the same results sent twice with the same 
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date with different visit, [eg, week 4 and early termination]) and updating a specific 
response if the confirming datum is provided in the “other, specify” field (eg, for race, 
reason for ending study). 
12.4 Investigator Responsibilities for Data Collection 
The investigator is responsible for complying with the requirements for all assessments 
and data collection (including subjects not receiving protocol-required therapies) as 
stipulated in the protocol for each subject in the study.  For subjects who withdraw prior 
to completion of all protocol-required visits and are unable or unwilling to continue the 
Schedule of Assessments (Table 1), the investigator can search publically available 
records [where permitted]) to ascertain survival status.  This ensures that the data set(s) 
produced as an outcome of the study is/are as comprehensive as possible.   
12.5 Language 
All written information and other material to be used by subjects and investigative staff 
must use vocabulary and language that are clearly understood. eCRFs must be 
completed in English.  TRADENAMES (if used) for concomitant medications may be 
entered in the local language.  
12.6 Publication Policy 
Authorship of any publications resulting from this study will be determined on the basis 
of the International Committee of Medical Journal Editors (ICMJE) Recommendations for 
the Conduct of Reporting, Editing, and Publication of Scholarly Work in Medical 
Journals, which states: 
• Authorship credit should be based on (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically for important intellectual content; (3) final approval of the 
version to be published; and (4) agreement to be accountable for all aspects of the 
work in ensuring that questions related to the accuracy or integrity of any part of the 
work are appropriately investigated and resolved.  Authors should meet conditions 1, 
2, and 3 and 4. 
• When a large, multicenter group has conducted the work, the group should identify 
the individuals who accept direct responsibility for the manuscript.  These individuals 
should fully meet the criteria for authorship defined above. 
• Acquisition of funding, collection of data, or general supervision of the research 
group, alone, does not justify authorship. 
• All persons designated as authors should qualify for authorship, and all those who 
qualify should be listed. 
• Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
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All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to Amgen for corporate review.  The Clinical Trial 
Agreement among the institution, investigator, and Amgen will detail the procedures for, 
and timing of, Amgen’s review of publications. 
12.7 Compensation 
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that 
is available as a separate document. 
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14. APPENDICES 
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Appendix A.  Additional Safety Assessment Information 
Adverse Event Grading Scale 
The Common Terminology Criteria for Adverse Events (CTCAE) is available at the 
following location:   
http://ctep.cancer.gov/protocolDevelopment/electronicapplications/ctc.htm. 
Drug-induced Liver Injury Reporting & Additional Assessments  
Reporting 
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or INR elevation according to the criteria specified in Section 6.2 require 
the following: 
• The event is to be reported to Amgen as a serious adverse event within 24 hours of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded) 
• The appropriate CRF (eg, Adverse Event CRF) that captures information necessary 
to facilitate the evaluation of treatment-emergent liver abnormalities is to be 
completed and sent to the Amgen.  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Section 9.1.2 
Additional Clinical Assessments and Observation 
All subjects in whom investigational product(s) or protocol-required therapies is/are 
withheld (either permanently or conditionally) due to potential DILI as specified in 
Section 6.2 or who experience AST or ALT elevations > 3 x ULN or 2-fold increase 
above baseline values for subjects with evaluated values before drug are to undergo a 
period of “close observation” until abnormalities return to normal or to the subject’s 
baseline levels.  Assessments that are to be performed during this period include:  
• Repeat AST, ALT, ALP, bilirubin (total and direct), and INR within 24 hours  
• In cases of TBL > 2x ULN or INR > 1.5, retesting of liver tests, BIL (total and direct), 
and INR is to be performed every 24 hours until laboratory abnormalities improve 
• Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the investigational product(s) or protocol-required therapies has/have 
been discontinued AND the subject is asymptomatic. 
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• Initiate investigation of alternative causes for elevated AST or ALT and/or elevated 
TBL.  The following are to be considered depending on the clinical situation: 
− Complete blood count (CBC) with differential to assess for eosinophilia 
− Serum total immunoglobulin IgG, Anti-nuclear antibody (ANA), Anti Smooth 
Muscle Antibody, and Liver Kidney Microsomal antibody 1 (LKM1) to assess for 
autoimmune hepatitis 
− Serum acetaminophen (paracetamol) levels 
− A more detailed history of:  
o Prior and/or concurrent diseases or illness 
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity-type reactions, fatigue, nausea, vomiting and fever 
o Prior and/or concurrent use of alcohol, recreational drugs and special diets 
o Concomitant use of medications (including non-prescription medicines and 
herbal and dietary supplements), plants, and mushrooms 
− Viral serologies 
− CPK, haptoglobin, LDH, and peripheral blood smear 
− Appropriate liver imaging if clinically indicated 
• Appropriate blood sampling for pharmacokinetic analysis if this has not already been 
collected  
• Hepatology consult (liver biopsy may be considered in consultation with an 
hepatologist) 
• Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  
The “close observation period” is to continue for a minimum of 4 weeks after 
discontinuation of all investigational product(s) and protocol-required therapies. 
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must be captured in corresponding CRFs. 
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Appendix B.  Sample Serious Adverse Event Form  
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Appendix C.  Pregnancy and Lactation Notification Worksheets 
 
A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 85 of 95 
CONFIDENTIAL   
 
A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 86 of 95 
CONFIDENTIAL   
Appendix D.  Response Evaluation Criteria in Solid Tumors Version 1.1 
(RECIST 1.1) 
Quick Reference 
Definitions 
• Measurable Lesions  
o Measurable Tumor Lesions - Lesions that can be accurately measured in 
at least 1 dimension with longest diameter ≥ 10 mm in CT/MRI scan with 
slice thickness no greater than 5 mm, When slice thickness is greater 
than 5 mm, the minimum size of measurable lesion should be twice the 
slice thickness. 
o Nodal Lesions - Lymph nodes are to be considered pathologically 
enlarged and measurable, a lymph node must be ≥ 15 mm in short axis 
when assessed by CT/MRI (scan slice thickness recommended to be no 
greater than 5 mm).  At baseline and in follow-up, only the short axis will 
be measured and followed. 
 Nodal size is normally reported as two dimensions in the axial 
plane.  The smaller of these measures is the short axis 
(perpendicular to the longest axis). 
o Irradiated Lesions - Tumor lesions situated in a previously irradiated area, 
or in an area subjected to other loco-regional therapy, are not 
measurable unless there has been demonstrated progression in the 
lesion prior to enrollment. 
• Non-Measurable Lesions - All other lesions, including small lesions (tumor 
lesions with longest diameter < 10 mm or pathological lymph nodes with ≥ 10 to 
< 15 mm short axis with CT scan slice thickness no greater than 5 mm) and truly 
non-measurable lesions (ie, blastic bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusion, inflammatory breast disease, lymphangitis 
cutis/pulmonis, cysts, and also abdominal masses that are not confirmed and 
followed by imaging techniques). 
Methods of Meseasurement 
• Measurement of Lesions - The longest diameter of selected lesions should be 
measured in the plane in which the images were acquired (axial plane). All 
measurements should be taken and recorded in metric notation.  All baseline 
evaluations should be performed as closely as possible to the beginning of 
treatment and not more than 4 weeks before study Day 1. 
• Methods of Assessment - The same method of assessment and the same 
technique should be used to characterize each identified and reported lesion 
throughout the trial. 
• CT/ MRI – Contrast-enhanced CT or MRI should be used to assess all 
lesions.  Optimal visualization and measurement of metastasis in solid tumors 
requires consistent administration (dose and rate) of IV contrast as well as 
timing of scanning.  CT and MRI should be performed with ≤ 5 mm thick 
contiguous slices.    
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Baseline documentation of “Target” and “non-Target” lesions 
• Target Lesions - All measurable lesions up to a maximum of five (5) lesions per 
organ and ten (10) lesions in total, representative of all involved organs should be 
identified as target lesions and recorded and measured at baseline. 
o Target lesions should be selected on the basis of their size (lesions with 
the longest diameter) and suitability for accurate repeated 
measurements. 
o Pathologic lymph nodes (with short axis ≥ 15 mm) may be identified as 
target lesions.  All other pathological nodes (those with short axis 
≥ 10 mm but < 15 mm) should be considered non-target lesions. 
o A sum of the diameters (longest for non-nodal lesions, short axis for nodal 
lesions) for all target lesions will be calculated and reported as the 
baseline sum of diameters. The baseline sum of diameters will be used 
as reference by which to characterize objective tumor response. 
• Non-Target Lesions - All other lesions (or sites of disease) including pathological 
lymph nodes should be identified as non-target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required and these 
lesions should be followed as “present”, “absent”, or “unequivocal progression” 
throughout the study.  In addition, it is possible to record multiple non-target 
lesions involving the same organ as a single item on the case report form 
(eg, “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”). 
Response Criteria 
Evaluation of Target Lesions 
 
* Complete Response 
(CR): 
 
 
 
* Partial Response (PR): 
 
 
* Progressive Disease 
(PD): 
 
 
 
 
    
Disappearance of all target lesions. Any 
pathological lymph nodes (whether target 
or non-target) must have reduction in 
short axis to < 10mm. 
At least a 30% decrease in the sum of 
the diameters of target lesions, taking 
as reference the baseline sum of 
diameters 
At least a relative 20% increase and an 
absolute increase of 5mm in the sum of 
the diameters of target lesions, taking as 
reference the smallest sum on study, or 
the appearance of one or more new 
lesions. 
Neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD, 
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Evaluation of Non-target Lesions 
 
1To achieve “unequivocal progression” on the basis of the non-target disease, there must be an overall level 
of substantial worsening in non-target disease such that, even in presence of SD or PR in target disease, 
the overall tumor burden has increased sufficiently to merit discontinuation of therapy.  A modest “increase” 
in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression 
status. 
Evaluation of Objective Response 
Time Point response: Subjects with Target (+/- Non-Target) Disease 
Target Lesions Non-target Lesions New Lesions Overall Response 
CR CR No CR 
CR Non-CR/non-PD No PR 
CR Not evaluated No PR 
PR Non-PD or  
not all evaluated 
No PR 
SD Non-PD or  
not all evaluated 
No SD 
Not all evaluated Non-PD No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
NE = Not evaluable 
Time Point Response: Subjects with Non-Target Disease Only 
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Overall Response: Confirmation of CR and PR required 
 
Special Notes on Response Assessment 
o Nodal lesions – Lymph nodes identified as target lesions should always have the 
actual short axis measurement recorded, even if the nodes regress to below 
10 mm on study. In order to qualify for CR, each node must achieve a short 
axis < 10 mm. For PR, SD and pharmacodynamics, the actual short axis 
measurement of the nodes is to be included in the sum of diameters. 
o Target lesions that become “too small to measure” – While on study, all lesions 
(nodal and non-nodal) recorded at baseline should have their actual 
measurements recorded at each subsequent evaluation, even when very small 
(eg, 2 mm). However, sometimes lesions at baseline become so faint on CT 
scan that the radiologist may not feel comfortable assigning an exact measure 
and may report them as being “too small to measure”. When this occurs it is 
important that a value be recorded on the case report form. If it is the opinion of 
the radiologist that the lesion has likely disappeared, the measurement should 
be recorded as 0 mm.  If the lesion is believed to be present and is faintly seen 
but too small to measure, a default value of 5 mm should be assigned.  
o New lesion – A lesion identified on a follow-up study in an anatomical location 
that was not scanned at baseline is considered a new lesion and will indicate 
disease progression.  If a new lesion is equivocal, for example because of its 
small size, continued therapy and follow-up evaluation will clarify if it represents 
A
pp
ro
ve
d 
  
Product:  AMG 510 
Protocol Number:  20170543 
Date:  14 May 2018 Page 90 of 95 
CONFIDENTIAL    
truly new disease.  If repeat scans confirm there is definitely a new lesion, then 
progression should be declared using the date of the initial scan. 
o Subjects with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should 
be classified as having “symptomatic deterioration.”  Every effort should be made 
to document the objective progression even after discontinuation of treatment. 
o In some circumstances it may be difficult to distinguish residual disease from 
normal tissue. When the evaluation of complete response depends on this 
determination, it is recommended that the residual lesion be investigated (fine 
needle aspirate/biopsy) to confirm the complete response status. 
Confirmation Measurement / Duration of Response 
 Response Confirmation - In non-randomized trials where response is the 
primary endpoint, confirmation of PR and CR is required to ensure responses 
identified are not the result of measurement error. 
 Duration of overall response – The duration of overall response is measured 
from the time measurement criteria are first met for CR/PR (whichever is first 
recorded) until the first date the recurrent or progressive disease is objectively 
documented. 
 Duration of Stable Disease - SD is measured from the start of the treatment 
until the criteria for disease progression are met, taking as reference the 
smallest measurements recorded since the treatment started. 
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Appendix E.  Two-Parameter BLRM Design 
A two-parameter Bayesian logistic regression model (BLRM, Neuenschwander et al, 
2008) is used to guide dose escalation.  The MTD target Toxicity Probability Interval 
(TPI) for DLT is (0.20, 0.33) and a TPI of (0.33, 1.00) is defined as excessive.  The 
design seeks to identify a dose most likely to have a DLT rate in the target TPI, but with 
overdose control that limits the possibility the dose has an excessive DLT rate 
(Babb et al, 1998).  The probability of a DLT at dose level di is assumed to follow a 
Bernoulli distribution with probability pi where the logit of pi increases linearly with the log 
of the standardized dose in the following 2-parameter logistic model: 
 log [pi / (1-pi)] = logit(pi) = log[a] + exp( log[b]) log (di / dref) 
where a and b are random variables and dref is one of the planned dose selected as the 
reference dose.   
A bi-variate normal prior distribution (Neuenschwander et al, 2008) was selected for 
theta = (log a, log b) where the probability that the true DLT rate is ≤ 0.40 at 
180 milligrams (mg) is 0.90 and the probability the true DLT rate is ≤ 0.05 at the 
reference dose (720 mg) is 0.05.  Additionally, the prior is such that pi is approximately 
0.05 for the 180 mg dose and 0.25 for the reference dose.   
The operating characteristics of the two-parameter BLRM design were evaluated via 
simulation.  The cohort size was fixed to 2 or 4 subjects. The initial dose level is 180 mg 
and subsequent doses were selected based on the following rules: 
• After each cohort, the next dose is the one with the highest probability of the target 
TPI, but with a less than 0.25 probability of an excessive TPI. 
• Escalation to a dose level that is greater than 2x the current dose level is not 
allowed. 
Dose escalation was stopped given 1 or more of the following conditions: 
• There have been at least 6 subjects treated at the dose recommended by the model. 
• A maximum number of 30 subjects are evaluated. 
Operating characteristics are described below. 
Operating characteristics  
A total of 4 planned dose levels (unit:  mg) were considered:  180, 360, 720 and 960. 
Two intermediate dose levels were also considered: 270 and 540 mg. The design was 
evaluated for 4 possible dose-response scenarios:  Low MTD, Mid MTD, High MTD and 
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a scenario where none of the planned dose levels are tolerable.Table 5 shows the dose 
level and true probability of DLT for each scenario used in the simulated studies 
estimating the MTD.  Table 6 reports the operating characteristics from 1000 simulated 
studies estimating the MTD when the target TPI is (0.20, 0.33).  The rate of MTD 
selected and the number of subjects assigned to each dose level are presented in 
Table 7 
Table 5.  True Probability of DLT by Scenario for Simulated Studies Estimating 
MTD 
Dose Level 180 270 360 540 720 960 
MTD Scenario       
High 0.01 0.01 0.05 0.15 0.25 0.33 
Mid 0.05 0.15 0.25 0.33 0.43 0.53 
Low 0.15 0.25 0.33 0.43 0.53 0.63 
No tolerable 
dose levels 
0.35 0.43 0.50 0.58 0.65 0.73 
DLT = dose-limiting toxicity; MTD = maximum tolerated dose 
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Table 6.  Operating Characteristics by Scenario for Simulated Studies Estimating 
the MTD When the Target TPI is (0.20, 0.33) 
MTD 
Scenario High Mid Low 
No tolerable dose 
levels 
Subjects per 
cohort 
4 2 4 2 4 2 4 2 
Number of 
Subjects 
 Median 
(IQR) 
20 
(16 to 24) 
12 
(12 to 14) 
20 
(16 to 24) 
12 
(10 to 14) 
16 
(12 to 20) 
10 
(2 to 14) 
8 
(4 to 12) 
2 
(2 to 8) 
Number of 
DLTs 
 Median 
(IQR) 
2 
(2 to 4) 
2 
(1 to 2) 
4 
(3 to 5) 
3 
(2 to 3) 
4 
(3 to 6) 
2 
(1 to 4) 
3 
(2 to 4) 
2 
(1 to 3) 
Proportion of 
DLT (%) 
 Median 
(IQR) 
12.5 
(10 to 17) 
14.3 
(8 to 19) 
25.0 
(19 to 25) 
25.0 
(19 to 35) 
26.7 
(25 to 37) 
37.5 
(25 to 50) 
50.0 
(37 to 50) 
50.0 
(43 to 50) 
Percentage of studies recommending dose with DLT probability of:   
 ≤ 10%  4.6 9.2 11.2 25.9 29.7* 53.6* 82.3* 89.3* 
 > 10% and 
≤ 20% 
47.2 55.6 4.6 2.0 10.3 0.9 NA NA 
 > 20% and 
≤ 33% 
48.2 35.2 78.2 64.3 47.5 30.3 NA NA 
 > 33% NA NA 6.0 7.8 12.5 15.2 17.7 10.7 
Probability of 
identifying 
MTD to have 
15% to 33% 
DLT 
probability 
95.4 90.8 82.8 66.3 57.8 31.2  
 
NA 
 
 
NA 
DLT = dose-limiting toxicity; IQR = interquartile range; MTD = maximum tolerated dose; TPI = toxicity 
probability interval; NA=not applicable 
*In the low MTD scenario and the scenario where all planned dose levels are intolerable, this represents the 
percent of studies declaring all planned dose levels as not tolerable. 
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Table 7.  Rate of MTD Selected and Number of Subjects Assigned at Each Dose 
Level by Scenario  
MTD Scenario High Mid Low 
No tolerable 
dose levels 
Number of 
Subjects Per 
Cohort 4 2 4  2  4 2 
 
4 
 
2 
Rate of MTD selected at each dose level (%):   
Below lowest 
dose 
0.2 2.6 8.1 25.0 29.7 53.6 82.3 89.3 
180 mg 0.1 0.0 3.1 0.9 10.3 0.9 9.2 0.9 
270 mg 0.0 0.0 4.6 2.0 9.0 2.2 3.2 1.0 
360 mg 4.3 6.6 43.8 31.3 38.5 28.1 4.7 7.4 
540 mg 47.2 55.6 34.4 33.0 10.8 14.3 0.5 1.4 
720 mg 44.3 33.2 5.2 7.8 1.6 0.9 0.1 0.0 
960 mg  3.9 2.0 0.8 0.0 0.1 0.0 0.0 0.0 
Average number of subjects at each dose level   
180 mg 4.1 2.0 4.7 2.3 5.3 2.4 5.1 2.4 
270 mg 0.2 0.2 1.6 0.8 2.1 0.9 1.4 0.5 
360 mg 4.3 2.5 6.0 3.5 5.1 3.1 1.6 1.7 
540 mg 5.3 4.3 4.7 3.2 2.6 1.9 0.3 0.6 
720 mg 5.6 3.3 1.8 1.4 0.7 0.5 0.1 0.1 
960 mg 0.5 0.2 0.2 0.0 0.1 0.0 0.0 0.0 
MTD = maximum tolerated dose. A
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Operating Characteristics for Standard 3+3 Design  
As a comparison, the operating characteristics from 1000 simulated studies estimating 
the MTD when using a standard 3+3 design are reported in Table 8. 
Table 8.  Operating Characteristics by Scenario for Simulated Studies Estimating 
the MTD Using a 3+3 Design 
MTD Scenario High Mid Low 
No 
tolerable 
dose 
levels 
Number of Subjects 
 Median (IQR) 
15 
(12 to 18) 
12 
(12 to 15) 
12 
(9 to 13) 
6 
(3 to 12) 
Number of DLTs 
 Median (IQR) 
2 
(2 to 3) 
3 
(2 to 4) 
3 
(2 to 4) 
3 
(2 to 3) 
Proportion of DLT (%) 
 Median (IQR) 
16.7 
(11 to 20) 
23.8 
(20 to 27) 
26.7 
(22 to 
33) 
33.3 
(33 to 67) 
Percentage of studies recommending dose with DLT probability of:  
 ≤ 10%  44.7 43.5 19.4* 65.9* 
 > 10% and ≤ 20% 0.0 0.0 47.4 NA 
 > 20% and ≤ 33% 55.3 43.3 29.5 NA 
 > 33% NA 13.2 3.7 34.1 
Probability of 
identifying MTD to 
have 15% to 33% DLT 
probability 
55.3 43.3 76.9 NA 
DLT = dose-limiting toxicity; IQR = interquartile range; MTD = maximum tolerated dose; NA=not applicable 
*In the low MTD scenario and the scenario where all planned dose levels are intolerable, this represents the 
percent of studies declaring all planned dose levels as not tolerable. 
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Confidentiality Notice
This document contains confidential information of Amgen Inc.
This document must not be disclosed to anyone other than the site study staff and
members of the institutional review board/independent ethics
committee/institutional scientific review board or equivalent.
The information in this document cannot be used for any purpose other than the
evaluation or conduct of the clinical investigation without the prior written consent
of Amgen Inc.
If you have questions regarding how this document may be used or shared, call
the Amgen Medical Information number: US sites, 1- 800-77-AMGEN, Canadian
sites,
1-866-50-AMGEN; for all other countries, insert the local toll-free Medical 
Information number Amgen’s general number in the US (1-805-447-1000).
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Investigator’s Agreement
I have read the attached protocol entitled “A Phase 1/2, Open-label Study Evaluating the
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510
Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS 
p.G12C Mutation”, dated 22 May 2019, and agree to abide by all provisions set forth
therein.
I agree to comply with the International Council for Harmonisation (ICH) Tripartite
Guideline on Good Clinical Practice (GCP) and applicable national or regional
regulations/guidelines.
I agree to ensure that Financial Disclosure Statements will be completed by:
 me (including, if applicable, my spouse [or legal partner] and dependent children)
 my subinvestigators (including, if applicable, their spouses [or legal partners] and
dependent children)
at the start of the study and for up to one year after the study is completed, if there are
changes that affect my financial disclosure status.
I agree to ensure that the confidential information contained in this document will not be
used for any purpose other than the evaluation or conduct of the clinical investigation
without the prior written consent of Amgen Inc.
Signature
Name of Investigator Date (DD Month YYYY)
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Protocol Synopsis
Title: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid
Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With 
Advanced NSCLC With KRAS p.G12C Mutation
Study Phase: 1/2
Indication: KRAS p.G12C mutant advanced solid tumors
Objectives
Phase 1  (Monotherapy - Parts 1a, 1b, and 2a)
 Primary Objectives:
 To evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C
mutant advanced solid tumors
 To estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose
(RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors
 Secondary Objectives:
 To characterize the pharmacokinetics (PK) of AMG 510 following administration as an oral
tablet formulation
 To evaluate tumor response assessed by response evaluation criteria in advanced solid 
tumors (RECIST) 1.1 of AMG 510 as monotherapy in advanced solid tumors with KRAS
p.G12C mutation
 To evaluate the effect of food on the oral PK of AMG 510
 To evaluate the relationship between changes in corrected QT interval (QTc) and
AMG 510 exposure
 
 
Phase 2 (AMG 510 Monotherapy):
 Primary Objective
 To evaluate tumor objective response rate (ORR), assessed by RECIST 1.1 criteria, of 
AMG 510 as monotherapy in subjects with KRAS p.G12C mutant advanced solid tumors 
(NSCLC, colorectal cancer [CRC], and other tumor types).
A
pp
ro
ve
d 
  
Product:  AMG 510
Protocol Number:  20170543
Date:  22 May 2019 Page 5 of 158
CONFIDENTIAL
 Secondary Objectives
 To evaluate other measures of AMG 510 efficacy as monotherapy in subjects with
KRAS p.G12C mutant advanced solid tumors by RECIST 1.1 (NSCLC, CRC, and other 
tumor types).
 Duration of response (DOR)
 Disease control rate (DCR)
 Time to response (TTR)
 Progression-free survival (PFS)
 Overall survival (OS)
 PFS rate at 6 months and 12 months
 OS rate at 12 months
 To evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C 
mutant advanced solid tumors (NSCLC, CRC, and other tumor types).
 To evaluate the PK of AMG 510 following administration as an oral tablet formulation
Hypotheses:
The following hypotheses will be tested with this clinical protocol:
Phase 1 (monotherapy :
 At least 1 dose level of AMG 510, in repeat oral administrations, will achieve acceptable safety
and tolerability in subjects with KRAS p.G12C mutant advanced solid tumors in  
monotherapy 
 A favorable PK profile will be achieved with AMG 510 administered orally as monotherapy 
 Responses will be observed at a monotherapy dose level that achieves acceptable safety 
and tolerability.
Phase 2 (AMG 510 monotherapy):
 A clinically relevant ORR will be observed in each tumor type (NSCLC, CRC or other tumor 
type) at a dose level that demonstrates acceptable safety and tolerability
Endpoints
Phase 1:
Monotherapy (Parts 1a, 1b, and 2a):
 Primary Endpoints:
 Safety: subject incidence of treatment-emergent adverse events, treatment-related 
adverse events, and clinically significant changes in vital signs, physical examinations, 
electrocardiograms (ECGs), and clinical laboratory tests
 Subject incidence of dose limiting toxicity (DLT)
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 Secondary Endpoints:
 PK parameters of AMG 510 including, but not limited to, maximum plasma concentration 
(Cmax), time to achieve Cmax (tmax), and area under the plasma concentration-time curve 
(AUC)
 ORR, DOR, DCR, PFS, duration of stable disease, and TTR measured by CT or MRI 
and assessed per RECIST 1.1.  Response will be assessed by independent radiologic 
review.  Complete response and PR require confirmatory CT or MRI repeat assessment 
4 weeks after the first detection of response.
 PK parameters of AMG 510 including, but not limited to, Cmax, tmax, and AUC in the fed 
and fasted states for the food effect assessment
 AMG 510 exposure/QTc interval relationship
 
 
 
 
 
Phase 2 (AMG 510 Monotherapy):
 Primary Endpoint
 Objective response rate (ORR = complete response [CR] + partial response [PR]), 
assessed per RECIST 1.1.  Response will be assessed by independent radiologic review.  
Complete response and PR require confirmatory CT or MRI repeat assessment 4 weeks 
after the first detection of response.
 Secondary Endpoints
 Duration of response - defined as time from first evidence of confirmed PR or CR to 
disease progression or death due to any cause, whichever occurs first.  Subjects without 
a duration ending event will be censored at their last evaluable disease assessment date.  
Progression will be based on an independent radiologic assessment of disease response 
per RECIST 1.1
 Disease control rate defined as CR + PR + stable disease rate measured as described 
for ORR
 Progression-free survival - defined as time from first dose of AMG 510 until disease 
progression or death from any cause, whichever occurs first.  Subjects who do not 
progress or die will be censored at their last evaluable disease assessment date.  
Progression will be on an independent radiologic assessment of disease response per 
RECIST 1.1.
 Overall survival - defined as time from first dose of AMG 510 until death from any cause.  
Subjects who do not die will be censored at the date of last contact.
 Progression-free survival rate at 6 months and 12 months
 Overall survival rate at 12 months
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 Incidence and severity of adverse events
 Pharmacokinteics parameters of AMG 510 including, but not limited to, Cmax, tmax, and 
AUC.
 Time to response - defined as time from first dose of AMG 510 until the first 
evidence of confirmed PR or CR
Study Design: This is a phase 1/2 multicenter, non-randomized, open-label study of orally 
administered AMG 510 in subjects with KRAS p.G12C mutant advanced solid tumors.  The study 
will be conducted at approximately 100 sites globally.
Phase 1 is a first in human (FIH) dose exploration/expansion study to define the MTD or RP2D, 
safety, tolerability, PK and pharmacodynamics of AMG 510 as monotherapy in subjects with 
KRAS p.G12C mutant advanced solid tumors (Phase 1, Part 1a, 1b, and 2a) and  
  The phase 1 portion of the study will be conducted in 2 parts: part 1 
– Dose Exploration and part 2 – Dose Expansion. Part 1 is aimed at evaluating the safety, 
tolerability, PK, and pharmacodynamics and determining the MTD of repeat daily (QD) (or twice 
daily [BID]) dosing for AMG 510 monotherapy in subjects with KRAS p.G12C mutant advanced 
solid tumors using a Bayesian Logistics Regression Model (BLRM) design and  
 
The dose expansion part of the study (part 2) can 
open once the MTD and/or a RP2D has been determined in part 1. The DLT evaluation period 
will be 21 days. 
Phase 2 is a multicenter, non-randomized, open-label, phase 2 study to evaluate efficacy and 
safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C mutant advanced 
solid tumors (NSCLC, CRC, and other tumors).
Administration of AMG 510 may continue until subject has confirmed disease progression, or 
discontinues from the treatment for reasons listed in Section 8.3.1.
Phase 1:
Dose Exploration – Part 1
Part 1a Monotherapy Cohorts (Once Daily Dosing – QD):
Dose exploration monotherapy cohorts will estimate the MTD, and evaluate the safety, 
tolerability, PK, and pharmacodynamics of different doses of AMG 510 administered orally once 
daily in subjects with KRAS p.G12C mutant advanced solid tumors. Enrollment into the dose 
exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 
2-4 subjects treated at the lowest planned dose level of 180 mg. Dose escalation will follow the 
planned schedule with 2-4 subjects treated in each cohort. If no DLT is observed, dose 
escalation will continue to the next planned dose cohort as per Table 1. In addition to the dose 
levels outlined in Table 1, intermediate doses of 270 mg and 540 mg may be explored.  
Upon escalation to the next planned dose cohort, sentinel dosing will apply.  There will be a 2-day 
window between the first subject dosed and subsequent subjects. Once a subject experiences a 
DLT, dosing for subsequent cohorts will be recommended using the dose level recommendation 
from the BLRM. The decision to advance to the next dose level will be recommended by the 
Dose Level Review Team (DLRT) using the dose level recommendation from BLRM, as 
appropriate, and by evaluating available safety data, laboratory, and PK information.
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Intra-subject dose escalations are allowed on this study. Subjects who complete the DLT period 
may proceed to a higher dose level for the following treatment cycle if the next dose cohort is
deemed safe at that time by the DLRT and after consultation with the sponsor if:
 no DLT has been reported for this subject during or after completion of the DLT period
 the subject has not experienced any  grade 2 adverse events (deemed treatment related by
the investigator) during treatment
Subjects who proceed to a higher dose level will be required to have back to back clinic visits on 
day 1 and day 2 at the beginning of the cycle with the higher dose.  The safety assessments of 
chemistry and urinalysis will be performed on day 1 and day 2.  A repeat of PK sample collection 
will be performed as on cycle 1 day 1 and cycle 1 day 2, regardless of actual study cycle.
Subjects who do not proceed to a higher dose may continue to receive additional cycles at the 
original dose.
Dose exploration will continue until any of the following events.
 the highest planned dose level is determined to be safe and tolerable (minimum of
6 DLT-evaluable subjects)
 the MTD is identified, BLRM recommends a dose level which already has 6 DLT-evaluable
subjects
Additional subjects (20 to 40) may be enrolled in one or more monotherapy dose levels that 
have been shown to be safe and tolerable; defined as backfill enrollment. This backfill enrollment 
will be done to better estimate the RP2D and better characterize the safety, efficacy, PK, and 
pharmacodynamics for AMG 510 monotherapy and may be concurrent with dose escalation to 
identify the MTD. Additionally, food effect assessment will be conducted in at least 6 subjects 
from backfill enrollment in cycle 2 or later.
Part 1b Monotherapy Cohorts (Twice Daily Dosing – BID):
A BID dosing schedule for AMG 510 may be investigated as a dose modification strategy to 
potentially optimize AMG 510 activity. The initiation of the BID dosing schedule will be based 
upon the totality of the data available from Part 1a and food effect assessment.  Approximately 
12 subjects may be enrolled in 2 cohorts of 3 to 6 subjects per cohort.  
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Dose Expansion – Part 2
Upon completing the dose exploration part of the study and depending on data obtained, dose
expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant solid
tumors:
 Part 2a subjects with KRAS p.G12C mutant advanced NSCLC, CRC, or other tumor types
administered AMG 510 monotherapy once daily (total approximately n = 20, maximum 
n = 60).
  
Dose expansion in these 2 groups may be done concurrently.
Transition From Monotherapy Phase 1 (Part 2a) Dose Expansion to Phase 2:
After a minimum of 20 subjects have been enrolled to the initial estimated monotherapy RP2D 
(including subjects enrolled to the RP2D in either the dose exploration or the dose expansion 
parts of the study) and have completed the 21-day DLT period, the DLRT will review all available 
safety, laboratory, PK, and efficacy (physician assessment) data (including all previous data from 
the dose expansion and backfill cohorts).  Antitumor activity will also be monitored in terms 
of ORR by tumor types (NSCLC, CRC).  Futility and efficacy thresholds will be calculated 
using Bayesian posterior probability approach based on the cumulative efficacy data and 
it will serve as a guidance to the DLRT.  DLRT will make a recommendation as to whether to 
proceed to the phase 2 monotherapy part of the study.  The DLRT may also recommend that 
additional subjects be enrolled at this estimated monotherapy RP2D or that a dose reduction or 
alternate dosing regimen be explored before proceeding to phase 2.  After this first review has 
been conducted, if a decision is made to continue to obtain additional data at the initial estimated 
RP2D prior to proceeding to phase 2, the intervals for subsequent reviews will be determined by 
the DLRT but should occur within a maximum of 20 additional subjects enrolled and dosed for 
21 days.  The maximum number of subjects that may be enrolled to the initial estimated RP2D in 
the monotherapy dose expansion group, without confirmation of this dose for phase 2, will not 
exceed 60.  If another dose (or schedule) needs to be explored, additional subjects on that dose
(or schedule), up to a total of 60, may be enrolled. Whenever DLRT will review the data, the 
futility and efficacy thresholds will be calculated based on all the cumulative efficacy data 
to provide the guidance.
Phase 2:
This is a multicenter, non-randomized, open-label, phase 2 study to evaluate efficacy and 
safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C mutant advanced 
solid tumors (NSCLC, CRC, and other tumors).  The dose (and schedule) administered in 
phase 2 will be that confirmed to be the RP2D from combined analyses of phase 1 part 1 and 2.  
Approximately 200 subjects (at least 105 for NSCLC and 60 CRC) will be enrolled.  The 
timing to start enrollment into each tumor type will be communicated to the sites and may 
be gated based on Amgen's internal decision based on several factors (ie, efficacy and 
availability of the drug supply).  Tumor response will be evaluated employing RECIST 1.1 
based on contrast enhanced computed tomography (CT)/magnetic resonance imaging (MRI) with 
assessments conducted by an independent radiological central laboratory.  Interim safety reviews 
will be conducted after 30, 50, 70, and 100 subjects have been enrolled and treated with 
AMG 510 for at least 21 days (enrollment will not be held for completion of these safety reviews).  
Interim futility analyses will be conducted as described in Section 10.4.1.3.2.  The primary 
analysis for the study will occur when there are 105 evaluable NSCLC subjects or 
60 evaluable CRC subjects in the phase 2 ORR analysis set (Section 10.1.2.5), whichever 
occurs first.
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Sample Size:
Phase 1:
It is anticipated that up to 158 subjects will be enrolled in the phase 1 part of the study.  No more 
than 92 subjects will be enrolled in part 1 (dose exploration) cohorts and up to 66 subjects
will be enrolled in part 2 (dose expansion) cohorts.  
Part 1 – Dose Exploration:
Part 1a
Approximately 30 subjects will be needed to estimate the AMG 510 monotherapy MTD in part 1a.
An additional 20 to 40 subjects may be enrolled by backfill enrollment and receive AMG 510 
monotherapy (part 1a) from which at least 6 subjects will be evaluated for food effect.  
Part 1b
Approximately 12 subjects may be enrolled in 2 cohorts of 3 to 6 subjects per cohort.
 
 
 
 
 
Phase 2:
In phase 2, it is anticipated that approximately 200 subjects (at least 105 subjects with NSCLC 
and 60 subjects with CRC) will be enrolled.  Actual enrollment for each tumor type (NSCLC, 
CRC) will be based on DLRT recommendations and Amgen's internal decision.  
The rationale for the number of subjects is provided in Section 10.2.
Summary of Subject Eligibility Criteria: 
Adult subjects (≥ 18 years old) with advanced solid tumors will be eligible for this study. 
Enrollment will be restricted to subjects with KRAS p.G12C mutant solid tumors as assessed by 
molecular testing of tumor biopsy specimens. 
 
Once consented to the study, subjects will provide a medical history and undergo screening 
safety tests to confirm all eligibility requirements of the study have been met.  
 
Amgen Investigational Product Dosage and Administration:
AMG 510 for phase 1 will be manufactured both by Amgen Inc. and Patheon.  AMG 510 for 
phase 2 will be manufactured by Patheon.  AMG 510 for both phases will be packaged and 
distributed by Amgen Inc., using Amgen clinical study drug distribution procedures.   
AMG 510 will be administered orally once or twice daily [BID]), depending on what phase 
and/or cohort of the study that the subject is enrolled.  No drug holidays are allowed.  
Non-Amgen Investigational Product Dosage and Administration (Phase 1 Parts 1c and 2c
Only):
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Procedures:
After written informed consent has been obtained, all screening tests and procedures will be
performed within 28 days of administration of the first dose of AMG 510 (day 1),. Subjects will be
seen in clinic where critical clinical safety and study evaluations will be performed including
physical examination, vital signs, clinical laboratory tests, imaging assessments, ECGs, PK, and
biomarker sample collections. Patient-reported outcomes will also be collected.  
Statistical Considerations: 
In the phase 1 dose exploration part of the study, the DLRT will review the safety data after each
cohort and make a decision on the next dose level to be explored for the estimate of RP2D/MTD
based on a BLRM design.  Before making a recommendation to proceed to the phase 2 part of 
the study, the DLRT will review all available safety, laboratory, PK, and efficacy after a minimum of 
20 subjects have been enrolled to the initial estimated monotherapy RP2D (including subjects 
enrolled to the RP2D in either the dose exploration or the dose expansion); all previous data from 
the dose expansion and backfill cohorts will also be reviewed.  Antitumor activity will also be 
monitored in terms of ORR by tumor types (NSCLC, CRC).  Whenever DLRT will review the 
data, ORR futility and efficacy thresholds by tumor type will be calculated based on the 
cumulative efficacy data using Bayesian posterior probability and the thresholds will serve 
as a guidance to the DLRT. The DLRT may review additional subjects at a given RP2D (not to 
exceed 60 subjects).
In the phase 2 part of the study, a data review team (DRT), internal to Amgen but external to the 
study team, will assess safety after approximately 30, 50, 70, and 100 subjects become 
evaluable.  The DRT will also oversee futility analyses based on ORR that will be performed by 
tumor type when 25 subjects become evaluable and every 10 subjects afterwards for NSCLC 
and when 20subjects become evaluable and every 10 subjects afterwards for CRC. Interim 
futility analyses will be conducted as described in Section 10.4.1.3.2.
The primary analysis will occur when either 105 NSCLC subjects or 60 CRC subjects enrolled in 
the phase 2 are treated at the monotherapy RP2D and become evaluable, whichever occurs 
first. This analysis will only include phase 2 subjects treated at the monotherapy RP2D.  
Efficacy and safety analyses will be summarized overall and by tumor type.  The percentage of 
subjects with an overall response (OR) will be summarized along with a Clopper-Pearson exact 
confidence interval.  DOR will be summarized with Kaplan-Meier quartiles and rates for select 
durations (eg, > 3, > 6, > 9, > 12 months).  Disease control will be analyzed by the same methods 
used to analyze OR.   Overall survival and PFS will be summarized with Kaplan-Meier curves, 
quartiles, and rates for select timepoints (eg, 6 and 12 months).
For a full description of statistical analysis methods, please refer to Section 10.
Sponsor: Amgen Inc.
Data element standards version: 6.0
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Schema. Study Design and Treatment
Figure 1.  Phase 1 Part 1 – Dose Exploration Schema
28 days Treatment period: subjects will be dosed daily with 21-day cycles and no drug holidays
30 (+7) 
days
Every 
12  weeks
Footnotes defined on next page
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DLRT = Dose Level Review Team; DLT = dose limiting toxicity; EOT = end of treatment; MTD = maximum tolerated dose; NSCLC = non-small cell lung carcinoma; 
PK = pharmacokinetic(s); TBD = to be determined.
Note:  DLT window is 21 days.  Additional subjects may be enrolled in 1 or more dose levels that have been shown to be safet and tolerable (backfill 
enrollment)
a  
 
 
c Optional food effect assessment will be conducted in at least 6 subjects from monotherapy dose exploration or expansion cohorts (preferably from 960 mg 
cohort) in cycle 2 or later.
d Japanese subjects will be enrolled in the dose exploration portion of the study and treated at the MTD or RP2D.
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Figure 2.  Phase 1 Part 2 – Dose Expansion Schema
28 days
Treatment period: subjects will be dosed daily with 21-day cycles and no drug holidays
30 (+7) 
days
Every 
12  weeks
EOT = end of treatment; NSCLC = non-small cell lung carcinoma.
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Figure 3.  Food Effect Assessment Schema (Phase 1 Part 1a or Part 2a)
Continue
with
AMG 510
dosinga
PK = pharmacokinetic.
a Administration of AMG 510 may continue until subject has confirmed disease progression, or discontinues from the treatment for reasons listed in 
Section 8.3.1.
AMG 510 in 
a fasted
state on
day 1
(PK and urine collection
up to 24 hrs)
AMG 510 in a fed
state (after a 
high-fat meal) 
on day 2
(PK collection up to
24 hrs)
Prior to day 1 of cycle
2 or later Day 1 to Day 3
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Figure 4.  Transition From Phase 1 to Phase 2 Study Schema
DLRT = Dose Level Review Team; EOS= end of study; EOT = end of treatment; MTD = maximum tolerated dose; OS = overall survival; RP2D = Recommended 
Phase 2 Dose.
DLRT will be responsible for reviewing data in the dose expansion phase to confirm the RP2D and determine the benefit/risk of proceeding to the phase 2 
part of the study according to the futility and efficacy threshold guidance described in Section 10.4.1.
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Study Glossary
Abbreviation or Term Definition/Explanation
ANC absolute neutrophil count
AUC area under the plasma concentration-time curve
ALT alanine aminotransferase
AST aspartate aminotransferase
BCRP breast cancer resistance protein
BID twice daily
BLRM Bayesian Logistics Regression Model
Cmax maximum plasma concentration
CNS central nervous system
CR complete response
CRC colorectal cancer
CRF case report form
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 cytotoxic T-lymphocyte associated protein 4
CYP3A cytochrome P450 3A
DCR disease control rate
DDI drug-drug interaction
DL dose level
DLRM Dose Level Review Meeting
DLRT Dose Level Review Team
DLT dose limiting toxicity
DILI drug induced liver injury
DOR Duration of response
DRT Data Review Team
ECG electrocardiogram
EQ-5D-5L EuroQol-5 Dimension
EGFR epidermal growth factor receptor
Electronic Source Data 
(eSource)
source data captured initially into a permanent electronic record 
used for the reconstruction and evaluation of a study
End of Study defined as the date when the last subject across all sites is
assessed or receives an intervention for evaluation in the study
(ie, last subject last visit), following any additional parts in the
study (eg, long-term follow-up), as applicable
End of Follow-up defined as when the last subject completes the last 
protocol-specified assessment in the study
End of Study for Individual 
Subject
defined as the last day that protocol-specified procedures are
conducted for an individual subject
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Abbreviation or Term Definition/Explanation
End of Treatment defined as the last assessment for the protocol specified
treatment phase of the study for an individual subject
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer
Quality-of-life Questionnaire Core 30
ERK extracellular signal-regulated kinase
Exposure-Response 
Analysis
mechanism-based modeling & simulation and statistical analyses
based on individual pharmacokinetic [PK] exposure (eg,
population pharmacokinetic modeling) and response, which may
include biomarkers, pharmacodynamic effects, efficacy and
safety endpoints
FDA Food and Drug Administration
FFPE formalin-fixedparaffin-embedded
FIH first-in-human
FOLFIRI folinic acid, 5-fluorouracil, and irinotecan hydrochloride
FOLFOX folinic acid, 5-fluorouracil and oxaliplatin
GAP GTPase-activating protein
GCP Good Clinical Practice
GDP guanosine diphosphate
GTP guanosine triphosphate
HBs hepatitis B surface antibody
HepBsAg Hepatitis B surface antigen
HepCAb Hepatitis C antibody
HLA human leukocyte antigen
HNSTD highest non-severely toxic dose
HRQOL Health-related Quality of Life
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonisation
Ig immunoglobulin
IgV Ig Variable-type
IPIM Investigational Product Instruction Manual
IUD intrauterine device
IUS intrauterine hormonal-releasing system
IV intravenous
IVD in vitro diagnostic
IVRS Interactive Voice Response System
IWRS Interactive Web Response System
KRAS Kirsten rat sarcoma viral oncogene homolog (protein)
KRAS Kirsten rat sarcoma viral oncogene homolog (DNA)
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Abbreviation or Term Definition/Explanation
KRASG12C KRAS protein with a G12C mutation at the protein level
KRAS p.G12C KRAS DNA with a mutation resulting in a G12C mutation at the 
protein level
mAb monoclonal antibody
MAPK mitogen-activated protein kinase
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MSI-H microsatellite instability-high
MTD maximum tolerated dose
NOEL no observed effect level
NRAS neuroblastoma RAS viral oncogene homolog
NSCLC non-small cell lung carcinoma
OR overall response
ORR objective response rate
OS overall survival
PET positron emission tomography
PD Progressive disease
P-gp P-glycoprotein
PCR polymerase chain reaction
PK pharmacokinetic(s)
PO oral(ly)
PFS progression-free survival
PR partial response
Primary Completion defined as the date when the last subject is assessed or receives
an intervention for the final collection of data for the primary
endpoint(s), whether the study concluded as planned in the
protocol or was terminated early
PRO patient-reported outcomes
PRO-CTCAE Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events
Q3W every 3 weeks
QD once daily
QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module 
QLQ-PAN26 Quality-of-Life Questionnaire Pancreatic Cancer Module 
QOL Quality of Life
QTc corrected QT (interval)
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Abbreviation or Term Definition/Explanation
RAF RAF proto oncogene serine/threonine-protein kinase
RAS rat sarcoma viral oncogene homolog
RECIST response evaluation criteria in solid tumors
RNAi RNA interference
RP2D recommended phase 2 dose
SD stable disease
STD10 severely toxic dose in 10% of animals
Source Data information from an original record or certified copy of the 
original record containing patient information for use in clinical 
research.  The information may include, but is not limited to, 
clinical findings, observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents (original 
records or certified copies).  (ICH Guideline [E6]).  Examples of 
source data include Subject identification, Randomization 
identification, and Stratification Value.
Study Day 1 defined as the first day that protocol specified investigational 
product(s)/protocol-required therapies is/are administered to the
subject
t1/2,z terminal half-life
TBL total bilirubin
tmax time to achieve Cmax
TGI tumor growth inhibition
TPI toxicity probability interval
TPS Tumor Proportion Score
ULN upper limit of normal
US United States
VEGF vascular endothelial growth factor
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1. OBJECTIVES 
1.1 Phase 1 (Monotherapy – Parts 1a, 1b, and 2a) 
1.1.1 Primary 
• To evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS 
p.G12C mutant advanced solid tumors 
• To estimate the maximum tolerated dose (MTD) and/or a recommended phase 
2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors 
1.1.2 Secondary 
• To characterize the pharmacokinetics (PK) of AMG 510 following administration as 
an oral tablet formulation 
• To evaluate tumor response assessed by response evaluation criteria in advanced 
solid tumors (RECIST) 1.1 of AMG 510 as monotherapy in advanced solid tumors 
with KRAS p.G12C mutation 
• To evaluate the effect of food on the oral PK of AMG 510 
• To evaluate the relationship between changes in corrected QT interval (QTc) and 
AMG 510 exposure 
1.1.3 Exploratory 
• To explore pharmacodynamic relationships for safety and/or efficacy endpoints  
• To characterize AMG 510 excretion in urine 
• To identify metabolites of AMG 510 in plasma and urine 
• To investigate potential biomarkers by biochemical and/or genetic analysis of blood 
and/or tumor tissue samples. 
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1.3 Phase 2 (AMG 510 Monotherapy)
1.3.1 Primary Objective
 To evaluate tumor objective response rate (ORR) assessed by RECIST 1.1 criteria 
of AMG 510 as monotherapy in subjects with KRAS p.G12C mutated advanced 
tumors (NSCLC, colorectal cancer [CRC], and other tumor types). 
1.3.2 Secondary Objectives
 To evaluate other measures of AMG 510 efficacy as monotherapy in subject with 
KRAS p.G12C mutant advanced tumors by RECIST 1.1 (NSCLC, CRC, and other 
tumor types).
 Duration of response (DOR)
 Disease control rate (DCR)
 Time to response (TTR)
 Progression-free survival (PFS)
 Overall survival (OS)
 PFS rate at 6 months and 12 months
 OS rate at 12 months
 To evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS 
p.G12C mutant advanced solid tumors (NSCLC, CRC, and other tumor types).
 To evaluate the PK of AMG 510 following administration as an oral tablet formulation
1.3.3 Exploratory Objectives
 To explore PK/pharmacodynamic relationships for safety and/or efficacy endpoints
 To explore biomarkers of response and resistance in tumor and blood specimens 
prior to exposure to AMG 510 and at the time of progression
 To explore the subject experience with AMG 510 treatment using patient-reported 
outcome instruments with respect to the following core concepts:
 Impact of treatment on disease-related symptoms and Health-related Quality of 
Life (HRQOL) 
 Treatment-related symptoms and impact on the subject
 Physical function
2. BACKGROUND AND RATIONALE
2.1 Oncogenic RAS Driven Tumorigenesis - Background
The rat sarcoma (RAS) proto-oncogene has been identified as an oncogenic driver of
tumorigenesis in both NSCLC and CRC (Der et al, 1982; Smith et al, 2010; 
Johnson et al, 2001).  The RAS family consists of 3 closely related genes that express
GTPases responsible for regulating cellular proliferation and survival
(Barbacid et al, 1987; Simanshu et al, 2017).  The RAS proteins, Kirsten rat sarcoma 
viral oncogene homolog (KRAS), Harvey rat sarcoma viral oncogene homolog (HRAS),
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and neuroblastoma RAS viral oncogene homolog (NRAS) (Hall et al, 1983;
Taparowsky et al, 1983; Chang et al, 1982; Kirsten and Mayer, 1967; Harvey, 1964), can 
be mutationally activated at codons 12, 13, or 61, leading to human cancers. Different 
tumor types are associated with mutations in certain isoforms of RAS, with KRAS being 
the most frequently mutated isoform in most cancers (Prior et al, 2012).  While the role 
of KRAS mutations in human cancers has been known for decades, no anti-cancer 
therapies specifically targeting KRAS mutations have been successfully developed, largely 
because the protein is intractable for inhibition by small molecules (McCormick, 2016).  
2.2 KRAS p.G12C Mutation and AMG 510
Of the KRAS mutations, it is estimated that approximately 80% occur at codon 12
(Prior et al, 2012).  The KRAS p.G12C mutation is estimated to occur in approximately 
13% of lung adenocarcinoma (including NSCLC), 3% of CRC, and 1% to 2% of numerous 
other solid tumors (including pancreatic, endometrial, bladder, ovarian, and small cell lung 
tumors) (Biernacka et al, 2016; Neumann et al, 2009; The AACR Project GENIE 
Consortium, 2017).  This specific mutation has been identified as a putative oncogenic 
driver in several types of solid tumors including NSCLC (Fernández-Medarde and Santos, 
2011) and CRC (Jones et al, 2017) and other solid tumors such as pancreatic, 
endometrial, bladder, ovarian, and small cell lung tumors (Zhou et al, 2016; The AACR 
Project GENIE Consortium, 2017).
The KRAS p.G12C mutation is a single guanine to thymine substitution that results in a
glycine to cysteine substitution at amino acid position 12.  This structural change in the
protein results in a defect in the association of GTPase-activating proteins (GAPs),
thereby reducing the hydrolysis of guanosine triphosphate (GTP) by KRAS.  The
resulting accumulation of active, GTP-bound KRAS leads to enhanced proliferative and 
survival signaling in tumor cells (Jones et al, 2017).  
AMG 510 is a small molecule that specifically and irreversibly inhibits the KRASG12C
mutant protein.  AMG 510 binds to the P2 pocket of KRAS adjacent to the mutant
cysteine at position 12 and the nucleotide-binding pocket.  The inhibitor contains a 
thiol-reactive portion which covalently modifies the cysteine residue and locks KRASG12C
in an inactive, guanosine diphosphate (GDP)-bound conformation.  This blocks the
interaction of KRAS with effectors such as RAF proto oncogene serine/threonine-protein
kinase (RAF), thereby preventing downstream signaling, including the phosphorylation 
of extracellular signal-regulated kinase (ERK) (Cully and Downward, 2008; 
Ostrem et al, 2013; Simanshu et al, 2017). Inactivation of KRAS by RNA interference 
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(RNAi) or small-molecule inhibition has previously demonstrated an inhibition of cell 
growth and induction of apoptosis in tumor cell lines and xenografts harboring KRAS
mutations (including the KRAS p.G12C mutation) (Janes et al, 2018; 
McDonald et al, 2017; Xie et al, 2017; Ostrem and Shokat, 2016; Patricelli et al, 2016). 
Studies with AMG 510 have confirmed these in vitro findings and have likewise
demonstrated inhibition of growth and regression of cells and tumors harboring KRAS 
p.G12C mutations (Section 5.1).  These data suggest that inhibition of KRAS p.G12C 
may have therapeutic benefit for subjects with KRAS p.G12C-driven cancers.  
Accordingly, the first-in-human (FIH) and Phase 2 Study 20170543, will evaluate the 
safety, tolerability, PK, and efficacy of AMG 510 in subjects with KRAS p.G12C mutant 
advanced NSCLC, CRC, and other solid tumors.
2.2.1 Current Therapy for Cancers Harboring the KRAS p.G12C Mutation
Worldwide, lung cancer (small cell and non-small cell) and CRC are the first and third
most common types of cancer occurring in both men and women (WHO statistics, 2015).
It is estimated that in 2018 there were approximately 234 030 new cases of lung cancer
and 140 250 new cases of CRC in the United States (US) alone (American Cancer
Society, 2018). The 5-year survival rate for advanced NSCLC cancer is between
1% and 10% depending on the stage. Similarly, the 5-year survival rate for advanced 
CRC is approximately 11% (American Cancer Society, 2018).  Therefore, while the 
incidence of the G12C KRAS mutation in these tumor types is relatively low 
(approximately 13% and 3%, respectively) the overall incidence of NSCLC and CRC and 
the poor prognosis of subjects with advanced/metastatic disease makes this mutation an 
important molecular target.  
There is currently no anticancer therapy specifically targeting tumors that harbor the 
KRAS p.G12C mutation.  Subjects with metastatic or unresectable NSCLC, CRC and 
other solid tumors (including pancreatic, endometrial, bladder, ovarian, appendiceal, 
ampullary, and small intestine) with the KRAS p.G12C mutation are generally being
treated with combinations of chemotherapy, immunotherapy or antiangiogenic agents.  
In NSCLC, until recently, most subjects with a KRAS p.G12C mutation would have 
received platinum containing doublets, typically cisplatin/pemetrexed as standard first 
line options (NCCN, 2018a) followed by second line therapy with a taxane with or 
without a VEGF inhibitor.  
Although somatic mutations in EGFR, BRAF, and HER2, and rearrangements in ALK, 
ROS, and RET have been validated as powerful predictive biomarkers, and have 
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expanded treatment options for these molecularly defined subsets of subjects, since the 
KRAS mutation rarely occurs concomitantly with these other molecular abnormalities, 
subjects with KRAS mutations are not usually candidates for these therapies
(Scheffler et al, 2018; Gainor et al, 2013).  Efforts to target KRAS mutant NSCLC by 
inhibiting downstream signaling mechanisms such as MEK1/2 or CDK4/6 inhibitors have 
been unsuccessful to date (Roman et al, 2018).  More recently, NSCLC subjects with the 
KRAS p.G12C mutation are, like subjects without other molecularly defined targets, 
receiving anti-programmed cell death-1 (PD-1) inhibitors with or without chemotherapy in 
first and/or second line therapy.
A similar situation exists for CRC subjects with the KRAS p.G12C mutation albeit due to 
lack of other effective therapies, chemotherapy with or without bevacizumab remains the 
standard of care in first and second line.  While EGFR inhibitors are an option for some 
subjects, they are not effective in subjects with KRAS mutations (Douillard et al, 2013; 
Amado et al, 2008; Karapetis et al, 2008).  Anti-PD1 inhibitors appear to be effective in 
CRC subjects who are microsatellite instability-high (MSI-H); however, this appears to 
constitute only approximately 5% to 15% of all CRC subjects (Fabrizio et al, 2018; 
Vanderwalde et al, 2018; Vilar and Gruber, 2010).  
Preliminary literature review performed by Amgen on KRAS p.G12C mutant subjects 
(from 15 publications with NSCLC and 4 publications with CRC G12C specific data over 
the past 10 years) suggests that in general, in NSCLC subjects, the KRAS p.G12C
mutation appeared to be associated with poorer progression-free and disease-free 
survival; in CRC subjects the KRAS p.G12C mutation appeared to be associated with 
less favorable survival outcomes.  However, the magnitude of these differences was 
modest and there were a few studies that reported no difference or slightly better 
outcomes of subjects with KRAS p.G12C mutations.  Amgen is performing a systematic 
literature review for treatment outcomes (ie, OS, PFS, ORR, DOR, etc) in KRAS and 
more specifically KRAS p.G12C mutant cancer subjects.
Amgen has also initiated 2 real-world data studies utilizing AACR project GENIE and 
Syapse genomic and linked EMR data.  AACR GENIE (~850 KRAS p.G12C subjects) 
and Syapse (~1,000 KRAS p.G12C subjects) will provide real world evidence on subject
characteristics, treatments, and outcomes (OS, PFS, etc).  These data will be used to 
provide context for the results that will be observed in the phase 1/2 trial of AMG 510 
study.  Results of these studies and the systematic literature review are anticipated to be 
available prior to primary analysis of this phase 1/2 trial of AMG 510.
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Pending the results of these investigations and based on the preliminary literature review 
described above, Amgen will assume that subjects with the KRAS p.G12C mutation 
respond similarly to chemotherapy, immunotherapy, and anti-angiogenic agents as 
subjects who do not harbor a KRAS p.G12C mutation.
For advanced/metastatic NSCLC subjects, multiple large phase 3 trials have 
demonstrated ORR in ≥ second line (following first line platinum-containing 
chemotherapy doublets, typically cisplatin/pemetrexed) of 5.5 to 13 % with 
chemotherapy (typically a taxane) and 9.7 to 22.5 % with chemotherapy plus a VEGFR 
inhibitor (Gridell et al, 2018; Rittmeyer et al, 2017; Herbst et al, 2016; 
Borghaei et al, 2015; Herbst et al, 2007).  These trials have also demonstrated PFS of
2.8 to 4.2 months and 4.8 to 5.4 months and OS of 6 to 11.4 months and 9.9 to
12.6 months for chemotherapy and chemotherapy plus a VEGFR inhibitor, respectively.  
Recent studies of ≥ second line NSCLC subjects receiving anti-PD1 therapy 
(post-chemo doublet therapy in first line) have yielded more substantial ORR and OS
(Vokes et al, 2018; Herbst et al, 2016; Borghaei et al, 2015); however, due to recent 
approvals of anti-PD1 therapy for first line NSCLC the sequence of immunotherapy in 
NSCLC is in flux and the standard of care (and outcomes) for subjects who progress or 
recur after first line anti-PD1 therapy remains unclear.  
In the case of advanced or metastatic RAS mutant CRC, standard of care therapy for 
second line subjects is generally folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX) or
folinic acid, 5-fluorouracil, and irinotecan hydrochloride (FOLFIRI) with or without the 
addition of a VEGF inhibitor with approximately 6% ORR, PFS of 5.3 to 7.7 months and 
OS of 11.2 to 14.1 months (Masi et al, 2015; Iwamoto et al, 2015; Bennouna et al, 2013; 
Giantonio et al, 2007; Tournigand et al, 2004).  For subjects who have progressed or 
recurred after both FOLFOX and FOLFIRI with addition of a VEGF inhibitor (ie,  3 line), 
chemo doublets, Regorafenib, or Trifluridine plus Tipiracil are options however ORR with 
these therapies is 1 to 4%, PFS 2 to 3 months and OS 6 to 9 months (Li et al, 2015; 
Mayer et al, 2015; Grothey et al, 2013).  Treatment options, response and survival for 
advanced/metastatic appendiceal and small intestinal cancers appear to be similar to 
those of advanced/metastatic CRC.  EGFR inhibitors are not recommended for subjects 
with KRAS mutations and although anti-PD1 inhibitors have been shown to be effective 
in MSI-H CRC this constitutes only approximately 5% to 15% of all CRC subjects
(Fabrizio et al, 2018; Vanderwalde et al, 2018; Vilar and Gruber, 2010).  
Advanced/metastatic pancreatic cancers are generally treated in first line with folinic 
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acid, 5-fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) or 
gemcitabine plus nab-paclitaxel.  Depending on which of these therapies is used in first
line, the alternate is the likely second line therapy of choice.  In subjects treated with a 
gemcitabine-based therapy in first line, recent studies with 5FU based therapies have 
resulted in ORR of 8.5 to 13.2%, PFS of approximately 2.9 to 3.1 months and OS of 4.2 
to 9.9 months.
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2.3 Amgen Investigational Product Background
AMG 510 is a small molecule that specifically and irreversibly inhibits the KRASG12C
mutant protein. AMG 510 binds to the P2 pocket of KRAS adjacent to the mutant
cysteine at position 12 and the nucleotide-binding pocket. The inhibitor contains a
thiol-reactive portion which covalently modifies the cysteine residue and locks KRASG12C
in the inactive GDP-bound conformation. This blocks the interaction of KRAS with
effectors like RAF, thus preventing downstream signaling, including the phosphorylation
of ERK (Ostrem et al, 2013; Simanshu et al, 2017). Inactivation of KRAS through a
small molecule inhibitor has previously demonstrated an inhibition of cell growth and 
induction of apoptosis in tumor cell lines and xenografts with the KRAS p.G12C
mutation (Ostrem and Shokat, 2016; Patricelli et al, 2016; Janes et al, 2018). Likewise,
studies of AMG 510 have demonstrated inhibition of growth and regression of cells and 
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tumors harboring KRAS p.G12C (Section 2.2.1). These data suggest that inhibition of
KRASG12C may have therapeutic benefit for subjects with KRAS p.G12C-driven cancers. 
Accordingly, the FIH and Phase 2 Study 20170543, will evaluate the safety and efficacy
of AMG 510 in subjects with KRAS p.G12C mutant advanced NSCLC, CRC, and other
solid tumors
2.3.1 AMG 510 Preclinical Experience
In vitro AMG 510 inhibited nucleotide exchange of recombinant mutant KRASG12C/C118A
(half maximal inhibitory concentration, IC50 = 0.09 M), but had minimal effect on
KRASC118A, which is wildtype at G12. In cells, AMG 510 covalently modified KRASG12C
and inhibited KRAS signaling as measured by phosphorylation of ERK1/2 in all KRAS
p.G12C-mutant cell lines tested (IC50 values from 0.01 to 0.12 M), but did not inhibit
phospho-ERK1/2 in cell lines with various other KRAS mutations. AMG 510 also
impaired viability in all but one p.G12C-mutant cell lines (IC50 values from 0.004 to
0.032 M), but did not affect the viability of cell lines that did not harbor the
KRAS p.G12C mutation. The cellular kinact and Ki values for AMG 510 were also
experimentally determined in MIA PaCa-2 cells to be 0.00133 sec-1 and 6.97×10-7 M,
respectively, with kinact/Ki ratio of 1.9×103 M-1 sec-1.
In vivo AMG 510 covalently modified KRASG12C and significantly inhibited
phosphor-ERK1/2 in human KRAS p.G12C MIA PaCa-2 T2 pancreatic and 
KRAS p.G12C NCI-H358 NSCLC tumor xenografts in mice in a dose-dependent manner 
at doses as low as 1 mg/kg in the MIA PaCa-2 T2 model. After a single, 10 mg/kg dose
in mice bearing MIA PaCa-2 T2 tumors, exposure of AMG 510 peaked at 0.5 hours,
followed closely by maximal inhibition of phospho-ERK1/2 by 1 hour to 2 hours.
Covalent modification of KRASG12C by AMG 510 tracked with inhibition and maximal
modification occurred after 2 hours.  Significant inhibition and modification of KRASG12C
persisted for 48 hours after a single, 10 mg/kg dose. In tumor xenograft studies
AMG 510 significantly inhibited the growth of MIA PaCa-2 T2 and NCI-H358 tumors at
doses as low as 3 mg/kg and achieved 62% and 49% regression, respectively, at
100 mg/kg. Notably AMG 510 had no effect on SW480-1AC (KRAS p.G12V) tumor
xenografts at 100 mg/kg and did not impact body weight in any study.
2.3.2 Pharmacokinetics
AMG 510 was characterized in vitro and in vivo preclinical studies. AMG 510 exhibited
moderate to high clearance (CL), moderate volume of distribution (Vss), and terminal
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elimination half-life (t1/2,z) of 0.34 to 0.71 hours in animal species. The oral bioavailability
of the suspension formulation was variable, ranging from 3.3 to 47% across the species
tested. AMG 510 has moderate binding to plasma proteins in all species including
humans. AMG 510 did not preferentially distribute into red blood cells in mouse, rat, 
dog, and human whereas it was preferentially distributed into red blood cells in monkey.
These data were used to predict the human AMG 510 PK parameters AMG 510 was 
predominantly eliminated in preclinical species in vivo through CYP3A-catalyzed 
formation of the metabolite, M24. M24 has > 1000-fold less pharmacological activity
than its parent, AMG 510. AMG 510 was also a substrate of P-glycoprotein in vitro.
AMG 510 has a potential to cause CYP3A-mediated drug-drug interaction (DDI) due to
reversible and irreversible time-dependent inhibition of CYP3A and induction of CYP3A4
in vitro. M24 also has a potential to cause CYP3A-mediated drug-drug interactions due
to reversible and irreversible time-dependent inhibition of CYP3A and induction of
CYP3A4 in vitro.  In vitro, AMG 510 was also shown to be an inhibitor of CYP2C8 and
CYP2D6, but not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP2E1.
M24 was an inhibitor of CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. In vitro,
AMG 510 was shown to be an inducer of CYP2B6, CYP2C8, CYP2C9, and CYP2C19,
while M24 was an inducer of CYP2B6, CYP2C8, CYP2C9 and CYP2C19.
In vitro, AMG 510 is a P-gp substrate, thus active transport by P-gp may affect AMG 510
absorption and elimination. AMG 510 is not a BCRP substrate. Additionally, AMG 510
and its metabolite M24 was identified as an inhibitor of human MATE1. AMG 510 was
also an inhibitor of human OAT3, OATP1B1, MATE2-K and P-gp. Incomplete inhibition
was observed up to the highest test concentration for human OAT1, OCT1, OATP1B3
and BCRP, suggesting weak inhibition. M24 was an inhibitor of human OAT1, OAT3,
OATP1B1, OATP1B3, and P-gp. Incomplete inhibition was observed up to the highest
test concentration for human MATE2-K and BCRP, suggesting weak inhibition.
Based on current in vitro data, AMG 510 has a potential to interact with CYP3A4 and
MATE1. The DDI potential for other enzymes and transporters is expected to be low.
2.3.3 Toxicology
Animal toxicology studies have been completed in both the rat and dog and support
development of AMG 510 for treatment of KRAS p.G12C mutated tumors. AMG 510 
was well tolerated in the GLP 28-day rat toxicology study at 0, 10, 30, and 200 mg/kg 
and in the GLP 28-day dog toxicology study at 0, 10, 30, and 300 mg/kg. Key
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AMG 510-related changes in the rat were minimal to mild and included kidney tubular
epithelial degeneration/necrosis; increased spleen weight, increased leukocytes; and a
decrease in red blood cell (RBC) mass (hemoglobin, RBC count, and hematocrit) that
was associated with changes in reticulocytes and RBC indices. In the rat,
AMG 510-related degeneration/necrosis of renal tubule epithelium primarily affected
tubules within the outer segment of the outer medulla and was characterized by
sloughing of degenerative/necrotic epithelial cells, tubular dilatation, and/or 
accumulation of eosinophilic material within the tubule. Reversibility data is pending in
the rat. The degeneration/necrosis observed in the kidney is expected to be fully
reversible based on the minimal to mild severity, the absence of tubular basement
membrane damage, and the normal regenerative capacity of the renal tubular
epithelium. Key AMG 510-related changes in the dog consisted of a minimal to mild
decrease in RBC mass associated with decreased reticulocytes. Taken together, the
AMG 510-related decrease in RBC mass and reticulocytes in the rat and dog are most
likely due to red blood cell/reticulocyte destruction and not decreased hematopoietic
production, given the absence of light microscopic changes in the bone marrow in dog
and the increased bone marrow erythroid cellularity in a few rats. The decreases in
RBC mass and reticulocytes are expected to be reversible based on the normal
regenerative capacity of the hematopoietic system, and the absence of overt bone 
marrow toxicity (eg, hypocellularity).  AMG 510 nonclinical safety studies have not
identified cardiovascular concerns.  Clinically significant interaction with the hERG 
channel are not expected over the proposed clinical dose range (hERG IC50 54.8 µM).
AMG 510 at doses up to 300 mg/kg did not result in changes to electrocardiogram 
(ECG) or hemodynamic parameters in a cardiovascular safety pharmacology study in
telemetered dogs or in a 28-day toxicology study. In exploratory genetic toxicology
studies, AMG 510 was not mutagenic in the Ames bacterial mutagenicity assay but was 
positive for clastogenicity in vitro. AMG 510 was not phototoxic in vitro.
There were no AMG 510-related changes in either the rat or dog repeat-dose toxicology
studies that were considered severely toxic; thus, the severely toxic dose in 10% of
animals (STD10) in rats was > 200 mg/kg and the highest non-severely toxic dose
(HNSTD) in dogs was ≥ 300 mg/kg. There was minimal toxicity at exposures up to 9-fold
above those expected in humans at the highest therapeutic dose. Overall, the results of
the nonclinical safety studies support the initiation of AMG 510 clinical trials and the
initial clinical plan.
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2.5 Risk Assessment
There are no identified risks associated with the administration of AMG 510. Based on
nonclinical toxicity studies of AMG 510, key safety information for AMG 510 includes
renal toxicity, anemia, leukocytosis, and splenomegaly. Clinical signs and symptoms of
this key safety information, along with safety laboratories, will be monitored during the
study to ensure subjects’ safety.
More detailed information about the risks of AMG 510 may be found in the AMG 510 
Investigator’s Brochure.
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2.6 Rationale
2.6.1 Phase 1
2.6.1.1 Dose Selection Rationale
The proposed AMG 510 doses are 180, 360, 720, and 960 mg administered once daily
(QD) orally (PO); a twice daily (BID) PO dose may be explored as discussed in 
Section 3.1.1.1.2. During dose exploration (part 1) and dose expansion (part 2), 
AMG 510 will be given QD (or BID) PO for a treatment cycle of 21 days in length that
include 21 administrations of AMG 510. The planned dose level(s) for dose expansion
(MTD/RP2D) will be determined based on data collected during dose exploration.
The proposed clinical starting dose of 180 mg administered QD PO is based on the
current guidance for starting dose of anti-cancer small molecule drugs (ICH S9) using
the methodology described by the Food and Drug Administration (FDA) for calculating 
the human equivalent dose (HED) on a body surface area basis (FDA, 2005). The rat
severely toxic dose in 10% of animals (STD10) and the dog highest non-severely toxic
dose (HNSTD) were 200 mg/kg/day PO and 300 mg/kg/day PO, respectively, as noted in 
the 28-day repeat-dose GLP toxicology studies. The proposed starting dose was
roughly the maximum recommended starting dose of 195 mg/day PO, which is based on
the lower value of 1/10th the HED for the rat STD10 (195 mg/day PO) and 1/6th the HED
for the dog HNSTD (1622 mg/day PO). To estimate AMG 510 exposures in humans,
AMG 510 human PK parameters were predicted using allometric scaling of PK 
parameters for clearance and volume obtained from nonclinical studies in mice, rats, 
monkeys, and dogs and absorption constant and oral bioavailability following oral tablet 
administration of AMG 510, the same tablet formulation to be used in this clinical study. 
At the starting dose of 180 mg administered QD PO, the predicted exposure margins of
steady-state maximum plasma concentration (Cmax) and area under the plasma 
concentration-time curve (AUC) exposures relative to the rat STD10 are 62-fold and
20-fold, respectively. The predicted exposure margins of steady-state Cmax and AUC
exposures relative to the dog highest severely toxic dose (HNSTD) are estimated at
50-fold and 12-fold, respectively, at the starting dose administered orally once daily.
The highest planned dose is 960 mg QD PO. The exposure margins for the predicted
human steady state AUC and Cmax exposures of this dose are 12-fold and 4-fold,
respectively relative to rat STD10 and 9-fold and 2-fold, respectively relative to dog
HNSTD. Safety and tolerability data from prior dose levels will guide the dose
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escalations and the planned top dose for AMG 510 in the dose exploration phase. The
MTD identified from the dose exploration phase will inform the dose expansion phase.
Efficacious doses were predicted with 2 PK/tumor growth inhibition (TGI) models that
describe the anti-tumor activity of AMG 510: (1) a tumor stasis model that estimates
human exposures to cause tumor stasis (ie, no net tumor growth) based on PK and TGI
of MIA-PaCa-2 T2 tumor xenograft mice treated with AMG 510 and (2) a tumor
regression model that utilizes clinical pancreatic cancer data and PK and TGI in
AMG 510-treated MIA-PaCa-2 T2 xenograft mice to predict the treatment effects of
AMG 510 on tumor growth dynamics in humans. Consolidating the results from both
models, the minimal efficacious dose for AMG 510 in humans was predicted to be
between 30 and 240 mg QD PO.
Integrating the toxicology, pharmacology, human PK and efficacious dose predictions,
the starting dose of 180 mg QD is expected to be safe as well as potentially efficacious.
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2.6.2 Phase 2
Based on preclinical PK/TGI modeling and the clinical data to date (safety/tolerability 
and responses described below), it is highly likely that one of the currently tested or 
planned monotherapy doses in phase 1 part 1 will be appropriate for expanded testing in 
a phase 2 trial.  This protocol will allow for transition to phase 2 once an RP2D has been 
confirmed.
2.6.2.1 Clinical Experience – in Phase 1
The phase 1 dose exploration part of this study is ongoing.  As of 24 January 2019, 
preliminary data were available for 22 subjects with KRASG12C advanced or metastatic 
tumors (6 NSCLC, 15 CRC, and 1 appendiceal) who had received at least 1 dose of
AMG 510:  6 subjects at 180 mg QD (dose level [DL] 1, cohort 1), 12 subjects at 360 mg 
QD (DL 2, cohort 2) and 4 subjects at 720 mg QD (DL 3, cohort 3).  The Dose Level 
Review Team (DLRT) convened on 31 January 2019 and after reviewing the safety data 
for the subjects in the 720 mg cohort and the cumulative safety data for all the subjects, 
4 subjects are allowed to enroll in cohort 4 (960 mg QD). The 5 active subjects at 
180 mg were allowed to dose escalate from 180 mg to 360 mg when the 360 mg dose 
was declared safe and tolerable by the dose level team.  Mean age of the subjects was 
56 years, (female, 53 years; male, 58 years) with a mean of 4 prior therapies.  Eighteen
(18) subjects remain on treatment with 4 discontinuations due to disease progression 
after 21, 42, 62, and 72 days, respectively.
No dose limiting toxicities (DLTs) have been observed at DL 1, DL 2, or DL 3. No 
serious adverse events were reported up to the snap shot date.  Treatment-emergent 
adverse events that were reported as related to AMG 510 included:
 180 mg cohort:  dry mouth, cheilitis, and hot flush (Common Terminology Criteria for 
Adverse Events [CTCAE] grades 1, 2, and 1, respectively)
 360 mg cohort:  pyrexia (CTCAE grade 1)
 720 mg cohort: nausea, diarrhea (CTCAE grade 1)
No significant trends in safety labs (hematology, chemistry, coagulation, and urinalysis), 
ECG, or vital signs were observed.  
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Tumor assessment (physician assessment from computed tomography [CT] or magnetic 
resonance imaging [MRI]) performed at 6 and 12 weeks are shown below:
Cohort 6-week scan response 12-week scan response
Subjects at 180 mg at C1D1 SDa SDa
SDb SDb
PRa PRa
SDb NE
SDb SDb
SDa --
Subjects at 360 mg at C1D1 PDb --
SDb --
SDb --
SDb SDb
C1D1 = cycle 1 day 1; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable 
disease.
a Non-small cell lung carcinoma
b Colorectal cancer
2.7 Clinical Hypotheses
The following hypotheses will be tested with this clinical protocol:
Phase 1 (Monotherapy 
 At least 1 dose level of AMG 510, in repeat oral administrations, will achieve
acceptable safety and tolerability in subjects with KRAS p.G12C mutant advanced 
solid tumors in both monotherapy 
 A favorable PK profile will be achieved with AMG 510 administered orally as
monotherapy 
 Responses will be observed at a monotherapy dose level that achieves acceptable
safety and tolerability.
Phase 2 (AMG 510 Monotherapy):
 A clinically relevant ORR will be observed in each tumor type (NSCLC, CRC or other 
tumor type) at a dose level that demonstrates acceptable safety and tolerability
3. EXPERIMENTAL PLAN
3.1 Study Design
This is a phase 1/2 multicenter, non-randomized, open-label study of orally administered 
AMG 510 in subjects with KRAS p.G12C mutant advanced solid tumors.  The study will be 
conducted at approximately 100 sites globally.
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Phase 1 is a FIH dose exploration/expansion study to define the MTD or RP2D, safety, 
tolerability, PK, and pharmacodynamics of AMG 510 as monotherapy in subjects with 
KRAS p.G12C mutant advanced solid tumors (Phase 1, Part 1a, 1b, and 2a)  
 
The phase 1 will be conducted in 2 parts: 
part 1 – Dose Exploration and part 2 – Dose Expansion. Part 1 is aimed at evaluating 
the safety, tolerability, PK, and pharmacodynamics and determining the MTD of repeat
daily (QD) (or twice daily [BID]) dosing for AMG 510 monotherapy in subjects with 
KRAS p.G12C mutant advanced solid tumors using a Bayesian Logistics Regression 
Model (BLRM) design (Neuenschwander et al, 2008)  
 
  The dose expansion part of the study (part 2)
can open once the MTD and/or a RP2D has been determined in part 1. The DLT
evaluation period will be 21 days.
Phase 2 is a multicenter, non-randomized, open-label, phase 2 study to evaluate efficacy 
and safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C mutant 
advanced solid tumors (NSCLC, CRC, and other tumors).
Administration of AMG 510 may continue until until subject has confirmed disease 
progression, or discontinues from the treatment for reasons listed in 
Section 8.3.1.
The overall study design is described by a study schema at the end of the protocol 
synopsis section.
The study endpoints are defined in Section 10.1.1.
3.1.1 Phase 1
3.1.1.1 Dose Exploration – Part 1
No more than 92 subjects will be enrolled to the dose exploration cohorts.  
 
 
 After completion of evaluation of preliminary food effect 
(Section 3.1.1.1.4), approximately 12 subjects in 2 cohorts of n = 3-6 subjects may be 
enrolled to evaluate initial safety, PK and pharmacodynamics of AMG 510 using BID 
dosing.  In order to better estimate the RP2D and to better characterize the safety,
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efficacy, PK, and pharmacodynamics for AMG 510 monotherapy, an additional 
20 to 40 subjects may be enrolled in one or more monotherapy dose levels that have
been deemed to be safe and tolerable, defined as backfill enrollment.  Subjects in
backfill enrollment will be allowed to proceed to higher dose levels when the higher dose
levels have been deemed safe and tolerable.  This backfill enrollment may be concurrent
with dose escalation to identify the MTD.  
For sites in Japan, an additional minimum of 3 Japanese subjects will be enrolled and 
treated at the MTD or RP2D in order to evaluate the tolerability of monotherapy AMG 
510 in Japanese subjects.  The DLRT will convene and review the safety and available 
PK data of the 21-day DLT evaluation period.  Additional Japanese subjects will be 
allowed to enroll in the dose expansion and phase 2 after the DLRT confirms the safety 
and tolerability of AMG 510 monotherapy in Japanese subjects.
Table 1.  Planned Escalation Dose Levels
Cohort AMG 510 Dose (mg)
1 180
2 360
3 720
4 960
 MTD = maximum tolerated dose; NA = not available; 
TBD = to be determined.
Note:  Potential intermediate doses of 270 mg and 540 mg
 
 
 
3.1.1.1.1 Part 1a Monotherapy Cohorts (Once Daily Dosing – QD)
Dose exploration monotherapy cohorts will estimate the MTD or R2PD and evaluate the
safety, tolerability, PK, and pharmacodynamics of different doses of AMG 510
administered orally QD in subjects with KRAS p.G12C mutant advanced solid tumors. 
Enrollment into the dose exploration cohorts may be from any eligible KRAS p.G12C
mutant solid tumor type. Dose escalation will begin with 2-4 subjects treated at the 
lowest planned dose level of 180 mg. Dose escalation will follow the planned schedule
with 2-4 subjects treated in each cohort. If no DLT is observed, dose escalation will
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continue to the next planned dose cohort as per Table 1. In addition to the dose levels 
outlined in Table 1, intermediate doses of 270 mg and 540 mg may be explored.  
Upon escalation to the next planned dose cohort, sentinel dosing will apply.  There will 
be a 2 day window between the first subject dosed and subsequent subjects.  Once a
subject experiences a DLT, dosing for subsequent cohorts will be recommended using
the dose level recommendation from the BLRM. After each cohort, the model’s
recommended MTD dose level for evaluation is the dose level with the highest 
probability of the target toxicity probability interval (TPI), but with a less than 0.25
probability of an excessive TPI. The target TPI is (0.20, 0.33], and a TPI of (0.33, 1.00] 
is defined as excessive. The decision to advance to the next dose level will be
recommended by the DLRT using the dose level recommendation from BLRM, as
appropriate, and by evaluating available safety data, laboratory, and PK information.
Intra-subject dose escalations are allowed in this study. Subjects who complete the DLT
period may proceed to a higher dose level for the following treatment cycle if the next
dose cohort is deemed safe at that time by the DLRT and after consultation with the
sponsor if:
 no DLT has been reported for this subject during or after completion of the DLT 
period
 the subject has not experienced any ≥ grade 2 adverse events (deemed treatment 
related by the investigator) during treatment
Subjects who proceed to a higher dose level will be required to have back to back clinic 
visits on day 1 and day 2 at the beginning of the cycle with the higher dose.  The safety 
assessments of chemistry and urinalysis will be performed on day 1 and day 2.  A repeat 
of PK sample collection will be performed as on cycle 1 day 1 and cycle 1 day 2, 
regardless of actual study cycle.
Subjects who do not proceed to a higher dose may continue to receive additional cycles
at the original dose.
Dose exploration will continue until any of the following events.
 The highest planned dose level is determined to be safe and tolerable (minimum of 
6 DLT-evaluable subjects).
 The MTD is identified, BLRM recommends a dose level which already has 
6 DLT-evaluable subjects.
Japanese subjects will be enrolled in the dose exploration portion of the study and 
treated at the MTD or RP2D.
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3.1.1.1.2 Part 1b Monotherapy Cohorts (Twice Daily Dosing – BID)
A BID dosing schedule for AMG 510 may be investigated as a dose modification 
strategy to potentially optimize AMG 510 activity. The initiation of the BID dosing 
schedule will be based upon the totality of the data available from Part 1a and food 
effect assessment. Approximately 12 subjects may be enrolled in 2 cohorts of 3 to 
6 subjects per cohort.  Enrollment in Part 1b may be performed in parallel with 
enrollment in Part 2 (monotherapy dose expansion) after availability of data from 
preliminary food effect cohort.  Select sites will be allowed to enroll subjects in Part 1b 
due to requirement for more intensive PK and additional safety assessments (Table 4).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.1.1.4 Optional Food Effect Assessment (For Monotherapy Part 1a or 
Monotherapy Part 2a)
Food effect assessment will be conducted in at least 6 subjects from monotherapy 
dose exploration or expansion cohorts (preferably from 960 mg cohort) in cycle 2 
or later who consent to participate in this optional evalution. On day 1 of the cycle 
in which the assessment will be conducted, subjects will receive their dose of AMG 510 
with approximately 240 mL (8 ounces) of water under fasted conditions (no food or 
liquids, except water) for ≥ 10 hours prior to ingesting their dose of AMG 510 at the
clinic. The subjects will fast overnight again (no food or liquids, except water for ≥ 10
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hours) before returning to the clinic on day 2 to ingest their dose of AMG 510 after eating
a standardized high-fat, high calorie meal. Subjects should eat the meal in 25 minutes
or less; AMG 510 should be administered 30 minutes after the start of the meal and after
at least 5 minutes of rest. Carryover of AMG 510 exposure from a prior dose is
expected to be minimal based on the predicted half-life of AMG 510. For both days, no
food is allowed for at least 3 hours after AMG 510 dosing.
Additional water can be consumed as desired, except for 1 hour prior to and 1 hour after
AMG 510 dosing. Pharmacokinetic samples will be collected prior to dosing and at 
various time points over a 24-hour period after dosing on both days. Urine will be 
collected for the 24-hour period following day 1 dosing.
3.1.1.2 Dose Expansion – Part 2
Upon completing the dose exploration part of the study and depending on data obtained,
dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C
mutant advanced solid tumors:
1. Part 2a subjects with KRAS p.G12C mutant advanced NSCLC, CRC, or other tumor 
types administered AMG 510 monotherapy once daily (total approximately n = 20, 
maximum n = 60)
 
Dose expansion in these 2 groups may be done concurrently.
3.1.2 Transition From Monotherapy Phase 1 (Part 2a) Dose Expansion to
Phase 2
The dose expansion part of the study (phase 1 - part 2) can open once an MTD or a 
RP2D and dosing schedule has been estimated in the dose exploration part of the study 
(phase 1 – part 1).  If no DLT is observed in phase 1 – part 1, the RP2D will be 
estimated based on composite review of PK, overall safety/tolerability and observed 
responses.  Further confirmation of the RP2D dose will be sought in the phase 1 part 2 
dose expansion.
In the dose expansion, additional patients will be enrolled at the RP2D estimated in the 
phase 1 part 1 dose exploration. After a minimum of 20 subjects have been enrolled to 
the initial estimated monotherapy RP2D (including subjects enrolled to the RP2D in 
either the dose exploration [approximately 6] or the dose expansion [approximately 14]
parts of the study) and have completed the 21 day DLT period, and after a minimum of 
10 of these subjects have at least 6 weeks of response data, the DLRT will review all 
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available safety, laboratory, PK, and efficacy (physician assessment) data (including all 
previous data from the dose expansion and backfill cohorts). Antitumor activity will 
also be monitored in terms of ORR by tumor types (NSCLC, CRC).  Futility and 
efficacy thresholds will be calculated using Bayesian posterior probability 
approach based on the cumulative efficacy data and it will serve as a guidance to 
the DLRT.  DLRT will make a recommendation as to whether to proceed to the phase 2 
monotherapy part of the study.  Enrollment will not be held to conduct this assessment.  
The decision to proceed to the phase 2 monotherapy will be based on the totality of data 
from both exploration and expansion parts of the study.  The DLRT may also 
recommend that additional subjects be enrolled at this estimated monotherapy RP2D or 
that a dose reduction or alternate dosing regimen be explored before proceeding to 
phase 2.  After this first review has been conducted, if a decision is made to continue to 
obtain additional data at the initial estimated RP2D prior to proceeding to phase 2, the 
intervals for subsequent reviews will be determined by the DLRT but should occur within 
a maximum of 20 additional subjects enrolled and dosed for 21 days.  The maximum 
number of subjects that may be enrolled to the initial estimated RP2D in the 
monotherapy dose expansion group, without confirmation of this dose for phase 2, will 
not exceed 60.  If another dose (or schedule) needs to be explored, additional subjects 
on that dose (or schedule), up to a total of 60, may be enrolled.  Based on emerging 
clinical efficacy data, the number of subjects with specific tumor types may be 
restricted/specified in the expansion part.  Whenever DLRT will review the data, the 
futility and efficacy thresholds will be calculated based on all the cumulative 
efficacy data to provide the guidance.
A final estimate of the MTD and/or RP2D using BLRM will be evaluated and confirmed
utilizing all DLT-evaluable subjects from the dose exploration and the dose expansion
cohorts. For definition of DLT-evaluable, see Section 3.3.
3.1.3 Phase 2 – AMG 510 Monotherapy
This is a multicenter, non-randomized, open-label, phase 2 study to evaluate efficacy 
and safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C
mutant advanced solid tumors (NSCLC, CRC, and other tumors).  Approximately 
200 subjects (at least 105 for NSCLC and 60 CRC) will be enrolled.  The timing to 
start enrollment into each tumor type will be communicated to the sites and may 
be gated based on Amgen's internal decision based on several factors (ie, efficacy 
and availability of the drug supply).  Tumor response will be evaluated employing 
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RECIST 1.1 criteria based on contrast enhanced CT/MRI imaging with assessments 
conducted by an independent radiological central laboratory.  A combined efficacy 
analysis of all subjects enrolled to the confirmed monotherapy RP2D will be performed.  
Subgroup analysis of each tumor type will also be performed. Interim safety reviews will 
be conducted after 30, 50, 70, and 100 subjects have been enrolled and treated with 
AMG 510 in the phase 2 for at least 21 days (enrollment will not be held for completion 
of these safety reviews).  Interim futility analysis will be conducted as described in 
Section 10.4.1.3.2.  The primary analysis for the study will occur after there are at least
105 evaluable NSCLC subjects or 60 evaluable CRC subjects in the phase 2 ORR 
analysis set (Section 10.1.2.5), whichever occurs first.  The data cutoff will be 
decided to allow sufficient time to demonstrate durability of ORR.
3.2 Number of Sites
This study will be conducted at approximately 100 sites globally.  Sites that do not enroll 
subjects into an open cohort within 6 months of site initiation may be closed or replaced.
3.3 Number of Subjects
Participants in this clinical investigation shall be referred to as “subjects”.
It is anticipated that up to 158 subjects will be enrolled in the phase 1 part of the study.
No more than 92 subjects will be enrolled in part 1 (dose exploration) cohorts and up to
66 subjects will be enrolled in part 2 (dose expansion) cohorts.
During part 1 (dose exploration), a subject that is not DLT-evaluable will be replaced with 
another subject to the same dose level. A subject is DLT-evaluable if either of the
following occurs:
 Subject experienced a DLT or
 Subject does not experience a DLT and subject received at least 80% of the planned 
doses of investigational product within the first treatment cycle (ie, 21 days)
Subjects will not be replaced after end of the DLT period.
In phase 2, it is anticipated that approximately 200 subjects (at least 105 subjects with 
NSCLC and 60 subjects with CRC) will be enrolled .  Actual enrollment for each 
tumor type (NSCLC, CRC) will be based on DLRT recommendations and Amgen's 
internal decision.  
The rationale for the number of subjects is provided in Section 10.2.
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3.4 Estimated Study Duration
3.4.1 Study Duration for Subjects
Subjects be on study for approximately 4 years: 28-day screening, 6 to 12 months 
on treatment, and 3 years of long-term follow up.
3.4.2 End of Study
Primary Completion: The primary completion date is defined as the date when the last
subject is assessed or receives an intervention for the final collection of data for the
primary endpoint(s), whether the study was conducted as planned in the protocol or was 
terminated early.  The primary completion date is the date when the last subject is 
assessed or receives an intervention for the final collection of data for the primary 
endpoint of Phase 2.
End of Study: The end of study date is defined as the date when the last subject across 
all sites is assessed or receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study (eg, long-term follow-up), as 
applicable.
4. SUBJECT ELIGIBILITY
4.1 Inclusion Criteria
101. Subject has provided informed consent prior to initiation of any study
specific activities/procedures
102. Men or women 18 years old
103. Pathologically documented, locally-advanced or metastatic malignancy
with KRAS p.G12C mutation identified through molecular testing. For 
phase 2, the mutation will be confirmed by central testing prior to 
enrollment.
a. For NSCLC:
Phase 1 subjects must have received platinum-based combination 
therapy AND/OR targeted therapies (ie, if molecular testing has identified 
mutations in EGFR, ALK, or proto-oncogene tyrosine-protein kinase ROS 
[ROS1] or expression of programmed death-ligand [PD-L1]), prior to 
receiving AMG 510.  
Phase 2 subjects must have progressed after receiving anti-PD1 or 
anti-PD-L1 immunotherapy (unless contraindicated) AND/OR 
platinum-based combination chemotherapy AND targeted therapy (if 
actionable oncogenic driver mutations were identified [ie, EGFR, 
ALK, and ROS1]).  Subjects must have received no more than 3 prior 
lines of therapy.
b. For CRC:
Phase 1 subjects must have received at least 2 prior systemic regimens 
in the metastatic setting. For those CRC subjects with tumors that are 
MSI-H, at least 1 of the prior systemic regimens must be treatment with 
either nivolumab or pembrolizumab if they were clinically able to receive 
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inhibitors and 1 of these agents is approved for that indication in the 
region or country. 
Phase 2 subjects must have progressed after receiving 
fluoropyrimidine AND oxaliplatin AND irinotecan.  For those CRC 
subjects with tumors that are MSI-H, at least 1 of the prior systemic 
regimens must have included an anti-PD1 therapy if they were 
clinically able to receive inhibitors and 1 of these agents is approved 
for that indication in the region or country.
c. For advanced solid tumor types other than NSCLC or CRC, subjects 
must have received at least one prior systemic therapy or be intolerant or 
ineligible for available therapies known to provide clinical benefit.
104. Subjects willing to provide archived tumor tissue samples (formalin fixed,
paraffin embedded [FFPE] sample collected within 5 years) or willing to 
undergo pretreatment tumor biopsy.  Phase 1 subjects and phase 2 
subjects with tumor types other than NSCLC or CRC with prior 
molecularly confirmed KRAS p.G12C mutation who do not have archived 
tissue available can be allowed to enroll without undergoing tumor biopsy 
upon agreement with investigator and the Medical Monitor if a tumor 
biopsy is not feasible.
122. Subjects who have lesions that can be feasibly biopsied will be asked to 
undergo an optional biopsy at the time of tumor progression.
106. Measurable disease per RECIST 1.1 criteria (Appendix D).
107. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
(phase 1) or  1 (phase 2)
108. Life expectancy of > 3 months, in the opinion of the investigator
109. Ability to take oral medications and willing to record daily adherence to 
investigational product utilizing a sponsor-provided dosing diary
110. QTc ≤ 470 msec (based on average of screening triplicates)
111. Adequate hematological laboratory assessments, as follows:
 Absolute neutrophil count (ANC) 1.5 x 109/L
 Platelet count 75 x 109/L
 Hemoglobin ≥ 9 g/dL (90 g/L)
112. Adequate renal laboratory assessments, as follows:
 Estimated glomerular filtration rate based on MDRD (Modification of Diet
in Renal Disease) calculation 60 ml/min/1.73 m2
113. Adequate hepatic laboratory assessments, as follows:
 Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN) (if liver
metastases are present,  5 x ULN)
 Alanine aminotransferase (ALT) < 2.5 x ULN (if liver metastases are present,
5 x ULN)
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 Total bilirubin < 1.5 x ULN (< 2.0 x ULN for subjects with documented
Gilbert’s syndrome or < 3.0 x ULN for subjects for whom the indirect
bilirubin level suggests an extrahepatic source of elevation)
114. Adequate coagulation laboratory assessments, as follows:
 Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x ULN,
OR International normalized ratio (INR) < 1.5 or within target range if on
prophylactic anticoagulation therapy
Optional Food Effect Assessment – Specific Inclusion Criteria
115. Subject able to eat a standardized high-fat, high-caloric meal within
25 minutes
116. Subject able to fast for ≥ 10 hours
117. Subject able to handle collection of his/her urine over a 24-hour period.
Non-small Cell Lung Cancer – Specific Inclusion Criteria
118. Pathologically documented, definitively diagnosed KRAS p.G12C mutant
NSCLC
 
Colorectal Cancer – Specific Inclusion Criteria
119. Pathologically documented, and definitively diagnosed KRAS p.G12C
mutant CRC
Other Solid Tumor Types – Specific Inclusion Criteria
120. Pathologically documented, definitively diagnosed, KRAS p.G12C mutant
advanced solid tumor
4.2 Exclusion Criteria
201. Active brain metastases from non-brain tumors. Subjects who have had
brain metastases resected or have received radiation therapy ending at
least 4 weeks prior to study day 1 are eligible if they meet all of the
following criteria: a) residual neurological symptoms grade ≤ 2; b) on
stable doses of dexamethasone, if applicable; and c) follow-up MRI 
performed within 30 days shows no new lesions appearing
202. History or presence of hematological malignancies unless curatively
treated with no evidence of disease 2 years
203. Myocardial infarction within 6 months of study day 1, symptomatic
congestive heart failure (New York Heart Association > class II), unstable
angina, or cardiac arrhythmia requiring medication
204. Gastrointestinal (GI) tract disease causing the inability to take oral
medication, malabsorption syndrome, requirement for intravenous
alimentation, uncontrolled inflammatory GI disease (eg, Crohn’s disease,
ulcerative colitis)
205. Active infection requiring IV antibiotics within 1 weeks of study enrollment 
(day 1)
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206. Exclusion of hepatitis infection based on the following results and/or 
criteria:  
 Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic 
Hepatitis B or recent acute hepatitis B)
 Negative HepBsAg with a positive for hepatitis B core antibody (Hepatitis B 
core antibody testing is not required for screening, however if this is done and 
is positive, then hepatitis B surface antibody [Anti-HBs] testing is necessary.  
Undetectable anti-HBs in this setting would suggest unclear and possible 
infection, and needs exclusion).
 Positive Hepatitis C virus antibody:  Hepatitis C virus RNA by PCR is 
necessary.  Detectable Hepatitis C virus RNA suggests chronic hepatitis C
207. Known positive test for HIV
208. Unresolved toxicities from prior anti-tumor therapy, defined as not having
resolved to CTCAE version 5.0 grade 0 or 1, or to levels dictated in the
eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities
from prior anti-tumor therapy that are considered irreversible [defined as
having been present and stable for > 6 months], such as ifosfamide
related proteinuria, may be allowed if they are not otherwise described in
the exclusion criteria AND there is agreement to allow by both the 
investigator and sponsor)
209. Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted
therapy, retinoid therapy, hormonal therapy [except for subjects with
breast cancer], or investigational agent) within 28 days of study day 1;
concurrent use of hormone deprivation therapy for hormone-refractory
prostate cancer or breast cancer is permitted
210. Therapeutic or palliative radiation therapy within 2 weeks of study day 1.  
Subjects must have recovered from all radiotherapy related toxicity.
211. Currently enrolled in another investigational device or drug study, or less
than 28 days since ending another investigational device or drug study(s),
or receiving other investigational agent(s)
212. Other investigational procedures are excluded
214. Major surgery within 28 days of study day 1
215. Monotherapy with AMG 510: Men and women of childbearing 
potential (WOCBP) who are unwilling to practice acceptable
methods of birth control during treatment and for at least 37 days
(women) or 97 days (men) after receiving the last dose of AMG 510.
Acceptable methods of highly effective birth control for women 
include sexual abstinence (refraining from heterosexual
intercourse); vasectomy (women with a single male sexual partner) 
with testing showing there is no sperm in the semen; bilateral tubal
ligation or occlusion; or intrauterine device.  Acceptable methods of
birth control for men include sexual abstinence (refraining from
heterosexual intercourse); vasectomy with testing showing there is 
no sperm in the semen; bilateral tubal ligation or occlusion in the 
partner; or a condom (the female partner should also consider a form 
of birth control).  
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Note:  A woman is considered of childbearing potential (WOCBP), ie, 
fertile, following menarche and until becoming postmenopausal 
unless permanently sterile.  Permanent sterilization methods include 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.  
A postmenopausal state is defined as no menses for 12 months 
without an alternative medical cause.  A high follicle stimulating 
hormone level in the postmenopausal range may be used to confirm 
a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy.  However, in the 
absence of 12 months of amenorrhea, a single follicle stimulating 
hormone measurement is insufficient.
216. Women who are lactating/breast feeding or who plan to breastfeed while
on study through 37 days  
 after receiving the last dose of study drug.
217. Women with a positive pregnancy test.
218. Women planning to become pregnant while on study through 37 days  
 after
receiving the last dose of study drug
219. Subject has known sensitivity to any of the products to be administered
during dosing
220. Subject will not be available for protocol-required study visits or
procedures, to the best of the subject and investigator’s knowledge
221. Subject has any kind of disorder that, in the opinion of the investigator,
may compromise the ability of the subject to give written informed consent
and/or to comply with all required study procedures
222. History or evidence of any other clinically significant disorder, condition or
disease (with the exception of those outlined above) that, in the opinion of
the investigator or Amgen physician would pose a risk to subject safety or
interfere with the study evaluation, procedures or completion
223. Use of known cytochrome P450 (CYP) 3A4 and MATE1 sensitive
substrates (with a narrow therapeutic window), within 14 days or
5 half-lives of the drug or its major active metabolite, whichever is longer,
prior to study day 1 that was not reviewed and approved by the principal
investigator and the Amgen medical monitor
224. Use of strong inhibitors of CYP3A4 or P-gp (including herbal supplements 
such as Goldenseal) within 14 days or 5 half-lives (whichever is longer) or
grapefruit juice or grapefruit containing products within 7 days prior to 
study day 1 that was not reviewed and approved by the principal
investigator and the Amgen medical monitor.
225. Use of strong inducers of CYP3A4 (including herbal supplements such 
as St. John’s wort) within 14 days or 5 half-lives (whichever is longer) 
prior to study day 1 that was not reviewed and approved by the principal
investigator and the Amgen medical monitor.
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227. History of other malignancy within the past 2 years, with the following 
exceptions:
 Malignancy treated with curative intent and with no known active 
disease present for ≥ 2 years before enrollment and felt to be at low 
risk for recurrence by the treating physician.
 Adequately treated non-melanoma skin cancer or lentigo maligna 
without evidence of disease.
 Adequately treated cervical carcinoma in situ without evidence of 
disease.
 Adequately treated breast ductal carcinoma in situ without evidence of 
disease.
 Prostatic intraepithelial neoplasia without evidence of prostate cancer.
 Adequately treated urothelial papillary non-invasive carcinoma or 
carcinoma in situ.
228. Previous treatment with a KRASG12C inhibitor 
5. SUBJECT ENROLLMENT
Before subjects begin participation in any study-specific activities/procedures, Amgen
requires a copy of the site’s written institutional review board/independent ethics
committee (IRB/IEC) approval of the protocol, informed consent form (ICF) (see
Section 11.2). All subjects or legally acceptable representatives must personally sign 
and date the ICF before commencement of study-specific activities/procedures.
Subject is considered enrolled when the investigator decides that the subject has 
met all eligibility criteria.  The investigator decision and date of enrollment must 
be documented in the subject’s medical records.
The Investigator is to document the enrollment decision and date, in the subject’s
medical record and in/on the enrollment case report form (CRF).
Each subject who enters into the screening period for the study receives a unique
subject identification number before any study procedures are performed. 
For phase 1, the subject identification number will be assigned manually and for 
phase 2, the subject identification number will be assigned by Interactive Voice 
Response System (IVRS)/Interactive Web Response System (IWRS).  The subject 
identification number must remain constant throughout the entire clinical study; it must 
not be changed after initial assignment, including if a subject is rescreened.
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5.1 Treatment Assignment
An Amgen representative will notify the site in writing when a cohort is open to screen
new subjects.
All screening tests and procedures must be performed within 28 days of study day 1,
unless specified otherwise in the study procedures listed in Section 7. For phase 1 only, 
once the site has established subject eligibility, a site representative will submit (via 
email) a completed subject Eligibility Worksheet to an Amgen representative. This will 
not be required for phase 2. The Amgen representative will acknowledge receipt of the 
paperwork and assign the AMG 510 dose level to confirm enrollment for that individual 
subject. The investigator or designee is responsible for ensuring that confirmation of
enrollment from Amgen (including subject number, dose assignment and enrollment
date) has been received prior to administration of study medication on day 1
The treatment assignment date is to be documented in the subject’s medical record and
on the enrollment CRF.
To acquire additional safety, efficacy, PK, and pharmacodynamic data to better fully
inform the RP2D, an additional 20 to 40 subjects may be enrolled in one or more dose 
levels that have been shown to be safe and tolerable. Intra-subject dose escalations
are allowed for these additional subjects. When the subject completes the DLT period 
the subject may proceed to a higher dose level for the following treatment cycle once the 
next dose cohort has been deemed safe by the DLRT and after consultation with the
sponsor as described in Section 3.1. For subjects participating in food effect 
assessment, intra-subject dose escalation should not occur for at least 5 days before or
during the food effect assessment.
6. TREATMENT PROCEDURES
AMG 510 is the Amgen investigational product used in this study.
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6.1 Investigational Product
6.1.1 Amgen Investigational Product AMG 510
AMG 510 for phase 1 will be manufactured both by Amgen Inc. and Patheon.  
AMG 510 for phase 2 will be manufactured by Patheon.  AMG 510 for both phases 
will be packaged and distributed by Amgen Inc., using Amgen clinical study drug 
distribution procedures.  AMG 510 will be provided as 30 mg and 120 mg tablets and
will be packaged in bottles of 30 tablets. A diary will be provided for subjects to record
their adherence to the oral medication.
6.1.1.1 Dosage, Administration, and Schedule
AMG 510 will be administered orally once or twice daily [BID]), depending on what 
phase and/or cohort of the study that the subject is enrolled.  No drug holidays are 
allowed. The effects of overdose of AMG 510 are not known. AMG 510 will be 
dispensed at the research facility by a qualified staff member. Subjects are required to
take AMG 510 at the research facility on clinic visit days as described in Table 2. 
Subjects will take AMG 510 at home on non-clinic visit days. AMG 510 must be
administered in the fasted state (no food or liquids, except water, 2 hours before to
1 hour after dosing). On PK days (eg, cycle 1 day 1, cycle 1 day 8, and cycle 2 day 1 for 
Phase 1), subjects should eat a standard meal at least 2 hours before dosing. Subjects
may eat the standard meal at home before clinic visit or in clinic.  
Subject should take the AMG 510 dose at approximately the same time(s) every day. 
The AMG 510 dose should also not be taken more than 2 hours earlier than the 
scheduled time.  A dose of AMG 510 can be replaced in the event of vomiting if the 
vomiting occur within 15 minutes of the dosing, all tablets administered have been 
accounted for (eg, 4 tablets must be collected if 4 tablets were administered) and are 
intact by visual inspection (not broken, partially dissolved, chewed, or crushed).  
Subjects who receive AMG 510 once daily, should skip the AMG 510 dose if 
6 hours have passed from the scheduled time of dosing.  If a subject is enrolled to 
a twice daily (BID) cohort, doses should be taken approximately every 12 hours.  
For BID dosing, a subject should skip the AMG 510 if 2 hours have passed from 
the scheduled time of dosing.
The planned dose, start date/time, stop date, quantity administered, unit, planned 
frequency, reason for dose change/withheld, package lot number of AMG 510 are
to be recorded on each subject's CRF(s).
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6.1.1.1.1 Food Effect Assessment Only
Subjects participating in the food effect assessment will receive AMG 510 in the fasted
state on day 1 and fed state on day 2. Subjects in the fasted state will receive AMG 510
on an empty stomach (no food or liquids, except water) following an overnight fast of
≥ 10 hours at home prior to clinic visit for dosing. Subjects will receive AMG 510 with
approximately 240 mL (8 ounces) of water. Water can be allowed as desired except for
1 hour before and 1 hour after AMG 510 administration. No food or liquid (except water)
will be allowed for at least 3 hours post-dose. Subjects in fed state will be fasted
overnight for at least 10 hours prior to consuming a high fat meal preferably in the clinic.
Subjects should start the recommended meal approximately 0.5 hours prior to dose
administration. Subjects should consume the entire meal in 25 minutes or less.
AMG 510 should be administered approximately 30 minutes after the start of the meal
with approximately 240 mL (8 ounces) of water. Water can be allowed as desired except
for 1 hour before and 1 hour after AMG 510 administration. No food or liquid (except
water) will be allowed for at least 3 hours post dose. See specific assessments for food
effect assessment in Table 3.
6.1.1.2 Dose-cohort Escalation and Stopping Rules (for Phase 1 Only)
After all DLT-evaluable subjects within a cohort have completed the DLT window, a
Dose Level Review Meeting (DLRM) will be held to review data, monitor safety, and 
recommend dose change decisions. The DLRT will be composed of the investigators,
Amgen Medical Monitor, Amgen Global Safety Officer, Amgen Early Clinical 
Development Manager, and Biostatistics representative. Additional members may be 
added as needed (eg, PK Scientist). A quorum, defined as the majority of actively
screening and enrolling investigators or their qualified designee (ie, sub-investigator 
possessing hard copy documentation [eg, email] of the investigator’s decision regarding 
the dose level review), must be in attendance for DLRM to proceed. The DLRM will be 
rescheduled if a quorum is not reached.
Voting members of the DLRM will include the Amgen medical monitor, the Amgen global
safety officer, and all actively screening and enrolling investigators or their qualified
sub-investigator designee. The team may recommend escalation to the next planned
dose, escalation to an intermediate dose (a dose lower than the next planned dose), 
continuation or delay in dosing, repetition or expansion of a cohort, de-escalation to a 
lower dose, or termination of the study. This same team will be responsible for reviewing 
data in the dose expansion phase to confirm the RP2D and determine the benefit/risk of 
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proceeding to the phase 2 part of the study.  The Amgen medical monitor and Global 
Safety Officer and the majority of actively screening and enrolling investigators
participating in the DLRM must cast a positive vote indicating an acceptable safety
profile was observed for AMG 510 to allow the dose level modification and/or cohort
continuation/expansion to proceed. All available study data including demographics, 
smoking status (prior and current), medical history, concomitant medications, adverse 
events, ECGs, vital signs, laboratory results, emerging PK or pharmacodynamics, and 
emerging efficacy data will be reviewed. Data to be reviewed may be unqueried.
The dosing schedule is described by a schema in the protocol synopsis.
6.1.1.2.1 DLT Definition
A DLT is defined as any adverse event meeting the criteria listed below occurring during
the first treatment cycle of AMG 510 (day 1 through day 21) where relationship to
AMG 510 cannot be ruled out.
The grading of adverse events will be based on the guidelines provided in the CTCAE 
version 5.0. A DLT is defined as any of the following events during the first treatment 
cycle and attributable to AMG 510:
 Hematological toxicity
 Febrile neutropenia
 Neutropenic infection
 Grade 4 neutropenia
 Grade ≥ 3 thrombocytopenia for > 7 days
 Grade 3 thrombocytopenia with grade ≥ 2 bleeding
 Grade 4 thrombocytopenia
 Grade 4 anemia
 Non-hematological toxicity
 Grade ≥ 4 vomiting or diarrhea
 Grade 3 diarrhea or grade 3 vomiting lasting more than 3 days despite optimal 
medical support
 Grade ≥ 3 nausea for 3 days or more despite optimal medical support
 Any other grade ≥ 3 adverse event
DLT-evaluable is defined as completion of 80% of AMG 510 doses within the first 
treatment cycle (ie, 21 days). A subject who experience a DLT within the first cycle is 
DLT evaluable regardless of number of doses taken. If a subject is withdrawn from 
study for any reason other than a DLT prior to completion of the 21-day safety 
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observation period, a replacement subject will be assigned the same dose as the 
replaced subject.  
6.1.1.3 Dosage Adjustments, Delays, Rules for Withholding or Restarting,
Permanent Discontinuation
Subjects experiencing any treatment-related toxicity meeting the DLT definition will not
receive additional AMG 510 treatment and will be followed until resolution of the event or
toxicity. Subjects will be withdrawn from AMG 510 treatment and will be treated as
deemed appropriate by the investigator or treating physician. In subjects with a 
favorable response to treatment, an option to continue at the same dose level or 1 dose 
level below that which the toxicity occurred can be considered. If deemed appropriate 
by the investigator in conjunction with the sponsor, AMG 510 treatment can resume 
once any non-hematological toxicity returns to the subject’s baseline value or grade ≤ 1
and subject meets the following hematological requirements: ANC ≥ 1.0 x 109/L, platelet
count ≥ 75 x 109/L and hemoglobin ≥ 9 g/dL. Subjects must not have received a platelet
transfusion for at least 7 days prior to assessing if re-exposure to AMG 510 can occur.
If a subject is noted to have ≥ grade 3 thrombocytopenia, grade 4 neutropenia, grade 4
anemia, grade 4 leukocytosis, or ≥ grade 3 non-hematological toxicity attributable to
AMG 510 at any point during study treatment, AMG 510 administration will be stopped
immediately. A repeat blood collection for hematology is to be performed within 3 days.
AMG 510 treatment can resume once subjects meet the following hematological
requirements: ANC ≥ 1.0x 109/L, platelet count ≥ 75 x 109/L and hemoglobin ≥ 9 g/dL,
leukocytosis < grade 3 and the non-hematological toxicity returns to the subject’s
baseline value or grade ≤ 1. Subjects requiring more than 2 weeks to recover from
grade ≥ 3 toxicities will be permanently discontinued from the study treatment.
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6.3 Hepatotoxicity Stopping and Rechallenge Rules (for Phase 1 and 
Phase 2)
Refer to Appendix F for details regarding drug-induced liver injury guidelines, as 
specified in the Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009. 
6.4 Prior Therapies
Prior anticancer therapies must date back to the original diagnosis and will be 
collected through enrollment on the appropriate eCRF.  For prior anticancer
therapies collect line of therapy, regimen/agent, type of therapy, setting, start
date, stop date, reason for stopping therapy, dose, unit, route, frequency, best 
response, date of best response, and date of progression documented.  For prior 
radiotherapy for current malignancy, collect body site, sub site, setting, type, start 
date, stop date, total dose, unit, best response, was chemotherapy part of 
concurrent therapy, did documented progression occur in this area, date 
progression documented.  For prior surgeries for current malignancies collect 
date of surgery, surgery, reason for surgery, body site, subsite, intent of surgery, 
residual disease.
All other prior therapies that were being taken 28 days before enrollment through 
enrollment should be collected on each subject’s eCRF(s).  Collect therapy name, 
indication, dose, unit, frequency, route, start date and stop date.
6.5 Concomitant Therapy (for Phase 1 and Phase 2)
Throughout the study, Investigators may prescribe any concomitant medications or
treatments deemed necessary to provide adequate supportive care except for those
listed in Section 6.5.
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Concomitant use of MATE1 substrates with AMG 510 may result in increase in systemic
concentrations of a MATE1 substrate as AMG 510 has a potential to inhibit MATE1.  
Gastric acid controllers may reduce the exposure to AMG 510. Consider the risks and
benefits of concomitant use. Monitor subjects receiving a MATE1 substrate or gastric
acid controller with AMG 510.
In the phase 1 part of the study, Amgen will review all concomitant medications with the 
investigators prior to dosing with AMG 510 to ensure patient safety.
Concomitant therapies are to be collected from enrollment through the end of 
safety follow-up period.
For concomitant therapies, collect therapy name, indication, dose, unit, frequency, 
route, start date and stop date. 
6.6 Product Complaints (for Phase 1 and Phase 2)
A product complaint is any written, electronic or oral communication that alleges
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or
performance of a drug(s) or device(s) after it is released for distribution to market or clinic
by either Amgen or by distributors and partners for whom Amgen manufactures the
material.
This includes any drug(s), device(s), or combination product(s) provisioned and/or
repackaged /modified by Amgen. Drug(s) or device(s) includes investigational product.
Any product complaint(s) associated with an investigational product(s) or
non-investigational product(s) or device(s) supplied by Amgen are to be reported
according to the instructions provided in the IPIM.
6.7 Excluded Treatments, Medical Device Use, and/or Procedures
During Study Period (for Phase 1 and Phase 2)
The following medications and supplements to be avoided for 14 days prior to enrollment 
and during the study period unless reviewed and approved by the principal investigator 
and the Amgen medical monitor:
 Known strong inhibitors of cytochrome P450 (CYP) 3A4 or P-gp including herbal 
supplements such as Goldenseal and grapefruit juice or other grapefruit containing 
products
 Known strong inducers of cytochrome P450 (CYP) 3A4 including herbal 
supplements, such as St. John’s wort
 Known cytochrome P450 (CYP) 3A4 and MATE1 sensitive substrates with a narrow 
therapeutic window
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If a subject needs palliative radiotherapy for pain control during the course of the study, 
all study drugs should be discontinued, and the investigator or designee should notify 
the sponsor as soon as possible.  A subject may be allowed to resume study drug after 
discussion between the Amgen medical monitor and the investigator to determine the 
appropriateness of treatment resumption.
Subjects must not schedule any major elective surgeries during the treatment period, 
and for at least 28 days after the last administration of AMG 510.  Minor elective surgery 
may be allowed after discussion with the Amgen medical monitor.  If a subject 
undergoes any unexpected surgery during the course of the study, all study drugs must 
be discontinued, and the investigator or designee should notify the sponsor as soon as 
possible.  A subject may be allowed to resume AMG 510  
 only if both the investigator and Amgen medical monitor agree to restart 
study therapy.
7. STUDY PROCEDURES
7.1 Schedule of Assessments
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Table 2.  Schedule of Assessment:  Phase 1 Part 1 Dose Exploration and Part 2 Dose Expansion 
 
 Screena Treatment EOTb SFU LTFU
 
Cycle  1 2 3,5 4,6 QC Q2C    
 Day -28 to 1 1 2 8 9 15 1 8 1 1 1 1    
Hours (relative to 
dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 pre 0 0.25 0.5 1      
   
GENERAL & SAFETY 
Informed consent X                                    
Eligibility criteria X                                    
Demographics X                                    
Medical history & 
height 
X                                    
Smoking status X                                    
Physical exam & 
weight 
X X          X          X  X      X X X   X  
ECOG X X                      X      X X X  X X  
Vital signs X X  X X X X X X X  X  X X X X X X X  X  X  X X  X X X X   X  
ECGc X X  X X X X X X X  X  X X X X X X X  X  X  X X   X X X   X  
Prior therapies X                                    
Anticancer therapy                                   X X 
Con medications  X ===========================================================================================  
Adverse events   ===========================================================================================  
Serious adverse 
 
===================================================================================================== 
Page 1 of 3 
Footnotes defined on last page of the table 
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Table 2.  Schedule of Assessment:  Phase 1 Part 1 Dose Exploration and Part 2 Dose Expansion 
 Screena
 
Treatment EOTb SFU LTFU 
Cycle  1 2 3,5 4,6 QC Q2C 
   
 Day -28 to 1 1 2 8 9 15 1 8 1 1 1 1    
Hours (relative to 
dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 pre 0 0.25 0.5 1      
   
Patient diaries   ===================================================================================
 
   
Laboratoryd 
Chemistry X X      X  X  X        X  X  X     X X X X     
HbA1c X                                    
Hematology X X      X  X  X        X  X  X     X X X X     
Coagulation X X      X  X  X        X  X  X     X X X X     
Urinalysise X X        X  X          X  X      X X X     
Serum pregnancy testf X                                  X  
Urine pregnancy testf  X                      X      X X X     
HIV X                                    
Hepatitis serology X                                    
DOSING 
AMG 510g   =====================================================================================    
   
 
   
IMAGING ASSESSMENTS 
Radiological imaging 
(CT/MRI) and tumor 
assessmenti 
X                             Xi   Xi Xi  (X)j 
MRI braink X                                    
Page 2 of 3 
Footnotes defined on last page of the table 
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Table 2.  Schedule of Assessment:  Phase 1 Part 1 Dose Exploration and Part 2 Dose Expansion 
 Screena Treatment EOTb SFU LTFU 
Cycle  
 
2 3,5 4,6 QC Q2C     1 
 
 Day -28 to 1 1 2 8 9 15 1 8 1 1 1 1    
Hours (relative to 
dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 pre 0 0.25 0.5 1         
PK ASSESSMENTS 
AMG 510 PKl  X X X X X X X X X  X  X X X X X X X    X  X X X  X   X    
BIOMARKER SAMPLES 
Tumor markers at 
sitem 
 (X) 
 
 
 
  
Cell pellet from 
plasman 
 
X                                   
Plasma ctDNAo 
 
 X          X            X      X X X  X   
Serum  X          X            X      X X X  X   
PB Paxgene RNA  
X          X            X      X X X  X   
Stool samplep  X                                X   
BIOMARKER DEVELOPMENT 
Tumor biopsy 
(optional, as 
applicable) or 
archived tumor 
tissue (FFPE) for 
solid tumors 
Xq                 (X)r                (X)r   
Page 3 of 3 
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BID = twice daily; CNS = central nervous system; Con = concomitant; CT =computed tomography; cfDNA = cell-free DNA; ECG = electrocardiogram; 
ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; FFPE = formalin-fixed paraffin-embedded; HbA1c = hemoglobin A1c; LTFU = long-term 
follow-up; MRI = magnetic resonance imaging; NSCLC = non-small cell lung carcinoma; PD-L1 = programmed cell death-1; PET = positron emission tomography; 
PB = peripheral blood; PK = pharmacokinetic(s); QC = every cycle from cycle 7 and beyond (cycles 7, 8, 9, etc), Q2C = every other cycle from cycle 7 and beyond 
(cycles 7, 9, 11 etc); Screen = screening; SFU = safety follow-up.
(X) = Parentheses indicate that the particular test is situational at that time point, as specified in the respective notes. 
a KRAS p.G12C testing results must be available prior to starting all other screening procedures; PD-L1 testing in NSCLC for Part 1c and 2c.
b For subjects who discontinue investigational product, the EOT visit should occur as soon as possible (within 14 days) after the last dose of 
investigational product. 
c Three triplicate ECGs must be performed at screening.  For all other visits, one triplicate ECG must be performed.  Each tracing must be at least 30 seconds 
apart.
d Assessments to be performed on day 1 of each cycle.  Laboratory assessments may be performed within 24 hours before day 1 of each cycle.  A window of ± 1 day 
is allowable for cycle 1 and cycle 2.  A window of ± 2 days is allowable after cycle 2.  Electrocardiograms, biomarker blood draws, safety labs, vital signs (including 
pulse oximetry): ± 5-minute window (for time points of 0.25 hr and 0.5 hr postdose), ± 15-minute window (all other time points).  
e Microscopic exam required to be performed with each time point collected.
f For women of childbearing potential only (defined in Criterion 215 in Section 4.2).
g AMG 510 will be administered daily on a repeated basis with no planned off treatment days.  AMG 510 must be administered in the fasted state (no food or liquids, 
except water, 2 hours before to 1 hour after dosing).  
i Radiological imaging and tumor assessments are required at screening and every 6 1 weeks.  After four 6-week response assessments, radiological imaging and 
tumor assessments will be performed every 12 ± 1 weeks.  Imaging and tumor assessments will continue until disease progression, start of new anticancer treatment, 
death, withdrawal of consent, or until end of study.  MRI/CT scans can be obtained earlier if clinical deterioration necessitates an earlier scan at the discretion of the 
managing physician.  End of treatment CT/MRI should be performed only for subjects that discontinue treatment for a reason other than disease progression per 
RECIST 1.1 criteria.  Every assessment must include the chest, abdomen, pelvis, and all other known sites of disease.  Tumor burden assessments will be performed 
based on RECIST 1.1 guidelines (Appendix D).  Radiographic response (CR and PR) requires confirmation by a repeat consecutive assessment 4 weeks after the first 
detection of response.
j For subjects who discontinued study treatment without confirmed disease progression or start of subsequent anticancer treatment, tumor assessments 
will continue during LTFU every 12 weeks (± 2 weeks) for up to 3 years after last subject enrolled or until confirmed disease progression, start of 
subsequent anticancer treatment, death, withdrawal of consent, loss to follow-up, or end of study.  
k All subjects with history of brain metastases must have MRI of the brain performed within 28 days prior to enrollment.  Only if MRI is contraindicated, then CT with 
contrast is acceptable.  Subsequently, MRI brain scans can be performed at any time if clinically indicated or per standard of care.  Any additional imaging used to 
evaluate or determine response (eg, PET, CT/PET, bone scan, etc) should be sent along with the required imaging to the central imaging vendor promptly upon 
completion.
l Pharmacokinetic blood samples should be collected at the exact nominal time point as noted above (see hour postdose column).  If unable to collect a blood sample 
at the specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  Pharmacokinetic samples not 
collected at exact nominal time point will not be considered protocol deviations.  Pharmacokinetic samples collected in cycle 3 and beyond should be performed prior to 
AMG 510 dosing.  
m Tumor markers will be performed as per standard of care and reported on the applicable eCRF.
n Cell pellet will be used for pharmacogenetics analysis in subjects who consent.
o Plasma ctDNA is to be collected as indicated in the Schedule of Assessments, and at response.
p Stool samples collected predose (-3 days) and at EOT ( 3 days).  
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q Subjects should provide archived FFPE samples (collected within 5 years) or undergo tumor biopsy for exploratory analysis and which may include KRAS p.G12C 
mutation testing if local results are not available.  PD-L1 testing will also be performed prior to enrollment for parts 1c and 2c. 
r After enrollment, optional tumor biopsy will be performed for subjects who consent to this assessment.  It will be performed, if feasible, on cycle 1 day 8 at 
least 4 hours (± 2 hours) after dosing, at response, and at the EOT.   
Table 3.  Schedule of Assessment:  Phase 1 Part 1a or Part 2a Food Effect Assessment Only 
 Treatment 
Cycle 2 or later 
Day 1 2 3 
Hours (relative to dosing)a pre 0 0.25 0.5 1 2 4 6 pre 0 0.25 0.5 1 2 4 6 pre 0 
DOSING 
AMG 510b  X        X        X 
PK ASSESSMENT 
AMG 510 PKc X  X X X X X X X  X X X X X X X  
RENAL EXCRETION ASSESSMENT 
Urine X (0 to 6 hours) X          
PK = pharmacokinetic(s). 
a Refer to Table 2 for assessments other than for dosing and PK and renal assessments on days 1 to 3. 
b Subjects will be administered AMG 510 on day 1 in the fasted state (no food 10 hours before dosing and 3 hours after dosing) and on day 2 in the fed state (dosing 
with a high fat meal).  On day 3, AMG 510 can be administered with or without food per subject discretion. 
c Pharmacokinetic blood samples should be collected at the exact nominal time point as noted above (see hour postdose column).  If unable to collect a blood sample 
at the specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  Pharmacokinetic samples not 
collected at exact nominal time point will not be considered protocol deviations. 
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Table 4.  Pharmacokinetic Schedule of Assessment:  Phase 1 Part 1b Dose Exploration (BID dosing only)
Screening Treatment EOT
1 2 3,5a Q2C
Day -28 to 1 1 2 8 9 1 1 1
Hours (relative to dosing)a pre 0 0.25 0.5 1 2 4 6 12 pre 0 pre 0 0.25 0.5 1 2 4 6 12 pre 0 pre 0 0.25 0.5 1
DOSING
AMG 510b X X X X X X X X X
PK ASSESSMENTS
AMG 510 PKc X X X X X X X X X X X X X X X X X X X X X X X X
BID = twice daily; EOT = end of therapy; PK = pharmacokinetic(s); Q2C = every other cycle from cycle 7 and beyond (cycles 7, 9, 11 etc).
a Refer to Table 2 for assessments other than for PK.
b AMG 510 will be administered twice-daily on a repeated basis with no planned off treatment days.  AMG 510 must be administered in the fasted state (no food or 
liquids, except water, 2 hours before to 1 hour after dosing).  On PK days (eg, cycle 1 day 1, cycle 1 day 8, and cycle 2 day 1), subjects should eat a standard meal at 
least 2 hours before dosing.    
c Pharmacokinetic blood samples should be collected at the exact nominal time point as noted above (see hour postdose column). If unable to collect a blood sample 
at the specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  Pharmacokinetic samples not 
collected at exact nominal time point will not be considered protocol deviations.  Pharmacokinetic samples collected in cycle 3 and beyond should be performed prior 
to AMG 510 dosing.  
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Table 5.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 1 Treatment 
 Screeninga Treatment 
Cycle  1 
Day -28 to 1 1 2 8 9 15 
Hours (relative to dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 
GENERAL & SAFETY 
Informed consent X                       
Eligiblity criteria X                       
Demographics X                       
Medical history & height X                       
Smoking status X                       
Physical exam & weight X X          X          X  
ECOG X X                      
Vital signs X X        X  X          X  
ECG (Group A)b, c X X  X X X X X X X  X  X X X X X X X  X  
ECG (Group B)b, c X X    X      X            
Prior therapies X                       
Anticancer therapy                        
Con medications X X ===================================================================================== 
Adverse events  ========================================================================================= 
Serious adverse events ================================================================================================== 
Patient diaries   =================================================================================== 
Page 1 of 4 
Footnotes defined on last page of Table 6. 
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Table 5.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 1 Treatment 
 Screening Treatment 
Cycle  1 
Day -28 to 1 1 2 8 9 15 
Hours (relative to dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 
Patient-reported Outcomes 
EORTC QLQ C30  X                      
QLQ LC13  X                      
NSCLC SAQ  X                      
QLQ PAN26  X                      
PRO-CTCAE  X                      
EQ-5D-5L  X                      
GP5 FACT-G  X                      
Laboratoryd 
Chemistry X X          X          X  
HbA1c X                       
Hematology X X          X          X  
Coagulation X X          X          X  
Urinalysise X X          X          X  
Serum pregnancy testf X                       
Urine pregnancy testf  X                      
HIV X                       
Hepatitis serology X                       
Page 2 of 4 
Footnotes defined on last page of Table 6. 
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Table 5.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 1 Treatment 
 Screening Treatment 
Cycle  1 
Day -28 to 1 1 2 8 9 15 
Hours (relative to dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 
DOSING 
AMG 510g   ===================================================================================== 
IMAGING ASSESSMENTS 
Radiological imaging, 
(CT/MRI) and tumor 
assessmenth 
X                       
MRI braini X                       
PK ASSESSMENTS 
AMG 510 PK (Group A)i  X X X X X X X X X  X  X X X X X X X    
AMG 510 PK (Group B)i  X    X  X                
BIOMARKER SAMPLES 
Tumor markers at sitek  (X) 
Plasma ctDNAl  X          X            
Cell pellet from plasmam  X                      
Page 3 of 4 
Footnotes defined on last page of Table 6. 
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Table 5.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 1 Treatment 
 Screening Treatment 
Cycle  1 
Day -28 to 1 1 2 8 9 15 
Hours (relative to dosing)  pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 0.25 0.5 1 2 4 6 pre 0 pre 0 
BIOMARKER SAMPLES Cont. 
Serum  X          X            
PB Paxgene RNA  X          X            
Stool samplen  X                      
BIOMARKER DEVELOPMENT 
Tumor biopsy (optional, as 
applicable) or archived 
tumor tissue (FFPE) for solid 
tumors 
Xo                 Xp      
Page 4 of 4 
Footnotes defined on last page of Table 6. 
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Table 6.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 2 Treatment and LTFU 
 Treatment EOT SFU LTFU 
Cycle 2 3,5a 4,6 QC Q2C    
Day 1 8 1 1 1 1    
Hours (relative to dosing) pre 0 0.25 0.5 1 4  pre 1 4       
GENERAL & SAFETY 
Physical exam & weight 
X       X   X X   X  
ECOG X       X   X X  X X  
Vital signs X                
ECG (Group A)b, c X    X X   X  X X   X  
ECG (Group B)b,c               X  
Anticancer therapy               X X 
Concomitant medications ======================================================================================  
Adverse events ======================================================================================  
Serious adverse events ============================================================================================= 
Patient diaries =========================================================================    
Page 1 of 4 
Footnotes defined on last page of the table. 
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Table 6.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 2 Treatment and LTFU 
 Treatment EOT SFU LTFU 
Cycle 2 3,5 4,6 QC Q2C    
Day 1 8 1 1 1 1    
Hours (relative to dosing) pre 0 0.25 0.5 1 4  pre 1 4       
Patient-reported Outcomes 
EORTC QLQ C30 X       X   X  X X X  
QLQ LC13 X       X   X  X X X  
NSCLC SAQ X       X   X  X X X  
QLQ PAN26 X       X   X  X X X  
PRO-CTCAE X       X   X  X X X  
EQ-5D-5L X       X   X  X X X  
GP5 of the FACT-G X       X   X  X X X  
Laboratoryd 
Chemistry X       X   X X     
Hematology X       X   X X     
Coagulation X       X   X X     
Urinalysise X       X   X X     
Serum pregnancy testf               X  
Urine pregnancy testf X       X   X X     
Page 2 of 4 
Footnotes defined on last page of the table. 
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Table 6.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 2 Treatment and LTFU 
 Treatment EOT SFU LTFU 
Cycle 2 3,5 4,6 QC Q2C    
Day 1 8 1 1 1 1    
Hours (relative to dosing) pre 0 0.25 0.5 1 4  pre 1 4       
DOSING 
AMG 510g ==========================================================================    
IMAGING ASSESSMENTS 
Radiological imaging, (CT/MRI) 
and tumor assessmenth 
       X     X X  (X)q 
MRI braini                 
PK ASSESSMENTS 
AMG 510 PK (Group A)i X    X X  X X X   X    
AMG 510 PK (Group B)i X    X X  X X X   X    
BIOMARKER SAMPLES 
Tumor markers at sitek (X) 
 
 
Plasma ctDNAl X       X   X X  X   
Cell pellet from plasmam                 
Page 3 of 4 
Footnotes defined on last page of the table. 
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Table 6.  Schedule of Assessment:  Phase 2 Study Visits Through Cycle 2 Treatment and LTFU 
 Treatment EOT SFU LTFU 
Cycle 2  3,5 4,6 QC Q2C    
Day 1 8 1 1 1 1    
Hours (relative to dosing) pre 0 0.25 0.5 1 4  pre 1 4       
BIOMARKER SAMPLES Cont.  
Serum X       X   X X  X   
PB Paxgene RNA X       X   X X  X   
Stool samplen              X   
BIOMARKER DEVELOPMENT 
Tumor biopsy (optional, as 
applicable) (X)
p Xp   
Page 4 of 4 
Footnotes defined on next page 
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CNS = central nervous system; CT =computed tomography; cfDNA = cell-free DNA; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; 
EOT = end of treatment; FFPE = formalin-fixed paraffin-embedded; HbA1c = hemoglobin A1c; LTFU = long-term follow-up; MRI = magnetic resonance imaging; 
NSCLC = non-small cell lung carcinoma; PD-L1 = programmed cell death-1; PET = positron emission tomography; PB = peripheral blood; PK = pharmacokinetic; 
PRO-CTCAE = Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; QC = every cycle from cycle 7 and beyond (cycles 7, 8, 
9, etc), Q2C = every other cycle from cycle 7 and beyond (cycles 7, 9, 11 etc); SFU = safety follow-up.
(X) = Parentheses indicate that the particular test is situational at that time point, as specified in the respective notes. 
a KRAS p.G12C testing results must be available prior to starting all other screening procedures
b Three triplicate ECGs must be performed at screening.  For all other visits, one triplicate ECG must be performed.  Each tracing must be at least 30 
seconds apart.
c Intense ECG collection will be performed in up to approximately 30 subjects at time points described for Group A. Sparse ECG collection will be performed in the 
remaining subjects at time points described for Group B.  
d Assessments to be performed on day 1 of each cycle.  Laboratory assessments may be performed within 24 hours before day 1 of each cycle.  A window of ± 1 day 
is allowable for cycle 1 and cycle 2.  A window of ± 2 days is allowable after cycle 2.  Electrocardiograms, biomarker blood draws, safety labs, vital signs (including 
pulse oximetry): ± 5 minute window (for time points of 0.25 hour and 0.5 hour postdose), ± 15-minute window (all other time points).  
e Microscopic exam required to be performed with each time point collected.
f For women of childbearing potential only (defined in Criterion 215 in Section 4.2.
g AMG 510 will be administered daily on a repeated basis with no planned off treatment days.  AMG 510 must be administered in the fasted state (no food or liquids, 
except water, 2 hours before to 1 hour after dosing).  
h Radiological imaging and tumor assessments are required at screening and every 6 1 weeks.  After four 6-week response assessments, radiological imaging and 
tumor assessment frequency will be performed every 12 ± 1 weeks until disease progression, start of new anti-cancer treatment, death, or withdrawal of consent until 
end of study.  MRI/CT scans can be obtained earlier if clinical deterioration necessitates an earlier scan at the discretion of the managing physician.  End of treatment 
CT/MRI should be performed only for subjects that discontinue treatment for a reason other than disease progression per RECIST 1.1 criteria.  Every assessment 
must include the chest, abdomen, pelvis, and all other known sites of disease.  Tumor burden assessments will be performed based on RECIST 1.1 guidelines 
(Appendix D).  Radiographic response (CR and PR) requires confirmation by a repeat consecutive assessment 4 weeks after the first detection of response.
i All subjects with history of brain metastasis must have MRI of the brain performed within 28 days prior to enrollment.  Only if MRI is contraindicated, then CT with 
contrast is acceptable.  Subsequently, MRI brain scans can be performed at any time if clinically indicated or per standard of care.  Any additional imaging used to 
evaluate or determine response (eg, PET, CT/PET, bone scan, etc) should be sent along with the required imaging to the central imaging vendor promptly upon 
completion.
j Intense PK collection will be performed at select sites in up to approximately 30 subjects at time points described for Group A.  Sparse PK collection will be 
performed in the remaining subjects at time points described for Group B.  Pharmacokinetic blood samples should be collected at the exact nominal time point as 
noted above (see hour postdose column).  If unable to collect a blood sample at the specified nominal time point, collect it as close as possible to the nominal time 
point and record the actual collection time.  Pharmacokinetic samples not collected at exact nominal time point will not be considered protocol deviations.  
Pharmacokinetic samples collected in cycle 7 and beyond should be performed prior to AMG 510 dosing.
k Tumor markers will be performed as per standard of care and reported on the applicable eCRF. 
l Plasma ctDNA is to be collected predose as indicated in the Schedule of Assessments, and at response.
m Cell pellet will be used for pharmacogenetics analysis in subjects who consent.
n Stool sample collected predose (-3 days) and at EOT.
o Subjects will provide archived FFPE samples (collected within 5 years) for KRAS p.G12C mutation confirmation or undergo tumor biopsy that enables KRAS p.G12C
testing prior to starting all other screening procedures.  .
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p After enrollment, optional tumor biopsy will be performed for subjects who consent to this assessment.  It will be performed, if feasible, on cycle 1 day 8 
at least 4 ( 2) hours after dosing, at response, and at the EOT.  
q For subjects who discontinued study treatment without confirmed disease progression or start of subsequent anticancer treatment, tumor assessments 
will continue during LTFU every 12 weeks (± 2 weeks) for up to 3 years after last subject enrolled or until confirmed disease progression, start of 
subsequent anticancer treatment, death, withdrawal of consent, loss to follow-up, or end of study.  
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7.2 General Study Procedures
Study procedures and their time points are summarized in the Schedule of 
Assessements (see Table 2 through Table 6).   Refer to the IPIM, laboratory and site 
imaging manuals for detailed collection and handling procedures.  
Adherence to the study design requirements, including those specified in the 
Schedule of Assessments, is essential and required for study conduct.
A signed and dated IRB/IEC approved ICF must be obtained prior to performing any
study specific procedures, including discontinuing standard therapy for observing study
specific washout periods.
Subjects will be seen in the clinic for study evaluations. During all visits invasive 
procedures like blood draws or biopsies should be completed after ECGs, vital 
signs, and COAs (as applicable). 
Blood samples for biomarker and PK assessments should be drawn from a peripheral
vein and not from a central venous catheter. The study specific lab manual will provide
additional detail on lab sampling and handling requirements.
Study procedures should be performed and samples obtained at the time points
stipulated in the Schedules of Assessments (Table 2, Table 3, Table 4, Table 5, and 
Table 6). Acceptable deviation windows for study procedures are listed below:
 ECGs, biomarker blood draws, safety labs, vital signs (including pulse oximetry):
± 5 minute window (for time points of 0.25 hr and 0.5 hr postdose), ± 15 minute
window (all other time points)
Acceptable deviation windows for study visits are listed below:
 visits during treatment: ± 1 day for cycle 1 and cycle 2
 visits during treatment: ± 2 days after cycle 2
 SFU: + 7 days
 LTFU: ± 2 weeks
Furthermore, start of a treatment can be delayed for administrative/logistical reasons for
up to 7 days to allow for appropriate scheduling after discussion with and final approval
by sponsor.
Any missed visits, tests not done, or examinations that are not conducted must be
reported as such on the eCRFs. Subsequent study visits should resume on the original
schedule. Missed assessments at prior visits should not be duplicated at subsequent
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visits.  Every effort should be taken to collect all biomarker and PK samples as described 
in the schedule of assessments.  However, if sample processing/shipment on a 
weekend/holiday is not logistically feasible for a site, this needs to be documented and 
will not be considered a deviation from the protocol. 
Additional procedures deemed necessary as part of standard of care or as required by 
local laws and regulations may be performed at the Investigator’s discretion. 
Table 7.  List of Analytes 
Local Laboratory Central Laboratory 
Chemistry Hematology Coagulation PK and Biomarker 
Sodium  
Potassium  
Chloride 
Bicarbonate Total 
protein  
Albumin 
Calcium  
Magnesium 
Phosphorous 
Glucose 
Blood urea nitrogen 
Ureaa 
Creatinine 
Total creatine kinase 
Total bilirubin 
Direct bilirubin 
Serum or Urine 
Pregnancy 
Alkaline phosphatase 
Alanine 
aminotransferase 
Aspartate 
aminotransferase 
HbA1c 
Hemoglobin 
Hematocrit 
Mean corpuscular 
volume 
Platelets  
RBC 
White blood cell 
Differential 
• Total neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
Monocytes 
PT or INR 
aPTT Fibrinogen 
D-Dimer 
PK sampling 
Plasma ctDNA 
Plasma cell pellet 
Serum 
PB Paxgene RNA 
Antibody 
Tumor biopsy
c
 
Serologyb Urinalysis 
HepBsAg 
HepCAb 
HIV 
 
Tumor markers 
-Carcinoembryonic 
embryonic antigen 
(CEA) 
-Carbohydrate 
antigen (CA 19-9) 
-Cancer antigen 
(CA 125) 
Specific gravity, pH, 
Blood protein, 
glucose, bilirubin, 
WBC, ketones, 
sodium, potassium 
RBC, epithelial cells, 
bacteria 
Microscopic exam: 
• Cellular casts 
• Granular casts 
• Hemoglobin casts 
• Hyaline casts 
• Mixed casts 
Footnotes defined on next page of this table 
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HbA1c = hemoglobin A1c; HepBsAg = hepatitis B surface antigen; HepCAb = hepatitis C antibody;  
INR = international normalized ratio; LDH = lactate dehydrogenase; PB = peripheraph blood; 
PK = pharmacokinetics; PT = prothrombin time; PTT = partial thromboplastin time; RBC = red 
blood cell count; WBC = white blood cell count.
a Urea collection is acceptable in absence of BUN.
b Hepatitis B surface antigen, hepatitis C antibody, PCR for Hepatitis C RNA (if Hepatitis C antibody 
is positive), and HIV assessments.
c Archived tumor tissue is acceptable.  If archived tumor tissues is not available, a tumor biopsy 
should be performed prior to treatment.
7.2.1 Screening
After written consent has been obtained, subjects will be screened in order to assess
eligibility for study participation. All screening procedures must be performed within
28 days prior to start of investigational product administration, unless otherwise noted. 
Subjects who meet the inclusion and exclusion criteria will be eligible to be enrolled in
the study. If a subject has not met all eligibility criteria at the end of the 28-day window,
the subject will be registered as a screen failure. Subjects who screen fail may be
eligible for re-screening at the investigator’s discretion after consultation with Amgen
(see also below for details on re-screening).
Laboratory assessments used to determine subject eligibility may be repeated once for
confirmation during the 28-day screening period before the subject is considered a
screen failure. If laboratory assessments are repeated during the screening period, the
result of the last sample taken prior to start of treatment with AMG 510 will be taken into
account for determination of subject eligibility.
The following procedures are to be completed during the screening period at the time
points designated in the Schedules of Assessments (Table 2 ,Table 5, and Table 6).
Assessments that were performed as standard of care prior to signature of informed
consent, but within 21 days prior to start of treatment with AMG 510 can be used as
screening assessments and do not need to be repeated to confirm subject eligibility.
Rescreening:
Subjects may be rescreened up to 2 times at the discretion of the investigator, after 
consultation with Amgen. The subject must be reconsented if a rescreening attempt 
occurs more than 30 days after the original signing of the ICF.
Rescreened subjects must be documented as screen failed in the subject’s medical 
record and subsequently documented as rescreened.  Subjects will retain the same 
subject identification number assigned at the time of initial screening. Once the subject 
is recorded as rescreened, a new 28-day screening window will begin. The following 
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assessments do not have to be repeated during rescreening, if they were performed as 
standard of care or during the initial screening attempt within the time frames specified 
below:
 Hepatitis serology does not need to be repeated if it was performed within 6 weeks
prior to start of treatment with AMG 510.
 Imaging assessments do not need to be repeated if they were performed within
4 weeks prior to start of treatment with AMG 510.
 Central confirmation of KRAS G12C status (if applicable)
Any other assessments do not need to be repeated if they were performed within
21 days prior to start of treatment with AMG 510.
7.2.2 Treatment
Treatment begins on Day 1 of cycle 1 when the first dose of investigational product is
administered to a subject.
During clinic visit days all protocol-required predose assessments have to be performed
prior to administration of AMG 510.
Results of any predose laboratory tests will not have to be available before the
administration of AMG 510. Laboratory assessments that were done within 24 hours
prior to AMG 510 administration do not need to be repeated.
AMG 510 will be dispensed to subjects at the beginning of each cycle and the subjects
are required to bring the bottle of AMG 510 to clinic during clinic visit days. AMG 510
administration should be done in the clinic after all pre-dose assessments have been
performed during clinic visit days.
For phase 1, a paper diary will be provided to subjects at the beginning of each cycle 
and the study staff will provide guidance to the subjects on how to complete the diary.
For phase 2, once a subject is confirmed as eligible and becomes enrolled, site 
study staff will assign and provide an eDiary (to capture compliance with AMG 510 
administration).  The site study staff will train the subject on how to use the eDiary (eg, 
turning on/off, charging, navigating screens, transmitting data, contacting the help desk 
for technical assistance) and complete the questions.  The subject will be instructed to 
interact with the eDiary every day and to bring the eDiary to every study visit. 
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Please refer to the eDiary manual for additional details. 
7.2.3 End-of-treatment Visit
For subjects who discontinue investigational product, the EOT visit should occur 
as soon as possible (within 14 days) after the last dose of investigational product.
7.2.4 Safety Follow-up Visit
The SFU visit should occur approximately 30 (+7) days after the last dose of AMG 510 or 
before any new anticancer treatment is started. 
7.2.5 Long-term Follow-up
Following the SFU visit, there will be an LTFU period during which data will be 
collected on the subjects’ health condition, disease status, and subsequent 
anticancer treatment.  
Also, for subjects who discontinued study treatment without confirmed disease 
progression or start of subsequent anticancer treatment, tumor assessments will 
continue during LTFU every 12 weeks (± 2 weeks) for up to 3 years after last 
subject enrolled or until confirmed disease progression, start of subsequent 
anticancer treatment, death, withdrawal of consent, loss to follow-up, or end of 
study.  
Subjects who had confirmed disease progression or started subsequent 
anticancer treatment, will be followed via telephone every 12 weeks (± 2 weeks) for 
assessment of survival and documentation of anticancer treatment. Subjects will be 
followed for up to 3 years after last subject enrolled or until withdrawal of consent, loss to 
follow-up, or subject death, whichever occurs first.
7.2.6 End of Study Visit
End of study is defined as the date of the final study visit (eg, LTFU) when assessments
and/or procedures are performed.
7.2.7 Demographics
Demographic data collection including sex, age, race, and/or ethnicity will be 
collected in order to study their possible association with subject safety and 
treatment effectiveness.  
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7.2.8 Physical Examination
Physical examination will be performed as per standard of care.  Physical 
examination findings should be recorded on the appropriate CRF (eg, medical 
history, event).
7.2.9 Physical Measurements
Height (in centimeters) should be measured without shoes.  Weight (in kilograms) 
should be measured without shoes. 
7.2.10 Performance Status 
The subject’s performance status will be assessed using the ECOG PS.  
7.2.11 Pharmacokinetic Blood Sampling
For PK assessment, blood samples for quantitative determination of AMG 510 will be 
collected at time points specified in the Schedule of Assessments (Section 7.1). Sample 
collection, processing, storage, and shipping instructions are provided in a separate 
laboratory manual.  For phase 2, intense PK collection will be performed at select sites 
in up to approximately 30 subjects at time points described for Group A.  Sparse PK 
collection will be performed in the remaining subjects at time points described for 
Group B.
7.2.12 Urine Collection For Food Effect Assessment
On day 1 of the cycle in which the food effect assessment is conducted, urine will be
collected to measure active metabolites of AMG 510 for the following time periods: 
(1) 0 to 6 hours postdose, and (2) 6 to 24 hours postdose.  
7.2.13 High-fat Meal
For the food effect assessment, the clinical site will provide standardized high-fat meal
as described in the Schedule of Assessment (Table 3). A standard high-fat meal
(approximately 50% of the total caloric content of the meal) and high calorie
(approximately 800 to 1000 calories) meal will be used as a test meal. The test meal
should derive approximately 150, 250 and 500 to 600 calories from protein, carbohydrate 
and fat, respectively. An example test meal would be 2 eggs fried in butter, 2 strips of
bacon, 2 slices of toast with butter, 4 ounces (approximately 120 mL) of hash brown 
potatoes, and 8 ounces (approximately 240 mL) of whole milk. Substitutions in this meal
can be made as long as the meal provides a similar amount of calories from protein, 
carbohydrate, and fat and has comparable meal volume and viscosity. Further details of
the high fat meal will be recorded in subject medical record and eCRF.
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7.2.14 Vital Signs
The following measurements must be performed:  systolic/diastolic blood pressure, heart 
rate, respiratory rate, pulse oximetry, and temperature.  Subject must be in a supine 
position in a rested and calm state for at least 5 minutes before blood pressure 
assessments are conducted.  If the subject is unable to be in the supine position, the 
subject should be in most recumbent position as possible.  The position selected for a 
subject should be the same that is used throughout the study and documented on the 
vital sign CRF.  The temperature location selected for a subject should be the same that 
is used throughout the study and documented on the vital signs CRF.  Record all 
measurements on the vital signs CRF.
7.2.15 Electrocardiograms (ECGs)
Subject must be in supine position in a rested and calm state for at least 10 minutes 
before ECG assessment is conducted.  If the subject is unable to be in the supine 
position, the subject should be in most recumbent position as possible.  ECGs should be 
performed in a standardized method, in triplicate, and run consecutively, prior to blood 
draws or other invasive procedures.  Each ECG must include the following 
measurements:  QRS, QT, QTc, RR, and PR intervals. 
  3 baseline ECGs collected at least  30 seconds apart, with each baseline ECG 
in triplicate run consecutively (ie, total  9 ECGs)
 Triplicate ECGs at time points after dosing 
Baseline is defined as prior to dosing on cycle 1 day 1.  The PI or central reader will 
review all ECGs. ECGs will be transferred electronically to an ECG central reader for 
analysis per Amgen instructions.  Once signed, the original ECG tracing will be retained 
with the subject's source documents. At the request of the sponsor, a copy of the original 
ECG will be made available to Amgen.  Standard ECG machines should be used for all 
study-related ECG requirements.  In certain circumstances Amgen may be able to 
provide a standard ECG machine if a site is unable to provide one.  
For phase 2, intense ECG collection will be performed at select sites in up to 
approximately 30 subjects at time points described for Group A.  Sparse ECG collection 
will be performed in the remaining subjects at time points described for Group B.
7.3 Intensive Procedures
All subjects in phase 1 (dose exploration and dose expansion) will have intensive PK 
and ECG data collected.  At select sites, up to a total of 30 phase 2 subjects will also be 
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consented to have intensive PK and ECG data collected.  Please refer to Table 5 and 
Table 6 for timing of collection.
7.4 Clinical Laboratory Assessments
Refer to Table 7 for the list of analytes to be performed and to the Schedule of 
Assessments (Table 2, Table 5, and Table 6) for the timing and frequency. 
The investigator is responsible for reviewing laboratory test results and recording any 
clinically relevant changes occurring during the study in the Event CRF.  The investigator 
must determine whether an abnormal value in an individual study subject represents a 
clinically significant change from the subject’s baseline values.  In general, abnormal 
laboratory findings without clinical significance (based on the investigator's judgment) 
are not to be recorded as adverse events.  However, laboratory value changes that 
require treatment or adjustment in current therapy are considered adverse events.  
Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded 
as the adverse event.
All protocol-required laboratory assessments, as defined in Table 7, must be conducted 
in accordance with the laboratory manual and the Schedule of Assessments (Table 2, 
Table 5, and Table 6).
7.5 Radiological Imaging Assessment
The extent of disease will be evaluated by contrast-enhanced MRI/CT according to
RECIST 1.1 (Appendix D). All radiological imaging will be performed as indicated in the
Site Imaging Manual provided by the central imaging core laboratory. In order to reduce
radiation exposure for subjects, low dose CT should be utilized whenever possible.
The screening scans must be performed within 28 days prior to enrollment and will be
used as baseline. All subsequent scans will be performed in the same manner as at
screening, with the same contrast, preferably on the same scanner.  Radiological 
assessment must include MRI/CT of the chest, abdomen and pelvis, as well as
assessment of all other known sites of disease as detailed within the Site Imaging 
Manual. Magnetic resonance imaging (MRI) of the brain should be performed if signs or 
symptoms suggestive of central nervous system metastases are present.
The same imaging modality, MRI field strength and intravenous and oral contrast agents 
should be used at screening should be used for all subsequent assessments. Liver 
specific MRI contrast agents should not be used.  To reduce potential safety concerns, 
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macrocyclic gadolinium contrast agents are recommended per National Health Institute 
guidelines, or follow local standards if more rigorous. 
During treatment and follow-up radiological imaging of the chest, abdomen, pelvis, as
well as all other known sites of disease, will be performed independent of treatment cycle
every 6 ± 1 weeks for the first 4 response assessments. After four 6-week response 
assessments, radiological imaging and tumor assessment will be performed every 
12  1 weeks.  Radiologic imaging and tumor assessment will be performed until disease 
progression, start of new anticancer treatment, death, withdrawal of consent or until end of 
study.  Imaging may also be performed more frequently if clinically necessitated at the
discretion of the managing physician. Radiographic response (complete response,
partial response) requires confirmation by a repeat, consecutive scan at least 4 weeks
after the first documentation of response and may be delayed until the next scheduled
scan to avoid unnecessary procedures.
All subjects with brain metastasis must have MRI of the brain performed within 28 days
prior to first dose of AMG 510. Subsequently, brain scans may be performed at any time
if, in the judgement of the managing physician. All brain scans on protocol are required
to be MRI unless MRI is contraindicated, and then CT with contrast is acceptable.
Radiological imaging assessment during the EOT visit should be performed only for
subjects that discontinue treatment for a reason other than disease progression per
RECIST 1.1 guidelines.
Determination of disease response for clinical management of subjects will be assessed
at the clinical sites per RECIST 1.1. Scans will be submitted to a central imaging core
laboratory for archival, response assessment including RECIST 1.1, and/or exploratory
analysis eg, volumetric and viable tumor measurements. Detailed information regarding
submission of images to the central imaging core laboratory is found in the Site Imaging
Manual.
7.6 Patient-reported Outcomes
Patient-reported outcomes (PRO) questionnaires will be administered via electronic 
tablet to subjects enrolled into the phase 2 monotherapy part of the study.
The impact of treatment on disease-related symptoms and HRQOL will be evaluated in 
all subjects (regardless of tumor type) using the European Organization for Research 
and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30).  In 
addition, disease specific modules will be employed: QLQ LC13 and NSCLC SAQ for 
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NSCLC, and QLQ-Pan26 for Pancreatic Cancer. Treatment-related symptoms and 
impact on the subject will be assessed in all subjects (regardless of tumor types) using 
selected questions from the Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events (PRO-CTCAE) library and a single item about 
symptom bother (GP5 of the FACT-G).  Physical function will be assessed in all subjects 
regardless of tumor type using the EORTC QLQ-C30.  Health-related quality of life will 
also be assessed in all subjects regardless of tumor type using the EuroQol-5 
Dimension (EQ-5D-5L).  
The PRO questionnaires should be completed by the subject prior to any other clinical 
assessments and before receiving any study medications.
The EORTC QLQ-C30 is a 2-page, self-reporting 30-item generic instrument for use in 
cancer subjects across tumor types. It assesses 15 domains consisting of 5 functional 
domains (physical, role, emotional, cognitive, social), 9 symptom domains (fatigue, 
nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, 
financial difficulties), and a global health status or Quality of Life (QOL) scale
(Aaronson et al, 1993).
The supplementary disease specific module, QLQ-LC13, is a validated questionnaire to 
assess the impact of treatment on lung cancer-associated symptoms (cough, 
hemoptysis, dyspnoea and site-specific pain) and treatment-related side effects (sore 
mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.  It contains 
13 questions.   
The NSCLC SAQ is a 7-item instrument intended to measure overall symptom 
severity (eg cough, pain, dyspnea, fatigue, and appetite) of NSCLC.  The NSCLC 
SAQ is intended to assess clinically meaningful change in overall symptoms of 
NSCLC and is suggested by the FDA to be used in early phase studies so that 
information to support thresholds for clinically meaningful, within-patient change 
in the NSCLC-SAQ total score can be established in the context of use.
The QLQ-PAN26 is a questionnaire consisting of 26 items developed to assess the 
symptoms and impact of treatment on symptoms related to pancreatic cancer . This 
module will be utilized to assess the small but important disease and treatment related 
HRQoL changes in pancreatic cancer.  For all items on the QLQ-PAN26, except 
satisfaction with health care, a higher score reflected worse HRQoL. 
A
pp
ro
ve
d 
  
Product:  AMG 510
Protocol Number:  20170543
Date:  22 May 2019 Page 91 of 158
CONFIDENTIAL
PRO-CTCAE is a subject-reported outcome measure developed to evaluate 
symptomatic toxicity in subjects on cancer clinical trials. The questionnaire was 
designed to be used as a companion to the CTCAE, the standard lexicon for adverse 
event reporting in cancer trials. PRO-CTCAE item library version 1.0 is comprised of 
124 individual questions developed to elicit 78 symptomatic AEs from subjects using 
between one to three attribute questions (ie, frequency, severity, and/or interference of 
the AE), (Basch et al, 2014).  The recall period for PRO-CTCAE is the past 7 days. The 
PRO-CTCAE has been tested and validated in terms of construct validity, test-retest 
reliability, and item responsiveness (Dueck et al, 2015).  In this study, the PRO-CTCAE 
will be administered via electronic tablet.  
The specific questions which will be administered to subjects in this study will be 
selected from the PRO-CTCAE item library following a review of the data from the phase 
1 dose exploration part of AMG 510 in KRAS p.G12C subjects and consideration of 
potential toxicities which may be relevant to future comparisons of AMG 510 to current 
standards of care. A customized form to collect these data will be developed using the 
online tool available at https://healthcaredelivery.cancer.gov/pro-ctcae/builder.html. 
The GP5 of the FACT-G is a single item “I am bothered by side effects of treatment” 
rated on a 5-point Likert scale from “not at all” to “very much” is an item included in the 
Physical Well-Being subscale of the PRO assessment instrument Functional 
Assessment of Cancer Therapy Tool General form (FACT-G). It has been evaluated 
and validated as a useful summary index of side effect impact or burden to the individual 
subject (Pearman et al, 2018).
The EQ-5D-5L questionnaire is a 2-page, standardized instrument for use as a measure 
of health outcome developed by the EuroQol group (Rabin and de Charro, 2001).  It is 
comprised of a 5-dimension health status measure and a visual analogue scale.  The 
5-dimension health status measure evaluates: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression based on a 5-level scale:  no problems, slight 
problems, moderate problems, severe problems, an extreme problem.  The visual 
analogue scale records the subject's self-rated health on a vertical, visual analogue 
scale where the endpoints are labelled 'Best imaginable health state' and 'Worst 
imaginable health state'.  The EQ-5D-5L takes about 3 minutes to complete.  
7.7 Biomarker Discovery
Samples will also be collected for biomarker analysis, eg, to evaluate potential 
biomarkers that may correlate with treatment response.  
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Blood Samples
Blood samples are to be collected for biomarker development as listed in the Section 7.1.
Plasma and/or serum may also be used for DNA, RNA, and protein expression analysis
in order to correlate levels of expression with response.
Tumor Tissues
Tissue for KRAS p.G12C Testing
All subjects in both phase 1 and phase 2 are expected to have been previously identified 
as expressing the KRAS p.G12C mutation in local laboratory testing. 
 For phase 1 (dose exploration and dose expansion), subjects may be enrolled based 
on their previous local laboratory testing.  However, prior to enrollment it must be 
determined that there is sufficient archived tumor tissue (collected within 5 years of 
enrollment) for subsequent exploratory biomarker analyses.  If archived tissue is not 
available, a tumor biopsy (core needle [NSCLC only] or excisional), if feasible, 
should be performed.  The tumor sample should be submitted (within 2 weeks of 
enrollment).  
 In phase 2, subjects with NSCLC and CRC, an archival tumor sample (collected 
within 5 years of enrollment) or tumor biopsy (core needle [NSCLC only] or 
excisional) must be submitted prior to enrollment for central laboratory testing with 
the investigational Qiagen assay for the KRAS p.G12C mutation as well as 
subsequent exploratory biomarker analyses. These subjects cannot be enrolled until 
results of the central laboratory testing have been reported and demonstrate that the 
subject has the KRAS p.G12C mutation.
 In both phase 1 and phase 2, tumor tissue for KRAS p.G12C mutation testing may 
be submitted to the central laboratory either as FFPE blocks or unstained slides (see 
study laboratory manual for details).  Tissue should be submitted along with the 
corresponding pathology report.  
Tissue for Exploratory Biomarker Testing
For all subjects FFPE blocks or unstained slides of archived tumor tissue (collected 
within 5 years of enrollment) or tumor biopsy (core needle [NSCLC only] or excisional), 
obtained prior to treatment with AMG 510, must be submitted along with pathology 
reports for exploratory biomarker testing. 
An optional tumor biopsy, if feasible, on cycle 1 day 8, obtained approximately 4 hours 
( 2 hrs) after dosing is encouraged.  Where feasible, a biopsy should be performed at
response and the EOT.
All tissue should be submitted along with the corresponding pathology report. 
A
pp
ro
ve
d 
  
Product:  AMG 510
Protocol Number:  20170543
Date:  22 May 2019 Page 93 of 158
CONFIDENTIAL
Tissue collection and submission:
When a tumor biopsy is needed for enrollment: Collection of tumor tissue following local 
standard of care procedure for KRAS p.G12C testing is not expected to present any 
additional risk to the health, safety, and welfare of the subject.  
The tumor block submitted is to be carefully selected by a pathologist or a skilled 
experienced histology associate to include generous tumor tissue using the Pathology 
Report as a guide.  In lieu of a block, 20 unstained sections on charged slides from the 
same block can be submitted; either is sufficient for both the KRAS p.G12C testing and 
for exploratory biomarker studies.
Rationale for baseline, on-treatment and post progression exploratory biomarker testing
Analyses of tumor specific mutations or epigenetic changes at baseline may be 
performed (eg, somatic mutations) to asses potential pre-existing resistance mechanism.  
Tumor tissue or biopsies at baseline, on-treatment, and at progression are to be 
collected and pharmacodynamic changes analyzed to determine the effect of the drug 
on target(s) in the tumor as well as to potentially analyze molecular mechanisms 
associated with acquired resistance.
 
 
 
 
 
 
Central Testing for KRAS p.G12C and PD-L1
The therascreen® KRAS RGQ PCR Kit from QIAGEN is a real-time qualitative PCR
assay performed on the Rotor-Gene Q MDx instrument for the detection of 7 somatic
mutations in the human KRAS oncogene using DNA extracted from FFPE tissue. The
mutations detected are: G12A, G12D, G12R, G12C, G12S, G12V, G13D. The
therascreen® KRAS RGQ PCR Kit is an investigational in vitro diagnostic device that will
be available to be used to test subjects with NSCLC and CRC for the KRAS p.G12C
mutation .  
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Subject testing with the therascreen® KRAS RGQ Assay and Dako PharmDx 22C3 will
take place at the NeoGenomics Central Testing Laboratory in Houston, Texas.
PD-L1 testing will be conducted at the central labs using the Dako PharmDx 22C3 
immunohistochemistry FDA-approved kit according to the instructions for use.
Stool Samples
Stool samples will be collected to determine whether there is a relationship 
between microbiota diversity and response to anti-PD-1 therapy and to 
understand the baseline microbiota diversity in monotherapy.
7.8 Pharmacogenetic Studies
If the subject consents to the optional pharmacogenetic portion of this study, DNA 
analyses may be performed. These optional pharmacogenetic analyses focus on 
inherited genetic variations to evaluate their possible correlation to the disease and/or 
responsiveness to the therapies used in this study. The goals of the optional studies 
include the use of genetic markers to help in the investigation of colorectal cancer, 
non-small cell lung cancer, pancreatic cancer as well as other solid tumors and/or to 
identify subjects who may have positive or negative response to AMG 510.  
Pharmacogenetic samples are collected for this part of the study.  Subjects who consent 
to this/these analysis/analyses, DNA may be extracted from blood.
7.9 Sample Storage and Destruction
Any blood or tissue samples collected according to the Schedule of Assessments
(Table 2) can be analyzed for any of the tests outlined in the protocol and for any tests
necessary to minimize risks to study subjects. This includes testing to ensure analytical
methods produce reliable and valid data throughout the course of the study. This can
also include, but is not limited to, investigation of unexpected results, incurred sample
reanalysis, and analyses for method transfer and comparability.
All samples and associated results will be coded prior to being shipped from the site for
analysis or storage. Samples will be tracked using a unique identifier that is assigned to
the samples for the study. Results are stored in a secure database to ensure
confidentiality.
If informed consent is provided by the subject, Amgen can do additional testing on
remaining samples (ie, residual and back-up) to investigate and better understand the
solid tumor cancers (eg, mCRC, NSCLC, pancreatic cancer) with the dose response
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and/or prediction of response to AMG 510, characterize antibody response, and
characterize aspects of the molecule (eg, mechanism of action/target, metabolites).
Results from this analysis are to be documented and maintained, but are not necessarily
reported as part of this study. Samples can be retained for up to 20 years.
Since the evaluations are not expected to benefit the subject directly or to alter the
treatment course, the results of pharmacogenetic, biomarker development, or other
exploratory studies are not placed in the subject’s medical record and are not to be made
available to the subject, members of the family, the personal physician, or other third
parties, except as specified in the informed consent.
The subject retains the right to request that the sample material be destroyed by
contacting the investigator. Following the request from the subject, the Investigator is to
provide the sponsor with the required study and subject number so that any remaining
samples and any other components from the cells can be located and destroyed.
Samples will be destroyed once all protocol-defined procedures are completed.
However, information collected from samples prior to the request for destruction, will be
retained by Amgen.  The sponsor is the exclusive owner of any data, discoveries, or 
derivative materials from the sample materials and is responsible for the destruction of
the sample(s) at the request of the subject through the investigator, at the end of the 
storage period, or as appropriate (eg, the scientific rationale for experimentation with a 
certain sample type no longer justifies keeping the sample). If a commercial product is 
developed from this research project, the sponsor owns the commercial product. The 
subject has no commercial rights to such product and has no commercial rights to the 
data, information, discoveries, or derivative materials gained or produced from the
sample.  See Section 11.3.  
Amgen or another third party manufacturer may attempt to develop test(s) 
designed to identify subjects most likely to respond positively or negatively to 
investigational product(s) to investigate and further understand the NSCLC or 
CRC.  
8. WITHDRAWAL FROM TREATMENT, PROCEDURES, AND STUDY
8.1 Subjects’ Decision to Withdraw
Subjects have the right to withdraw from the study at any time and for any reason without
prejudice to their future medical care by the physician or at the institution.
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Subjects (or a legally acceptable representative) can decline to continue receiving
investigational product and/or other protocol-required therapies or procedures at any
time during the study but continue participation in the study. If this occurs, the
investigator is to discuss with the subject the appropriate processes for discontinuation
from investigational product, device or other protocol-required therapies and must
discuss with the subject the options for continuation of the Schedule of Assessments
(Section 7.1) including different options of follow-up (eg, in person, by phone/mail, 
through family/friends, in correspondence/communication with other treating physicians, 
from the review of medical records) and collection of data, including endpoints, adverse
events, Subjects who have discontinued investigational product and/or protocol required 
therapies or procedures should not be automatically removed from the study. Whenever 
safe and feasible it is imperative that subjects remain on-study to ensure safety 
surveillance and/or collection of outcome data. The investigator must document the level
of follow-up that is agreed to by the subject.
Withdrawal of consent for a study means that the subject does not wish to receive further 
protocol-required therapies or procedures, and the subject does not wish to or is unable 
to continue further study participation.  Subject data up to withdrawal of consent will be 
included in the analysis of the study, and where permitted, publicly available data can be 
included after withdrawal of consent. The investigator is to discuss with the subject
appropriate procedures for withdrawal from the study.
8.2 Investigator or Sponsor Decision to Withdraw or Terminate
Subjects’ Participation Prior to Study Completion
The investigator and/or sponsor can decide to withdraw a subject(s) from investigational
product, medical device(s), and/or other protocol required therapies, protocol procedures,
or the study as a whole at any time prior to study completion.
Subjects may be eligible for continued treatment with Amgen investigational product(s)
and/or other protocol required therapies by a separate protocol or as provided for by the
local country’s regulatory mechanism, based on parameters consistent with Section 12.1.
8.3 Reasons for Removal From Treatment or Study
8.3.1 Reasons for Removal From Treatment
Reasons for removal from protocol-required investigational product(s) or procedural
assessments include any of the following:
 subject request
 adverse event
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 intolerance to AMG 510
 death
 lost to follow-up
 decision by Sponsor
 non-compliance
 requirement for alternative therapy
 disease progression as defined by RECIST 1.1 criteria (Appendix D) or disease
progression accompanied by worsening of symptoms or deterioration of the subject’s
general condition.
 pregnancy

 
 
  
8.3.2 Reasons for Removal From Study
Reasons for removal of a subject from the study are:
 decision by sponsor
 withdrawal of consent from study
 death
 lost to follow-up
9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING
9.1 Definition of Safety Events
9.1.1 Adverse Events
An adverse event is defined as any untoward medical occurrence in a clinical trial 
subject. The event does not necessarily have a causal relationship with study treatment. 
The investigator is responsible for ensuring that any adverse events observed by the
investigator or reported by the subject are recorded in the subject’s medical record.
The definition of adverse events includes worsening of a pre-existing medical condition.
Worsening indicates that the pre-existing medical condition or underlying disease (eg,
diabetes, migraine headaches, gout) has increased in severity, frequency, and/or
duration more than would be expected and/or has an association with a significantly
worse outcome than expected. A pre-existing condition that has not worsened more
than anticipated (ie, more than usual fluctuation of disease) during the study, or involves
an intervention such as elective cosmetic surgery or a medical procedure while on study,
is not considered an adverse event.
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If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the highest grade on the Events eCRF.
For situations when an adverse event or serious adverse event is due to non-small cell
carcinoma of lung, colorectal cancer, or pancreatic adenocarcinoma report all known 
signs and symptoms. Death due to disease progression in the absence of signs and 
symptoms should be reported as the primary tumor type (eg, metastatic pancreatic
cancer).
Note: The term “disease progression” should not be used to describe the adverse
event.
The investigator’s clinical judgment is used to determine whether a subject is to be
removed from treatment due to an adverse event. In the event a subject, or subject’s 
legally acceptable representative requests to withdraw from protocol-required therapies
or the study due to an adverse event, refer to Section 8.1 for additional instructions on
the procedures recommended for safe withdrawal from protocol-required therapies or the 
study.
9.1.2 Serious Adverse Events
A serious adverse event is defined as an adverse event that meets at least 1 of the
following serious criteria:
 fatal
 life threatening (places the subject at immediate risk of death)
 requires in subject hospitalization or prolongation of existing hospitalization
 results in persistent or significant disability/incapacity
 congenital anomaly/birth defect
 other medically important serious event
An adverse event would meet the criterion of “requires hospitalization”, if the event
necessitated an admission to a health care facility (eg, overnight stay).
If an investigator considers an event to be clinically important, but it does not meet any of
the serious criteria, the event could be classified as a serious adverse event under the
criterion of “other medically important serious event”. Examples of such events could
include allergic bronchospasm, convulsions, blood dyscrasias, drug induced liver injury
(DILI) (see Appendix F for DILI reporting criteria), or events that necessitate an
emergency room visit, outpatient surgery, or urgent intervention.
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9.2 Safety Event Reporting Procedures
9.2.1 Adverse Events
9.2.1.1 Reporting Procedures for Adverse Events That do not Meet Serious
Criteria
The investigator is responsible for ensuring that all adverse events observed by the
investigator or reported by the subject that occur after enrollment through the safety 
follow-up visit are reported using the Event CRF.
The investigator must assign the following adverse event attributes:
 Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms),
 Dates of onset and resolution (if resolved),
 Severity and/or toxicity per protocol,
 Assessment of relatedness to investigational product and
 Action taken.
The adverse event grading scale used will be the CTCAE version 5.0. The grading scale 
used in this study is described in Appendix A The investigator must assess whether the 
adverse event is possibly related to AMG 510  For each agent 
this relationship is indicated by a “yes” or “no” response to the questions: ‘Is there a
reasonable possibility that the event may have been caused by investigational 
product?’ and  
The investigator must assess whether the adverse event is possibly related to any study
mandated activity (eg, administration of investigational product, protocol-required
therapies, use of medical device(s) and/or procedure (including any screening
procedure(s)). This relationship is indicated by a “yes” or “no” response to the question:
“Is there a reasonable possibility that the event may have been caused by a study
activity (eg, administration of investigational product, protocol-required therapies, use of
medical device(s)), and/or procedure”?
The investigator is responsible for reviewing laboratory test results and determining
whether an abnormal value in an individual study subject represents a clinically
significant change from the subject’s baseline values. In general, abnormal laboratory
findings without clinical significance (based on the Investigator's judgment) are not to be
recorded as adverse events. However, laboratory value changes that require treatment
or adjustment in current therapy are considered adverse events. Where applicable,
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clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse
event.
The investigator is expected to follow reported adverse events until stabilization or
reversibility.
9.2.1.2 Reporting Procedures for Serious Adverse Events
The investigator is responsible for ensuring that all serious adverse events observed by
the investigator or reported by the subject that occur after signing of the informed
consent through 30 days after the last day of the dosing interval of investigational
product are recorded in the subject’s medical record and are submitted to Amgen.
Serious adverse events observed by the investigator or reported by the subject that 
occur after the safety follow-up visit through the end of the long-term follow-up period 
should be reported if there is a reasonable possibility that the event may have been 
caused by AMG 510.  All serious adverse events must be submitted to Amgen within
24 hours following the investigator’s knowledge of the event via the Event CRF.
If the electronic data capture (EDC) system is unavailable to the site staff to report the
serious adverse event, the information is to be reported to Amgen via an electronic
Serious Adverse Event (eSAE) Contingency Report Form within 24 hours of the
investigator’s knowledge of the event. See Appendix B for a sample of the Serious
Adverse Event Worksheet/electronic Serious Adverse Event Contingency Report Form.
The investigator must assess whether the serious adverse event is possibly related to
the investigational product. This relationship is indicated by a “yes” or “no” response to
the question: Is there a reasonable possibility that the event may have been caused by
the investigational product(s), and/or other protocol-required therapies? Relatedness
means that there are facts or reasons to support a relationship between investigational
product and the event.
The investigator is expected to follow reported serious adverse events until stabilization
or reversibility.
New information relating to a previously reported serious adverse event must be
submitted to Amgen. All new information for serious adverse events must be sent to
Amgen within 24 hours following knowledge of the new information. If specifically
requested, the investigator may need to provide additional follow-up information, such as
discharge summaries, medical records, or extracts from the medical records.
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Information provided about the serious adverse event must be consistent with that
recorded on the Event CRF.
If a subject is permanently withdrawn from protocol-required therapies because of a
serious adverse event, this information must be submitted to Amgen.
Amgen will report serious adverse events and/or suspected unexpected serious adverse
reactions as required to regulatory authorities, investigators/institutions, and IRBs/IECs
in compliance with all reporting requirements according to local regulations and good
clinical practice.
The investigator is to notify the appropriate IRB/IEC of serious adverse events occurring
at the site and other adverse event reports received from Amgen, in accordance with
local regulatory requirements and procedures.
9.2.1.3 Reporting Serious Adverse Events After the Protocol-required
Reporting Period
There is no requirement to monitor study subjects for serious adverse events following
the protocol-required reporting period or after end of study. However, these serious
adverse events can be reported to Amgen. In some countries (eg, European Union [EU]
member states), investigators are required to report serious adverse events that they
become aware of after end of study. If serious adverse events are reported, the
investigator is to report them to Amgen within 24 hours following the investigator’s
knowledge of the event.
Serious adverse events reported outside of the protocol-required reporting period will be
captured within the safety database as clinical trial cases for the purposes of expedited
reporting.
9.3 Pregnancy and Lactation Reporting
If a female subject becomes pregnant, or a male subject fathers a child, while the subject
is taking AMG 510 report the pregnancy to Amgen Global Patient 
Safety as specified below.
In addition to reporting any pregnancies occurring during the study, investigators should
report pregnancies that occur in a female subject through 37 days after the last dose of
AMG 510  
or in a male subject's female partner through
97 days after the last dose of AMG 510 .  Female subjects who 
become pregnant while on study or within 37 days after receiving the last dose of study 
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drug will not receive subsequent scheduled doses and will be followed for safety until 
end-of-study visit.
The pregnancy should be reported to Amgen Global Patient Safety within 24 hours of the 
investigator’s knowledge of the pregnancy. Report a pregnancy on the Pregnancy
Notification Worksheet (Appendix C). Amgen Global Patient Safety will follow-up with
the investigator regarding additional information that may be requested.
If a female subject becomes pregnant during the study, the investigator should attempt to 
obtain information regarding the birth outcome and health of the infant.
If the outcome of the pregnancy meets a criterion for immediate classification as a
Serious Adverse Event (eg, female subject experiences a spontaneous abortion,
stillbirth, or neonatal death or there is a fetal or neonatal congenital anomaly) the
investigator will report the event as a Serious Adverse Event.
If a female breastfeeds while taking protocol-required therapies report the lactation case
to Amgen as specified below.
In addition to reporting a lactation case during the study, investigators should report
lactation cases that occur through 37 days after the last dose of AMG 510  
 
Any lactation case should be reported to Amgen Global Patient Safety within 24 hours of
the Investigator’s knowledge of event. Report a lactation case on the Lactation
Notification Worksheet (Appendix C). Amgen Global Patient Safety will follow-up with
the investigator regarding additional information that may be requested.  If a male
subject's female partner becomes pregnant, the investigator should discuss obtaining
information regarding the birth outcome and health of the infant from the pregnant 
partner.
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10. STATISTICAL CONSIDERATIONS
10.1 Study Endpoints, Analysis Sets, and Covariates
10 .1 .1 Study Endpoints
10.1.1.1 Phase 1
10.1.1.1.1 Monotherapy (Parts 1a, 1b, and 2a)
10.1.1.1.1.1 Primary Endpoints:
 Safety: subject incidence of treatment-emergent adverse events, treatment-related 
adverse events, and clinically significant changes in vital signs, physical 
examinations, ECGs, and clinical laboratory tests
 Subject incidence of DLT
10.1.1.1.1.2 Secondary Endpoints:
 PK parameters of AMG 510 including, but not limited to Cmax, time to achieve Cmax
(tmax), and AUC
 ORR, DOR, DCR, PFS, duration of stable disease, and TTR measured by CT or 
MRI and assessed per RECIST 1.1.  Response will be assessed by independent 
radiologic review.  Complete response and PR require confirmatory CT or MRI 
repeat assessment 4 weeks after the first detection of response.
 PK parameters of AMG 510 including, but not limited to, Cmax, tmax, and AUC in the 
fed and fasted state
 AMG 510 exposure/QTc interval relationship
10.1.1.1.1.3 Exploratory Endpoints:
 AMG 510 exposure/safety and exposure/efficacy relationships
 AMG 510 excretion in urine
 Characterization of potential metabolites of AMG 510 in plasma and urine, if 
appropriate
 Pharmacodynamic changes observed in blood and/or biopsies if available
 Quantification of biomarker expression at protein, RNA, and DNA levels, as 
appropriate
 Potential biomarkers by biochemical and/or genetic analysis of blood and/or tumor 
tissue samples
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10.1.1.2 Phase 2 (Monotherapy)
10.1.1.2.1 Primary Endpoint
 Objective response rate (ORR = CR + PR), measured by CT or MRI and assessed 
per RECIST 1.1.  Response will be assessed by independent radiologic review.  
Complete response and PR require confirmatory CT or MRI repeat assessment 
4 weeks after the first detection of response.
10.1.1.2.2 Secondary Endpoints
 DOR - defined as time from first evidence of confirmed PR or CR to disease 
progression or death due to any cause, whichever occurs first.  Subjects without a 
duration ending event will be censored at their last evaluable disease assessment 
date.  Progression will be based on an independent radiologic assessment of 
disease response per RECIST 1.1.
 DCR defined as CR + PR + stable disease rate measured as described for ORR.
 PFS - defined as time from first dose of AMG 510 until disease progression or death 
from any cause, whichever occurs first.  Subjects who do not progress or die will be 
censored at their last evaluable disease assessment date.  Progression will be on an 
independent radiologic assessment of disease response per RECIST 1.1.
 OS - defined as time from first dose of AMG 510 until death from any cause.  
Subjects who do not die will be censored at the date of last contact. 
 PFS rate at 6 months and 12 months.
 OS rate at 12 months.
 Incidence and severity of adverse events.
 PK parameters of AMG 510 including, but not limited to, Cmax, tmax, and AUC.
 TTR - defined as time from first dose of AMG 510 until the first evidence of 
confirmed PR or CR.
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10.1.1.2.3 Exploratory Endpoints
 AMG 510 exposure/safety and exposure/efficacy relationships
 Pharmacodynamic changes observed in blood and/or biopsies if available
 Biomarkers of response and resistance to AMG 510 at the time of progression
 Quantification of biomarker expression at protein, RNA, and DNA levels, as 
appropriate
 Potential biomarkers by biochemical and/or genetic analysis of blood and/or 
tumor tissue samples
 Changes in cancer-specific symptoms and overall health status using 
subject-reported outcome instruments:
 Impact of treatment on disease-related symptoms and HRQOL (instruments; 
EORTC QLQ-C30 + disease-specific modules QLQ LC13 and NSCLC SAQ for 
NSCLC, and QLQ Pan 26 for pancreatic cancer) 
 Treatment-related symptoms and impact on the subject (EORTC QLQ-C30, 
selected questions from the PRO-CTCAE library and a single item about 
symptom bother, item GP5 of the FACT-G)
 Physical function (instrument: EORTC QLQ-C30, Physical function scale)
10.1.2 Analysis Sets
10.1.2.1 Safety Analysis Set
The safety analysis set (SAS) will consist of all subjects who receive at least one dose of 
AMG 510.  The analysis of all safety endpoints, unless noted otherwise, will be 
conducted on the SAS.  For the phase 1 part of the study, the analysis of DLT will be 
restricted to DLT-evaluable subjects (see Section 3.3 for definition).
10.1.2.2 Pharmacokinetic Analysis Set
The PK Analysis Set will contain all subjects who have received at least 1 dose of the
investigational product and have at least 1 PK sample collected. These subjects will be
evaluated for PK analysis unless the number of data points required for analysis is not
enough, or significant protocol deviations have affected the data, or if key dosing or
sampling information is missing.
10.1.2.3 Phase 1 Monotherapy RP2D ORR Analysis Set
The phase 1 monotherapy RP2D ORR analysis set (P1OAS) will consist of all 
subjects with confirmed KRASp.G12C status whose initial dose of AMG 510 is at 
the RP2D and received at least 1 dose of AMG 510 in the phase 1 monotherapy 
dose exploration part, or the phase 1 monotherapy dose expansion part, and had 
at least 6-week response data.  Subjects who stopped disease assessments prior 
to 6 weeks will be included in this analysis set if the data cutoff is at least 6 weeks 
after their first dose date.  The futility and efficacy thresholds will be calculated for 
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monitoring the antitumor activity of monotherapy of AMG 510 during phase 1 
expansion part using this analysis dataset.
10.1.2.4 Phase 2 Full Analysis Set
The phase 2 full analysis set (P2FAS) will consist of all phase 2 subjects who 
received at least 1 dose of AMG 510.  The primary analysis (excluding the analysis 
of ORR) and the final analysis will be performed on the P2FAS.
10.1.2.5 Phase 2 ORR Analysis Set
The phase 2 ORR analysis set (P2OAS) will consist of all subjects in the phase 2 
full analysis set who have had at least 6 weeks response data starting from day 1. 
Subjects who stopped disease assessments prior to 6 weeks will be included in 
this analysis set if the data cutoff is at least 6 weeks after their first dose date.  
The interim futility analysis and primary analysis of ORR will be performed on the 
P2OAS.  
10.1.3 Covariates and Subgroups
10.1.3.1 Covariates
The relationship between covariates and efficacy endpoints may be explored if 
appropriate.
10.1.3.2 Subgroups
Subgroup analysis will be performed by tumor type.  Other potential subgroups will be 
pre-specified in the statistical analysis plan.
10.2 Sample Size Considerations
10.2.1 Phase 1
Phase 1 part 1 – Dose Exploration:  No more than 92 subjects will be enrolled in the 
dose exploration part of the study.  Approximately 30 subjects enrolled in cohorts of 
n = 2-4 subjects (n = 4-8 at the highest planned dose level) will be used to estimate the
monotherapy QD dosing MTD.  
 
 
 
  These sample sizes are based on practical considerations 
and are consistent with conventional oncology studies with the objective to estimate the 
MTD and to evaluate initial safety and tolerability.  The probability of observing at least 
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1 DLT if the true DLT rate is 10 to 33% is provided in Table 8 for various number of 
subjects.
Table 8.  Probability of Observing at Least 1 DLT
Number of Subjects 10% DLT Rate 33% DLT Rate
2 19 55
3 27 70
4 34 80
6 47 91
8 57 96
10 65 98
12 72 99
DLT = dose limiting toxicity
In order to better estimate the RP2D and to better characterize the safety, efficacy, PK,
and pharmacodynamics for AMG 510 monotherapy, an additional 20 to 40 subjects may 
be enrolled to one or more monotherapy dose levels that have been shown to be safe 
and tolerable from which at least 6 subjects will be evaluated for food effect. The 
sample size of at least 6 subjects for food effect assessment is based on practical 
considerations and judged sufficient for the evaluation; no formal calculation was made.
Phase 1 part 2– Dose Expansion: The maximum sample size in the dose expansion 
part to evaluate AMG 510 monotherapy is 60 in subjects with KRAS p. G12C mutant 
advanced solid tumor types.  The actual sample size will depend on DLRT review 
with monitoring criteria defined in Section 10.4.1.2.  With 20 subjects receiving 
monotherapy AMG 510 in dose expansion, there is an 88% to 99% probability of 
observing at least 1 adverse event if the true event rate is 10% to 20% with 60 subjects 
there is a 45% to 95% probability of observing at least 1 adverse event if the true event 
rate is 1% to 5%.  
The ORR will be reported by tumor types.  For NSCLC, with 60 subjects, 95% of the 
times the true ORR will be between 0.188 and 0.432, when the observed ORR is 0.3; 
and when the true ORR is 0.3, the chance that the 95% CIs of ORR will be > 0.15 is 
76%.  For CRC, with 60 subjects, 95% of the times the true ORR will be between 
0.108 and 0.323, when the observed ORR is 0.2; and when the true ORR is 0.2, the 
chance that the 95% CIs of ORR will be > 0.05 is 93%.  Below table describes the 
scenarios with sample size of 20 to 60.
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Table 9.  Sample Size Justification
NSCLC
Sample 
Size
95% Exact CI of the True ORR 
Given an Observed ORR = 0.3
Probability (ORR 95% CI Lower Bound 
> 0.15) Given True ORR = 0.3)
20 (0.119, 0.543) 39%
30 (0.147, 0.494) 41%
40 (0.166, 0.465) 56%
50 (0.179, 0.446) 67%
60 (0.188, 0.432) 76%
CRC
Sample 
Size
95% Exact CI of the True ORR 
Given an Observed ORR = 0.2
Probability (ORR 95% CI Lower 
Bound > 0.05) given true ORR = 0.2)
20 (0.057, 0.437) 59%
30 (0.077, 0.386) 75%
40 (0.091, 0.356) 84%
50 (0.100, 0.337) 90%
60 (0.108, 0.323) 93%
ORR = objective response rate
 
 
 
 
  
10.2.2 Phase 2
The phase 2 part of the study will target an ORR over a benchmark rate to exclude 
based on the lower limit of the 95% CI for the observed ORR for each tumor type 
(NSCLC, CRC).
For NSCLC subjects, a large phase 3 trial (REVEL) for second-line treatment after 
disease progression on platinum-based therapy showed that an ORR of 23% was 
observed with ramucirumab plus docetaxel (Garon et al 2014, NCT01168973).
For CRC subjects, althouth the treatment for ≥ third line subjects with Regorafenib 
or TAS 102 has demonstrated ORR of only 1% to 4% (Li et al, 2015; 
Mayer et al, 2015; Grothey et al, 2013), these therapies has demonstrated survival 
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benefits. To justify the use of surrogate endpoint ORR in this phase 2 trial, a 
higher benchmark ORR for CRC is selected.  
The benchmark ORR to exclude is selected as 23% for NSCLC and 10% for CRC. 
No benchmark ORR will be set for tumor types other than NSCLC and CRC 
because of low expected enrollment. A sample size of 105 subjects for NSCLC 
and 60 subjects for CRC will provide approximately a 90% probability that the 
lower limit of the ORR 95% CI exceeds the tumor-specific benchmark ORR.
The minimum observed ORRs that would exclude the benchmark ORR with 105 
NSCLC subjects and 60 CRC subjects are 32% and 20%, respectively. 
10.3 Adaptive Design
For phase 1 dose exploration, the adaptive features of the BLRM design are described in
Appendix E.  For phase 1 dose expansion, the futility and efficacy thresholds are 
calculated and specified in Section 10.4.1.2.  For phase 2, futility analyses are 
described in Section 10.4.1.3.2.
10.4 Planned Analyses
10.4.1 Interim Analyses
10.4.1.1 Phase 1 (Part 1 - Dose Exploration)
Safety data will be reviewed on an ongoing basis by Amgen. Based on accumulating 
toxicity information, BLRM will be used to make dosing recommendations. After each 
cohort completes enrolment and after all DLT-evaluable subjects within the cohort have 
completed the DLT window, Amgen, in consultation with DLRT, will review the DLRM 
recommended dose level and will review all available cumulative data by cohort prior to 
making dose exploration decisions.  As a sensitivity analysis, a one-parameter Continual 
Reassessment Method (CRM) model may be used to estimate the dose-toxicity
relationship to help making dose escalation decisions.  Adverse events and DLTs 
observed in all subjects will be evaluated continually and considered in all enrollment
and dosing decisions.
The DLRT will be composed of the investigators, Amgen Medical Monitor, Amgen Global 
Safety Officer, Amgen Early Clinical Development Manager, and Biostatistics 
representative.  Additional members may be added as needed (eg, PK Scientist).  A 
quorum, defined as the majority of actively screening and enrolling investigators or their 
qualified designee (ie, sub-investigator possessing hard copy documentation [eg, email] 
of the investigator’s recommendation regarding the dose level review), must be in 
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attendance for DLRM to proceed.  The DLRM will be rescheduled if a quorum is not 
reached.  Voting members of the DLRM will include the Amgen medical monitor, the 
Amgen global safety officer, and all actively screening and enrolling investigators or their 
qualified sub-investigator designee.  The team may recommend escalation to the next 
planned dose, escalation to an intermediate dose (a dose lower than the next planned 
dose), continuation or delay in dosing, repetition or expansion of a cohort, de-escalation 
to a lower dose, or termination of the study.  The Amgen medical monitor and Global 
Safety Officer and the majority of actively screening and enrolling investigators 
participating in the DLRM must cast a positive vote indicating an acceptable safety 
profile was observed for AMG 510 to allow the dose level modification and/or cohort 
continuation/expansion to proceed.  All available study data including demographics, 
smoking status (prior and current), medical history, concomitant medications, AEs, 
ECGs, vital signs, laboratory results, emerging PK or pharmacodynamics, and emerging 
efficacy data will be reviewed.
The following recommendations will be made by the DLRT:
 dose escalation/de-escalation decisions
 number of subjects per cohort
 continuation, delay or termination of dosing
 change of the dosing schedule
 termination of the study
10.4.1.2 Phase 1 (Part 2 - Dose Expansion)
This same DLRT will be responsible for reviewing data in the dose expansion 
phase to confirm the RP2D and determine the benefit/risk of proceeding to the 
phase 2 part of the study.  The dose expansion part of the study (phase 1 - part 2) can 
open once an MTD or a RP2D and dosing schedule has been estimated in the dose 
exploration part of the study (phase 1 – part 1).  If no DLT is observed in phase 1 – part 
1, the RP2D will be estimated based on composite review of PK, overall 
safety/tolerability, and observed responses.  Further confirmation of the RP2D dose will 
be sought in the phase 1 part 2 dose expansion.
In the dose expansion, additional subjects will be enrolled at the RP2D estimated in the 
phase 1 part 1 dose exploration. After a minimum of 20 subjects have been enrolled to 
the initial estimated monotherapy RP2D (including subjects enrolled to the RP2D in 
either the dose exploration [approximately 6] or the dose expansion [approximately 14]
parts of the study) and have completed the 21-day DLT period, and after a minimum of 
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10 of these subjects have at least 6 weeks of response data (including all previous data 
from the dose expansion and backfill cohorts), the DLRT will review all available safety, 
laboratory, PK, and efficacy (physician assessment) data.
After the first review has been conducted, if a decision is made to continue to obtain 
additional data at the initial estimated RP2D prior to proceeding to phase 2, the intervals 
for subsequent reviews will be determined by the DLRT but should occur within a 
maximum of 20 additional subjects enrolled and dosed for 21 days.  The maximum 
number of subjects that may be enrolled to the initial estimated RP2D in the 
monotherapy dose expansion group, without confirmation of this dose for phase 2, will 
not exceed 60.  If another dose (or schedule) needs to be explored, additional subjects 
on that dose (or schedule), up to a total of 60, may be enrolled. 
Based on emerging clinical efficacy data, the number of subjects with specific tumor 
types may be restricted/specified in the expansion part.  
Antitumor activity will be monitored in terms of ORR by tumor types (NSCLC, 
CRC). Futility and efficacy thresholds will be calculated using Bayesian posterior 
probability approach based on the cumulative efficacy data and it will serve as a 
guidance to the DLRT.  Enrollment will not be held to conduct this assessment.    
Whenever DLRT will review the data, and there are at least 5 evaluable subjects in 
the tumor type, the futility and efficacy thresholds for that tumor type will be 
calculated using all the cumulative efficacy data in phase 1 Monotherapy RP2D 
ORR Analysis Set to provide the guidance.  In the calculation of thresholds, a 
response is defined as either a confirmed or unconfirmed CR or PR as per 
RECIST 1.1. 
10.4.1.2.1 Futility Thresholds
For NSCLC, the futility thresholds are calculated such that the Bayesian posterior 
probability of a true ORR ≤ 0.15 is > a high probability of 75%. For CRC, the futility 
thresholds are calculated such that the Bayesian posterior probability of a true 
ORR ≤ 0.05 is > than a high probability of 75%.  A noninformative prior distribution 
of beta (1, 1) will be used.
NSCLC: probability (ORR ≤ 0.15) > 75%
CRC: probability (ORR ≤ 0.05) > 75%
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10.4.1.2.2 Efficacy Thresholds
For NSCLC, the efficacy thresholds are calculated such that the Bayesian 
posterior probability of a true ORR > 0.25 is ≥ to a high probability of 60%.  For 
CRC, the efficacy thresholds are calculated such that the Bayesian posterior 
probability of a true ORR > 0.1 is ≥ to a high probability of 60%.  A noninformative 
prior distribution of beta (1, 1) will be used. 
NSCLC: probability [ORR > 0.25] ≥ 60%
CRC: probability [ORR > 0.1] ≥ 60%
Table 10 and Table 11 are look up tables calculated for NSCLC and CRC, providing 
the detailed futility and efficacy thresholds with different numbers of 
response-evaluable subjects (having at least 6-week response data) when DLRT 
review the data. For example, at the time when DLRT plan to review the data, 
there are a total of 25 response-evaluable NSCLC subjects. If observing number 
of the response is ≤ 2, based on the table, the guidance will recommend not to 
continue due to the lack of efficacy. If observing number of the response is ≥ 7, 
the guidance will recommend continuing to phase 2. If the observing number of 
the response is in between and the total number of response-evaluable subjects 
at that RP2D has not reached the maximum 60, the guidance will recommend 
enrolling more patients in the phase 1 expansion cohort. 
The operating characteristics of these thresholds are demonstrated assuming a 
minimal of 5 response-evaluable subjects per tumor type for the first DLRT review 
and every 5 response-evaluable subjects thereafter. The actual sample size per 
tumor type at each look will depend on tumor type distribution.  Table 12 and 
Table 13 show the cumulative probabilities of recommending DLRT to stop the 
trial due to lack of efficacy and the cumulative probabilities of recommending 
DLRT to continue to phase 2 given the true ORR ranging from 0.1 to 0.5 for NSCLC 
subjects and 0.05 to 0.25 for CRC subjects.
A
pp
ro
ve
d 
  
Product:  AMG 510
Protocol Number:  20170543
Date:  22 May 2019 Page 113 of 158
CONFIDENTIAL
Table 10.  Look Up Table for NSCLC Subjects
Number of Subjects
Recommend Not to Continue if Observing the 
Number of Responses Below
5 ~ 7
Never stop for futility with this number of 
subjects
8 ~ 16 0
17 ~ 24 ≤ 1
25 ~ 31 ≤ 2
32 ~ 39 ≤ 3
40 ~ 47 ≤ 4
48 ~ 54 ≤ 5
55 ~ 60 ≤ 6
Number of Subjects
Recommend Go to Phase 2 if Observing the 
Number of Responses below
5 ~ 8 ≥ 2
9 ~ 11 ≥ 3
12 ~ 15 ≥ 4
16 ~ 19 ≥ 5
20 ~ 23 ≥ 6
24 ~ 26 ≥ 7
27 ~ 30 ≥ 8
31 ~ 34 ≥ 9
35 ~ 38 ≥ 10
39 ~ 42 ≥ 11
43 ~ 46 ≥ 12
47 ~ 50 ≥ 13
51 ~ 54 ≥ 14
55 ~ 57 ≥ 15
58 ~ 60 ≥ 16
NSCLC = non-small cell lung carcinoma
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Table 11.  Look Up Table for CRC Subjects
Number of 
Subjects
Recommend Not to Continue if Observing the Number of 
Responses Below
5 ~ 26 Never stop for futility with this number of subjects
27 ~ 52 0
53 ~ 60 ≤ 1
Number of 
Subjects
Recommend Go to Phase 2 if Observing the Number of Responses 
Below
5 ~ 12 ≥ 1
13 ~ 21 ≥ 2
22 ~ 31 ≥ 3
32 ~ 40 ≥ 4
41 ~ 49 ≥ 5
50 ~ 59 ≥ 6
60 ≥ 7
CRC = colorectal cancer
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Table 12.  Cumulative Probability of Go/NoGo for NSCLC Subjects
Number of 
Subjects
True ORR
0.1 0.3 0.5
NoGo Go NoGo Go NoGo Go
5 0% 8% 0% 47% 0% 81%
10 35% 11% 3% 67% 0% 96%
15 35% 13% 3% 77% 0% 99%
20 48% 13% 3% 79% 0% 99%
25 60% 13% 4% 83% 0% 100%
30 60% 13% 4% 85% 0% 100%
35 65% 13% 4% 86% 0% 100%
40 70% 13% 4% 87% 0% 100%
45 70% 13% 4% 89% 0% 100%
50 73% 13% 4% 90% 0% 100%
55 76% 13% 4% 90% 0% 100%
60 76% 13% 4% 91% 0% 100%
ORR = objective response rate. 
Numbers are for demonstration purpose.  The actual sample size per tumor type at each look will 
depend on tumor type distribution.  
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Table 13.  Cumulative Probability of Go/No Go for CRC Subjects
Number of 
Subjects
True ORR
0.05 0.15 0.25
NoGo Go NoGo Go NoGo Go
5 0% 23% 0% 56% 0% 76%
10 0% 40% 0% 80% 0% 94%
15 0% 41% 0% 84% 0% 96%
20 0% 45% 0% 89% 0% 99%
25 0% 46% 0% 91% 0% 99%
30 21% 47% 1% 93% 0% 100%
35 21% 48% 1% 94% 0% 100%
40 21% 48% 1% 95% 0% 100%
45 21% 48% 1% 96% 0% 100%
50 21% 48% 1% 96% 0% 100%
55 28% 49% 1% 96% 0% 100%
60 28% 49% 1% 96% 0% 100%
ORR = objective response rate.
Numbers are for demonstration purpose.  The actual sample size per tumor type at each look will 
depend on tumor type distribution.
Based on emerging clinical efficacy data, the number of subjects with specific 
tumor types may be restricted/specified in the expansion part.
The DLRT may also recommend that additional subjects be enrolled at this 
estimated monotherapy RP2D or that a dose reduction or alternate dosing 
regimen be explored before proceeding to phase 2. The decision to proceed to 
the phase 2 monotherapy will be based on the totality of data from both 
exploration and expansion parts of the study.  
A final estimate of the MTD and/or RP2D using BLRM will be evaluated and confirmed
utilizing all DLT-evaluable subjects from the dose exploration and the dose expansion
cohorts.
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10.4.1.3 Phase 2
10.4.1.3.1 Safety
A data review team (DRT), internal to Amgen but external to the study team, will assess 
safety after approximately 30, 50, 70, and 100 subjects have been treated for 21 days.  
Based on their reviews, the DRT will make recommendations to Amgen regarding the 
continuation of the study.  There will be no formal guidelines to stop for safety.  The DRT 
will consist of 3 or more members including 2 or more clinicians with relevant specialties 
and 1 or more statisticians.  The DRT will be supported by an independent statistician 
who is responsible for preparing reports that describe the ongoing clinical study data.  
Details regarding the responsibilities of the DRT and the independent statistician will be 
described in the DRT Charter.
10.4.1.3.2 Futility
The DRT will also oversee futility analyses performed by tumor type and based on 
the phase 2 ORR analysis set.  The interim futility analyses will be conducted in a 
continuous manner using Bayesian predictive probability (Lee and Liu, 2008) for 
NSCLC and CRC separately.  Interim futility analysis will be performed by tumor 
types (NSCLC, CRC).  For NSCLC subjects, it will begin after approximately 25 
response-evaluable subjects, defined as received at least 1 dose of AMG 510 and 
have had at least 6 weeks response data starting from day 1.  For CRC subjects, it 
will begin after approximately 20 response-evaluable subjects. Subjects who 
stopped disease assessments prior to 6 weeks will be included in this analysis if 
the data cutoff is at least 6 weeks after their first dose date.  Following this initial 
interim anlaysis, for each tumor type, subsequent interim analyses will be 
performed after every 10 subjects in each tumor type becomes response 
evaluable. 
The Go criterion will be met if the probability that the true ORR exceeds the 
benchmark ORR is ≥ to a high probability of:
Go Criterion for NSCLC: probability [ORR > 0.23] ≥ 80%
Go Criterion for CRC: probability [ORR > 0.1] ≥ 95%
Given the existing observed data during the continuous monitoring stage, the 
Bayesian predictive probability is obtained by calculating the probability of 
reaching a Go Criterion should the treatment group be enrolled and evaluated to 
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the maximum planned final sample size of 105 NSCLC subjects and 60 CRC 
subjects.  The Go criterion is for interim futility analysis purpose only. 
Futility will be met if it is predicted that there is a small probability of reaching a 
Go Criterion upon full enrollment of 105 NSCLC subjects and 60 CRC subjects 
given the existing observed data.  A noninformative prior distribution of beta (1, 1) 
will be used.
Futility NSCLS:  Predictive probability of a Go decision < 5%
Futility CRC: Predictive probability of a Go decision < 30%
Further enrollment may be terminated if futility is met.  The futility analyses will be 
based on site-assessed disease response and the futility rules will be nonbinding.  
Due to the efficacy already observed in NSCLC during dose escalation phase, 
there will be no enrollment pause for NSCLC during the futility analyses. 
Enrollment will be paused for CRC at the first interim futility analysis and may be 
paused at the subsequent interim analyses upon DRT’s recommendation.
The decision rule and operating charateristics for continuous monitoring of ORR 
in NSCLC subjects and CRC subjects are provided in Table 14 and Table 15, 
respectively. For example, observing 3 or fewer observed responders after 25 
NSCLC subjects have become evaluable would be considered futile due to a small 
probability of reaching a Go Criterion upon full enrollment of 105 subjects given 
the existing observed data. A
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Table 14.  Stopping Boundary and Operating Characteristics in NSCLC Subjects
Number 
of 
Subjects
Considered 
Futile If 
Observing 
Number of 
Responses
Cumulative Probability of Futility
True 
ORR=0.1
True 
ORR=0.2
True 
ORR=0.3
True 
ORR=0.4
True 
ORR=0.5
True 
ORR=0.6
25 ≤ 3 76% 23% 3% 0.2% 0.0% 0.0%
35 ≤ 5 89% 32% 4% 0.3% 0.0% 0.0%
45 ≤ 7 94% 39% 5% 0.3% 0.0% 0.0%
55 ≤ 10 98% 51% 6% 0.3% 0.0% 0.0%
65 ≤ 13 100% 63% 8% 0.3% 0.0% 0.0%
75 ≤ 16 100% 73% 10% 0.3% 0.0% 0.0%
85 ≤ 19 100% 80% 12% 0.4% 0.0% 0.0%
95 ≤ 22 100% 85% 14% 0.4% 0.0% 0.0%
105 ≤ 27 100% 94% 23% 0.5% 0.0% 0.0%
Average Number of 
Subjects
29 60 99 105 105 105
NSCLC = non-small cell lung carcinoma; ORR = objective response rate
Table 15.  Stopping Boundary and Operating Characteristics in CRC Subjects
Number 
of 
Subjects
Considered 
Futile If 
Observing 
Number of 
Responses
Cumulative Probability of Futility
True 
ORR=0.05
True 
ORR=0.1
True 
ORR=0.15
True 
ORR=0.2
True 
ORR=0.25
True 
ORR=0.3
20 ≤ 2 92% 68% 41% 20% 9% 4%
30 ≤ 3 96% 75% 45% 23% 10% 4%
40 ≤ 5 99% 85% 55% 27% 11% 4%
50 ≤ 7 100% 92% 63% 32% 12% 4%
60 ≤ 9 100% 95% 70% 35% 13% 4%
Average Number of 
Subjects 21 28 40 50 56 58
CRC = colorectal cancer; ORR = objective response rate
10.4.2 Primary Analysis
The primary analysis will occur after there are at least 105 NSCLC evaluable subjects 
or 60 CRC evaluable subjects in the phase 2 ORR analysis set, whichever occurs first.  
The data cutoff will be decided to allow sufficient time to demonstrate durability of 
ORR.  The data will be analyzed once they have been entered, cleaned, and locked.  
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The primary analysis will summarize for all tumor types even if it is triggered by 
105 NSCLC subjects or 60 CRC subjects.
10.4.3 Additional Analysis Subsequent to Primary Analysis
If the primary analysis is triggered by 105 NSCLC (60 CRC) subjects before 60 CRC 
(105 NSCLC) subjects become evaluable, a subsequent analysis will occur when 
60 CRC (105 NSCLC) subjects become evaluable in the phase 2 ORR analysis set.  
The data will be analyzed once they have been entered, cleaned, and locked.
10.4.4 Final Analysis
The final analysis will occur when the end of study as described in Section 3.4.2 has 
been reached.  The data will be analyzed once they have been entered, cleaned, and 
locked.  The purpose of this analysis is to summarize efficacy and safety after all 
subjects have complete follow-up.
10.5 Planned Methods of Analysis
10.5.1 General Considerations
Efficacy and safety analyses will pool together all tumor types and also present tumor 
types separately.  In addition, safety analyses will be summarized by planned dose level 
and treatment (monotherapy or combination therapy).  
Futility and efficacy threshold in phase 1 and futility interim in phase 2 will be based 
on site-assessed disease response per RECIST 1.1.  Primary, final, and any additional 
efficacy analyses will be based on an independent radiologic assessment of disease 
response per RECIST 1.1.
Nominal 95% confidence intervals will be calculated.
10.5.2 Efficacy Analysis
Endpoint Statistical Analysis Methods
Primary The percentage of subjects with an OR will be summarized along with a
Clopper-Pearson exact confidence interval.  Subjects without a post-baseline 
tumor assessment will be considered non-responders. 
Secondary DOR will be summarized with Kaplan-Meier quartiles and rates for select 
durations (eg, > 3, > 6, > 9, > 12 months).
Disease control will be analyzed by the same methods used to analyze OR.
OS will be summarized with Kaplan-Meier curves, quartiles, and rates for 
select timepoints (eg, 6 and 12 months).
PFS will be summarized using the same methods as OS.
TTR will be summarized by the nonmissing sample size (n), mean, 
standard deviation, median, minimum, and maximum for responders
Exploratory Will be described in the statistical analysis plan finalized before database lock
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10.5.3 Safety Analyses
Unless otherwise specified, analyses of safety endpoints will be done using subjects in 
the SAS, which includes subjects that are enrolled and received at least 1 dose of
AMG 510.  In addition, the analyses below apply to both the phase 1 and phase 2 
portions of the study unless otherwise specified.
10.5.3.1 Dose Limiting Toxicity
Phase 1 Monotherapy:  The number and subject incidence of DLTs will be tabulated by 
dose level.  Subject incidence of DLTs will be used to fit the BLRM model to estimate the 
probability of having a DLT across dose levels; the median probability of a DLT and 95% 
credible interval will be reported (see Appendix E for details on BLRM model).
Phase 1 Combination Therapy:  The number and subject incidence of DLTs will be 
tabulated by dose level.
10.5.3.2 Adverse Events
Subject incidence of all treatment-emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, 
and adverse events leading to withdrawal from investigational product or other 
protocol-required therapies will also be provided.
10.5.3.3 Clinical Laboratory Tests
Summaries of laboratory data over time and/or changes from baseline over time will be
provided. Tables of maximum shifts from baseline for selected laboratory values may
also be provided.
10.5.3.4 Vital Signs
Summaries of vital signs data over time and/or changes from baseline over time will be
provided.
10.5.3.5 Electrocardiograms
Summaries over time and/or changes from baseline over time will be provided for all
ECG parameters.  Subjects’ maximum change from baseline in QT interval corrected by
Fridericia’s formula will be categorized and the number and percentage of subjects in
each group will be summarized.
Subjects’ maximum post baseline values will also be categorized and the number and
percentage of subjects in each group will be summarized.
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10.5.3.6 Exposure to Investigational Product
Descriptive statistics of cumulative dose, number of cycles, duration of usage, number 
and percentage of subjects with dose modifications and reasons will be produced to 
describe the exposure to AMG 510.
 
10.5.3.8 Exposure to Concomitant Medication
Number and proportion of subjects receiving therapies of interest will be summarized by 
preferred term or category for each treatment group as coded by the World Health 
Organization Drug dictionary.
10.5.3.9 Other Analyses
Phase 1:  The food-effect cohort PK parameter estimates will help assess the impact of 
food on the PK of AMG 510.  The geometric means and 90% CI for the ratio of the 
geometric means (fed state/fasted state) will be estimated using a mixed effects model.  
The model will use the log-transformed PK parameters as the dependent variable (or 
response) and treatment conditions (fed versus fasted) as the independent variable.  
The median of tmax will be compared between fasted and fed conditions as well.
The relationship between AMG 510 exposure and QT/QTc interval changes will be 
inspected graphically and model-based PK/pharmacodynamic analyses may be 
conducted to examine the relationship further.
10.5.4 Pharmacokinetics Analysis
In phase 1, for AMG 510, PK parameters including, but not limited to Cmax, tmax, and AUC
will be determined from the concentration-time profile using standard non-compartmental
approaches and considering the profile over the complete sampling interval. Based on
the review of the data, analyses to describe the relationship between AMG 510 exposure
and either pharmacodynamic effect and/or clinical outcome may also be performed.
In phase 2, for AMG 510, PK parameters (eg, Cmax, tmax and AUC) will be determined 
where possible.  Based on the review of the data, analyses to describe the relationship 
between AMG 510 exposure and either pharmacodynamic effect and/or clinical outcome 
may also be performed.
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11. REGULATORY OBLIGATIONS
11.1 Informed Consent
An initial sample ICF is provided for the investigator to prepare the informed consent
document to be used at his or her site. Updates to the template are to be communicated
formally in writing from the Amgen Study Manager to the investigator. The written ICF is
to be prepared in the language(s) of the potential subject population.
Before a subject’s participation in the clinical study, the investigator is responsible for
obtaining written informed consent from the subject or legally acceptable representative
after adequate explanation of the aims, methods, anticipated benefits, and potential
hazards of the study and before any protocol specific screening procedures or any
investigational product(s) is/ are administered. A legally acceptable representative is an
individual or other body authorized under applicable law to consent, on behalf of a
prospective subject, to the subject’s participation in the clinical study.
The investigator is also responsible for asking the subject if the subject has a primary
care physician and if the subject agrees to have his/her primary care physician informed
of the subject’s participation in the clinical study. If the subject agrees to such
notification, the investigator is to inform the subject’s primary care physician of the
subject’s participation in the clinical study. If the subject does not have a primary care
physician and the investigator will be acting in that capacity, the investigator is to
document such in the subject’s medical record.
The acquisition of informed consent and the subject’s agreement or refusal of his/her
notification of the primary care physician is to be documented in the subject’s medical
records, and the ICF is to be signed and personally dated by the subject or a legally
acceptable representative and by the person who conducted the informed consent
discussion. The original signed ICF is to be retained in accordance with institutional
policy, and a copy of the signed ICF is to be provided to the subject or legally acceptable
representative.
If a potential subject is illiterate or visually impaired and does not have a legally
acceptable representative, the investigator must provide an impartial witness to read the
ICF to the subject and must allow for questions. Thereafter, both the subject and the
witness must sign the ICF to attest that informed consent was freely given and
understood.
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11.2 Institutional Review Board/Independent Ethics Committee
A copy of the protocol, proposed ICF, other written subject information, and any
proposed advertising material must be submitted to the IRB/IEC for written approval. A
copy of the written approval of the protocol and ICF must be received by Amgen before
recruitment of subjects into the study and shipment of Amgen investigational product.
The investigator must submit and, where necessary, obtain approval from the IRB/IEC
for all subsequent protocol amendments and changes to the informed consent
document. The investigator is to notify the IRB/IEC of deviations from the protocol or
serious adverse events occurring at the site and other adverse event reports received
from Amgen, in accordance with local procedures.
The investigator is responsible for obtaining annual IRB/IEC approval/renewal
throughout the duration of the study. Copies of the investigator’s reports and the
IRB/IEC continuance of approval must be sent to Amgen.
11.3 Subject Confidentiality
The investigator must ensure that the subject’s confidentiality is maintained:
 Subjects are to be identified by a unique subject identification number.
 Where permitted, date of birth is to be documented and formatted in accordance with
local laws and regulations.
 On the demographics page, in addition to the unique subject identification number,
include the age at the time of enrollment.
 For Serious Adverse Events reported to Amgen, subjects are to be identified by their
unique subject identification number, initials (for faxed reports, in accordance with
local laws and regulations), and date of birth (in accordance with local laws and
regulations).
 Documents that are not submitted to Amgen (eg, signed ICFs) are to be kept in strict
confidence by the investigator, except as described below.
In compliance with governmental/ICH GCP Guidelines, it is required that the investigator
and institution permit authorized representatives of the company, of the regulatory
agency(s), and the IRB/IEC direct access to review the subject’s original medical records
for verification of study related procedures and data. Direct access includes examining,
analyzing, verifying, and reproducing any records and reports that are important to the
evaluation of the study. The investigator is obligated to inform and obtain the consent of
the subject to permit named such individuals to have access to his/her study related
records, including personal information.
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11.4 Investigator Signatory Obligations
Each clinical study report is to be signed by the investigator or, in the case of multi-center 
studies, the coordinating investigator.
The coordinating investigator, identified by Amgen, will be any or all of the following:
 a recognized expert in the therapeutic area
 an investigator who provided significant contributions to either the design or 
interpretation of the study
 an investigator contributing a high number of eligible subjects
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS
12.1 Protocol Amendments and Study Termination
Amgen may amend the protocol at any time. After Amgen amends the protocol, the
Investigator is to return the signed Investigator’s Signature page confirming agreement to 
continue participation in the study according to the amendment. The IRB/IEC must be
informed of all amendments and give approval. The investigator must send a copy of the 
approval letter from the IRB/IEC and amended protocol Investigator’s Signature page to
Amgen prior to implementation of the protocol amendment at their site.
Amgen reserves the right to terminate the study at any time. Both Amgen and the
investigator reserve the right to terminate the Investigator’s participation in the study
according to the Clinical Trial Agreement. The investigator is to notify the IRB/IEC in
writing of the study’s completion or early termination and send a copy of the notification
to Amgen.  Subjects may be eligible for continued treatment with Amgen investigational
product by an extension protocol or as provided for by the local country’s regulatory
mechanism. However, Amgen reserves the unilateral right, at its sole discretion, to
determine whether to supply Amgen investigational product(s), and by what mechanism, 
after termination of the study and before it is available commercially.
12.2 Study Documentation and Archive
The investigator is to maintain a list of appropriately qualified persons to whom he/she
has delegated study duties. All persons authorized to make entries and/or corrections on
CRFs will be included on the Amgen Delegation of Authority Form.
Source documents are original documents, data, and records from which the subject’s
CRF data are obtained. These include but are not limited to hospital records, clinical
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs,
and correspondence.  The CRF is the source document for ethnic origin.
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The Investigator and study staff are responsible for maintaining a comprehensive and
centralized filing system of all study related (essential) documentation, suitable for
inspection at any time by representatives from Amgen and/or applicable regulatory
authorities.
Elements to include:
 Subject files containing completed CRF, ICFs, and subject identification list
 Study files containing the protocol with all amendments, Investigator’s Brochure,
copies of prestudy documentation, and all correspondence to and from the IRB/IEC
and Amgen
 Investigational product-related correspondence including Proof of Receipts (POR),
Investigational Product Accountability Record(s), Return of Investigational Product
for Destruction Form(s), Final Investigational Product Reconciliation Statement, as
applicable.
 Non-investigational product(s), and/or medical device(s) or combination product(s)
documentation, as applicable.
In addition, all original source documents supporting entries in the CRFs must be
maintained and be readily available.
Retention of study documents will be governed by the Clinical Trial Agreement.
12.3 Study Monitoring and Data Collection
The Amgen representative(s) and regulatory authority inspectors are responsible for
contacting and visiting the investigator for the purpose of inspecting the facilities and,
upon request, inspecting the various records of the clinical study (eg, CRFs and other
pertinent data) provided that subject confidentiality is respected.
The Clinical Monitor is responsible for verifying the CRFs at regular intervals throughout
the study to verify adherence to the protocol; completeness, accuracy, and consistency
of the data; and adherence to local regulations on the conduct of clinical research. The
Clinical Monitor is to have access to subject medical records and other study related
records needed to verify the entries on the CRFs.
The investigator agrees to cooperate with the clinical monitor to ensure that any
problems detected in the course of these monitoring visits, including delays in completing
CRFs, are resolved.
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected
for audit by representatives from Amgen’s Global Compliance Auditing function (or
designees). Inspection of site facilities (eg, pharmacy, protocol-required therapy storage
areas, laboratories) and review of study related records will occur to evaluate the study
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conduct and compliance with the protocol, ICH GCP, and applicable regulatory
requirements.
Data capture for this study is planned to be electronic:
 All source documentation supporting entries into the electronic CRFs must be 
maintained and readily available.
 Updates to electronic CRFs will be automatically documented through the software’s 
“audit trail”.
 To ensure the quality of clinical data across all subjects and sites, a clinical data 
management review is performed on subject data received at Amgen.  During this 
review, subject data are checked for consistency, omissions, and any apparent 
discrepancies. In addition, the data are reviewed for adherence to the protocol and 
GCP. To resolve any questions arising from the clinical data management review 
process, data queries are created in the EDC system database for site resolution 
and subsequently closed by the EDC system or by an Amgen reviewer.
 The investigator signs only the Investigator Verification Form for this electronic data 
capture study. This signature indicates that the investigator inspected or reviewed 
the data on the CRF, the data queries, and agrees with the content.
12.4 Investigator Responsibilities for Data Collection
The investigator is responsible for complying with the requirements for all assessments
and data collection (including subjects not receiving protocol-required therapies) as
stipulated in the protocol for each subject in the study. For subjects who withdraw prior
to completion of all protocol-required visits and are unable or unwilling to continue the
Schedule of Assessments (Table 2 through Table 6), the investigator can search publicly
available records [where permitted]) to ascertain survival status. This ensures that the
data set(s) produced as an outcome of the study is/are as comprehensive as possible.
12.5 Language
All written information and other material to be used by subjects and investigative staff
must use vocabulary and language that are clearly understood. eCRFs must be
completed in English. TRADENAMES (if used) for concomitant medications may be
entered in the local language.
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12.6 Publication Policy
Authorship of any publications resulting from this study will be determined on the basis of
the International Committee of Medical Journal Editors (ICMJE) Recommendations for
the Conduct of Reporting, Editing, and Publication of Scholarly Work in Medical Journals, 
which states:
 Authorship credit should be based on (1) substantial contributions to conception and
design, acquisition of data, or analysis and interpretation of data; (2) drafting the
article or revising it critically for important intellectual content; (3) final approval of the
version to be published; and (4) agreement to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any part of the
work are appropriately investigated and resolved. Authors should meet conditions 1,
2, and 3 and 4.
 When a large, multicenter group has conducted the work, the group should identify
the individuals who accept direct responsibility for the manuscript. These individuals
should fully meet the criteria for authorship defined above.
 Acquisition of funding, collection of data, or general supervision of the research
group, alone, does not justify authorship.
 All persons designated as authors should qualify for authorship, and all those who
qualify should be listed.
 Each author should have participated sufficiently in the work to take public
responsibility for appropriate portions of the content.
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters)
based on this study must be submitted to Amgen for corporate review. The Clinical Trial
Agreement among the institution, investigator, and Amgen will detail the procedures for,
and timing of, Amgen’s review of publications.
12.7 Compensation
Any arrangements for compensation to subjects for injury or illness that arises in the
study are described in the Compensation for Injury section of the Informed Consent that
is available as a separate document.
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Appendix A. Additional Safety Assessment Information
Adverse Event Grading Scale
The Common Terminology Criteria for Adverse Events (CTCAE version 5.0) is available 
at the following location:
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
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Appendix B.  Sample Serious Adverse Event Form
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Appendix C.  Pregnancy and Lactation Notification Worksheets
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Appendix D.  Response Evaluation Criteria in Solid Tumors Version 1.1 
(RECIST 1.1) 
Quick Reference 
Definitions 
• Measurable Lesions 
o Measurable Tumor Lesions – Non-nodal lesions with clear borders that 
can be accurately measured in at least 1 dimension with longest diameter 
≥ 10 mm in CT/MRI scan with slice thickness no greater than 5 mm.  
When slice thickness is greater than 5 mm, the minimum size of 
measurable lesion should be twice the slice thickness. 
o Nodal Lesions - Lymph nodes are to be considered pathologically 
enlarged and measurable, a lymph node must be ≥ 15 mm in short axis 
when assessed by CT/MRI (scan slice thickness recommended to be no 
greater than 5 mm).  At baseline and in follow-up, only the short axis will 
be measured and followed. 
 Nodal size is normally reported as two dimensions in the axial 
plane.  The smaller of these measures is the short axis 
(perpendicular to the longest axis). 
o Irradiated Lesions - Tumor lesions situated in a previously irradiated area, 
or in an area subjected to other loco-regional therapy, are not measurable 
unless there has been demonstrated progression in the lesion prior to 
enrollment. 
• Non-measurable Lesions 
o All other lesions, including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 mm but to < 15 mm short axis with 
CT scan slice thickness no greater than 5 mm) are considered 
non-measurable and characterized as non-target lesions. 
o Other examples of non-measurable lesions include: 
 Lesions with prior local treatment:  tumor lesions situated in a 
previously irradiated area, or an area subject to other loco-
regional therapy, should not be considered measurable unless 
there has been demonstrated progression in the lesion. 
 Biopsied lesions 
 Categorially, clusters of small lesions, bone lesions, 
inflammatory breast disease, and leptomeningeal disease are 
non-measurable. 
Methods of Measurement 
• Measurement of Lesions - The longest diameter of selected lesions should be 
measured in the plane in which the images were acquired (axial plane).  All 
measurements should be taken and recorded in metric notation.  All baseline 
evaluations should be performed as closely as possible to the beginning of 
treatment and not more than 4 weeks before study Day 1. 
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 Methods of Assessment - The same method of assessment and the same
technique should be used to characterize each identified and reported lesion
throughout the trial.
 CT/ MRI – Contrast-enhanced CT or MRI should be used to assess all
lesions. Optimal visualization and measurement of metastasis in solid
tumors requires consistent administration (dose and rate) of IV contrast as
well as timing of scanning. CT and MRI should be performed with ≤ 5 mm
thick contiguous slices.
Baseline documentation of “Target” and “Non-target” lesions
 Target Lesions - All measurable lesions up to a maximum of five (5) lesions
per organ and ten (10) lesions in total, representative of all involved organs
should be identified as target lesions and recorded and measured at
baseline.
o Target lesions should be selected on the basis of their size (lesions with
the longest diameter) and suitability for accurate repeated
measurements.
o Pathologic lymph nodes (with short axis ≥ 15 mm) may be identified as
target lesions. All other pathological nodes (those with short axis
≥ 10 mm but < 15 mm) should be considered non-target lesions.
o A sum of the diameters (longest for non-nodal lesions, short axis for nodal
lesions) for all target lesions will be calculated and reported as the baseline
sum of diameters. The baseline sum of diameters will be used as
reference by which to characterize objective tumor response.
 Non-Target Lesions - All other lesions (or sites of disease) including
pathological lymph nodes should be identified as non-target lesions and
should also be recorded at baseline. Measurements of these lesions are not
required, and these lesions should be followed as “present”, “absent”, or
“unequivocal progression” throughout the study. In addition, it is possible to
record multiple non-target lesions involving the same organ as a single item
on the case report form (eg, “multiple enlarged pelvic lymph nodes” or
“multiple liver metastases”).
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Response Criteria
Evaluation of Target Lesions
* CompleteResponse (CR): Disappearance of all target lesions. Any pathological
lymph nodes (whether target or non-target) must have
reduction in short axis to < 10 mm.
* Partial Response (PR): At least a 30% decrease in the sum of the diameters of
target lesions, taking as reference the baseline sum of
diameters.
* ProgressiveDisease (PD): At least a relative 20% increase and an absolute increase 
of 5 mm in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study, or the 
appearance of one or more new lesions.
* Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for PD, taking as reference the smallest 
sum of diameters since the treatment started.
Evaluation of Non-target Lesions
1 To achieve “unequivocal progression” on the basis of the non-target disease, there must be an overall level
of substantial worsening in non-target disease such that, even in presence of SD or PR in target disease,
the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest “increase”
in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression
status.
Evaluation of Overall Response
The best overall response is the best response recorded from the start of the study 
treatment until the end of treatment or disease progression/recurrence (taking as 
reference for PD the smallest measurements recorded since the treatment started).  
In general, the subject's best response assignment will depend on the findings of both 
target and non-target disease and will also take into consideration the appearance of 
new lesions.
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Time Point response: Subjects with Target (+/- Non-target) Disease
Target Lesions Non-target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PR Non-PD or not all 
evaluated
No PR
SD Non-PD or not all 
evaluated
No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
NE = Not evaluable
Time Point Response: Subjects with Non-Target Disease Only
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Overall Response: Confirmation of Complete Response (CR) and Partial 
Response (PR) required
Special Notes on Response Assessment
 Nodal lesions – Lymph nodes identified as target lesions should always have the
actual short axis measurement recorded, even if the nodes regress to below
10 mm on study. In order to qualify for CR, each node must achieve a short axis
< 10 mm, NOT total disappearance.  Nodal target lesion short axis measurements 
are added together with target lesion’ longest diameter measurements to create 
the sum of target lesion diameters for a particular assessment (timepoint).
 Target lesions that become “too small to measure” – While on study, all lesions
(nodal and non-nodal) recorded at baseline should have their measurements
recorded at each subsequent evaluation.  If a lesion becomes less than 5 mm, the 
accuracy of the measurement becomes reduced.  Therefore, lesions less than 
5 mm are considered as being “too small to measure”, and are not measured.  With 
this designation, they are assigned a default measurement of 5mm.  No lesion 
measurement less then 5mm should be recorded, unless a lesion totally disappears 
and “0” can be recorded for the measurement.
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 New lesions – The term “new lesion” always refers to the presence of a new 
finding that is definitely tumor.  New findings that only may be tumor, but may be 
benign (infection, inflammation, etc.) are not selected as new lesions, until that 
time when the review is certain they represent tumor.  
 If a new lesion is equivocal, for example because of its small size, continued 
therapy and follow-up evaluation will clarify if it represents truly new disease.  
If repeat scans confirm there is definitely a new lesion, then progression
should be declared using the date of the initial scan.
 A lesion identified on a follow-up study in an anatomical location that was not 
scanned at baseline is considered a new lesion and will indicate disease
progression, regardless of any response that may be seen in target or non-
target lesions present from baseline.
 Subjects with a global deterioration of health status requiring discontinuation of
treatment without objective evidence of disease progression at that time should be
classified as having “symptomatic deterioration.” Every effort should be made to
document the objective progression with an additional imaging assessment even
after discontinuation of treatment.
 In some circumstances it may be difficult to distinguish residual disease from scar or 
normal tissue. When the evaluation of complete response (CR) depends on this
determination, it is recommended that the residual lesion be further investigated by 
fluorodeoxyglucose-positron emission tomography (FDG-PET) or PET/computed 
tomography (PET/CT), or possibly fine needle aspirate/biopsy, to confirm the CR
status.
Confirmation Measurement / Duration of Response
 Response Confirmation - In non-randomized trials where response is the
primary endpoint, confirmation of PR and CR is required to ensure
responses identified are not the result of measurement error.
 Duration of overall response – The duration of overall response is
measured from the time measurement criteria are first met for CR/PR 
(whichever is first recorded) until the first date the recurrent or progressive
disease is objectively documented.
 Duration of Stable Disease - SD is measured from the start of the
treatment until the criteria for disease progression are met, taking as
reference the smallest measurements recorded since the treatment started.
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Appendix E.  Two-parameter BLRM Design
A two-parameter Bayesian logistic regression model (BLRM,
Neuenschwander et al, 2008) is used to guide dose escalation. The maximum 
tolerated dose (MTD) target Toxicity Probability Interval (TPI) for dose limiting toxicity 
(DLT) is (0.20, 0.33) and a TPI of (0.33, 1.00) is defined as excessive. The design
seeks to identify a dose most likely to have a DLT rate in the target TPI, but with
overdose control that limits the possibility the dose has an excessive DLT rate
(Babb et al, 1998). The probability of a DLT at dose level di is assumed to follow a
Bernoulli distribution with probability pi where the logit of pi increases linearly with the log 
of the standardized dose in the following 2-parameter logistic model:
log [pi / (1-pi)] = logit(pi) = log[a] + exp( log[b]) log (di / dref)
where a and b are random variables and dref is one of the planned dose selected as the
reference dose.
A bi-variate normal prior distribution (Neuenschwander et al, 2008) was selected for
theta = (log a, log b) where the probability that the true DLT rate is ≤ 0.40 at
180 milligrams (mg) is 0.90 and the probability the true DLT rate is ≤ 0.05 at the
reference dose (720 mg) is 0.05. Additionally, the prior is such that pi is approximately
0.05 for the 180 mg dose and 0.25 for the reference dose.
The operating characteristics of the two-parameter BLRM design were evaluated via
simulation. The cohort size was fixed to 2 or 4 subjects. The initial dose level is 180 mg
and subsequent doses were selected based on the following rules:
 After each cohort, the next dose is the one with the highest probability of the target
TPI, but with a less than 0.25 probability of an excessive TPI.
 Escalation to a dose level that is greater than 2x the current dose level is not
allowed.
Dose escalation was stopped given 1 or more of the following conditions:
 There have been at least 6 subjects treated at the dose recommended by the 
model.
 A maximum number of 30 subjects are evaluated. Operating characteristics are
described below.
Operating characteristics
A total of 4 planned dose levels (unit: mg) were considered: 180, 360, 720 and 960.
Two intermediate dose levels were also considered: 270 and 540 mg. The design was
evaluated for 4 possible dose-response scenarios: Low MTD, Mid MTD, High MTD and
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a scenario where none of the planned dose levels are tolerable.  Table 16 shows the 
dose level and true probability of DLT for each scenario used in the simulated studies
estimating the MTD. Table 17 reports the operating characteristics from 1000 simulated 
studies estimating the MTD when the target TPI is (0.20, 0.33). The rate of MTD 
selected and the number of subjects assigned to each dose level are presented in
Table 18.
Table 16.  True Probability of DLT by Scenario for Simulated Studies Estimating
MTD
Dose Level 180 270 360 540 720 960
MTD Scenario
High 0.01 0.01 0.05 0.15 0.25 0.33
Mid 0.05 0.15 0.25 0.33 0.43 0.53
Low 0.15 0.25 0.33 0.43 0.53 0.63
No tolerable
dose levels
0.35 0.43 0.50 0.58 0.65 0.73
DLT = dose-limiting toxicity; MTD = maximum tolerated dose
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Table 17.  Operating Characteristics by Scenario for Simulated Studies Estimating
the MTD When the Target TPI is (0.20, 0.33)
MTD
Scenario High Mid Low
No tolerable dose
levels
Subjects per
cohort
4 2 4 2 4 2 4 2
Number of 20 12 20 12 16 10 8 2
Subjects (16 to 24) (12 to 14) (16 to 24) (10 to 14) (12 to 20) (2 to 14) (4 to 12) (2 to 8)
Median
(IQR)
Number of 2 2 4 3 4 2 3 2
DLTs (2 to 4) (1 to 2) (3 to 5) (2 to 3) (3 to 6) (1 to 4) (2 to 4) (1 to 3)
Median
(IQR)
Proportion of 12.5 14.3 25.0 25.0 26.7 37.5 50.0 50.0
DLT (%) (10 to 17) (8 to 19) (19 to 25) (19 to 35) (25 to 37) (25 to 50) (37 to 50) (43 to 50)
Median
(IQR)
Percentage of studies recommending dose with DLT probability of:
≤ 10% 4.6 9.2 11.2 25.9 29.7* 53.6* 82.3* 89.3*
> 10% and 47.2 55.6 4.6 2.0 10.3 0.9 NA NA
≤ 20%
> 20% and 48.2 35.2 78.2 64.3 47.5 30.3 NA NA
≤ 33%
> 33% NA NA 6.0 7.8 12.5 15.2 17.7 10.7
Probability of 95.4 90.8 82.8 66.3 57.8 31.2
identifying
MTD to have
15% to 33% NA NA
DLT
probability
DLT = dose-limiting toxicity; IQR = interquartile range; MTD = maximum tolerated dose; TPI = toxicity
probability interval; NA=not applicable
* In the low MTD scenario and the scenario where all planned dose levels are intolerable, this represents the
percent of studies declaring all planned dose levels as not tolerable.
A
pp
ro
ve
d 
  
Product:  AMG 510
Protocol Number:  20170543
Date:  22 May 2019 Page 153 of 158
CONFIDENTIAL
Table 18.  Rate of MTD Selected and Number of Subjects Assigned at Each Dose
Level by Scenario
MTD Scenario High Mid Low
No tolerable
dose levels
Number of
Subjects Per
Cohort 4 2 4 2 4 2 4 2
Rate of MTD selected at each dose level (%):
Below lowest 0.2 2.6 8.1 25.0 29.7 53.6 82.3 89.3
dose
180 mg 0.1 0.0 3.1 0.9 10.3 0.9 9.2 0.9
270 mg 0.0 0.0 4.6 2.0 9.0 2.2 3.2 1.0
360 mg 4.3 6.6 43.8 31.3 38.5 28.1 4.7 7.4
540 mg 47.2 55.6 34.4 33.0 10.8 14.3 0.5 1.4
720 mg 44.3 33.2 5.2 7.8 1.6 0.9 0.1 0.0
960 mg 3.9 2.0 0.8 0.0 0.1 0.0 0.0 0.0
Average number of subjects at each dose level
180 mg 4.1 2.0 4.7 2.3 5.3 2.4 5.1 2.4
270 mg 0.2 0.2 1.6 0.8 2.1 0.9 1.4 0.5
360 mg 4.3 2.5 6.0 3.5 5.1 3.1 1.6 1.7
540 mg 5.3 4.3 4.7 3.2 2.6 1.9 0.3 0.6
720 mg 5.6 3.3 1.8 1.4 0.7 0.5 0.1 0.1
960 mg 0.5 0.2 0.2 0.0 0.1 0.0 0.0 0.0
MTD = maximum tolerated dose. A
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Operating Characteristics for Standard 3+3 Design
As a comparison, the operating characteristics from 1000 simulated studies estimating
the MTD when using a standard 3+3 design are reported in Table 19.
Table 19.  Operating Characteristics by Scenario for Simulated Studies Estimating
the MTD Using a 3+3 Design
MTD Scenario High Mid Low
No
tolerable
dose
levels
Number of Subjects 15 12 12 6
Median (IQR) (12 to 18) (12 to 15) (9 to 13) (3 to 12)
Number of DLTs 2 3 3 3
Median (IQR) (2 to 3) (2 to 4) (2 to 4) (2 to 3)
Proportion of DLT (%) 16.7 23.8 26.7 33.3
Median (IQR) (11 to 20) (20 to 27) (22 to (33 to 67)
33)
Percentage of studies recommending dose with DLT probability of:
≤ 10% 44.7 43.5
> 10% and ≤ 20% 0.0 0.0
> 20% and ≤ 33% 55.3 43.3
> 33% NA 13.2
Probability of 55.3 43.3
identifying MTD to
have 15% to 33% DLT
probability
19.4*
47.4
29.5
3.7
76.9
65.9*
NA
NA
34.1
NA
DLT = dose-limiting toxicity; IQR = interquartile range; MTD = maximum tolerated dose; NA=not applicable
* In the low MTD scenario and the scenario where all planned dose levels are intolerable, this represents the
percent of studies declaring all planned dose levels as not tolerable.
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Appendix F.  Hepatotoxicity Stopping Rules:  Suggested Actions and Follow-up 
Assessments and Study Treatment Rechallenge Guidelines
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) 
and/or international normalized ratio (INR) and/or signs/symptoms of hepatitis (as 
described below) may meet the criteria for withholding or permanent discontinuation of 
Amgen investigational product or other protocol-required therapies, as specified in the 
Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical Evaluation, 
July 2009.
Criteria for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol-required Therapies Due to Potential 
Hepatotoxicity
The following stopping and/or withholding rules apply to subjects for whom another 
cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been 
identified. 
Important alternative causes for elevated AST/ALT and/or TBL values include, but are 
not limited to:
 Hepatobiliary tract disease
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein-Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus)
 Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
ischemia
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants and mushrooms
 Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler-Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)
 Alpha-one antitrypsin deficiency
 Alcoholic hepatitis
 Autoimmune hepatitis
 Wilson’s disease and hemochromatosis
 Nonalcoholic fatty liver disease including steatohepatitis
 Non-hepatic causes (eg, rhabdomyolysis, hemolysis)
If investigational product(s) is/are withheld, the subject is to be followed for possible drug 
induced liver injury (DILI) according to recommendations in the last section of this 
appendix. 
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Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, 
AST, ALP) and/or elevated TBL, is discovered and the laboratory abnormalities resolve 
to normal or baseline (see next section in this appendix).
Table 20.  Conditions for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol-required Therapies Due to Potential 
Hepatotoxicity
Analyte Temporary Withholding Permanent Discontinuation
TBL > 3x ULN 
at any time
> 2x ULN
OR
INR -- > 1.5x (for subjects not on 
anticoagulation therapy)
OR AND
AST/ALT > 8x ULN at any time
> 5x ULN but < 8x ULN for
≥ 2 weeks
> 5x ULN but < 8x ULN and unable to 
adhere to enhanced monitoring schedule
> 3x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, 
fever, nausea, vomiting, and jaundice)
In the presence of no important 
alternative causes for elevated 
AST/ALT and/or TBL values
> 3x ULN (when baseline was < ULN)
OR
ALP > 8x ULN at any time --
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = total bilirubin; ULN = upper limit of normal
Criteria for Rechallenge of Amgen Investigational Product and Other 
Protocol-required Therapies After Potential Hepatotoxicity
The decision to rechallenge the subject is to be discussed and agreed upon 
unanimously by the subject, investigator, and Amgen.
If signs or symptoms recur with rechallenge, then [Amgen investigational product and 
other protocol-required therapies, as appropriate] is to be permanently discontinued.  
Subjects who clearly meet the criteria for permanent discontinuation (as described in
Table 20) are never to be rechallenged.
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Drug-induced Liver Injury Reporting and Additional Assessments
Reporting
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or INR elevation, according to the criteria specified in the above, require 
the following:
 The event is to be reported to Amgen as a serious adverse event within 24 hours of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded)
 The appropriate Case Report Form (CRF) (eg, Event CRF) that captures information 
necessary to facilitate the evaluation of treatment-emergent liver abnormalities is to 
be completed and sent to Amgen 
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Section 9.1.2.
Additional Clinical Assessments and Observation
All subjects in whom investigational product(s) or protocol-required therapies is/are 
withheld (either permanently or conditionally) due to potential DILI as specified in 
Table 20 or who experience AST or ALT elevations > 3 x upper limit of normal (ULN) or 
2-fold increases above baseline values for subjects with elevated values before drug are 
to undergo a period of “close observation” until abnormalities return to normal or to the 
subject’s baseline levels.  
Assessments that are to be performed during this period include: 
 Repeat AST, ALT, ALP, bilirubin (BIL) (total and direct), and INR within 24 hours 
 In cases of TBL > 2x ULN or INR > 1.5, retesting of liver tests, BIL (total and direct), 
and INR is to be performed every 24 hours until laboratory abnormalities improve
Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the investigational product(s) or protocol-required therapies has/have been 
discontinued AND the subject is asymptomatic.
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending on the clinical situation:
 Complete blood count with differential to assess for eosinophilia
 Serum total immunoglobulin (Ig)G, anti-nuclear antibody anti-smooth muscle 
antibody, and liver kidney microsomal antibody-1 to assess for autoimmune hepatitis
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 Serum acetaminophen (paracetamol) levels
 A more detailed history of: 
 Prior and/or concurrent diseases or illness
 Exposure to environmental and/or industrial chemical agents 
 Symptoms (if applicable) including right upper quadrant pain, hypersensitivity-
type reactions, fatigue, nausea, vomiting and fever
 Prior and/or concurrent use of alcohol, recreational drugs and special diets
 Concomitant use of medications (including non-prescription medicines and 
herbal and dietary supplements), plants, and mushrooms
 Viral serologies
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase and peripheral blood 
smear
 Appropriate liver imaging if clinically indicated
 Appropriate blood sampling for pharmacokinetic analysis if this has not already been 
collected
 Hepatology consult (liver biopsy may be considered in consultation with a 
hepatologist)
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  The 
“close observation period” is to continue for a minimum of 4 weeks after discontinuation 
of all investigational product(s) and protocol-required therapies.
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must be captured in the corresponding CRFs. A
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Summary of Changes Protocol Amendment 1 to Amendment 3 
Protocol Title:  A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, 
Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in 
Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 
Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C 
Mutation 
 
Amgen Protocol Number (AMG 510) 20170543 
EudraCT Number 2018-001400-11 
NCT Number NCT03600883 
 
Amendment Dates: 28 March 2019 and 22 May 2019 
 
Rationale for Protocol Amendment 1 to Superseding Protocol Amendment 2: 
The main change for Protocol Amendment 2 is the addition of the phase 2 portion of the 
study.  The ongoing phase 1 portion was also amended as described below. 
The protocol is being amended to incorporate changes in the study design as follows: 
Overall, the addition of the phase 2 and the updates to the ongoing phase 1 portion of 
the study required updates across multiple sections of protocol including but not limited 
to the following:  Protocol Synopsis, Study Schemas, Objectives and Endpoints 
(Section 1.0), Hypothesis (Section 2.7), Experimental Plan (Section 3.0), Subject 
Eligibility (Section 4.0), Treatment Procedures (Section 7.0), Schedule of Assessments 
(Section 7.1), Study Procedures (Section 7.2) and Statistical Considerations 
(Section 10).  The first in human (FIH) portion of the study will continue as planned and 
in the protocol is noted as the Phase 1 portion. 
Phase 2: 
• Phase 2 is a multicenter, non-randomized, open-label study to evaluate efficacy and 
safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C mutant 
advanced solid tumors (NSCLC, CRC, and other tumors) 
Updates to Phase 1: 
• A phase 1, BID cohort was added to evaluate initial safety, PK and 
pharmacodynamics of AMG 510 
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•  
 
   
• Modify the phase 1 dose expansion cohort (part 2a) to allow enrollment of subjects 
with any tumor type into 1 cohort of up to 60 subjects 
• Clarify that the backfill enrollment in phase 1 part 1a will be expanded up to 
40 subjects 
• Add details on the subjects being enrolled in the phase 1 part 1a portion of the study 
at sites in Japan 
Additional changes to the protocol include: 
• Update the number sites that will be included in the study 
• Update RECIST text to align with the RECIST templated language. 
• Removal of self-evident corrections language 
• Administration, typographical, and formatting changes were made throughout the 
protocol 
 
Rationale for Superseding Protocol Amendment 2 to Protocol Amendment 3: 
The protocol is being amended to incorporate following key changes in the study design 
based on the feedback received from the regulatory agency on protocol amendment 2: 
Updates to Phase 1: 
• Sample size justification is provided for enrollment up to 60 subjects in phase 1 
expansion portion. 
• Futility/efficacy thresholds are added to monitor antitumor activities in phase 1 
expansion to provide guidance to DLRM for determining RP2D and continuing to 
phase 2. 
• Revision to use standard RECIST 1.1 for analysis of tumor response. 
Updates to Phase 2: 
• Revised patient population for NSCLC and CRC as defined by the eligibility criteria in 
terms of the extent of prior therapies. 
• Clarified that twice-daily dosing cohort (phase 1 part 1b) will only be initiated after 
completion of preliminary food effect evaluation.  
• Sample sizes for NSCLC, CRC are adjusted based on new benchmark rates  
− For NSCLC, revised the benchmark rate to 23% to exclude from the lower limit of 
the 95% confidence interval for observed ORR. 
− For CRC, revised the benchmark rate to 10% to exclude from the lower limit of 
the 95% confidence interval for observed ORR. 
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• Clarified that efficacy analysis will be performed using only “Phase 2” portion.  
Language pertaining to pooling subjects at RP2D from phase 1 and phase 2 for 
efficacy analysis is removed. 
• Removed interim analysis for efficacy. 
• Futility interim analysis in phase 2 portion is updated to allow continuous monitoring 
using Bayesian predictive probability method. 
• Revision to use standard RECIST 1.1 for analysis of tumor response. 
• Additional changes were made to the protocol with the following rationales. 
• Time to response was added as an secondary endpoint in all phases to describe 
timing aspect of AMG 510 response profile. 
• Removed the inclusion criteria requirement for alkaline phosphatase . Alkaline 
phosphatase (ALP) is often elevated in advance solid tumor with bone or liver 
metastasis and may not reflect liver function required to participate in the clinical trial 
when other liver function parameter criteria (AST, ALT, INR, Bilirubin) are met. 
• Clarification of the inclusion criteria 215 pertaining birth control methods in 
accordance to Clinical Trial Facilitation and Coordination Gropu (CTFG) guidance. 
•  
 
 
 
 
 
 
 
• Additional patient-reported outcomes (NSCLC SAQ and GP5 FACT-G) were added 
to fully understand the impact of treatment on patients from their perspective.  
• Addition of urine pregnancy test on day 1 of every cycle in female subjects with child 
bearing potential to meet CTFG guidance related to pregnancy testing in clinical 
trials. 
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List of Abbreviations and Definition of Terms
Abbreviation or Term Definition/Explanation
ANC Absolute neutrophil count
AUC Area under the concentration-time curve
ALK Anaplastic lymphoma kinase
BCRP Breast cancer resistance protein
BLRM Bayesian Logistic Regression Model
Cmax Maximum observed concentration
CR Complete response
CRC Colorectal cancer
CT Computed tomography
CYP3A Cytochrome P450 3A
DDI Drug-drug interaction
DLRM Dose Level Review Meeting
DLRT Dose Level Review Team
DILI Drug induced liver injury
DOR Duration of response
EC50 Half-maximal effective concentration
ECG Electrocardiogram
EGFR Epidermal growth factor receptor
End of Study Defined as the date when the last subject is assessed or 
receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study 
(eg, long-term follow-up), as applicable
End of Follow-up Defined as when the last subject completes the last
protocol-specified assessment in the study
End of Treatment Defined as the last assessment for the protocol specified 
treatment phase of the study for an individual subject
Exposure-Response Analysis Mechanism-based modeling & simulation and statistical 
analyses based on individual pharmacokinetic [PK] exposure 
(eg, population pharmacokinetic modeling) and response, which 
may include biomarkers, pharmacodynamics effects, efficacy 
and safety endpoints
FDA Food and Drug Administration
FFPE Formalin-fixed paraffin-embedded
FIH First-in-human
HepBsAg Hepatitis B surface antigen
Product:  AMG 510
Protocol Number:  20170543
Date:  14 November 2018 Page 5 of 33
CONFIDENTIAL 
Abbreviation or Term Definition/Explanation
HepCAb Hepatitis C antibody
HNSTD Highest non-severely toxic dose
ICF Informed consent form
ICH International Conference of Harmonization
IVD In vitro diagnostic
IR Immediate-release
KRAS Kirsten rat sarcoma viral oncogene homolog (protein)
KRAS Kirsten rat sarcoma viral oncogene homolog (DNA)
KRASG12C KRAS protein with a G12C mutation at the protein level
KRAS p.G12C KRAS DNA with a mutation resulting in a G12C mutation at the 
protein level
MRI Magnetic resonance imaging
mRNA Messenger ribonucleic acid
NOEL No observed effect level
NRAS Neuroblastoma RAS viral oncogene homolog
NSCLC Non-small-cell lung carcinoma
ORR Objective response rate
PD Progressive disease
PD-1 Programmed cell death-1
PD-L1 Programmed death-ligand 1
P-gp P-glycoprotein
PCR Polymerase chain reaction
PK Pharmacokinetic(s)
PO Oral(ly)
PFS Progression-free survival
PR Partial response
Primary Completion Defined as the date when the last subject is assessed or 
receives an intervention for the final collection of data for the 
primary endpoint(s), for the purposes of conducting the primary 
analysis, whether the study concluded as planned in the protocol 
or was terminated early
QD Once daily
QTc Corrected QT (interval)
RAS Rat sarcoma viral oncogene homolog
RECIST Response evaluation criteria in solid tumors
RP2D Recommended Phase 2 Dose
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Abbreviation or Term Definition/Explanation
SD Stable disease
STD10 Severely toxic dose in 10% of animals
Source Data Information from an original record or certified copy of the 
original record containing patient information for use in clinical 
research. The information may include, but is not limited to, 
clinical findings, observations, or other activities in a clinical trial 
necessary for the
Study Day 1 Defined as the first day that protocol specified investigational 
product(s)/protocol-required therapies is/are administered to the 
subject
tmax Time to reach maximum concentration
TGI Tumor growth inhibition
VEGF Vascular endothelial growth factor
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1. Introduction
The purpose of this Statistical Analysis Plan (SAP) is to provide details of the statistical
analyses that have been outlined within Amendment 1 of the protocol for 
study 20170543, AMG 510 dated 12 July 2018. The scope of this plan includes the 
interim analysis, the primary analysis and the final that are planned and will be executed 
by the Amgen Global Biostatistical Science department unless otherwise specified.
2. Objectives, Endpoints and Hypotheses
2.1 Objectives and Endpoints
Objectives Endpoints
Primary
 Evaluate the safety and tolerability 
of AMG 510 in adult subjects with 
KRAS p.G12C mutant solid 
tumors & Estimate the maximum 
tolerated dose (MTD) and/or a 
biologically active dose
 Safety: subject incidence of dose 
limiting toxicity (DLTs), 
treatment-emergent adverse 
events, treatment-related adverse 
events, and clinically significant 
changes in vital signs, physical 
examinations, electrocardiogram 
(ECGs), and clinical laboratory 
tests
Secondary
 Characterize the 
pharmacokinetics (PK) of 
AMG 510 following administration 
as an oral tablet formulation
 PK parameters of AMG 510 
including, but not limited to, 
maximum observed plasma 
concentration (Cmax), time to 
achieve Cmax (tmax), and area 
under the plasma 
concentration-time curve (AUC)
 To evaluate tumor response 
assessed by CT or MRI using 
RECIST 1.1 criteria of AMG 510 
as monotherapy in subsets of 
solid tumors with KRAS p.G12C 
mutation
 Objective response rate (ORR), 
duration of overall response 
(DOR), overall survival (OR), 
progression-free survival (PFS), 
and duration of stable disease 
measured by CT or MRI and 
assessed per RECIST 1.1 criteria
 To evaluate the effect of food on 
the oral pharmacokinetics of 
AMG 510
 PK parameters of AMG 510 
including, but not limited to, Cmax, 
tmax, and AUC in the fed and 
fasted states for the food effect 
assessment
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Objectives Endpoints
Secondary (Continued)
 To evaluate the relationship 
between changes in QTc and 
AMG 510 exposure
 AMG 510 exposure/QTc interval 
relationship
Exploratory
 To explore pharmacokinetic/
pharmacodynamic relationships
for safety and/or efficacy
endpoints
 AMG 510 exposure/safety and 
exposure/efficacy relationships
 To characterize AMG 510
excretion in urine
 AMG 510 excretion in urine
 To identify metabolites of
AMG 510 in plasma and urine
 Characterization of potential 
metabolites of AMG 510 in plasma 
and urine, if appropriate
 To investigate potential biomarkers
by biochemical and/or genetic
analysis of blood and/or tumor
samples.
 Quantification of biomarker 
expression at protein, RNA, and 
DNA levels, as appropriate
 Potential biomarkers by 
biochemical and/or genetic 
analysis of blood and/or tumor 
samples
2.2 Hypotheses and/or Estimations
At least 1 dose level of AMG 510, in repeat oral administrations, will achieve acceptable 
safety and tolerability in subjects with advanced KRAS p.G12C mutant solid tumors, with 
evidence of anti-tumor activity.
3. Study Overview
3.1 Study Design
This is a first-in-human (FIH), multicenter, non-randomized, open-label, phase 1 study to
evaluate safety and tolerability of AMG 510 in subjects with advanced KRAS p.G12C
mutant solid tumors. AMG 510 will be evaluated as an oral therapeutic. The study will be
conducted in 2 parts: Part 1 – Dose Exploration and Part 2 – Dose Expansion.
Part 1 is aimed at evaluating the safety, tolerability, PK and pharmacodynamics of
AMG 510 and determining the MTD of repeat daily (QD) dosing schedule in subjects with
advanced KRAS p.G12C mutant solid tumors using a Bayesian Logistic Regression
Model (BLRM) design.
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Part 2, the dose expansion part of the study, can open once the MTD and/or a
biologically active dose (eg, recommended phase 2 dose [RP2D]) has been determined
in Part 1. The dose exploration part of the study will consist of approximately 50 subjects
and the dose expansion part will consist of approximately 60 additional subjects,
including at least 3 groups with specific tumors harboring KRAS p.G12C mutations
(non-small cell lung cancer [NSCLC], colorectal cancer [CRC], and all other solid
tumors). Different schedules can be used in the dose expansion part based on clinical
and PK data from all parts of the dose exploration. The DLT evaluation period will be
21 days. Based on emerging clinical efficacy data, the groups explored in the expansion
part can be modified.
Dose Exploration – Part 1
Dose exploration cohorts will estimate the safety, tolerability, PK, and pharmacodynamics
of different doses of AMG 510 in subjects with advanced KRAS p.G12C mutant solid
tumors. Subjects will receive AMG 510 daily administered orally. Enrollment into the
dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will
begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. Dose
escalation will follow the planned Study Schema schedule with 2-4 subjects treated in 
each cohort. If no DLT is observed, dose escalation will continue to the next planned
dose cohort as per Study Schema. Once a subject experience a DLT, dosing for
subsequent cohorts will be recommended using the dose level recommendation from the
Bayesian Logistic Regression Model (BLRM). The decision to advance to the next dose
level will be recommended by the Dose Level Review Team (DLRT) using the dose level
recommendation from BLRM, as appropriate, and by evaluating available safety data,
laboratory, and PK information.
Intra-subject dose escalations are allowed on this study. Subjects who complete the DLT
period may proceed to a higher dose level for the following treatment cycle once the next
dose cohort has been deemed safe by the DLRT and after consultation with the sponsor
if:
 no DLT has been reported for this subject during or after completion of the DLT
period
 the subject has not experienced any ≥ grade 2 adverse events (deemed treatment
related by the investigator) during treatment
Subjects who do not proceed to a higher dose may receive extra cycles at the original
dose.
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Dose exploration will continue until any of the following events.
 The highest planned dose level is determined to be safe and tolerable (minimum 
of 6 DLT-evaluable subjects)
 The MTD is identified, BLRM recommends a dose level which already has 
6 DLT-evaluable subjects
Additional subjects (up to 20) may be enrolled in one or more dose levels that have been 
shown to be safe and tolerable, defined as backfill enrollment. This backfill enrollment will 
be done to better estimate the RP2D and better characterize the safety, efficacy and 
pharmacodynamics for AMG 510 and may be concurrent with dose escalation to identify 
the MTD. Additionally, food effect evaluation will be conducted in at least 6 subjects from 
backfill enrollment in cycle 2 or later.
Dose Expansion – Part 2
Upon completing the dose exploration part of the study and depending on data obtained, 
dose expansion may proceed with three groups consisting of subjects with KRAS p.G12C 
mutant solid tumors:
 Group 1 (NSCLC) - subjects with advanced KRAS p.G12C mutant NSCLC
 Group 2 (CRC) - subjects with advanced KRAS p.G12C mutant CRC
 Group 3 (Other) - subjects with advanced KRAS p.G12C mutant solid tumor types 
other than the tumor types specified in Groups 1 and 2
Figure 1.  Study Design and Treatment
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Figure 2.  Study Design and Treatment
Figure 3.  Food Effect Assessment
3.2 Sample Size
Part 1 – Dose Exploration:
No more than 50 subjects will be enrolled to the dose escalation cohorts. Approximately 
30 subjects will be needed to estimate the MTD.
An additional 20 subjects may be enrolled by backfill enrollment from which at least 
6 subjects will be evaluated for food effect.
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Part 2 – Dose Expansion:
Approximately 60 subjects will be enrolled in the dose expansion part of the study, which 
will be conducted in at least 3 groups.
 Group 1: up to 20 subjects with advanced KRAS G12C mutant NSCLC.
 Group 2: up to 20 subjects with advanced KRAS G12C mutant CRC.
 Group 3: up to 20 subjects with advanced KRAS G12C mutant solid tumor types 
other than specified in Groups 1 and 2.
3.3 Adaptive Design
A two-parameter Bayesian Logistic Regression Model (BLRM, Neuenschwander et al,
2008) is used to guide dose escalation.
Details of the adaptive BLRM design are described in the Protocol Appendix E
4. Covariates and Subgroups
4.1 Planned Covariates
The following baseline covariates may be used to evaluate efficacy endpoints in 
subgroups or in multivariate analysis: Age at baseline (< 65, >= 65 years), prior lines of 
anti-cancer therapy (1, 2, > 2) and ECOG performance status.
4.2 Subgroups
Biomarker data may be incorporated in additional exploratory subgroup or multivariate
analyses. The analyses of biomarkers may be performed after collection of all samples
during the conduct of the study and therefore may be reported after the primary analysis
of efficacy endpoints.
5. Definitions
Adverse Event (AE):
An adverse event is defined as any untoward medical occurrence in a clinical trial 
subject. The event does not necessarily have a causal relationship with study treatment.
The definition of adverse events includes worsening of a preexisting medical condition. A
preexisting condition that has not worsened during the study, or involves an intervention,
is not considered an adverse event.
Age at Enrollment:
Subject age at enrollment will be determined using the age in years reported in the
clinical database.
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AUC:
The area under the plasma drug concentration-time curve (AUC) reflects the actual body 
exposure to drug after administration of a dose of the drug.
Baseline:
For any variable, unless otherwise specified the baseline is the last assessment taken
prior to the first administration of AMG 510. For parameters/assessments not scheduled
to be performed (or scheduled but not performed) on the same day as the first
administration of AMG 510, the baseline value is the value from the screening period
measured closest to the day of first administration of AMG 510.
Baseline ECG Values in Triplicate:
The mean of values in a triplicate should be calculated for Baseline. For all post-baseline 
ECG, the mean value for measurements taken at the same assessment will be 
calculated and used in the analysis.
When an ECG is missing within a triplicate, all available data will be averaged for that 
time point.
Best Overall Response (BOR):
Best overall response (BOR) for a subject is the best observed post baseline disease 
response. Overall response assessments occurring after the start of the first subsequent 
anticancer therapy will not be included. The investigator reported response information 
collected on the CRF will be used to determine the response. No additional derivations 
will be required to classify the response.
BOR is defined as the best response in the following order: CR, PR, SD, PD, or NE, 
where CR and PR require confirmation by a repeat, consecutive scan at least 4 weeks 
after the first documentation of response.
Please refer Protocol Appendix D for more details.
Body Mass Index (BMI):
Body Mass Index should be calculated using the following formula:
BMI (kg/m2) = weight (kg) / [height (cm)/100]2 
Body Surface Area (BSA):
The Body Surface Area should be calculated using the following formula:
BSA= 0.007184 × weight(kg)0.425 × height(cm)0.725
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Cmax:
Maximum observed drug concentration.
Change From Baseline:
Change from Baseline is the arithmetic difference between post-dose assessments and 
Baseline value.
Change (absolute) from Baseline = (Post-baseline Value – Baseline Value)
Change (percent) from Baseline = [(Post-baseline Value – Baseline Value) /
Baseline Value] x 100
Dose Limiting Toxicity (DLT):
Dose-limiting toxicity (DLT) is defined as AMG 510-related toxicity with an onset within 
the first 21 days following first dose with the criteria defined in section 6.1.1.2.1 of the 
Protocol.
Disease control rate (DCR):
DCR is defined as the proportion of patients in whom the best overall response is 
determined as complete response (CR), partial response (PR) or stable disease (SD) > 
6 months.
Duration of overall response:
The duration of overall response is measured from the time measurement criteria are 
first met for CR/PR (whichever is first recorded) until the first date that recurrent or 
progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded on study) or death in the absence of 
progression. 
The duration of overall complete response is measured from the time measurement 
criteria are first met for CR until the first date that recurrent disease is objectively 
documented.
DOR includes those subjects who have confirmed overall response.
Subjects who maintain their objective response, whether on-study or lost to follow-up, 
will be censored on date of last contact.
Duration of stable disease:
Duration of stable disease will be measured from the start of treatment until the earlier of 
time criteria for progression are met or death in the absence of progression.
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If the subject hasn’t met the criteria for progression during the study, then the subject will 
be censored at last evaluable tumor assessment date.
End of Follow-Up:
It is defined as when the last subject completes the last protocol-specified assessment in 
the study. 
End of IP administration (End of IP Admin):
End of IP Admin for each subject is defined as the date the decision was made to end IP 
as recorded on the End of Investigational Product Administration CRF page.
End of Study (Individual Subject):
End of study for each subject is defined as the date the subject last completed a 
protocol-specified procedure. The date will be recorded on the End of Study CRF page.
End of Study (Primary Completion):
It is defined as when the last subject is assessed or receives an intervention for the 
purposes of final collection of data for the primary endpoint(s).
End of Study (End of Trial):
It is defined as when the last subject is assessed or receives an intervention for 
evaluation in the study; if the study includes multiple parts (eg, safety follow-up or 
survival assessment), the end of study would include these additional parts. 
End of Treatment:
It is defined as the last assessment for the protocol-specified treatment phase of the 
study for an individual subject.
Fridericia-corrected QT Interval (QTcF):
The Fridericia correction will be calculated from the investigator reported QT (msec) and
RR interval (msec), as follows:
QTcF=QT/(RR/1000)1/3
Investigational Product:
The term ‘investigational product’ is used in reference to AMG 510.
Last Investigational Product Dose Date:
The last IP date for each subject is defined as the latest date IP administered.
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Long Term Follow-Up:
Following the SFU visit, there will be a LTFU period for clinical evaluation of disease 
status and survival.  Subjects will be followed via telephone every 12 weeks (± 2 weeks) 
for assessment of survival and documentation of anti-cancer treatment. Subjects will be 
followed for a maximum of 2 years from the first dose of AMG 510, or until subject death, 
whichever occurs first.
Subjects will allow Amgen continued access to medical records so that information 
related to subjects’ health condition, including disease status and survival, may be 
obtained.
Maximum Tolerated Dose (MTD): 
A final estimate of the MTD will be made based on a Bayesian Logistic Regression 
Model (BLRM) utilizing all DLT-evaluable subjects from the dose exploration and dose 
expansion cohorts. Based on the BLRM, the MTD is defined as the dose with the highest 
probability of a DLT rate between the targeted toxicity (0.2, 0.33) interval while 
controlling the probability of excessive and unacceptable toxicity below 25%. The MTD 
will estimated separately by dosing regimen if multiple regimens are evaluated.
Objective Response Rate (ORR):
Objective response rate is defined as the proportion of patients with a BOR of CR or PR. 
Overall survival (OS):
Overall survival (OS) is defined as the time from treatment start with AMG 510 until
event of death due to any cause. Subjects without event will be censored at their last 
contact date.
Primary Completion:
Defined as the date when the last subject is assessed or receives an intervention for the 
final collection of data for the primary endpoint(s), for the purposes of conducting the 
primary analysis, whether the study concluded as planned in the protocol or was 
terminated early.
Progression Free-Survival (PFS):
The PFS is defined as interval between the date of first dose of AMG 510 and the date 
of disease progression or death due to any cause (whichever comes first).
Subjects who are alive and have not progressed, whether on-study or lost to follow-up, 
will be censored at their last evaluable tumor assessment date.
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Relative Dose Intensity for First Cycle:
Relative DI will be calculating by using the below formula for first cycle as follows:
RDI = [non-missing (dose*days) / planned (dose*days)] *100
Safety Follow-Up:
It is defined as the subject visit up to 30 (+7) days after last dose of AMG 510 is 
received.
Study Day:
Post-study day: study day= (date – date of Study Day 1) + 1 
Pre-study day: study day= (date – date of Study Day 1) 
Study Day 1:
It is defined as the first day that AMG 510 is administered to the subject. 
Treatment-Emergent Adverse Event (TEAE):
An adverse event that occurs on or after the first administration of AMG 510 or within 
30 days after the last dose of AMG 510. The severity of each adverse event will be 
graded using the CTCAE version 4.0. Adverse events will be coded using 
MedDRA 21.0.
Treatment-Related AE:
A treatment-related AE is any treatment-emergent AE that per investigator review has a 
reasonable possibility of being caused by the investigational product. 
Toxicity Probability Interval (TPI):
Toxicity probability intervals for dose-limiting toxicity (DLT) are defined as (0.20, 0.33]
and (0.33, 1.00] for target and excessive, respectively.
6. Analysis Sets
The following sub-sections describe the analysis sets to be used.
6.1 Full Analysis Set
Not applicable to this study.
6.1.1 Primary Analysis Set
Not applicable to this study.
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6.2 Safety Analysis Set
Safety Analysis Set is defined as all subjects that are enrolled and receive at least 
1 dose of AMG 510. The analysis of all endpoints, unless noted otherwise will be 
conducted on the Safety Analysis Set.
6.3 Per Protocol Set(s)
Not applicable to this study.
6.4 Pharmacokinetic/Pharmacodynamic Analyses Set(s)
The PK Analysis Set will contain all subjects who have received at least 1 dose of the 
investigational product and have at least 1 PK sample collected. These subjects will be 
evaluated for PK analysis unless the number of data points required for analysis is not 
enough, or significant protocol deviations have affected the data, or if key dosing or 
sampling information is missing. The PK Analysis Set will be used to conduct the 
analysis of PK data, unless otherwise specified.
6.5 Interim Analyses Set(s)
Not applicable to this study. At interim analysis with cutoff determined, the DLT data will 
be analyzed based on DLT analysis set, PK parameters will be analyzed based on PK 
Analysis Set, and other data will be reported using Safety Analysis Set, unless otherwise 
specified.
6.6 DLT Evaluable Set
The Dose Limiting Toxicity Analysis Set will contain DLT-evaluable subjects. For 
dose-escalation decisions, backfill subjects will not be included (see protocol 
Section 5.1).  The details of DLT evaluable subjects are given below:
Dose Cohort Duration of DLT Window DLT Evaluable Subject
Multiple subject cohorts 21 days from C1D1 Subject experienced a DLT or 
Subject does not experience a 
DLT and subject received at 
least 80% of the planned doses
(ie, no more than 4 days without 
dosing) of investigational 
product within the first treatment 
cycle of 21 days.
C1D1 = Cycle 1 Day 1; DLT = Dose-Limiting Toxicity
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7. Planned Analyses
The following data analyses are planned:
 An interim analysis for efficacy parameters will be conducted after dose
escalation is completed.
 The primary analysis will occur when target enrollment is complete, and each 
subject has had the opportunity to receive up to 6 months of treatment or 
terminated the study early.
 The final analysis is planned after all dose-escalation cohorts and 
dose-expansion subjects have ended the study.
7.1 Interim Analysis and Early Stopping Guidelines
Safety data will be reviewed on an ongoing basis. Based on accumulating toxicity
information, BLRM will be used to make dosing recommendations based on the DLT 
Evaluable Set. In DLRMs, Amgen, in consultation with the site investigators, will review 
the BLRM recommended dose level and will review all available cumulative data by
cohort prior to making dose escalation decisions. As a sensitivity analysis, a
one-parameter Continual Reassessment Method (CRM) model may be used to estimate
the dose-toxicity relationship to help make dose escalation decisions. Adverse events
and DLTs observed in all subjects (including backfill subjects) will be evaluated
continually and fully integrated into all DLRMs and considered in all enrollment and
dosing decisions.
An interim analysis for efficacy parameters will be conducted after dose escalation is
completed.
7.2 Primary Analysis
The primary analysis will occur when target enrollment is complete, and each subject has 
had the opportunity to receive up to 6 months of treatment or has terminated the study 
early.
7.3 Final Analysis
A final analysis is planned after all dose-escalation cohorts and dose-expansion subjects
have ended the study. Primary and final analysis may be combined in case all subjects
have ended study close to the time point of the primary analysis.
8. Data Screening and Acceptance
8.1 General Principles
The objective of the data screening is to assess the quantity, quality, and statistical
characteristics of the data relative to the requirements of the planned analyses.
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8.2 Data Handling and Electronic Transfer of Data
The Amgen Global Study Operations-Data Management (GSO-DM) department will 
provide all data to be used in the planned analyses. This study will use the RAVE 
database. The database will be subject to edit checks outlined in the Clinical Data 
Management Plan (DMP). See details of this section in the DMP.
8.3 Handling of Missing and Incomplete Data
Incomplete adverse event and concomitant medication dates missing data will be 
imputed as described in Appendix A.
8.4 Detection of Bias
Lack of protocol compliance and the potential for biased statistical analyses will be 
examined by assessing the incidence of important protocol deviations in each cohort. 
The clinical study team will identify and document the criteria for important protocol 
deviations.
8.5 Outliers
PK concentration data will be evaluated for outliers by visual inspection, and decisions to 
re-assay individual samples will be made in accordance with standard PK evaluation 
practice. 
8.6 Distributional Characteristics
Where appropriate, the assumptions underlying the proposed statistical methodologies 
will be assessed. If required data transformations of analyses will be utilized.
8.7 Validation of Statistical Analyses
Programs will be developed and maintained and output will be verified in accordance 
with current risk-based quality control procedures.
Tables, figures, and listings will be produced with validated standard macro programs 
where standard macros can produce the specified outputs.
The production environment for statistical analyses consists of Amgen-supported 
versions of statistical analysis software; for example, the SAS System version 9.4 or 
later.
9. Statistical Methods of Analysis
9.1 General Considerations
Descriptive statistics will be provided for selected demographic, safety and PD data.
Unless otherwise stated, the data analysis will be conducted using subjects in the Safety 
Product:  AMG 510
Protocol Number:  20170543
Date:  14 November 2018 Page 21 of 33
CONFIDENTIAL 
Analysis Set. Descriptive statistics on continuous data will include means, medians, 
standard deviations, minimums & maximums while categorical data will be summarized 
using frequency counts and percentages. Graphical summaries of the data may also be 
presented.
9.2 Subject Accountability
The number and percent of subjects who were enrolled, received investigational product, 
discontinued from investigational product (including reasons for discontinuing, completed 
study, discontinued the study (including reasons for discontinuing) will be summarized. 
Key study dates for the first subject enrolled, last subject enrolled, and last subject’s end 
of study will be presented.
A subject listing and summary noting inclusion in each analysis subset will be provided 
for all subjects enrolled. A subject listing noting AMG 510 administration start and end 
time, reason for discontinuation of treatment, and reason for discontinuing the study will 
be provided. A list of subjects screened but not enrolled (screen failures) may be 
provided.
9.3 Important Protocol Deviations
Important Protocol Deviations (IPDs) categories are defined by the study team before 
the first subject’s initial visit and updated during the IPD reviews throughout the study 
prior to database lock. These definitions of IPD categories, subcategory codes, and 
descriptions will be used during the study. The final IPD list is used to produce the 
Summary of IPDs table and the List of Subjects with IPDs. In addition, a separate listing 
of all inclusion and exclusion deviations will be provided.
9.4 Demographic and Baseline Characteristics
The following descriptive summaries of the demographic and baseline characteristics will 
be produced: Demographic (ie, age, age groups [< 65, >= 65 and >= 75], sex, race, 
ethnicity) and baseline characteristics, which may include height, weight, BMI, Eastern 
Cooperative Oncology Group (ECOG) Performance Status, ECHO or MUGA, prior 
anti-cancer systemic therapy [1, 2, >2)) will be summarized using descriptive statistics. If 
multiple races have been reported for a subject, the subject will be categorized as 
multiple.
A listing of the demographic and baseline characteristics will be provided. In addition,
listings of medical and surgical history, prior anti-cancer therapy, prior surgery and prior 
radiotherapy usage will be provided.
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9.5 Efficacy Analyses
The efficacy endpoints include ORR, OS, DCR, DOR and PFS. In general, the analysis 
of efficacy endpoints will be based on the Safety Analysis Set unless otherwise 
specified.  The efficacy endpoints will be analyzed overall, by dose (eg, MTD / RP2D), 
regimen (if more than one evaluated), and by histologic type, if appropriate.
9.5.1 Analyses of Primary Efficacy Endpoint(s)
No efficacy parameter is considered in primary endpoints.
9.5.2 Analyses of Secondary Efficacy Endpoint(s)
The number and percent of subjects with best overall response of complete response, 
partial response, stable disease, and progressive disease as determined will be 
tabulated.
The proportion of subjects with an objective response (CR or PR) and disease control
(CR, PR or SD > 6 months) with corresponding exact 95% CI will be calculated using the
Clopper-Pearson method (Clopper and Pearson, 1934) and tabulated for subjects
treated at the MTD or RP2D.
A Kaplan-Meier (K-M) curve may be presented for duration of overall response, duration 
of stable disease, overall survival and progression-free survival with estimates for rates
and 95% CI at selected months. K-M curve can be done for DOR, if at least 10 subjects 
have a CR/PR.
Descriptive statistics including means, standard deviations, medians, minimums, and 
maximums for duration of overall response and duration of stable disease.
Listings will be produced for all subjects in Safety Analysis Set indicating their best 
overall response, duration of overall response, overall survival, progression-free survival, 
and duration of stable disease.
9.5.3 Analyses of Exploratory Efficacy Endpoint(s)
No efficacy parameter is considered in primary endpoints.
9.6 Safety Analyses
9.6.1 Analyses of Primary Safety Endpoint(s)
Unless otherwise specified, statistical analyses on safety endpoints will be done using
subjects from the Safety Analysis Set, which includes subjects that are enrolled and
received at least 1 dose of AMG 510.
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Subject incidence of DLTs will be used to fit the BLRM model to estimate the probability
of having a DLT across dose levels.
9.6.2 Adverse Events and Disease-related Events
The Medical Dictionary for Regulatory Activities (MedDRA) version 21.0 or later will be 
used to code all events categorized as adverse events to a system organ class and a 
preferred term.
The subject incidence of adverse events will be summarized for all treatment-emergent 
adverse events, serious adverse events, adverse events leading to withdrawal of 
investigational product, and death due to adverse events.
Subject incidence of all treatment-emergent adverse events, serious adverse events, 
adverse events leading to withdrawal of investigational product, and fatal adverse events 
will be tabulated by system organ class and preferred term in alphabetical order.  
The number and percentage of subjects reporting adverse events will be evaluated
overall and by dose level and will also be tabulated by relationship to study drug.
The severity of each adverse event will be graded using The Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0 criteria
 http://ctep.cancer.gov/protocolDevelopment/electronicapplications/ctc.htm.
Summaries of treatment-emergent and serious adverse events will be tabulated by 
system organ class, preferred term, and grade.
A listing of the adverse events & serious adverse events will be provided.
9.6.3 Laboratory Test Results
Individual chemistry, hematology, urinalysis, coagulation urine/serum pregnancy test 
(females only and not required if surgically sterile or ≥ 2 years postmenopausal)
laboratory data will be listed and selected parameters may be plotted. Values outside the 
normal laboratory reference ranges will be flagged as high or low on the listings.
CTCAE grades will also be highlighted where appropriate. The number and percentage 
of subjects experiencing treatment emergent laboratory toxicities with worst post dose 
CTCAE grades of ≥ 1, ≥ 2, ≥ 3 and 4 will be presented. The direction of the laboratory 
worsening will be denoted. The summary will be presented for all laboratory parameters 
for which at least one subject experienced a treatment emergent toxicity with a worst 
grade ≥ 3. Additionally, the number and percentage of subjects experiencing 1, 2, 3 and 
4 worsening CTCAE grade shifts from baseline will be presented. The direction of the 
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laboratory worsening will again be denoted. Unscheduled assessments will be 
incorporated in the laboratory analyses where possible.
Shifts tables indicating the change between the baseline and the maximum post dose 
CTCAE grades for an increased value and the maximum post dose grade for a 
decreased value will be provided for selected laboratory parameters of interest.
A listing of CTCAE grade 3 or higher laboratory toxicities will be provided. This listing will 
include all laboratory data for the subject and laboratory parameter of interest in order to 
provide proper context. A flag will indicate the grade 3 or higher toxicity.
Summaries of the absolute value and/or changes from baseline at each scheduled 
assessment may be provided for selected laboratory parameters.
A summary of the change from baseline to the post dose maximum, time to post-dose 
maximum, change from baseline to the post dose minimum, and the time to the post
dose minimum may also be provided for selected parameters.
Potential Hy’s law cases will be listed and may also be summarized.
9.6.4 Vital Signs
Vital signs data (eg, systolic / diastolic blood pressure, heart rate, respiratory rate,
temperature and pulse oximetry) will be listed and reviewed for each subject. Summary 
statistics for each vital sign parameter will be provided for baseline and each scheduled 
post-baseline assessment. Depending on the size and scope of changes, summaries of 
changes from baseline over time may be provided. Unscheduled assessments will be 
included in this summary. 
Shifts in scores for ECOG performance status scores between the baseline and each 
assessed time point will be tabulated. ECOG performance status scores will be 
summarized at relevant time points.
9.6.5 Physical Measurements
Physical measurement data will be listed and reviewed for each subject. Depending on 
the size and scope of changes, summaries of changes from baseline over time may be 
provided. Unscheduled assessments will be included in this summary
9.6.6 Electrocardiogram
A set of triplicate ECGs must be performed at screening; all ECGs will be triplicates with 
each tracing 30 seconds apart
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Summaries over time and/or changes from baseline over time will be provided for all
ECG parameters.
Subjects’ maximum change from baseline in QT interval corrected by Fridericia’s formula
will be categorized and the number and percentage of subjects in each group will be
summarized.
Subjects’ maximum post baseline values will also be categorized and the number and
percentage of subjects in each group will be summarized.
All on-study ECG data will be presented and select parameters of interest may be
plotted.
In addition, the relationship between AMG 510 exposure and change from baseline in 
QTc will be explored graphically.
9.6.7 Exposure to Investigational Product
Descriptive statistics will be produced to describe the exposure to investigational product 
by treatment dose, combining data for each study part. Number of cycles started, 
number of doses of investigational product, the cumulative dose by unit and average
dose delivered per day will be summarized. Summaries of the number and percentage 
of subjects with dose modifications and reason for modification will be provided. 
Details for each AMG 510 administration will be listed for every subject. In addition, a 
listing of the unique manufacturing lot numbers, and a listing of the subjects 
administered each manufacturing lot number will be provided.
9.6.8 Exposure to Other Protocol-required Therapy
Not applicable for the study.
9.6.9 Exposure to Concomitant Medication
The number and proportion of subjects receiving therapies of interest will be 
summarized by preferred term or category as coded by the World Health Organization 
Drug (WHO DRUG) dictionary.
A subject listing of all prior and concomitant medications will be presented.
9.7 Other Analyses
9.7.1 Analyses of Pharmacokinetic or Pharmacokinetic/Pharmacodynamic 
Endpoints
Nominal sampling times will be used for individual concentration-time plots and tables. 
Actual dose administered, and actual sampling times will be used for the calculation of 
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PK parameters for each subject. The reasons for excluding any sample from the 
analyses will be provided.
Individual concentration-time data will be tabulated and presented graphically. Summary 
of PK concentration over time and PK parameters will be provided.  Mean 
concentration-time profiles for each dose will be provided. 
PK parameters will include, but are not limited to maximum observed concentration 
(Cmax), time to maximum concentration (tmax) and area under the plasma 
concentration-time curve (AUC). Other PK parameters such as AUC from time 0 to the 
time extrapolated to infinity (AUCinf), apparent clearance (CL/F), and terminal half-life 
(t1/2) may be analyzed. Pharmacokinetic parameters will be estimated using standard 
non-compartmental approaches based on the PK Analysis Set and summarized by dose 
level using descriptive statistics including, but not limited to means, standard deviations, 
medians, minimums, and maximums. Above analyses will be conducted by Amgen 
Clinical Pharmacology Modeling and Simulation (CPMS).
For the food-effect assessment, PK parameter estimates will help assess the impact of 
food on the pharmacokinetics of AMG 510. The geometric means and 90% confidence 
interval for the ratio of the geometric means (fed state/fasted state) will be estimated 
using a mixed-effects model. The model will use the log-transformed PK parameters as 
the dependent variable (or response) and treatment conditions (fed versus fasted) as the 
independent variable.
The median of tmax will be compared between fasted and fed conditions.
9.7.2 Analyses of Clinical Outcome Assessments
Not applicable for this study.
9.7.3 Analyses of Health Economic Endpoints
Not applicable for this study.
9.7.4 Analyses of Biomarker Endpoints
Relationships between changes in tumor dynamics and above biomarkers of interest 
listed as exploratory endpoints will be explored. Changes in expression levels of 
biomarkers and their relationship to dose may also be explored. Summary statistics over 
time will be provided and graphical presentations may be used.
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The relationship between AMG 510 exposure and related biomarkers in blood will be also
explored if deemed appropriate. As appropriate, details of analysis will be provided in a 
supplemental analysis plan for exploratory biomarker analysis.
10. Changes From Protocol-specified Analyses
Overall Survival added for the secondary endpoint analyses.
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12. Prioritization of Analyses
No priority of output is planned for this study.
13. Data Not Covered by This Plan
The analysis of Biomarkers is not covered in this plan
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Appendix A. Technical Detail and Supplemental Information Regarding Statistical
Procedures and Programs
Imputation Rules for Partial or Missing Stop Dates
If the month and year are present, impute the last day of the month. If only the year is 
present, impute December 31 of that year. If the stop date is entirely missing, assume 
the event or medication is ongoing. If a partial or complete stop date is present and the 
‘ongoing’ or ‘continuing’ box is checked, then it will be assumed that the AE or conmed 
stopped and the stop date will be imputed, if partial.
Stop Date
Complete: 
yyyymmdd Partial: yyyymm Partial: yyyy
Missing
Start 
Date
< 1st
Dose
 1st
Dose
< 1st
Dose 
yyyymm
 1st
Dose 
yyyymm
< 1st
Dose 
yyyy
 1st
Dose 
yyyy
Partial: 
yyyymm
=1st Dose 
yyyymm
2
1
2
1 N/A 1 1
 1st Dose 
yyyymm
2 2 2 2 2
Partial: 
yyyy
=1st Dose 
yyyy
3
1
3
1 N/A 1 1
 1st Dose 
yyyy
3 3 3 3 3
Missing 4 1 4 1 4 1 1
Imputation Rules for Partial or Missing Start Date:
1 = Impute the date of first dose
2 = Impute the first of the month
3 = Impute January 1 of the year
4 = Impute January 1 of the stop year
Note: For subjects who were never treated (first dose date is missing), partial start dates 
will be set to the first day of the partial month.
Note: If the start date imputation leads to a start date that is after the stop date, then do
not impute the start date.
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Appendix B. Code Fragments 
Provisional Code Fragments for calculating a confidence interval using the Clopper 
Pearson Method. The following example SAS code will be utilized for the response rate 
analysis providing the proportion of subjects responding to treatment with corresponding 
95% confidence intervals and 90% confidence intervals. 
For 95% confidence intervals: 
data propci (keep = ns p low_ci upp_ci); 
n=xx; * total n within the treatment group; 
ns= xx; *number of responders; 
p=ns/n; * response rate; 
q=1-p; 
lowF=FINV(0.025, 2*ns, 2*(n-ns+1)); /* use for 2-sided 95% CI */ 
UppF=FINV(1-0.025, 2*(ns+1), 2*(n-ns)); /* use for 2-sided 95% CI */ 
low_ci = 1 / (1+(n-ns+1) / (ns*lowf)); * lower CI for response rate; 
upp_ci = 1 / (1+(n-ns) / ((ns+1)*uppf)); *upper CI for response rate; 
if p=1 then upp_ci=1; 
if p=0 then low_ci =0;
output; 
end;run;
For 90% confidence intervals. 
data propci (keep = ns p low_ci upp_ci); 
n=xx; * total n within the treatment group; 
ns= xx; *number of responders; 
p=ns/n; * response rate; 
q=1-p; 
lowF=FINV(0.05, 2*ns, 2*(n-ns+1)); /* use for 2-sided 90% CI */ 
UppF=FINV(1-0.05, 2*(ns+1), 2*(n-ns)); /* use for 2-sided 90% CI */ 
low_ci = 1 / (1+(n-ns+1) / (ns*lowf)); * lower CI for response rate; 
upp_ci = 1 / (1+(n-ns) / ((ns+1)*uppf)); *upper CI for response rate; 
if p=1 then upp_ci=1; 
if p=0 then low_ci =0; 
output;
A linear mixed effect model using Proc Mixed of SAS was used to analyze 
logarithmically transformed AUC and Cmax in fasted vs. fed state. The geometric means 
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and 90% confidence interval for the ratio of the geometric means (fed state/fasted state) 
will be estimated using a mixed-effects model.
proc mixed data=<data_set_name> method=reml;
    class subject visit food_conditions;
    model response = food_conditions /outp=outp ddfm=kr residual;
    random usubjid / type=un;
    lsmeans food_conditions *visit/ ALPHA=0.1cl;
    ods output lsmeans=lsmeans diffs=diffs;
run;
conditions 
Where,
response = log-transformed PK parameters
food_conditions = fed & fasted
Programming Note: In case if model doesn’t converge change the covariance 
structure from type=UN to the below order
1.  type = AR(1); if AR(1) doesn’t converge then use
2.  type = CS 
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Abbreviation or Term Definition/Explanation
ANC Absolute neutrophil count
AUC Area under the concentration-time curve
ALK Anaplastic lymphoma kinase
BID Twice daily
BLRM Bayesian Logistic Regression Model
Cmax Maximum observed concentration
CR Complete response
CRC Colorectal cancer
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
DCR Disease control rate
DLRM Dose Level Review Meeting
DLRT Dose Level Review Team
DOR Duration of response
DRT Data Review Team
ECG Electrocardiogram
EQ-5D-5L EuroQol-5 Dimension
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer 
Quality-of-life Questionnaire Core 30
FDA Food and Drug Administration
FIH First-in-human
ICF Informed consent form
ICH International Conference of Harmonization
IVD In vitro diagnostic
IR Immediate-release
KRAS Kirsten rat sarcoma viral oncogene homolog (protein)
KRAS Kirsten rat sarcoma viral oncogene homolog (DNA)
KRASG12C KRAS protein with a G12C mutation at the protein level
KRAS p.G12C KRAS DNA with a mutation resulting in a G12C mutation at the 
protein level
MRI Magnetic resonance imaging
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ORR Objective response rate
OS Overall survival
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Abbreviation or Term Definition/Explanation
PD Progressive disease
PK Pharmacokinetic(s)
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PRO patient-reported outcomes
PRO-CTCAE Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events
QD Once daily
QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module 
QLQ-PAN26 Quality-of-Life Questionnaire Pancreatic Cancer Module 
QOL Quality of Life
QTc Corrected QT (interval)
RAS Rat sarcoma viral oncogene homolog
RECIST Response evaluation criteria in solid tumors
RP2D Recommended Phase 2 Dose
SD Stable disease
tmax Time to reach maximum concentration
TTR Time to response
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1. Introduction
The purpose of this Statistical Analysis Plan (SAP) is to provide details of the statistical 
analyses that have been outlined within Amendment 3 of the protocol for 
study 20170543, AMG 510 dated 22 May 2019. The scope of this plan includes the 
interim analysis, the primary analysis and the final analysis in Phase 1 and the interim 
analysis, the primary analysis, additional analysis subsequent to the primary analysis, 
and the final analysis in Phase 2 that are planned and will be executed by the Amgen 
Global Biostatistical Science department unless otherwise specified.
2. Objectives, Endpoints and Hypotheses
2.1 Objectives and Endpoints
2.1.1 Phase 1 (Monotherapy - Parts 1a, 1b, and 2a)
Objectives Endpoints
Primary
 To evaluate the safety and tolerability of
AMG 510 in adult subjects with
KRAS p.G12C mutant advanced solid
tumors
 To estimate the maximum tolerated dose
(MTD) and/or a recommended phase 2
dose (RP2D) in adult subjects with 
KRAS p.G12C mutant advanced solid 
tumors
 Subject incidence of treatment-emergent 
adverse events, treatment-related 
adverse events, and clinically significant 
changes in vital signs, physical 
examinations, electrocardiograms 
(ECGs), and clinical laboratory tests
 Subject incidence of dose limiting toxicity 
(DLT)
Secondary
 To characterize the pharmacokinetics (PK)
of AMG 510 following administration as an
oral tablet formulation
 PK parameters of AMG 510 including, 
but not limited to, maximum plasma 
concentration (Cmax), time to achieve 
Cmax (tmax), and area under the plasma 
concentration-time curve (AUC)
 To evaluate tumor response assessed by
response evaluation criteria in advanced 
solid tumors (RECIST) 1.1 of AMG 510 as
monotherapy in advanced solid tumors with
KRAS p.G12C mutation
 ORR, DOR, DCR, PFS, duration of 
stable disease, and TTR measured by 
CT or MRI and assessed per RECIST 
1.1.  Response will be assessed by 
independent radiologic review.  
Complete response and PR require 
confirmatory CT or MRI repeat 
assessment 4 weeks after the first 
detection of response.
 To evaluate the effect of food on the oral
PK of AMG 510
 PK parameters of AMG 510 including, 
but not limited to, Cmax, tmax, and AUC in 
the fed and fasted states for the food 
effect assessment
 To evaluate the relationship between
changes in corrected QT interval (QTc) and
AMG 510 exposure
 AMG 510 exposure/QTc interval 
relationship
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Objectives Endpoints
Exploratory
 To explore pharmacodynamic
relationships for safety and/or efficacy
endpoints 
 AMG 510 exposure/safety and 
exposure/efficacy relationships
 Pharmacodynamic changes observed in 
blood and/or biopsies if available
 To characterize AMG 510 excretion in 
urine
 AMG 510 excretion in urine
 To identify metabolites of AMG 510 in 
plasma and urine
 Characterization of potential metabolites of 
AMG 510 in plasma and urine, if appropriate
 To investigate potential biomarkers by
biochemical and/or genetic analysis of
blood and/or tumor tissue samples.
 Quantification of biomarker expression at 
protein, RNA, and DNA levels, as 
appropriate
 Potential biomarkers by biochemical and/or 
genetic analysis of blood and/or tumor tissue 
samples
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2.1.3 Phase 2 (AMG 510 Monotherapy)
Objectives Endpoints
Primary
 To evaluate tumor objective response rate 
(ORR), assessed by RECIST 1.1 criteria, 
of AMG 510 as monotherapy in subjects 
with KRAS p.G12C mutant advanced 
solid tumors (NSCLC, colorectal cancer 
[CRC], and other tumor types).
 Objective response rate (ORR = complete 
response [CR] + partial response [PR]), 
assessed per RECIST 1.1.  Response will 
be assessed by independent radiologic 
review.  Complete response and PR 
require confirmatory CT or MRI repeat 
assessment 4 weeks after the 
first detection of response.
Secondary
 To evaluate other measures of 
AMG 510 efficacy as monotherapy in 
subjects with KRAS p.G12C mutant 
advanced solid tumors by 
RECIST 1.1 (NSCLC, CRC, and other 
tumor types).
 Duration of response (DOR)
 Disease control rate (DCR)
 Time to response (TTR)
 Progression-free survival (PFS)
 Overall survival (OS)
 PFS rate at 6 months and 
12 months
 OS rate at 12 months
 Duration of response - defined as time 
from first evidence of confirmed PR or CR 
to disease progression or death due to 
any cause, whichever occurs first.  
Subjects without a duration ending event 
will be censored at their last evaluable 
disease assessment date.  Progression 
will be based on an independent 
radiologic assessment of disease 
response per RECIST 1.1
 Disease control rate defined as 
CR + PR + stable disease rate measured 
as described for ORR
 Time to response - defined as time from 
first dose of AMG 510 until the 
first evidence of confirmed PR or CR
 Progression-free survival - defined as 
time from first dose of AMG 510 until 
disease progression or death from any 
cause, whichever occurs first.  Subjects 
who do not progress or die will be 
censored at their last evaluable disease 
assessment date.  Progression will be on 
an independent radiologic assessment of 
disease response per RECIST 1.1.
 Overall survival - defined as time from 
first dose of AMG 510 until death from 
any cause.  Subjects who do not die will 
be censored at the date of last contact.
 Progression-free survival rate at 6 months 
and 12 months
 Overall survival rate at 12 months
 To evaluate the safety and tolerability of 
AMG 510 in adult subjects with 
KRAS p.G12C mutant advanced solid 
tumors (NSCLC, CRC, and other tumor 
types). 
 Subject incidence and severity of adverse 
events
 To evaluate the PK of AMG 510 following 
administration as an oral tablet 
formulation
 Pharmacokinetics parameters of 
AMG 510 including, but not limited to, 
Cmax, tmax, and AUC.
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Objectives Endpoints
Exploratory
 To explore PK/pharmacodynamic 
relationships for safety and/or efficacy 
endpoints
 AMG 510 exposure/safety and 
exposure/efficacy relationships
 Pharmacodynamic changes observed in 
blood and/or biopsies if available
 To explore biomarkers of response and 
resistance in tumor and blood specimens 
prior to exposure to AMG 510 and at the 
time of progression
 Biomarkers of response and resistance to 
AMG 510 at the time of progression
 Quantification of biomarker 
expression at protein, RNA, and DNA 
levels, as appropriate
 Potential biomarkers by biochemical 
and/or genetic analysis of blood 
and/or tumor tissue samples
 To explore the subject experience with 
AMG 510 treatment using 
patient-reported outcome instruments with 
respect to the following core concepts:
 Impact of treatment on 
disease-related symptoms and 
Health-related Quality of Life 
(HRQOL) 
 Treatment-related symptoms and 
impact on the subject
 Physical function
 Changes in cancer-specific symptoms 
and overall health status using 
subject-reported outcome instruments:
 Impact of treatment on 
disease-related symptoms and 
HRQOL (instruments; 
EORTC QLQ-C30 + disease-specific 
modules QLQ LC13 and NSCLC SAQ 
for NSCLC, and QLQ Pan 26 for 
pancreatic cancer) 
 Treatment-related symptoms and 
impact on the subject (EORTC 
QLQ-C30, selected questions from 
the PRO-CTCAE library and a 
single item about symptom bother, 
item GP5 of the FACT-G)
 Physical function (instrument:  
EORTC QLQ-C30, Physical function 
scale)
2.2 Hypotheses and/or Estimations
Phase 1 (monotherapy 
 At least 1 dose level of AMG 510, in repeat oral administrations, will achieve
acceptable safety and tolerability in subjects with KRAS p.G12C mutant advanced 
solid tumors in both monotherapy 
 A favorable PK profile will be achieved with AMG 510 administered orally as 
monotherapy 
 Responses will be observed at a monotherapy dose level that achieves acceptable 
safety and tolerability.
Phase 2 (AMG 510 monotherapy):
A clinically relevant ORR will be observed in each tumor type (NSCLC, CRC or other 
tumor type) at a dose level that demonstrates acceptable safety and tolerability
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3. Study Overview
3.1 Study Design
This is a phase 1/2 multicenter, non-randomized, open-label study of orally administered 
AMG 510 in subjects with KRAS p.G12C mutant advanced solid tumors.  The study will 
be conducted at approximately 100 sites globally.
Phase 1 is a first in human (FIH) dose exploration/expansion study to define the MTD or 
RP2D, safety, tolerability, PK and pharmacodynamics of AMG 510 as monotherapy in 
subjects with KRAS p.G12C mutant advanced solid tumors (Phase 1, Part 1a, 1b, and 
2a)  
  The phase 1 portion of the study 
will be conducted in 2 parts:  part 1 – Dose Exploration and part 2 – Dose Expansion.  
Part 1 is aimed at evaluating the safety, tolerability, PK, and pharmacodynamics and 
determining the MTD of repeat daily (QD) (or twice daily [BID]) dosing for AMG 510 
monotherapy in subjects with KRAS p.G12C mutant advanced solid tumors using a 
Bayesian Logistics Regression Model (BLRM) design and evaluating the safety, 
tolerability,  
  The dose expansion part of the study (part 2) 
can open once the MTD and/or a RP2D has been determined in part 1.  The DLT 
evaluation period will be 21 days.  
Phase 2 is a multicenter, non-randomized, open-label, phase 2 study to evaluate 
efficacy and safety/tolerability of AMG 510 as monotherapy in subjects with 
KRAS p.G12C mutant advanced solid tumors (NSCLC, CRC, and other tumors).
Administration of AMG 510 may continue until subject has confirmed disease 
progression or discontinues from the treatment for reasons listed in Protocol 
Section 8.3.1.
Phase 1:
Dose Exploration – Part 1
Part 1a Monotherapy Cohorts (Once Daily Dosing – QD):
Dose exploration monotherapy cohorts will estimate the MTD, and evaluate the safety, 
tolerability, PK, and pharmacodynamics of different doses of AMG 510 administered 
orally once daily in subjects with KRAS p.G12C mutant advanced solid tumors.  
Enrollment into the dose exploration cohorts may be from any eligible solid tumor type.  
Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 
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180 mg.  Dose escalation will follow the planned schedule with 2-4 subjects treated in 
each cohort.  If no DLT is observed, dose escalation will continue to the next planned 
dose cohort as per Protocol Table 1.  In addition to the dose levels outlined in Protocol 
Table 1, intermediate doses of 270 mg and 540 mg may be explored.  Upon escalation 
to the next planned dose cohort, sentinel dosing will apply.  There will be a 2-day 
window between the first subject dosed and subsequent subjects.  Once a subject 
experience a DLT, dosing for subsequent cohorts will be recommended using the dose 
level recommendation from the BLRM.  The decision to advance to the next dose level 
will be recommended by the Dose Level Review Team (DLRT) using the dose level 
recommendation from BLRM, as appropriate, and by evaluating available safety data, 
laboratory, and PK information. 
Intra-subject dose escalations are allowed on this study.  Subjects who complete the 
DLT period may proceed to a higher dose level for the following treatment cycle if the 
next dose cohort is deemed safe at that time by the DLRT and after consultation with the 
sponsor if:
 no DLT has been reported for this subject during or after completion of the
DLT period
 the subject has not experienced any  grade 2 adverse events (deemed treatment
related by the investigator) during treatment 
Subjects who proceed to a higher dose level will be required to have back to back clinic 
visits on day 1 and day 2 at the beginning of the cycle with the higher dose.  The safety 
assessments of chemistry and urinalysis will be performed on day 1 and day 2.  A repeat 
of PK sample collection will be performed as on cycle 1 day 1 and cycle 1 day 2, 
regardless of actual study cycle.
Subjects who do not proceed to a higher dose may continue to receive additional cycles 
at the original dose.
Dose exploration will continue until any of the following events.
 the highest planned dose level is determined to be safe and tolerable (minimum of
6 DLT-evaluable subjects)
 the MTD is identified, BLRM recommends a dose level which already has
6 DLT-evaluable subjects
Additional subjects (20 to 40) may be enrolled in one or more monotherapy dose levels 
that have been shown to be safe and tolerable; defined as backfill enrollment.  This 
backfill enrollment will be done to better estimate the RP2D and better characterize the 
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safety, efficacy, PK, and pharmacodynamics for AMG 510 monotherapy and may be 
concurrent with dose escalation to identify the MTD.  Additionally, food effect 
assessment will be conducted in at least 6 subjects from backfill enrollment in cycle 2 or 
later.
Part 1b Monotherapy Cohorts (Twice Daily Dosing – BID):
A BID dosing schedule for AMG 510 may be investigated as a dose modification 
strategy to potentially optimize AMG 510 activity.  The initiation of the BID dosing 
schedule will be based upon the totality of the data available from Part 1a and food 
effect assessment.  Approximately 12 subjects may be enrolled in 2 cohorts of 
3 to 6 subjects per cohort.  
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Dose Expansion – Part 2
Upon completing the dose exploration part of the study and depending on data obtained,
dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C
mutant solid tumors:
 Part 2a subjects with KRAS p.G12C mutant advanced NSCLC, CRC, or other tumor 
types administered AMG 510 monotherapy once daily (total approximately n = 20, 
maximum n = 60).
  
Dose expansion in these 2 groups may be done concurrently.
Transition from Monotherapy Phase 1 (Part 2a) Dose Expansion to Phase 2:
After a minimum of 20 subjects have been enrolled to the initial estimated monotherapy 
RP2D (including subjects enrolled to the RP2D in either the dose exploration or the dose 
expansion parts of the study) and have completed the 21-day DLT period, the DLRT will 
review all available safety, laboratory, PK, and efficacy (physician assessment) data 
(including all previous data from the dose expansion and backfill cohorts).  Antitumor 
activity will also be monitored in terms of ORR by tumor types (NSCLC, CRC).  Futility 
and efficacy thresholds will be calculated using Bayesian posterior probability approach 
based on the cumulative efficacy data and it will serve as a guidance to the DLRT.  
DLRT will make a recommendation as to whether to proceed to the phase 2 
monotherapy part of the study.  The DLRT may also recommend that additional subjects 
be enrolled at this estimated monotherapy RP2D or that a dose reduction or alternate 
dosing regimen be explored before proceeding to phase 2.  After this first review has 
been conducted, if a decision is made to continue to obtain additional data at the initial 
estimated RP2D prior to proceeding to phase 2, the intervals for subsequent reviews will 
be determined by the DLRT but should occur within a maximum of 20 additional subjects 
enrolled and dosed for 21 days.  The maximum number of subjects that may be enrolled 
to the initial estimated RP2D in the monotherapy dose expansion group, without 
confirmation of this dose for phase 2, will not exceed 60.  If another dose (or schedule) 
needs to be explored, additional subjects on that dose (or schedule), up to a total of 60, 
may be enrolled.  Whenever DLRT will review the data, the futility and efficacy 
thresholds will be calculated based on all the cumulative efficacy data to provide the 
guidance.
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Phase 2:
This is a multicenter, non-randomized, open-label, phase 2 study to evaluate efficacy 
and safety/tolerability of AMG 510 as monotherapy in subjects with KRAS p.G12C
mutant advanced solid tumors (NSCLC, CRC, and other tumors).  The dose (and 
schedule) administered in phase 2 will be that confirmed to be the RP2D from combined 
analyses of phase 1 part 1 and 2.  Approximately 200 subjects (at least 105 for NSCLC 
and 60 CRC) will be enrolled.  The timing to start enrollment into each tumor type will be 
communicated to the sites and may be gated based on Amgen's internal decision based
on several factors (ie, efficacy and availability of the drug supply).  Tumor response will 
be evaluated employing RECIST 1.1 based on contrast enhanced computed 
tomography (CT)/magnetic resonance imaging (MRI) with assessments conducted by an 
independent radiological central laboratory.  Interim safety reviews will be conducted 
after 30, 50, 70, and 100 subjects have been enrolled and treated with AMG 510 for at 
least 21 days (enrollment will not be held for completion of these safety reviews).  
Interim futility analyses will be conducted as described in Section 7.1 Interim Analysis 
and Early Stopping Guideline..  The primary analysis for phase 2 will occur when
105 NSCLC subjects or 60 CRC subjects are enrolled and have 6-month follow-ups
(Section 7.2 Primary Analysis), whichever group occurs first. The data cutoff was
decided to allow sufficient time to demonstrate durability of ORR. 
3.2 Sample Size
It is anticipated that up to 158 subjects will be enrolled in the phase 1 part of the study.  
No more than 92 subjects will be enrolled in part 1 (dose exploration) cohorts and up to
66 subjects will be enrolled in part 2 (dose expansion) cohorts.  
Part 1 – Dose Exploration:
Part 1a
Approximately 30 subjects will be needed to estimate the AMG 510 monotherapy MTD in 
part 1a. An additional 20 to 40 subjects may be enrolled by backfill enrollment and 
receive AMG 510 monotherapy (part 1a) from which at least 6 subjects will be evaluated
for food effect.  
Part 1b
Approximately 12 subjects may be enrolled in 2 cohorts of 3 to 6 subjects per cohort.
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Part 2 – Dose Expansion:  Approximately 20 subjects (maximum of 60 subjects) with 
KRAS p.G12C mutant advanced tumors (of any tumor type) will be enrolled at the initial 
estimated RP2D in the part 2a monotherapy dose expansion part of the study.  
 
Phase 2:
In phase 2, it is anticipated that approximately 200 subjects (at least 105 subjects with 
NSCLC and 60 subjects with CRC) will be enrolled.  Actual enrollment for each tumor 
type (NSCLC, CRC) will be based on DLRT recommendations and Amgen's internal 
decision.  
The rationale for the number of subjects is provided in protocol Section 10.2.
3.3 Adaptive Design
For Phase 1 dose exploration, the adaptive features of the BLRM design are described 
in Protocol Appendix E.  For Phase 1 dose expansion, the futility and efficacy thresholds 
are calculated and specified in Section 7.1.2.  For Phase 2, futility analyses are 
described in Section 7.1.3.2.
4. Covariates and Subgroups
4.1 Planned Covariates
The following baseline covariates may be used to evaluate efficacy endpoints in 
subgroups or in multivariate analysis: Age at baseline (< 65, >= 65 years), prior lines of 
anti-cancer therapy (1, 2, >2) and ECOG performance status.
4.2 Subgroups
In Phase 2, the following subgroup may be used to examine the primary and selected 
secondary endpoints, as appropriate. When there is not a sufficient number of subjects 
in the subgroup (ie, less than 10% of the whole population), relevant subgroups may be 
combined. 
 Age at baseline (<65, >=65 years)
 Prior lines of anti-cancer therapy (1, 2, >2)
 Prior immunotherapy treatment 
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 ECOG (0, 1)
 Race (Caucasian, black, other)
 Sex (male, female)
 Histology (adenocarcinoma or squamous cell carcinoma)
 Stages (locally advanced and unresectable vs metastatic)
 Presence of liver metastasis (yes, no)
 Presence of brain metastasis (yes, no)
 Co-mutation of interest
 Smoking history
 Region (North America and Europe vs rest of world)
 Best response on prior therapy 
Biomarker data may be incorporated in additional exploratory subgroup or multivariate
analyses. The analyses of biomarkers may be performed after collection of all samples
during the conduct of the study and therefore may be reported after the primary analysis
of efficacy endpoints.
5. Definitions
Adverse Event (AE):
An adverse event is defined as any untoward medical occurrence in a clinical trial 
subject. The event does not necessarily have a causal relationship with study treatment.
The definition of adverse events includes worsening of a preexisting medical condition. 
A preexisting condition that has not worsened during the study, or involves an 
intervention, is not considered an adverse event.
Age at Enrollment:
Subject age at enrollment will be determined using the age in years reported in the 
clinical database.
AUC:
The area under the plasma drug concentration-time curve (AUC) reflects the actual body 
exposure to drug after administration of a dose of the drug.
Baseline:
For any variable, unless otherwise specified the baseline is the last non-missing 
assessment taken prior to the first administration of any study specified treatment.  
Where baseline measurements are taken on the same day as the study specified 
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treatment and no times are present, it will be assumed that these measurements are 
taken prior to the study specified treatment being administered. 
Baseline ECG Values in Triplicate:
The mean of the three triplicate ECG results should be calculated for Baseline.  If fewer 
than three triplicate ECG results are available, the mean of available triplicate should be 
calculated.  For all post-baseline ECG, the mean of one triplicate ECG results at the 
same assessment will be calculated and used in the analysis.
When an ECG is missing within a triplicate, all available data will be averaged for that 
time point.
Best Overall Response (BOR):
Best overall response (BOR) for a subject is the best observed disease response per 
RECIST v1.1.  Overall response assessments occurring after the start of the 
first subsequent anticancer therapy will not be included.  No additional derivations will be 
required to classify the response.
BOR is defined as the best response in the following order: CR, PR, SD, PD, or NE, 
where CR and PR require confirmation by a repeat, consecutive scan at least 4 weeks 
after the first documentation of response.  A best overall response of SD requires an 
on-study imaging of SD or better no earlier than 6 weeks after cycle 1 day 1; otherwise 
the best overall response will be not evaluable (NE)
Please refer Protocol Appendix D for more details.
Body Mass Index (BMI):
Body Mass Index should be calculated using the following formula: 
BMI (kg/m2) = weight (kg) / [height (cm)/100]2 
Body Surface Area (BSA):
The Body Surface Area should be calculated using the following formula: 
BSA= 0.007184 × weight(kg)0.425 × height(cm)0.725
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Change from Baseline:
Change from Baseline is the arithmetic difference between post-dose assessments and 
Baseline value.
Change (absolute) from Baseline = (Post-baseline Value – Baseline Value)
Change (percent) from Baseline = [(Post-baseline Value – Baseline Value) /
Baseline Value] x 100
Dose Limiting Toxicity (DLT):
Dose-limiting toxicity (DLT) is defined as AMG 510-related toxicity with an onset within 
the first 21 days following first dose with the criteria defined in section 6.1.1.2.1 of the 
Protocol.
Disease control rate (DCR):
DCR is defined as the proportion of patients in whom the best overall response is 
determined as complete response (CR), partial response (PR) or stable disease (SD) 
> 6 weeks.
Duration of response (DOR):
The duration of response is defined as time from first evidence of PR or CR to disease 
progression or death due to any cause.  
The duration of complete response is defined as time from the first evidence of CR to 
disease progression or death due to any cause.  
DOR will be calculated only for subjects who achieve a confirmed best overall response
of PR or better.
Subjects will be censored following the censoring strategy described in the definition of 
PFS time in Table 1.
Duration of stable disease:
Duration of stable disease will be measured from the start of treatment to disease 
progression or death due to any cause.  
Subjects will be censored following the censoring strategy described in the definition of 
the PFS time in Table 1.
End of IP administration (End of IP Admin):
End of IP Admin for each subject is defined as the date the decision was made to end IP 
as recorded on the End of Investigational Product Administration CRF page.
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End of Study (Individual Subject):
End of study for each subject is defined as the date the subject last completed a 
protocol-specified procedure.  The date will be recorded on the End of Study CRF page.
End of Study (Primary Completion):
It is defined as when the last subject is assessed or receives an intervention for the 
purposes of final collection of data for the primary endpoint(s), whether the study was 
conducted as planned in the protocol or was terminated early.  
End of Study (End of Trial):
The end of study date is defined as the date when the last subject across all sites is
assessed or receives an intervention for evaluation in the study (ie, last subject 
last visit), following any additional parts in the study (eg, long-term follow-up), as 
applicable.
Fridericia-corrected QT Interval (QTcF):
The Fridericia correction will be calculated from the investigator reported QT (msec) and
RR interval (msec), as follows:
QTcF=QT/(RR/1000)1/3
Investigational Product:
The term ‘investigational product’ is used in reference to AMG 510.
Last Investigational Product Dose Date:
The last IP date for each subject is defined as the latest date IP administered.
Long Term Follow-Up:
Following the SFU visit, there will be a LTFU period during which data will be collected 
on the subjects’ health condition, disease status, survival and subsequent anticancer
treatment.
Also, for subjects who discontinued study treatment without confirmed disease 
progression or start of subsequent anticancer treatment, tumor assessments will 
continue during LTFU every 12 weeks (± 2 weeks) for up to 3 years after last subject 
enrolled or until confirmed disease progression, start of subsequent anticancer 
treatment, death, withdrawal of consent, loss to follow-up, or end of study.  
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Subjects who had confirmed disease progression or started subsequent anticancer 
treatment, will be followed via telephone every 12 weeks (± 2 weeks) for assessment of 
survival and documentation of anticancer treatment.  Subjects will be followed for up to 
3 years after last subject enrolled or until withdrawal of consent, loss to follow-up, or 
subject death, whichever occurs first.
Maximum Tolerated Dose (MTD): 
A final estimate of the MTD will be made based on a Bayesian Logistic Regression 
Model (BLRM) utilizing all DLT-evaluable subjects from the dose exploration and dose 
expansion cohorts.  Based on the BLRM, the MTD is defined as the dose with the 
highest probability of a DLT rate between the targeted toxicity (0.2, 0.33) interval while 
controlling the probability of excessive and unacceptable toxicity below 25%.  The MTD 
will estimated separately by dosing regimen if multiple regimens are evaluated.
Objective Response Rate (ORR):
Objective response rate is defined as the proportion of patients with a BOR of CR or PR. 
Overall survival (OS):
Overall survival (OS) is defined as the time from the start of treatment until event of 
death due to any cause.  Subjects still alive will be censored at the date last known to be 
alive.  If the date last known to be alive is after the date that triggers the analysis (ie, the 
data cutoff date), the subject will be censored at the analysis trigger date.
Primary Completion:
Defined as the date when the last subject is assessed or receives an intervention for the 
final collection of data for the primary endpoint(s) of Phase 2, for the purposes of 
conducting the primary analysis, whether the study concluded as planned in the protocol 
or was terminated early.
Progression Free-Survival (PFS):
The PFS is defined as interval from the start of treatment to disease progression or 
death due to any cause (whichever comes first).  The censoring rules for the 
progression-free survival analysis are detailed in Table 1.
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Table 1.  Main PFS Definition 
Situation Date of Event or Censor Outcome 
No evaluable post-baseline tumor assessments, no 
death by data cutoff
Date of first dose Censor 
No surgical resection, no new anti-cancer therapy, did not withdraw consent to participate in 
the study and :
Progression documented per RECIST v1.1 before 
any death by data cutoff
Date of first observation date 
of disease progression
Event 
No progression, but death recorded by data cutoff Date of death Event
No progression nor death by data cutoff Date of last evaluable 
assessment 
Censor 
Surgical resection/new anti –cancer therapy started or withdraw consent to participate in the 
study and:
Progression documented per RECIST v1.1 before 
surgical resection/new anti-cancer therapy started 
or withdraw consent to participate in the study by 
data cutoff
Date of first observation date 
of disease progression
Event 
Progression documented per RECIST v1.1 after 
surgical resection/new anti-cancer therapy started 
or withdraw consent  to participate in the study and 
alive by data cutoff
Date of last evaluable scan 
before start of new 
ant-cancer therapy/surgical 
resection
Censor 
Subject died subsequently on or prior to data cutoff Date of death Event 
No progression nor death by data cutoff Date of last evaluable scan
before start of new 
anti-cancer therapy/surgical 
resection
Censor 
Relative Dose Intensity:
Relative dose intensity is calculated as actual dose intensity / planned dose intensity, 
where
 Cumulative actual dose [mg] is defined as the total dose given during the study 
treatment exposure.  For subjects who did not take any drug the cumulative 
actual dose by definition is 0 mg.
 Actual dose intensity for subjects with non-zero duration of exposure is defined 
as: cumulative actual dose [mg] / duration of exposure [days] where duration of 
exposure = date of last dose – date of first dose + 1.  For subjects who did not 
take any drug the actual dose intensity is 0 mg/day.
 Cumulative planned dose is the per-protocol planned dose accumulated over the 
actual duration on study treatment.
 Planned dose intensity for subjects with non-zero duration of exposure is defined 
as: cumulative planned dose [mg] / duration of exposure [days] where duration of 
exposure = date of last dose – date of first dose + 1.  
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Safety Follow-Up:
It is defined as the subject visit up to 30 (+7) days after last dose of AMG 510 is 
received.
Study Day:
Post-study day: study day= (date – date of Study Day 1) + 1 
Pre-study day: study day= (date – date of Study Day 1) 
Study Day 1:
It is defined as the first day of  the treatment being administered to the subject. 
Time to Response (TTR):
Time to response is defined as time from the start of treatment until the first evidence of 
confirmed PR or CR.TTR will be calculated only for subjects who achieve a best overall 
response of PR or better
Treatment-Emergent Adverse Event (TEAE):
Events categorized as Adverse Events (AEs) starting on or after first dose of 
investigational product as determined by the flag indicating if the adverse event started
prior to the first dose on the Events CRF and up to and including 30 days after the 
last dose of investigational product or the End of Study date, whichever is earlier. 
Treatment-Related AE:
A treatment-related AE is any treatment-emergent AE that per investigator review has a 
reasonable possibility of being caused by the investigational product. 
Toxicity Probability Interval (TPI):
Toxicity probability intervals for dose-limiting toxicity (DLT) are defined as (0.20, 0.33] 
and (0.33, 1.00] for target and excessive, respectively.
6. Analysis Sets
6.1 Full Analysis Set
6.1.1 Phase 1 Full Analysis Set
The Phase 1 Full Analysis Set (P1FAS) is defined as all subjects that are enrolled in 
phase 1 and receive at least 1 dose of AMG 510.  All safety and efficacy analysis for 
Phase 1 except the DLT analysis and interim ORR analysis will be performed on the 
P1FAS.
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6.1.2 Phase 2 Full Analysis Set
The phase 2 full analysis set (P2FAS) will consist of all subjects that are enrolled in 
phase 2 and receive at least 1 dose of AMG 510.  The analysis of safety, PFS, and OS 
for Phase 2 will be performed on the P2FAS.
6.2 Safety Analysis Set
The integrated Safety Analysis Set is defined as all subjects that are enrolled in phase 1 
and phase 2 and receive at least 1 dose of AMG 510. 
6.3 Per Protocol Set(s)
Not applicable to this study
6.4 Health-related Quality-of-Life or Health Economics Analyses Set(s)
The analysis set for Health-related Quality of Life outcomes will be defined in a 
Supplemental Statistical Analysis Plan along with the planned analyses for these 
endpoints.
6.5 Pharmacokinetic/Pharmacodynamic Analyses Set(s)
The PK Analysis Set will contain all subjects who have received at least 1 dose of the
investigational product and have at least 1 PK sample collected.  These subjects will be 
evaluated for PK analysis unless the number of data points required for analysis is not 
enough, or significant protocol deviations have affected the data, or if key dosing or 
sampling information is missing.  The PK Analysis Set will be used to conduct the analysis 
of PK data, unless otherwise specified.
6.6 Interim Analyses Set(s)
Interim analyses for specific endpoints will use P1FAS, P2FAS, or those defined in 
Section 6.7.
6.7 Study-specific Analysis Sets
6.7.1 DLT Evaluable Set
The Dose Limiting Toxicity Analysis Set will contain DLT-evaluable subjects.  The details
of DLT evaluable subjects are given below:
Dose Cohort Duration of DLT Window DLT Evaluable Subject
Multiple 
subject 
cohorts
21 days from C1D1 Subject experienced a DLT or Subject does not 
experience a DLT and subject received at least 
80% of the planned doses (ie, no more than 
4 days without dosing) of investigational product 
within the first treatment cycle of 21 days.
C1D1 = Cycle 1 Day 1; DLT = Dose-Limiting Toxicity
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6.7.2 Phase 1 Monotherapy RP2D ORR Analysis Set
The phase 1 monotherapy RP2D ORR analysis set (P1OAS) will consist of all subjects 
with confirmed KRASp.G12C status whose initial dose of AMG 510 is at the RP2D and 
received at least 1 dose of AMG 510 in the phase 1 monotherapy dose exploration part, 
or the phase 1 monotherapy dose expansion part, and had at least 6-week response 
data.  Subjects who stopped disease assessments prior to 6 weeks will be included in 
this analysis set if the data cutoff is at least 6 weeks after their first dose date.  The
futility and efficacy thresholds will be calculated for monitoring the antitumor activity of 
monotherapy of AMG 510 during phase 1 expansion part using this analysis dataset.
6.7.3 Phase 2 ORR Analysis Set
The phase 2 ORR analysis set (P2OAS) will consist of all subjects in the phase 2 full 
analysis set who have had at least 6 weeks response data starting from day 1.  Subjects 
who stopped disease assessments prior to 6 weeks will be included in this analysis set if 
the data cutoff is at least 6 weeks after their first dose date.  The interim futility analysis, 
primary analysis, and final analysis of ORR, DOR, and TTR will be performed on the 
P2OAS.
7. Planned Analyses
The following interim, primary, and final analyses for phase 1 and phase 2 portions of 
the study are planned.
7.1 Interim Analysis and Early Stopping Guidelines
7.1.1 Phase 1 (Part 1 - Dose Exploration)
Safety data will be reviewed on an ongoing basis by Amgen.  Based on accumulating 
toxicity information, BLRM will be used to make dosing recommendations based on the 
DLT Evaluable Set.  In DLRMs, Amgen, in consultation with DLRT, will review the BLRM
recommended dose level and will review all available cumulative data by cohort prior to
making dose escalation decisions. As a sensitivity analysis, a one-parameter Continual 
Reassessment Method (CRM) model may be used to estimate the dose-toxicity
relationship to help make dose escalation decisions. Adverse events and DLTs
observed in all subjects (including backfill subjects) will be evaluated continually and fully
integrated into all DLRMs and considered in all enrollment and dosing decisions.
The DLRT members, quorum, voting members, and recommendations are described in 
Protocol Section 10.4.1.1.
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7.1.2 Phase 1 (Part 2 – Dose Expansion)
This same DLRT will be responsible for reviewing data in the dose expansion phase to 
confirm the RP2D and determine the benefit/risk of proceeding to the phase 2 part of the 
study.  The dose expansion part of the study (phase 1 - part 2) can open once an MTD 
or a RP2D and dosing schedule has been estimated in the dose exploration part of the 
study (phase 1 – part 1).  If no DLT is observed in phase 1 – part 1, the RP2D will be 
estimated based on composite review of PK, overall safety/tolerability, and observed 
responses.  Further confirmation of the RP2D dose will be sought in the phase 1 part 2 
dose expansion.
In the dose expansion, additional subjects will be enrolled at the RP2D estimated in the 
phase 1 part 1 dose exploration.  After a minimum of 20 subjects have been enrolled to 
the initial estimated monotherapy RP2D (including subjects enrolled to the RP2D in 
either the dose exploration [approximately 6] or the dose expansion [approximately 14] 
parts of the study) and have completed the 21-day DLT period, and after a minimum of 
10 of these subjects have at least 6 weeks of response data (including all previous data 
from the dose expansion and backfill cohorts), the DLRT will review all available safety, 
laboratory, PK, and efficacy (physician assessment) data.
After the first review has been conducted, if a decision is made to continue to obtain 
additional data at the initial estimated RP2D prior to proceeding to phase 2, the intervals 
for subsequent reviews will be determined by the DLRT but should occur within a 
maximum of 20 additional subjects enrolled and dosed for 21 days. The maximum 
number of subjects that may be enrolled to the initial estimated RP2D in the 
monotherapy dose expansion group, without confirmation of this dose for phase 2, will 
not exceed 60.  If another dose (or schedule) needs to be explored, additional subjects 
on that dose (or schedule), up to a total of 60, may be enrolled. 
Based on emerging clinical efficacy data, the number of subjects with specific tumor 
types may be restricted/specified in the expansion part.  
Antitumor activity will be monitored in terms of ORR by tumor types (NSCLC, CRC). 
Futility and efficacy thresholds will be calculated using Bayesian posterior probability 
approach based on the cumulative efficacy data and it will serve as a guidance to the
DLRT.  Enrollment will not be held to conduct this assessment.    
Whenever DLRT will review the data, and there are at least 5 evaluable subjects in the 
tumor type, the futility and efficacy thresholds for that tumor type will be calculated using 
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all the cumulative efficacy data in phase 1 Monotherapy RP2D ORR Analysis Set to 
provide the guidance.  In the calculation of thresholds, a response is defined as either a 
confirmed or unconfirmed CR or PR as per RECIST 1.1. 
7.1.2.1 Futility Thresholds
For NSCLC, the futility thresholds are calculated such that the Bayesian posterior 
probability of a true ORR ≤ 0.15 is > a high probability of 75%.  For CRC, the futility 
thresholds are calculated such that the Bayesian posterior probability of a true 
ORR ≤ 0.05 is > than a high probability of 75%.  A noninformative prior distribution of 
beta (1, 1) will be used.
NSCLC: probability (ORR ≤ 0.15) > 75%
CRC: probability (ORR ≤ 0.05) > 75%
7.1.2.2 Efficacy Thresholds
For NSCLC, the efficacy thresholds are calculated such that the Bayesian posterior 
probability of a true ORR > 0.25 is ≥ to a high probability of 60%.  For CRC, the efficacy 
thresholds are calculated such that the Bayesian posterior probability of a true 
ORR > 0.1 is ≥ to a high probability of 60%.  A noninformative prior distribution of 
beta (1, 1) will be used. 
NSCLC: probability [ORR > 0.25] ≥ 60%
CRC: probability [ORR > 0.1] ≥ 60%
Table 2 and Table 3 are look up tables calculated for NSCLC and CRC, providing the 
detailed futility and efficacy thresholds with different numbers of response-evaluable 
subjects (having at least 6-week response data) when DLRT review the data.  For 
example, at the time when DLRT plan to review the data, there are a total of 
25 response-evaluable NSCLC subjects.  If observing number of the response is ≤ 2, 
based on the table, the guidance will recommend not to continue due to the lack of 
efficacy.  If observing number of the response is ≥ 7, the guidance will recommend 
continuing to phase 2.  If the observing number of the response is in between and the 
total number of response-evaluable subjects at that RP2D has not reached the 
maximum 60, the guidance will recommend enrolling more patients in the phase 1 
expansion cohort. 
The operating characteristics of these thresholds are demonstrated assuming a minimal 
of 5 response-evaluable subjects per tumor type for the first DLRT review and 
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every 5 response-evaluable subjects thereafter.  The actual sample size per tumor type 
at each look will depend on tumor type distribution.  Table 4 and Table 5 show the 
cumulative probabilities of recommending DLRT to stop the trial due to lack of efficacy 
and the cumulative probabilities of recommending DLRT to continue to phase 2 given 
the true ORR ranging from 0.1 to 0.5 for NSCLC subjects and 0.05 to 0.25 for 
CRC subjects.
Table 2.  Look Up Table for NSCLC Subjects
Number of Subjects
Recommend Not to Continue if Observing the 
Number of Responses Below
5 ~ 7 Never stop for futility with this number of subjects
8 ~ 16 0
17 ~ 24 ≤ 1
25 ~ 31 ≤ 2
32 ~ 39 ≤ 3
40 ~ 47 ≤ 4
48 ~ 54 ≤ 5
55 ~ 60 ≤ 6
Number of Subjects Recommend Go to Phase 2 if Observing the 
Number of Responses below
5 ~ 8 ≥ 2
9 ~ 11 ≥ 3
12 ~ 15 ≥ 4
16 ~ 19 ≥ 5
20 ~ 23 ≥ 6
24 ~ 26 ≥ 7
27 ~ 30 ≥ 8
31 ~ 34 ≥ 9
35 ~ 38 ≥ 10
39 ~ 42 ≥ 11
43 ~ 46 ≥ 12
47 ~ 50 ≥ 13
51 ~ 54 ≥ 14
55 ~ 57 ≥ 15
58 ~ 60 ≥ 16
NSCLC = non-small cell lung carcinoma
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Table 3.  Look Up Table for CRC Subjects
Number of 
Subjects
Recommend Not to Continue if Observing the Number of Responses 
Below
5 ~ 26 Never stop for futility with this number of subjects
27 ~ 52 0
53 ~ 60 ≤ 1
Number of 
Subjects
Recommend Go to Phase 2 if Observing the Number of Responses Below
5 ~ 12 ≥ 1
13 ~ 21 ≥ 2
22 ~ 31 ≥ 3
32 ~ 40 ≥ 4
41 ~ 49 ≥ 5
50 ~ 59 ≥ 6
60 ≥ 7
CRC = colorectal cancer
Table 4.  Cumulative Probability of Go/No Go for NSCLC Subjects
Number of Subjects
True ORR
0.1 0.3 0.5
No Go Go No Go Go No Go Go
5 0% 8% 0% 47% 0% 81%
10 35% 11% 3% 67% 0% 96%
15 35% 13% 3% 77% 0% 99%
20 48% 13% 3% 79% 0% 99%
25 60% 13% 4% 83% 0% 100%
30 60% 13% 4% 85% 0% 100%
35 65% 13% 4% 86% 0% 100%
40 70% 13% 4% 87% 0% 100%
45 70% 13% 4% 89% 0% 100%
50 73% 13% 4% 90% 0% 100%
55 76% 13% 4% 90% 0% 100%
60 76% 13% 4% 91% 0% 100%
ORR = objective response rate. 
Numbers are for demonstration purpose.  The actual sample size per tumor type at each look will depend on 
tumor type distribution
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Table 5.  Cumulative Probability of Go/No Go for CRC Subjects
Number of Subjects
True ORR
0.05 0.15 0.25
No Go Go No Go Go No Go Go
5 0% 23% 0% 56% 0% 76%
10 0% 40% 0% 80% 0% 94%
15 0% 41% 0% 84% 0% 96%
20 0% 45% 0% 89% 0% 99%
25 0% 46% 0% 91% 0% 99%
30 21% 47% 1% 93% 0% 100%
35 21% 48% 1% 94% 0% 100%
40 21% 48% 1% 95% 0% 100%
45 21% 48% 1% 96% 0% 100%
50 21% 48% 1% 96% 0% 100%
55 28% 49% 1% 96% 0% 100%
60 28% 49% 1% 96% 0% 100%
ORR = objective response rate.
Numbers are for demonstration purpose.  The actual sample size per tumor type at each look will depend on 
tumor type distribution.
Based on emerging clinical efficacy data, the number of subjects with specific tumor 
types may be restricted/specified in the expansion part.
The DLRT may also recommend that additional subjects be enrolled at this estimated 
monotherapy RP2D or that a dose reduction or alternate dosing regimen be explored 
before proceeding to phase 2.  The decision to proceed to the phase 2 monotherapy will 
be based on the totality of data from both exploration and expansion parts of the study.  
A final estimate of the MTD and/or RP2D using BLRM will be evaluated and confirmed
utilizing all DLT-evaluable subjects from the dose exploration and the dose expansion
cohorts.
7.1.3 Phase 2 
7.1.3.1 Safety
A data review team (DRT), internal to Amgen but external to the study team, will assess 
safety after approximately 30, 50, 70, and 100 subjects have been treated for 21 days.  
Based on their reviews, the DRT will make recommendations to Amgen regarding the 
continuation of the study.  There will be no formal guidelines to stop for safety.  The DRT 
will consist of 3 or more members including 2 or more clinicians with relevant specialties 
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and 1 or more statisticians.  The DRT will be supported by an independent statistician 
who is responsible for preparing reports that describe the ongoing clinical study data.  
Details regarding the responsibilities of the DRT and the independent statistician will be 
described in the DRT Charter.
7.1.3.2 Futility
The DRT will also oversee futility analyses performed by tumor type and based on the 
phase 2 ORR analysis set.  The interim futility analyses will be conducted in a 
continuous manner using Bayesian predictive probability (Lee and Liu, 2008) for NSCLC 
and CRC separately.  Interim futility analysis will be performed by tumor types (NSCLC, 
CRC).  For NSCLC subjects, it will begin after approximately 25 response-evaluable 
subjects, defined as received at least 1 dose of AMG 510 and have had at least 6 weeks 
response data starting from day 1.  For CRC subjects, it will begin after approximately 
20 response-evaluable subjects. Subjects who stopped disease assessments prior to 
6 weeks will be included in this analysis if the data cutoff is at least 6 weeks after their 
first dose date.  Following this initial interim analysis, for each tumor type, subsequent 
interim analyses will be performed after every 10 subjects in each tumor type becomes 
response evaluable. 
The Go criterion will be met if the probability that the true ORR exceeds the benchmark 
ORR is ≥ to a high probability of:
Go Criterion for NSCLC: probability [ORR > 0.23] ≥ 80%
Go Criterion for CRC: probability [ORR > 0.1] ≥ 95%
Given the existing observed data during the continuous monitoring stage, the Bayesian 
predictive probability is obtained by calculating the probability of reaching a Go Criterion 
should the treatment group be enrolled and evaluated to the maximum planned final 
sample size of 105 NSCLC subjects and 60 CRC subjects.  The Go criterion is for 
interim futility analysis purpose only. 
Futility will be met if it is predicted that there is a small probability of reaching a Go 
Criterion upon full enrollment of 105 NSCLC subjects and 60 CRC subjects given the 
existing observed data.  A noninformative prior distribution of beta (1, 1) will be used.
Futility NSCLS:  Predictive probability of a Go decision < 5%
Futility CRC: Predictive probability of a Go decision < 30%
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Further enrollment may be terminated if futility is met.  The futility analyses will be based 
on site-assessed disease response and the futility rules will be nonbinding.  Due to the 
efficacy already observed in NSCLC during dose escalation phase, there will be no 
enrollment pause for NSCLC during the futility analyses.  Enrollment will be paused for 
CRC at the first interim futility analysis and may be paused at the subsequent interim 
analyses upon DRT’s recommendation.
The decision rule and operating characteristics for continuous monitoring of ORR in 
NSCLC subjects and CRC subjects are provided in Table 6 and Table 7, respectively. 
For example, observing 3 or fewer observed responders after 25 NSCLC subjects have 
become evaluable would be considered futile due to a small probability of reaching a Go 
Criterion upon full enrollment of 105 subjects given the existing observed data.
Table 6.  Stopping Boundary and Operating Characteristics in NSCLC Subjects
Number 
of 
Subjects
Considered 
Futile If 
Observing 
Number of 
Responses
Cumulative Probability of Futility
True 
ORR=0.1
True 
ORR=0.2
True 
ORR=0.3
True 
ORR=0.4
True 
ORR=0.5
True 
ORR=0.6
25 ≤ 3 76% 23% 3% 0.2% 0.0% 0.0%
35 ≤ 5 89% 32% 4% 0.3% 0.0% 0.0%
45 ≤ 7 94% 39% 5% 0.3% 0.0% 0.0%
55 ≤ 10 98% 51% 6% 0.3% 0.0% 0.0%
65 ≤ 13 100% 63% 8% 0.3% 0.0% 0.0%
75 ≤ 16 100% 73% 10% 0.3% 0.0% 0.0%
85 ≤ 19 100% 80% 12% 0.4% 0.0% 0.0%
95 ≤ 22 100% 85% 14% 0.4% 0.0% 0.0%
105 ≤ 27 100% 94% 23% 0.5% 0.0% 0.0%
Average Number of 
Subjects
29 60 99 105 105 105
NSCLC = non-small cell lung carcinoma; ORR = objective response rate
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Table 7.  Stopping Boundary and Operating Characteristics in CRC Subjects
Number 
of 
Subjects
Considered 
Futile If 
Observing 
Number of 
Responses
Cumulative Probability of Futility
True 
ORR=0.05
True 
ORR=0.1
True 
ORR=0.15
True 
ORR=0.2
True 
ORR=0.25
True 
ORR=0.3
20 ≤ 2 92% 68% 41% 20% 9% 4%
30 ≤ 3 96% 75% 45% 23% 10% 4%
40 ≤ 5 99% 85% 55% 27% 11% 4%
50 ≤ 7 100% 92% 63% 32% 12% 4%
60 ≤ 9 100% 95% 70% 35% 13% 4%
Average Number of 
Subjects
21 28 40 50 56 58
CRC = colorectal cancer; ORR = objective response rate
7.2 Primary Analysis
7.2.1 Phase 1 
The primary analysis for phase 1 will occur when target enrollment in phase 1 dose
escalation and dose expansion is complete and each subject either completes 6 months
on study or withdraws from the study.
7.2.2 Phase 2
The primary analysis for phase 2 will occur after 105 NSCLC or 60 CRC subjects are 
enrolled in phase 2 and have 6-month follow-up, whichever group occurs first.  The data 
cutoff was decided to allow sufficient time to demonstrate durability of ORR. Subjects 
who end the study prior to 6 months will be counted.  The data will be analyzed once 
they have been entered, cleaned, and locked.  The primary analysis will summarize for 
all tumor types even if it is triggered by 105 NSCLC subjects or 60 CRC subjects.
Results from the tumor cohort without sufficient subjects with 6-month follow up will be 
used descriptively. A subsequent analysis when the prespecified number of subjects in 
this cohort reach 6 months follow-up is outlined in Section 7.3.2.
7.3 Additional Analysis Subsequent to Primary Analysis
7.3.1 Phase 1 
At the time of Phase 2 Primary Analysis, phase 1 analyses will be updated to capture 
additional durable response after Phase 1 Primary Analysis. 
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7.3.2 Phase 2
If the primary analysis is triggered by 105 NSCLC (60 CRC) subjects reaching 6-month
follow-up, a subsequent analysis will occur when  60 CRC (105 NSCLC) subjects have
6-month follow-up.  The data will be analyzed once they have been entered, cleaned, 
and locked.
7.4 Final Analysis
The final analysis will occur when the end of study as defined in Section 5 has been 
reached.  The data will be analyzed once they have been entered, cleaned, and locked.  
The purpose of this analysis is to summarize efficacy and safety after all subjects have 
completed follow-up.
8. Data Screening and Acceptance
8.1 General Principles
The objective of the data screening is to assess the quantity, quality, and statistical 
characteristics of the data relative to the requirements of the planned analyses.
8.2 Data Handling and Electronic Transfer of Data
The Amgen Global Study Operations-Data Management (GSO-DM) department will 
provide all data to be used in the planned analyses.  This study will use the 
RAVE database. The database will be subject to edit checks outlined in the Clinical Data 
Management Plan (DMP).  See details of this section in the DMP.
8.3 Handling of Missing and Incomplete Data
Incomplete adverse event and concomitant medication dates missing data will be 
imputed as described in Appendix A.
8.4 Detection of Bias
Lack of protocol compliance and the potential for biased statistical analyses will be 
examined by assessing the incidence of important protocol deviations in each cohort. 
The clinical study team will identify and document the criteria for important protocol 
deviations.
8.5 Outliers
PK concentration data will be evaluated for outliers by visual inspection, and decisions to 
re-assay individual samples will be made in accordance with standard PK evaluation 
practice.
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8.6 Distributional Characteristics
Where appropriate, the assumptions underlying the proposed statistical methodologies 
will be assessed.  If required data transformations of analyses will be utilized.
8.7 Validation of Statistical Analyses
Programs will be developed and maintained, and output will be verified in accordance 
with current risk-based quality control procedures.  
Tables, figures, and listings will be produced with validated standard macro programs 
where standard macros can produce the specified outputs.  
The production environment for statistical analyses consists of Amgen-supported 
versions of statistical analysis software; for example, the SAS System version 9.4 or 
later.
9. Statistical Methods of Analysis
9.1 General Considerations
Descriptive statistics will be provided for selected demographic, safety and efficacy data. 
Descriptive statistics on continuous data will include means, medians, standard 
deviations, minimums & maximums while categorical data will be summarized using 
frequency counts and percentages.  For time-to-event variables, the Kaplan-Meier (KM) 
estimates and corresponding two-sided 95% confidence intervals for the median and 
quartiles will be provided.  Graphical summaries of the data may also be presented.  The 
K-M plot may also be provided.
Efficacy and safety analyses will pool together all tumor types and also present tumor 
types separately. Efficacy analysis for Phase 1 and Phase 2 will be analyzed 
separately.  In addition, integrated safety analyses will be done by different planned 
dose levels and treatments (monotherapy or combination therapy) and phases, using the 
Safety Analysis Set. 
Futility and efficacy thresholds in phase 1 and futility interim in phase 2 will be based on 
site-assessed disease response per RECIST 1.1. Primary, final, and any additional 
efficacy analyses will be based on an independent radiologic assessment of disease 
response per RECIST 1.1. 
Nominal 95% confidence intervals will be calculated.
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9.2 Subject Accountability
The number and percent of subjects who were enrolled, received investigational product, 
discontinued from investigational product (including reasons for discontinuing, completed 
study, discontinued the study (including reasons for discontinuing) will be summarized. 
Key study dates for the first subject enrolled, last subject enrolled, and last subject’s end 
of study will be presented.
9.3 Important Protocol Deviations
Important Protocol Deviations (IPDs) categories are defined by the study team before 
the first subject’s initial visit and updated during the IPD reviews throughout the study 
prior to database lock.  These definitions of IPD categories, subcategory codes, and 
descriptions will be used during the study.  The final IPD list is used to produce the 
Summary of IPDs table and the List of Subjects with IPDs.  In addition, a separate listing 
of all inclusion and exclusion deviations will be provided.
9.4 Demographic and Baseline Characteristics
The following descriptive summaries of the demographic and baseline characteristics will 
be produced: 
 Race: (White, Asian, Black or African American, vs other categories depending 
on frequency observed) If multiple races have been reported for a subject, the 
subject will be categorized as multiple.
 Gender: (male vs. female)
 Age at enrollment categories (< 65 vs. ≥ 65)
 Age at enrollment in years (summary statistics)
 Baseline weight (summary statistics)
 ECOG Performance Status at baseline (0 vs. 1)
 Time from initial diagnosis to enrollment
 Primary tumor location (NSCLC, CRC vs other tumor types)
 Disease Stage at Initial Diagnosis (I, II, III, IV)
 Disease Stage at Screening (I, II, III, IV)
 Histopathology Type (Adenocarcinoma, squamous cell carcinoma, Large cell 
carcinoma, Bronchoalveolar carcinoma, undifferentiated, other)
 Prior lines of therapy (0, 1, 2)
 Prior anti-cancer therapy for current malignancy (yes, no)
 Response to prior anti-cancer (yes, no)
 Prior radiotherapy for current malignancy (yes, no)
 Prior surgery for current malignancy (yes, no)
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 Number of metastatic sites (0,1, 2 or more)
 Brain metastases (yes, no)
 Liver metastases (yes, no)
 History of tobacco use (yes, no)
 ECHO or MUGA, if available
9.5 Efficacy Analyses
Table 8.  Phase 1 Efficacy Endpoint Summary Table
Endpoint Primary Summary and Analysis Method Analysis Set
Sensitivity 
Analysis
Primary Endpoint
None - - -
Secondary Endpoint
ORR The percentage of subjects with an OR will 
be summarized along with a 
Clopper-Pearson exact confidence interval.  
Subjects without a post-baseline tumor 
assessment will be considered 
non-responders. 
Interim during 
dose 
expansion: 
P1OAS
Primary and 
Final: P1FAS
None
DOR Kaplan-Meier quartiles and rates for select 
durations (eg, > 3, > 6, > 9, > 12 months)
P1FAS None
DCR The percentage of subjects with disease 
control will be summarized along with a 
Clopper-Pearson exact confidence interval.  
Subjects without a post-baseline tumor 
assessment will be considered 
non-responders.
P1FAS None
Duration of 
stable 
disease
Kaplan-Meier quartiles and rates for select 
durations (eg, > 3, > 6, > 9, > 12 months)
P1FAS None
PFS Kaplan-Meier curves, quartiles, and rates 
for select timepoints (eg, 6 and 12 months)
P1FAS None
P1OAS = Phase 1 monotherapy RP2D ORR Analysis Set. P1FAS = Phase 1 Full Analysis Set
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Table 9.  Phase 2 Efficacy Endpoint Summary Table
Endpoint Primary Summary and Analysis Method Analysis Set
Sensitivity 
Analysis
Primary Endpoint
ORR The percentage of subjects with an OR 
in Phase 2 ORR Analysis Set will be 
summarized along with a 
Clopper-Pearson exact confidence 
interval.  Subjects without a 
post-baseline tumor assessment will be 
considered non-responders. 
P2OAS None
Secondary Endpoints
DOR Kaplan-Meier quartiles and rates for 
select durations (eg, > 3, > 6, > 9, 
> 12 months)
P2OAS None
DCR The percentage of subjects with disease 
control will be summarized along with a 
Clopper-Pearson exact confidence 
interval.  Subjects without a 
post-baseline tumor assessment will be 
considered non-responders.
P2FAS None
OS Kaplan-Meier curves, quartiles, and 
rates for select timepoints (eg, 6 and 
12 months)
P2FAS None
PFS Kaplan-Meier curves, quartiles, and 
rates for select timepoints (eg, 6 and 
12 months)
P2FAS None
TTR Summary of non-missing sample size 
(n), mean, standard deviation, median, 
minimum, and maximum for responders
P2OAS None
P2OAS = Phase 2 ORR Analysis Set. P2FAS = Phase 2 Full Analysis Set
9.5.1 Analyses of Primary Efficacy Endpoint(s)
The number and percentage of subjects with a best overall response of Complete 
Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease 
(PD), Not Evaluable (NE) will be presented. ORR will be summarized along with a 
Clopper-Pearson exact 95% confidence interval (Clopper and Pearson, 1934).  Subjects 
without a post-baseline tumor assessment will be considered non-responders.
9.5.2 Analyses of Secondary Efficacy Endpoint(s)
DOR will be calculated only for subjects who achieve a best overall response of PR or 
better.  Subjects will be censored following the censoring strategy described in the 
definition of PFS time in Table 1.  The distribution of DOR, including the median and 
quartiles will be characterized using the Kaplan-Meier(KM) method based on the 
subjects who achieve a best response of PR or better.  The 95% CIs for the median and 
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quartiles of PFS will be constructed using the method of Klein and Moeschberger (1997)
with log-log transformation.  The rates for select durations (eg, > 3, > 6, > 9, 
> 12 months) will be reported.  The 95% CIs for PFS rates will be estimated using the 
methods by Kalbfleisch and Prentice (1980) with log-log transformation.  KM curve can 
be done for DOR if at least 10 subjects have a CR/PR.
The proportion of subjects with disease control (CR, PR or SD> 6 weeks) with 
corresponding exact 95% CI will be calculated using the Clopper-Pearson method.
Duration of Stable Disease will be analyzed using the same method as describe for 
DOR.
The distribution of PFS, including median, will be estimated using the Kaplan-Meier 
method.  PFS rate at the selected time points (6 months and 12 months) will be 
reported.  The 95% CIs for the median and other percentiles of PFS will be constructed 
using the method of Klein and Moeschberger (1997) with log-log transformation.  The 
95% CIs for PFS rates will be estimated using the methods by Kalbfleisch and 
Prentice (1980) with log-log transformation.
OS will be analyzed using the same method as describe for the PFS endpoints.
Time to response will be summarized with the non-missing sample size (n), mean, 
standard deviation, median, minimum, and maximum for responders, ie, subjects who 
achieve best overall response of sCR, CR, BGPR, or PR.
9.5.3 Analyses of Exploratory Efficacy Endpoint(s)
PFS2 is defined as time from start of the treatment to objective disease progression on 
next-line treatment or death from any cause, whichever occurs first.  If the date of the 
second disease progression is not available, then the start date of the next line of 
therapy following the second disease progression will be used as the surrogate for the 
date of the second disease progression and it will be considered as a PFS2 event.  For a 
subject who is alive and without second disease progression date or the start date of the 
next line of therapy, PFS2 will be right-censored at the date on which the subject is last 
known to be alive.  The analysis method will be the same as that for the PFS and 
OS analysis.
9.6 Safety Analyses
9.6.1 Analyses of Primary Safety Endpoint(s)
Unless otherwise specified, statistical analyses on safety endpoints in Phase 1 will be 
done using subjects from the Phase 1 Full Analysis Set; statistical analyses on safety 
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endpoint in Phase 2 will be done using subjects from the Phase 2 Full Analysis Set; 
integrated safety analysis will be done using subjects from integrated Safety Analysis 
Set, which includes all subjects that are enrolled and received at least 1 dose of 
AMG 510.  DLT analysis will be done using DLT-evaluable subjects.
Subject incidence of DLTs will be used to fit the BLRM model to estimate the probability
of having a DLT across dose levels
9.6.2 Adverse Events
The Medical Dictionary for Regulatory Activities (MedDRA) version 21.0 or later will be 
used to code all events categorized as adverse events to a system organ class and a 
preferred term.
The subject incidence of adverse events will be summarized for all treatment-emergent 
adverse events, serious adverse events, adverse events leading to withdrawal of 
investigational product, and death due to adverse events. 
Subject incidence of all treatment-emergent adverse events, serious adverse events, 
adverse events leading to withdrawal of investigational product, and fatal adverse events 
will be tabulated by system organ class and preferred term in alphabetical order.  
The number and percentage of subjects reporting adverse events will be evaluated 
overall and by dose level and will also be tabulated by relationship to study drug.
The severity of each adverse event will be graded using The Common Terminology
Criteria for Adverse Events (CTCAE) version 5.0 criteria.
 http://ctep.cancer.gov/protocolDevelopment/electronicapplications/ctc.htm.
Summaries of treatment-emergent and serious adverse events will be tabulated by 
system organ class, preferred term, and grade.
9.6.3 Laboratory Test Results
Laboratory data will be summarized using standard descriptive statistics at each 
scheduled time point in the study.  For continuous parameters, a summary of the 
changes from baseline to each post dose laboratory assessment will also be produced. 
Shifts in selected laboratory parameters between baseline and the worst on-study value 
will be summarized according to the NCI CTCAE toxicity grades.  Safety Laboratory 
collection includes chemistry, hematology, pregnancy test (for women of child-bearing 
potential) either urine or serum, and urine albumin-creatinine ratio 
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The parameters described in Table 7 of the protocol will be collected, converted to 
Amgen standard units and summarized.
Selected individual analytes will be summarized by cohort using standard descriptive 
statistics at each of the scheduled time points through the study up to the safety 
follow-up visit.  For continuous parameters, a summary of the changes from baseline to 
each post-dose laboratory assessment will be produced for each cohort.
Tables of shifts from baseline to the worst-case on-study increased and decreased 
values (graded according to the NCI Common Toxicity Grading Criteria) will be provided 
for selected laboratory parameters with available NCI-CTCAE grades.  Unscheduled 
assessments will be included in the shift tables.
Subject incidence of suspected Hy’s law cases (Hy’s law predicts potential for 
drug-related hepatotoxicity) will be summarized by cohort.  A listing of alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin 
values at each time point will be produced for the subjects suspected of Hy’s law case.
Boxplots may be plotted by time point and cohort for selected analytes.
9.6.4 Vital Signs
Vital signs data (eg, systolic / diastolic blood pressure, heart rate, respiratory rate, 
temperature and pulse oximetry) will be summarized using descriptive statistics. 
Summary statistics for each vital sign parameter will be provided for baseline and each 
scheduled post-baseline assessment.  Depending on the size and scope of changes, 
summaries of changes from baseline over time may be provided.  Unscheduled 
assessments will be included in this summary. 
Shifts in scores for ECOG performance status scores between the baseline and each 
assessed time point will be tabulated. ECOG performance status scores will be 
summarized at relevant time points.
9.6.5 Physical Measurements
Physical measurement data will be listed and reviewed for each subject.  Depending on 
the size and scope of changes, summaries of changes from baseline over time may be 
provided.  Unscheduled assessments will be included in this summary.
9.6.6 Electrocardiogram
Summaries over time and/or changes from baseline over time will be provided for all
ECG parameters.
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Subjects’ maximum change from baseline in QT interval corrected by Fridericia’s formula
will be categorized and the number and percentage of subjects in each group will be
summarized.  Unscheduled assessments will be included in the determination of the 
maximum change.  The categories are <= 30 msec, > 30 – 60 msec, > 60 msec.
Subjects’ maximum post baseline values will also be categorized and the number and
percentage of subjects in each group will be summarized.  The categories are 
<= 450 msec, > 450 – 480 msec, > 480 – 500 msec, > 500 msec.
All on-study ECG data will be presented and select parameters of interest may be
plotted.
In addition, the relationship between AMG 510 exposure and change from baseline in 
QTc will be explored graphically.  More details on analyses of ECG data are available in 
Supplemental Statistical Analysis Plan for ECGs Analyses.
9.6.7 Exposure to Investigational Product
Descriptive statistics will be produced to describe the exposure to investigational product 
by cohorts, combining data for each study part.  Number of cycles started, number of 
doses of investigational product, the cumulative dose by unit and average dose 
delivered per day, relative dose intensity will be summarized.  Summaries of the number 
and percentage of subjects with dose modifications and reason for modification will be 
provided.
 
 
9.6.9 Exposure to Other Protocol-required Therapy
Not applicable. 
9.6.10 Exposure to Concomitant Medication
The number and proportion of subjects receiving therapies of interest will be 
summarized by preferred term or category as coded by the World Health Organization 
Drug (WHO DRUG) dictionary.
9.7 Other Analyses
Other analyses in the study include analyses for PK endpoints, PRO, and biomarker
endpoints.
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9.7.1 Analyses of Pharmacokinetic or Pharmacokinetic/Pharmacodynamic 
Endpoints
Phase 1: 
Nominal sampling times will be used for individual concentration-time plots and tables. 
Actual dose administered, and actual sampling times will be used for the calculation of 
PK parameters for each subject.  The reasons for excluding any sample from the 
analyses will be provided.
Individual concentration-time data will be tabulated and presented graphically.  Summary 
of PK concentration over time and PK parameters will be provided.  Mean 
concentration-time profiles for each dose will be provided. 
PK parameters will include, but are not limited to, maximum observed concentration 
(Cmax), time to maximum concentration (tmax) and area under the plasma 
concentration-time curve (AUC).  Other PK parameters such as AUC from time 0 to the 
time extrapolated to infinity (AUCinf), apparent clearance (CL/F), and terminal half-life 
(t1/2) may be analyzed.  Pharmacokinetic parameters will be estimated using standard 
non-compartmental approaches based on the PK Analysis Set and summarized by dose 
level using descriptive statistics including, but not limited to means, standard deviations, 
medians, minimums, and maximums.  Above analyses will be conducted by Amgen 
Clinical Pharmacology Modeling and Simulation (CPMS).
For the food-effect assessment, PK parameter estimates will help assess the impact of 
food on the pharmacokinetics of AMG 510. The geometric means and 90% confidence 
interval for the ratio of the geometric means (fed state/fasted state) will be estimated 
using a mixed-effects model.  The model will use the log-transformed PK parameters as 
the dependent variable (or response) and treatment conditions (fed versus fasted) as the 
independent variable. 
Phase 2:
For AMG 510, PK parameters (eg, Cmax, tmax and AUC) will be determined where 
possible.  Based on the review of the data, analyses to describe the relationship between 
AMG 510 exposure and either pharmacodynamic effect and/or clinical outcome may also 
be performed
9.7.2 Analyses of Clinical Outcome Assessments
Clinical outcome assessment will be collected to subjects enrolled into the Phase 2 part 
of the study. The questionnaires should be completed by the subject prior to any other 
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clinical assessments and before receiving any study medications.  The details of the 
analyses will be specified in another Supplement SAP.
9.7.3 Analyses of Health Economic Endpoints
Not applicable.
9.7.4 Analyses of Biomarker Endpoints
Relationships between changes in tumor dynamics and above biomarkers of interest 
listed as exploratory endpoints will be explored. Changes in expression levels of 
biomarkers and their relationship to dose may also be explored.  Summary statistics over 
time will be provided and graphical presentations may be used.
The relationship between AMG 510 exposure and related biomarkers in blood will be also
explored if deemed appropriate. As appropriate, details of analysis will be provided in a 
supplemental analysis plan for exploratory biomarker analysis.
10. Changes From Protocol-specified Analyses
PFS2 is added as exploratory endpoint analyses. 
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12. Prioritization of Analyses
No priority of output is planned for this study.
13. Data Not Covered by This Plan
The analysis of Biomarkers and PRO endpoints is not covered in this plan.
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Appendix A.  Technical Detail and Supplemental Information Regarding Statistical 
Procedures and Programs
Imputation Rules for Partial or Missing Stop Dates
If the month and year are present, impute the last day of the month.  If only the year is 
present, impute December 31 of that year.  If the stop date is entirely missing, assume 
the event or medication is ongoing.  If a partial or complete stop date is present and the 
‘ongoing’ or ‘continuing’ box is checked, then it will be assumed that the AE or con-med 
stopped and the stop date will be imputed, if partial.
Imputation Rules for Partial or Missing Start Date:
Stop Date
Complete: 
yyyymmdd Partial: yyyymm Partial: yyyy
Missing
Start 
Date
< 1st
Dose
 1st
Dose
< 1st Dose 
yyyymm
 1st Dose 
yyyymm
< 1st Dose 
yyyy
 1st Dose 
yyyy
Partial: 
yyyymm
= 1st Dose 
yyyymm
2
1
2
1 N/A 1 1
 1st Dose 
yyyymm
2 2 2 2 2
Partial: 
yyyy
= 1st Dose 
yyyy
3
1
3
1 N/A 1 1
 1st Dose 
yyyy
3 3 3 3 3
Missing 4 1 4 1 4 1 1
1 = Impute the date of first dose
2 = Impute the first of the month
3 = Impute January 1 of the year
4 = Impute January 1 of the stop year
Note: For subjects who were never treated (first dose date is missing), partial start dates 
will be set to the first day of the partial month.
Note: If the start date imputation leads to a start date that is after the stop date, then do 
not impute the start date.
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Appendix B.  Code Fragments
Provisional Code Fragments for calculating a confidence interval using the 
Clopper Pearson Method.  The following example SAS code will be utilized for the 
response rate analysis providing the proportion of subjects responding to treatment with 
corresponding 95% confidence intervals and 90% confidence intervals. 
For 95% confidence intervals: 
data propci (keep = ns p low_ci upp_ci); 
n=xx; * total n within the treatment group; 
ns= xx; *number of responders; 
p=ns/n; * response rate; 
q=1-p; 
lowF=FINV(0.025, 2*ns, 2*(n-ns+1)); /* use for 2-sided 95% CI */ 
UppF=FINV(1-0.025, 2*(ns+1), 2*(n-ns)); /* use for 2-sided 95% CI */ 
low_ci = 1 / (1+(n-ns+1) / (ns*lowf)); * lower CI for response rate; 
upp_ci = 1 / (1+(n-ns) / ((ns+1)*uppf)); *upper CI for response rate; 
if p=1 then upp_ci=1; 
if p=0 then low_ci =0; 
output; 
end;run;
For 90% confidence intervals. 
data propci (keep = ns p low_ci upp_ci); 
n=xx; * total n within the treatment group; 
ns= xx; *number of responders; 
p=ns/n; * response rate; 
q=1-p; 
lowF=FINV(0.05, 2*ns, 2*(n-ns+1)); /* use for 2-sided 90% CI */ 
UppF=FINV(1-0.05, 2*(ns+1), 2*(n-ns)); /* use for 2-sided 90% CI */ 
low_ci = 1 / (1+(n-ns+1) / (ns*lowf)); * lower CI for response rate; 
upp_ci = 1 / (1+(n-ns) / ((ns+1)*uppf)); *upper CI for response rate; 
if p=1 then upp_ci=1; 
if p=0 then low_ci =0; 
output;
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